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Stress-related psychiatric disorders have been characterized by dysregulated 
rhythms of the hypothalamic-pituitary-adrenal axis (HPA axis) and a dysfunctional 
serotonergic system. However, the molecular mechanism of this relationship is not 
entirely described. This thesis has explored the link between an altered HPA axis 
circadian rhythm and the effect on tryptophan hydroxylase 2 (tph2) mRNA 
expression, the rate-limiting enzyme in the biosynthesis of serotonin. Three 
different experimental conditions were used in this study: 1) normal control 
conditions, 2) administration of the long-acting synthetic glucocorticoid 
methylprednisolone (MPL), and 3) constant light exposure for five weeks (LL). To 
evaluate the effects of these models, Radioimmunoassays (RIA) were used to assess 
plasma corticosterone (CORT) levels, and in situ hybridization histochemistry 
(ISHH) was used to measure tph2 mRNA in six different regions (interfascicular 
part DRI, caudal part DRC, ventral part DRV, dorsal part DRD, ventrolateral 
part/ventrolateral periaqueductal grey part DRVL/VLPAG and medium raphe 
nucleus MnR) of the Raphe Complex over a 24-hour period within 5 different time 
points (3 am, 9 am, 3pm, 6 pm, 9 pm). Relative to controls, the MPL model 
suppressed CORT, while the LL model displayed a hyperactive CORT secretion. 
Linear Mixed Model analyses showed that tph2 mRNA expression changed in the 
DRD, DRV, DRVL/VLPAG and in the MnR nucleus. The MPL induced a bi-phasic 
rhythm in expression with the loss of the nadir at 9 am and the peak at 6 pm whereas 
the LL treatment triggered high-levels of expression at 3 am and 9 pm with a flat 
expression between 9 am and 6 pm. This altered expression of tph2 mRNA was 
specific to the caudal levels of each area, with exception of the DRD. Measurements 
from each rostro-caudal bregma level showed precise changes which might be 








In correspondence to the help, not only financial, but superior in experience, 
innovation, training and professionalism from the Mexican government through the 
National Council of Science and Technology (CONACyT), I thank my country very 
much for the opportunity and support granted. An additional thanks for the financial 
support from the Neuroendocrinology Charitable Trust which allowed me to 
dedicate my entire time to this PhD.  
I want to thank Professor Stafford who with credulity chose me to be a part of their 
team and has been a good mentor. To Becky for her interest in my research, whose 
guide based on the confidence of my knowledge set the course to achieve a joint 
goal in favour of science. And to Jamie who in a rational and assertive manner 
landed my rumbling ideas. 
To all the members of the Lightman group, for their time and shared expertise. A 
special mention to Yvonne for her patience, dedication and time devoted to the 
experiments of this project and to Fran for her pertinent comments and the precision 
of her knowledge which enlarged the level of this research. 
A special thanks to Dr Chris Lowry, worldwide expert in the area, who invited me 
to his lab and shared with me all the tools and knowledge to develop this project. A 
big thanks to James Hazell who guided me step by step in the Linear Mixed Model 
Analysis.  
I also extend my appreciations to the reviewers who will invest their time in the 
revision of this thesis, whose knowledge and experience will extend the results of 
all the work of this PhD. 
In the personal field, I firstly thank my parents who undoubtedly have taught me by 
their example that with discipline and perseverance great things can be achieved in 
the personal and academic field. I enjoy very much having their scientific virtues, 
without them, this PhD would not have been possible. To my mother, who has 




of weakness and held firmly when I needed it most, who has even sometimes defied 
her limits of patience but never succumbed to restlessness when it comes to giving 
me encouragement, skill that has not been absent during this doctorate, for her, my 
love, gratitude and heart. To my father, whose tenacity and perseverance devoted 
to the scientific research are examples of academic excellence, thanks for your 
example of dedication that has allowed me not to give in to the moments of 
scientific frustration. 
To my Sister, for her technical, moral, inspiring, strengthening and complicity 
support, for the hours listened to on points in the void, for the advice, for the love 
and the best friendship that may exist between two who know each other. To her, 
who has always been an example to me. Thank you (and Juan) for welcoming me 
in your home during the writing months of this thesis and for giving me the greatest 
joy in the world, the best gift of all, my nephew, that only with his petite existence 
gives me an extra motivation of being.  
To my brother, who has not only taught me perseverance and hard work but has 
showed me that whatever you do and wherever you are, care for others, be noble 
and smile. To him, who is the greatest example of nobility.  
To all my friends, who with patience about my absence but with the insistence of 
their presence have make me strong every single day. For all their messages and 
audios which made me feel closer to home. For them, who made this time easier.   
Finally, to Nirvana, the person who accompanied me all this time. For all the 
conversations, laughs, tears and pints we shared. To her, who had the courage to 
stay with me during this journey called PhD. For the borrowed dream of others that 








I declare that the work in this dissertation was carried out in accordance with the 
requirements of the University's Regulations and Code of Practice for Research 
Degree Programmes and that it has not been submitted for any other academic 
award. Except where indicated by specific reference in the text, the work is the 
candidate's own work. Work done in collaboration with, or with the assistance of, 
others, is indicated as such. Any views expressed in the dissertation are those of the 
author. 
 





Table of contents 
Abstract ................................................................................................................... I 
Acknowledgements ............................................................................................... II 
Author’s declaration ........................................................................................... IV 
Table of contents .................................................................................................. V 
List of Figures ....................................................................................................... X 
List of tables ...................................................................................................... XVI 
Abbreviations ................................................................................................. XVII 
Chapter 1 General introduction ....................................................................... 1 
1.1 Introduction ..................................................................................................... 2 
1.2 The importance of rhythms ............................................................................. 3 
1.2.1 Rhythms .................................................................................................................. 3 
1.3 The circadian clock system in mammals ......................................................... 4 
1.3.1 The SCN ................................................................................................................. 5 
1.3.2 Peripheral oscillators and rhythms .......................................................................... 8 
1.3.3 Molecular circadian clockwork (gene network) ...................................................... 8 
1.3.4 Circadian rhythms in health and disease ............................................................... 11 
1.4 The HPA axis ................................................................................................ 12 
1.4.1 Structure, physiology and function of the HPA axis ............................................. 13 
1.4.2 Glucocorticoids ..................................................................................................... 15 
1.4.3 Glucocorticoid and Mineralocorticoid Receptors ................................................. 17 
1.4.4 Mechanism of action; ligand-receptor complex .................................................... 19 
1.4.5 Circadian and ultradian rhythms of glucocorticoids ............................................. 20 
1.4.6 Glucocorticoid rhythms in health and disease ....................................................... 22 
1.5 Serotonergic systems ..................................................................................... 23 




1.5.2 Brain serotonergic system anatomy and functional correlates ............................. 32 
1.5.3 Brain serotonergic system and circadian rhythms ................................................ 43 
1.5.4 Brain serotonergic systems in health and disease ................................................. 43 
1.6 Relating systems in health and disease ......................................................... 44 
1.7 Hypothesis and Aims ..................................................................................... 45 
1.7.1 Hypothesis ............................................................................................................ 45 
1.7.2 Aims ..................................................................................................................... 45 
Chapter 2 General Methods and Materials ................................................... 48 
2.1 Animal experiments ....................................................................................... 50 
2.2 Sample collection .......................................................................................... 50 
2.2.1 Plasma sample collection ..................................................................................... 50 
2.2.2 Brain and pituitary collection ............................................................................... 51 
2.3 Plasma sample analysis: Corticosterone radioimmunoassay (CORT RIA) .. 51 
2.3.1 Diluting samples ................................................................................................... 51 
2.3.2 Adding tracer and antibody .................................................................................. 52 
2.3.3 Adding charcoal solution for counting ................................................................. 52 
2.4 Cryosectioning of the Dorsal and Median Raphe nuclei .............................. 52 
2.4.1 Mounting the brain. .............................................................................................. 52 
2.4.2 Slicing of the brain and collection of brain sections. ........................................... 53 
2.5 In situ hybridization histochemistry (ISHH).................................................. 55 
2.5.1 Riboprobes ........................................................................................................... 55 
2.5.2 Transcription of sense and antisense DNA. ......................................................... 58 
2.5.3 Prehybridization ................................................................................................... 60 
2.5.4 Hybridization........................................................................................................ 60 
2.5.5 Riboprobe washing ............................................................................................... 61 
2.5.6 ISHH solutions ..................................................................................................... 61 
2.5.7 Film exposure ....................................................................................................... 62 
2.6 Image quantification ..................................................................................... 64 
2.6.1 Acquiring images ................................................................................................. 64 
2.6.2 Cataloguing images by rostro-caudal level. ......................................................... 65 




2.7 Statistical analysis......................................................................................... 71 
2.7.1 Statistical analyses of circulating CORT levels .................................................... 72 
2.7.2 Statistical analyses of the DR and MnR nuclei ..................................................... 72 
Chapter 3 Circadian rhythm of corticosterone and tph2 mRNA expression 
in the Dorsal and Median Raphe nuclei ............................................................ 78 
3.1 Introduction ................................................................................................... 79 
3.2 Methods ......................................................................................................... 79 
3.2.1 Study design to assess the natural rhythm of CORT and tph2 mRNA expression.
 79 
3.2.2 Statistical analysis ................................................................................................. 80 
3.3 Results ........................................................................................................... 81 
3.3.1 Circadian rhythm of circulating corticosterone ..................................................... 81 
3.3.2 Circadian rhythmicity of tph2 mRNA expression in the Raphe complex. ............ 82 
3.3.3 Circadian changes in tph2 mRNA expression in subregions of the Dorsal Raphe 
and the MnR nucleus. ..................................................................................................... 84 
3.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR subregions and MnR 
nucleus; analysis across the full rostro-caudal gradient. ................................................ 93 
3.3.5 Summary of results ............................................................................................. 102 
3.4 Discussion ................................................................................................... 104 
Chapter 4 Effect of the long-acting synthetic glucocorticoid 
Methylprednisolone on the circadian expression profile of tph2 mRNA 
expression in the Dorsal and Median Raphe nuclei. ...................................... 106 
4.1 Introduction ................................................................................................. 107 
4.2 Methods: Experimental Design ................................................................... 109 
4.2.1 Study design to assess the rhythm of CORT and tph2 mRNA expression after 
methylprednisolone (MPL) treatment. ......................................................................... 109 
4.2.2 Statistical analysis ............................................................................................... 110 
4.3 Results ......................................................................................................... 111 
4.3.1 Circadian rhythm of circulating Corticosterone after MPL treatment. ............... 111 
4.3.2 Circadian rhythmicity of tph2 mRNA expression in the Raphe complex after MPL 




4.3.3 Circadian changes in tph2 mRNA expression in subregions of the Dorsal Raphe 
and the MnR nucleus after MPL treatment. ................................................................. 115 
4.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR subregions and MnR 
nucleus; analysis across the full rostro-caudal gradient. .............................................. 132 
4.3.5 Summary of results ............................................................................................ 154 
4.4 Discussion ................................................................................................... 156 
Chapter 5 Circadian changes in the rhythm of tph2 mRNA expression in the 
Dorsal and Median Raphe nuclei following chronodisruption by five weeks of 
constant light exposure. ..................................................................................... 160 
5.1 Introduction ................................................................................................. 161 
5.2 Methods: Experimental design .................................................................... 163 
5.2.1 Study design to assess the circadian rhythm of CORT and tph2 mRNA expression 
after constant light exposure for five weeks. ............................................................... 163 
5.2.2 Statistical analysis .............................................................................................. 164 
5.3 Results ......................................................................................................... 165 
5.3.1 Circadian rhythm of circulating Corticosterone after constant light (LL) treatment.
 165 
5.3.2 Circadian rhythmicity of tph2 mRNA expression in the Raphe complex after LL 
treatment. ..................................................................................................................... 167 
5.3.3 Circadian changes on tph2 mRNA expression in subregions of the Dorsal Raphe 
and the MnR nucleus after LL treatment. .................................................................... 170 
5.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR subregions and MnR 
nucleus after LL treatment; analysis across the full rostro-caudal gradient. ................ 189 
5.3.5 Summary of Results ........................................................................................... 212 
5.4 Discussion ................................................................................................... 214 
Chapter 6 General Discussion ...................................................................... 218 
6.1 Introduction ................................................................................................. 219 
6.2 Natural rhythm of tp2 mRNA Expression .................................................... 220 
6.3 Effect of the long-acting synthetic GC MPL on rhythmic tph2 mRNA 




6.4 Effect of chronodisruption on the circadian GC profile and tph2 mRNA 
expression ............................................................................................................. 231 
6.5 Summary table of changes found after treatments. ..................................... 238 
6.6 Clinical relevance ....................................................................................... 240 
6.7 Limitations of the study ............................................................................... 242 
6.8 Future directions ......................................................................................... 244 
6.9 Conclusions ................................................................................................. 245 
References .......................................................................................................... 247 






List of Figures 
Figure 1-1: Suprachiasmatic Nucleus.. ............................................................................... 6 
Figure 1-2: Molecular circadian clockwork. ..................................................................... 10 
Figure 1-3: HPA axis. ....................................................................................................... 15 
Figure 1-4:  Circadian and Ultradian rhythm of plasma corticosterone.. .......................... 21 
Figure 1-5: Biosynthesis of serotonin. .............................................................................. 25 
Figure 1-6: Schematic representation of tph1 and tph2 associated functions.. ................. 28 
Figure 1-7: Line drawings and stereotaxic schematics of coronal sections of the Raphe 
complex ............................................................................................................................. 33 
Figure 2-1: Schematic representation of the sectioning of the Dorsal and Median Raphe 
nuclei. ................................................................................................................................ 53 
Figure 2-2: Collection of brain sections.. .......................................................................... 55 
Figure 2-3: Plasmid map for tph2 riboprobe. .................................................................... 56 
Figure 2-4: Schematic map of tph2a and tph2b splice variants.. ....................................... 56 
Figure 2-5: Schematic representation of autoradiography film set up. ............................. 63 
Figure 2-6: Montage of pictures of  tph2 mRNA expression in the Raphe complex ........ 65 
Figure 2-7: Schematic of rostro-caudal levels of DR subregions and MnR nucleus. ....... 66 
Figure 2-8: Diagram of reorganization of pictures. ........................................................... 68 
Figure 2-9: Matrix used for the expression of tph2 mRNA quantification.. ..................... 70 
Figure 2-10: Flow chart of the LMM analysis procedure. ................................................ 76 
Figure 3-1: Experimental design for the natural rhythm of CORT and tph2 mRNA 
expression. ......................................................................................................................... 80 
Figure 3-2: Circadian changes in circulating CORT of control animals.. ......................... 82 
Figure 3-3: Raphe complex. .............................................................................................. 83 
Figure 3-4: Circadian variation in tph2 mRNA expression in the Raphe complex of control 




Figure 3-5: Circadian variation in tph2 mRNA expression in the DRC of control animals.
 .......................................................................................................................................... 86 
Figure 3-6: Circadian variation in tph2 mRNA expression in the DRI of control animals..
 .......................................................................................................................................... 87 
Figure 3-7: Circadian variation in tph2 mRNA expression in the DRD of control animals.
 .......................................................................................................................................... 88 
Figure 3-8: Circadian variation in tph2 mRNA expression profile of the DRV of control 
animals. ............................................................................................................................. 90 
Figure 3-9: Circadian variation in tph2 mRNA expression profile of the DRVL/VLPAG of 
control animals. ................................................................................................................. 91 
Figure 3-10: Circadian variation in tph2 mRNA expression profile of the whole MnR of 
control animals. ................................................................................................................. 93 
Figure 3-11: Rostro-caudal level variation of tph2 mRNA expression profile in the DRC of 
control animals. ................................................................................................................. 97 
Figure 3-12: Rostro-caudal level variation of tph2 mRNA expression profile in the DRI of 
control animals. ................................................................................................................. 98 
Figure 3-13: Rostro-caudal level variation of tph2 mRNA expression profile in the DRD 
of control animals. ............................................................................................................ 99 
Figure 3-14: Rostro-caudal level variation of tph2 mRNA expression profile in the DRV 
of control animals. .......................................................................................................... 100 
Figure 3-15; Rostro-caudal level variation of tph2 mRNA expression profile in the 
DRVL/VLPAG of control animals ................................................................................. 101 
Figure 3-16: Rostro-caudal level variation of tph2 mRNA expression profile in the MnR of 
control animals. ............................................................................................................... 102 
Figure 4-1: Experimental design for the assessment of the altered rhythm of CORT and 
tph2 mRNA expression after MPL treatment. ................................................................ 110 
Figure 4-2: Circadian suppression of circulating CORT of MPL treated animals. ......... 112 
Figure 4-3: Circadian changes in CORT of Control versus MPL treated animals ......... 113 
Figure 4-4: Circadian variation in Tph2 mRNA expression in the DR and MnR complex of 




Figure 4-5: Circadian variation in Tph2 mRNA expression in the DR and MnR complex of 
control vs MPL treated animals. ..................................................................................... 115 
Figure 4-6: Circadian variation in tph2 mRNA expression in the DRC of MPL treated 
animals. ........................................................................................................................... 117 
Figure 4-7: Changes in circadian variation of tph2 mRNA expression in the DRC of Control 
versus MPL treated animals. ........................................................................................... 118 
Figure 4-8: Circadian variation in tph2 mRNA expression in DRI of MPL treated animals.
 ......................................................................................................................................... 119 
Figure 4-9: Changes in circadian variation of tph2 mRNA expression in the DRI of Control 
versus MPL treated animals. ........................................................................................... 120 
Figure 4-10: Circadian variation in tph2 mRNA expression in the DRD of MPL treated 
animals.   ......................................................................................................................... 122 
Figure 4-11:  Changes in circadian variation of tph2 mRNA expression in the DRD of 
Control vs MPL treated animals. ..................................................................................... 124 
Figure 4-12: Circadian variation in tph2 mRNA expression in the DRV of MPL treated 
animals. ........................................................................................................................... 125 
Figure 4-13: Changes in circadian variation of tph2 mRNA expression in the DRV of 
Control vs MPL treated animals. ..................................................................................... 126 
Figure 4-14: Circadian variation in tph2 mRNA expression profile in the DRVL/VLPAG 
of MPL treated animals. .................................................................................................. 127 
Figure 4-15: Changes in circadian variation of tph2 mRNA expression in the 
DRVL/VLPAG of Control vs MPL treated animals ....................................................... 129 
Figure 4-16: Circadian variation in tph2 mRNA expression in the MnR of MPL treated 
animals. ........................................................................................................................... 130 
Figure 4-17: Changes in circadian variation of tph2 mRNA expression in the MnR of 
Control vs MPL treated animals ...................................................................................... 132 
Figure 4-18: Rostro-caudal level variation of tph2 mRNA expression profile in the DRC of 
MPL treated animals. ...................................................................................................... 139 
Figure 4-19: Circadian changes in tph2 mRNA expression at each rostro-caudal level in 




Figure 4-20: Rostro-caudal level variation of tph2 mRNA expression profile in the DRI of 
MPL treated animals. ...................................................................................................... 141 
Figure 4-21: Circadian changes in tph2 mRNA expression at each rostro-caudal level in 
the DRI of Controls versus MPL treated animals. .......................................................... 142 
Figure 4-22: Rostro-caudal level variation of tph2 mRNA expression profile in the DRD 
of MPL treated animals ................................................................................................... 143 
Figure 4-23: Circadian changes in tph2 mRNA expression at each rostro-caudal level in 
the DRD of Controls vs MPL treated animals ................................................................ 144 
Figure 4-24: Rostro-caudal level variation of tph2 mRNA expression profile in the DRV 
of MPL treated animals ................................................................................................... 145 
Figure 4-25: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRV of Controls vs MPL treated animals .......................................... 147 
Figure 4-26: Rostro-caudal level variation of tph2 mRNA expression profile in the 
DRVL/VLPAG of MPL treated animals. ....................................................................... 148 
Figure 4-27: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRVL/VLPAG of Controls vs MPL treated animals ......................... 150 
Figure 4-28: Rostro-caudal level variation of tph2 mRNA expression profile in the MnR of 
MPL treated animals ....................................................................................................... 151 
Figure 4-29: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the MnR of Controls vs MPL treated animals .......................................... 153 
Figure 4-30 Representative image of tph2 mRNA expression of Ctrl (left) vs MPL (right).
 ........................................................................................................................................ 156 
Figure 5-1: Experimental design for the assessment of the altered rhythm of CORT and 
tph2 mRNA expression after five weeks of constant light (LL). .................................... 164 
Figure 5-2: Circulating CORT of LL treated animals in a 24-hour period. .................... 166 
Figure 5-3: Circadian changes in circulating CORT of Control versus LL treated animals.
 ........................................................................................................................................ 167 
Figure 5-4: Circadian variation in Tph2 mRNA expression in the DR and MnR complex of 




Figure 5-5: Circadian variation in tph2 mRNA expression in the DR and MnR complex of 
control vs LL treated animals.. ........................................................................................ 169 
Figure 5-6: Circadian variation in tph2 mRNA expression in the DRC of LL treated 
animals. ........................................................................................................................... 171 
Figure 5-7: Changes in circadian variation of tph2 mRNA expression in the DRC of Control 
versus LL treated animals. .............................................................................................. 172 
Figure 5-8: Circadian variation in tph2 mRNA expression in DRI of LL treated animals.
 ......................................................................................................................................... 173 
Figure 5-9:  Changes in circadian variation of tph2 mRNA expression in the DRI of Control 
versus LL treated animals. .............................................................................................. 174 
Figure 5-10: Circadian variation in tph2 mRNA expression in the DRD of LL treated 
animals.   ......................................................................................................................... 176 
Figure 5-11: Changes in circadian variation of tph2 mRNA expression in the DRD of 
Control vs LL treated animals.   ...................................................................................... 178 
Figure 5-12: Circadian variation in tph2 mRNA expression in the DRV of LL treated 
animals. ........................................................................................................................... 179 
Figure 5-13: Changes in circadian variation of tph2 mRNA expression in the DRV of 
Control vs LL treated animals ......................................................................................... 181 
Figure 5-14: Circadian variation in tph2 mRNA expression profile in the DRVL/VLPAG 
of LL treated animals. ..................................................................................................... 183 
Figure 5-15: Changes in circadian variation of tph2 mRNA expression in the 
DRVL/VLPAG of Control vs LL treated animals. ......................................................... 185 
Figure 5-16: Circadian variation in tph2 mRNA expression in the MnR of LL treated 
animals ............................................................................................................................ 187 
Figure 5-17: Changes in circadian variation of tph2 mRNA expression in the MnR of 
Control vs LL treated animals.   ...................................................................................... 189 
Figure 5-18: Rostro-caudal level variation of tph2 mRNA expression profile in the DRC of 
LL treated animals ........................................................................................................... 196 
Figure 5-19: Circadian changes in tph2 mRNA expression at each rostro-caudal level in 




Figure 5-20: Rostro-caudal level variation of tph2 mRNA expression profile in the DRI of 
LL treated animals. T ...................................................................................................... 198 
Figure 5-21: Circadian changes in tph2 mRNA expression at each rostro-caudal level in 
the DRI of Controls versus LL treated animals.. ............................................................ 199 
Figure 5-22: Rostro-caudal level variation of tph2 mRNA expression profile in the DRD 
of LL treated animals. ..................................................................................................... 201 
Figure 5-23: Circadian changes in tph2 mRNA expression at each rostro-caudal level in 
the DRD of Controls vs LL treated animals. .................................................................. 202 
Figure 5-24: Rostro-caudal level variation of tph2 mRNA expression profile in the DRV 
of LL treated animals. ..................................................................................................... 204 
Figure 5-25: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRV of Controls vs LL treated animals.. ........................................... 205 
Figure 5-26: Rostro-caudal level variation of tph2 mRNA expression profile in the 
DRVL/VLPAG of LL treated animals.. .......................................................................... 206 
Figure 5-27: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRVL/VLPAG of Controls vs LL treated animals............................. 208 
Figure 5-28: Rostro-caudal level variation of tph2 mRNA expression profile in the MnR of 
LL treated animals. ......................................................................................................... 210 
Figure 5-29: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the MnR of Controls vs LL treated animals. ............................................. 211 
Figure 5-30: Representative image of tph2 mRNA expression of Ctrl (left) vs LL (right). 
 ........................................................................................................................................ 215 
Figure 6-1: Schematic representation of the proposed relationships involved in stress-
related psychiatric disorders. .......................................................................................... 220 
Figure 6-2: Schematic representation of the mechanism involved in the neuropsychiatric 
side effects of sGC therapy. ............................................................................................ 230 
Figure 6-3: Schematic representation of the mechanisms involved in the development of 





List of tables  
Table 1-1: Brain regions projecting directly to the rat SCN.  . ........................................... 7 
Table 1-2: Main clock genes in mammals........................................................................... 9 
Table 1-3: Families of 5-HT receptors. ............................................................................. 29 
Table 1-4; Summary of Afferent and efferent connections of all subdivisions from the DR 
complex. ............................................................................................................................ 40 
Table 2-1: Level code of the rostro-caudal level used in this study .................................. 67 
Table 3-1: Linear mixed model analysis results for tph2 mRNA expression in Control SD 
male animals. ..................................................................................................................... 95 
Table 3-2: Table 3-3: Key findings on the circadian expression of tph2 mRNA.by 
subdivision of the Raphe complex and by bregma level.. ............................................... 103 
Table 4-1: Linear mixed model analysis results for tph2 mRNA expression in MPL treated 
SD male rats .................................................................................................................... 134 
Table 4-2: Linear mixed model analysis results for tph2 mRNA expression in Control vs 
MPL treated SD male rats. .............................................................................................. 136 
Table 4-3: Key findings of the circadian expression of tph2 mRNA after MPL treatment. 
Data shown by subdivision of the Raphe complex and by bregma level. ....................... 154 
Table 5-1: Linear mixed model analysis results for tph2 mRNA expression in LL treated 
SD male rats .................................................................................................................... 191 
Table 5-2: Linear mixed model analysis results for tph2 mRNA expression in Control vs 
LL treated SD male rats. ................................................................................................. 193 
Table 5-3: Key findings of the circadian expression of tph2 mRNA after MPL treatment. 
Data shown by subdivision of the Raphe complex and by bregma level.. ...................... 213 







5-HIAA   5-hydroxyindoleacetic acid 
5-HT Serotonin 
5-HTR Serotonin receptor 
AA  Acetic anhydride 
ACTH Adrenocorticotropic hormone  
ADX Adrenalectomy 
AIC  Akaike information criterion 
AVP  Arginine vasopressin peptide 
AVP1BR  AVP 1B receptor 
BMAL1  Brain-muscle-arntl-like protein 1 
CLOCK  Circadian loco-motor output cycle kaput 
CNS  Central nervous system  
CORT  Corticosterone  
CRH  Corticotropin-releasing hormone 
CRHR1  CRH receptor 1 
CRY   Cryptochromes 
CTRL  Control  
DBD DNA binding domain  
DNA  Deoxyribonucleic acid 
DR    Dorsal Raphe Nucleus 
DRC  Caudal part of the dorsal raphe 
DRD  Dorsal part of the dorsal raphe 
DRI  Intrafascicular part of the dorsal raphe 
DRV  Ventral part of the dorsal raphe 
DRVL Ventrolateral part of the dorsal raphe 
DTT  Dithlothreitol 
GC Glucocorticoids 
GR Glucocorticoid Receptor  




HDC  Histidine decarboxylase 
HPA Hypothalamic-pituitary-adrenal  
ISHH In situ hybridization histochemistry 
LBD  Ligand binding domain  
LD  Light-Dark 
LL  Constant light  
LMM  Linear Mixed effects Models  
LSD Least Significant Difference 
MAO  Monoamine oxidase  
MDD  Mayor depressive disorder 
MnR Median raphe nucleus 
mPFC  Medial prefrontal cortex 
MPL Methylprednisolone  
MR Mineralocorticoid receptor 
mRNA  Messenger RNA 
 NTD N-terminal domain  
PAH  Phenylalanine 
PBS  Phosphate buffered saline 
PER  Period genes 
PH Posterior hypothalamus 
PTSD  Post-traumatic stress disorder  
PVN   Paraventricular nucleus 
RHT Retino-hypothalamic tract 
RIA Radioimmunoassay 
SCN  Suprachiasmatic nuclei 
SD Sprague-Dawley 
SERT Serotonin transporter  
sGCs  Synthetic glucocorticoids  
SSC  Saline sodium citrate 
StAR  Steroidogenic acute regulatory 




TF  Transcription factor  
TH  Tyrosine hydroxylase 
TM Tuberomammillary nucleus 
Tph  Tryptophan 5-hydroxylase 
Tph2  Tryptophan hydroxylase protein2  
VIP  Vasoactive intestinal peptide  
VLPAG  Ventrolateral periaqueductal grey 
VMAT Vesicular monoamine transporter 
VP Vasopressin  
VTA Ventral tegmental area 
WB  Western blotting 
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1.1 Introduction  
Mental disorders account for 30% of the global non-fatal disease burden, with 
approximately 10% of the world’s population affected by depression and/or anxiety 
(World Health Organization, 2017). It is important, therefore, to understand the 
fundamental mechanisms of these disorders. In neuroscience, we think about the 
mechanisms involved in the aetiology of these conditions in terms of natural 
rhythms of the neuroendocrine response system, and how changes in these rhythms 
may promote disease development.  
Altered biological rhythms are associated with many important pathologies (Archer 
et. al, 2014; Bailey & Silver, 2014; Benca et. al, 2009; Kaper, Kramer, & Rotstein, 
2013). For example, hypothalamic-pituitary-adrenal (HPA) axis activity has been 
widely considered as an element of study for mental disorders because of the altered 
HPA axis rhythms found in patients with these particular illnesses (Arborelius, 
Owens, Plotsky, & Nemeroff, 1999; Orchinik, 1998; Stamper et. al, 2015; Vincent 
et. al, 2013) and the strong relationship between stressful events and symptoms of 
psychiatric disorders (Faravelli et. al, 2012; Heim, Owens, Plotsky, & Nemeroff, 
1997; Juruena, 2014).  
On the other hand, alterations in the serotonergic system have also been widely 
associated with mental disorders. For example, an elevated serotonin turnover, a 
deficient 5-HT receptor system and an impairment of serotonin neurotransmission 
have been observed in depressed patients (Cowen, 2002; Esler et. al, 2007; Sharp 
& Cowen, 2011), modified genetic components in serotonin receptors (5-HTR), 
tryptophan hydroxylase (TPH) and the serotonin transporter (SERT) have been 
found in patients suffering from mental disorders (Lemonde et al., 2003; Barton et 
al., 2008; Le François et al., 2008), and serotonin reuptake and/or degradation 
inhibitors have been shown to be an effective therapeutic treatment for mental 
disorders such as depression, anxiety and bipolar disorder (Owens and Nemeroff, 
1998; Mcelroy et al., 2006; Beyer and Cremers, 2008; Pringle et al., 2013).  
The work described in this thesis is concerned with understanding the connections 
between these two systems and their specific activity. Characterising this 
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connection could reveal an underlying cause of these pathologies, which could in 
turn benefit people suffering from mental disorders. The following introduction will 
describe the three basic elements considered for the development of this study. 
1.2 The importance of rhythms 
Behaviour and physiology, from human to cyanobacteria, display clear fluctuations 
across the day (24-hr period). In the early history of science, it was believed that 
these daily fluctuations were driven by external temporal cues (i.e. day/night, 
temperature, food availability, seasons). Subsequently, the concept of internal or 
“endogenous” rhythmicity emerged with the observation of persistent rhythmic 
activity in a “light-sensitive” plant maintained under constant darkness (De Mairan, 
1729) and with observations that in humans, even under complete darkness for over 
a month, the sleep-wake cycle is kept synchronized to a nearly 24-hour period 
(Kleitman, 1939). 
It is now known that most living organisms on earth have an endogenous 
rhythmicity which guarantees the proper organization of processes and adaptation 
to a rhythmic environment (day/night, seasons) (Moore MD, 1997; Czeisler and 
Gooley, 2007; Huang et al., 2011). By contemplating the crucial role of this internal 
clock and the idea that disruption of this “endogenous rhythmic activity” could lead 
to disease, the understanding of how this clock works became of great importance 
to the scientific community several decades ago. 
1.2.1 Rhythms  
After the emergence of the idea of an “internal clock”, researchers in this area have 
established many characteristics of this endogenous rhythmicity. Today it is well 
known that endogenous rhythmicity can occur across a large range of time domains; 
circannual rhythms (once a year) (Sweeney, 1987), infradian rhythms (>24 h) 
(Moore-Ede, 1986), circadian rhythms (nearly 24 h) and ultradian rhythms (<24 h) 
(Edmunds, 1988).  
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Circannual rhythms manifest, for example, in mating, hibernation, and flowering 
(Edmunds, 1988; Sveeney, 1987). Infradian rhythms are present in the oestrus 
cycles of some rodents and the menstrual cycle in higher primates (Moore-Ede, 
1986). Examples of ultradian rhythms can be seen in growth hormone secretion 
(Tannenbaum and Martin, 1976) or blood circulation (Yosipovitch et al., 2004). 
Circadian rhythms are far more prominent, with great examples in the sleep-wake 
cycle (Beersma and Gordijn, 2007), hormone secretion (Tsang, Barclay and Oster, 
2013) and body-temperature cycle (Benstaali et al., 2001). Although all these 
rhythms are of great relevance, for the interest of this study, we will focus only on 
circadian rhythms. 
1.2.1.1 Circadian rhythms  
Circadian (from the Latin “circa” meaning around and “diem” meaning day) 
rhythms have an endogenous period of approximately 24 hours. The period of this 
type of rhythm is closely matched to the rotation of the earth (Moore-Ede, 1986; 
Gachon et al., 2004). 
These rhythms have to meet the following specific requirements  to be considered 
as a circadian rhythm; 1) they should persist even when they are removed from all 
daily temporal cues, and the maintenance of an oscillation without periodic clues 
from the outside response should persist for a minimum of two or more cycles 
(Edmunds, 1988; Silver and Kriegsfeld, 2014); 2) they should have the ability to be 
entrained (synchronized) to the outside world. Until today, the main synchronizers 
described are the light/dark and temperature cycles (Somers, 1999); 3) they should 
demonstrate temperature compensation. Although a temperature shift can reset the 
phase of the rhythm, when stabilized, this new temperature regime should have very 
little effect on the endogenous pattern (Pittendrigh and Caldarola, 1973). 
1.3 The circadian clock system in mammals 
Circadian rhythms exist in all organisms including, plants, animals, fungi and 
cyanobacteria (Edgar et al., 2012). However, when it comes to research done in 
mammals, the idea of endogenous daily rhythms gave rise to a proposed 
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endogenous circadian clock system, which includes a central biological clock 
(Moore and Eichler, 1972a; Klein, Moore and S.M., 1991; Moore, Speh and Leak, 
2002), peripheral oscillators (Zylka et al., 1998; Balsalobre et al., 2000; Kamphuis 
et al., 2009) and a complete molecular clock network depending mainly on genetic 
mechanisms (Konopka and Benzer, 1971; Buijs and Kalsbeek, 2001; Zhang and 
Kay, 2010; Partch, Green and Takahashi, 2014). 
The circadian clock system in mammals is autonomous and self-sustained, but it 
can also be entrained by external cues, which are called “zeitgebers” (Aschoff, 
1965). This system involves three specific elements: 1) input pathways receiving 
environmental cues (zeitgebers); 2) a circadian oscillator (the generator of rhythm); 
and 3) output pathways which control responses (metabolic, physiological or 
behavioural) (Chung, Son and Kim, 2011b, 2011a; Son, Chung and Kim, 2011a). 
In mammals, the circadian clock system is organized in a hierarchy, with the master 
clock residing in the suprachiasmatic nucleus (SCN) in the hypothalamus (Moore 
and Eichler, 1972a; Moore, Speh and Leak, 2002; Welsh, Takahashi and Kay, 
2010), and secondary peripheral clocks in other brain regions and peripheral tissues 
(Ko and Takahashi, 2006; Kornmann et al., 2007; Mukherjee et al., 2010). 
1.3.1 The SCN 
In complex organisms such as mammals, a central pacemaker (biological clock) has 
evolved and concentrated in the central nervous system (CNS). In 1972, the 
“master” circadian pacemaker was found in the SCN of the anterior hypothalamus 
in mammals (Hendrickson, Wagoner and Cowan, 1972; Moore and Eichler, 1972a; 
Stephan and Zucker, 1972). After its discovery, the SCN was established as the 
internal timekeeper essential for the circadian timing of mammals. This nucleus 
presented rhythmicity even when isolated in vitro (Gillette and Prosser, 1988) or in 
vivo (Inouye and Kawamura, 1979) from the rest of the brain. 
The SCN is a tear-drop shaped nucleus (Figure 1-1) which contains about 20,000 
clock oscillating cells that form a highly organized and synchronized network 
(Klein, Moore and S.M., 1991; Welsh, Takahashi and Kay, 2010). This specialized 
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nucleus receives environmental information to adjust physiological and 
behavioural functions, such as locomotor activity, body temperature and hormonal 
secretion of the organism in the form of the alternating day/night cycle (Moore and 
Eichler, 1972a; Schibler and Sassone-Corsi, 2002; Dibner, Schibler and Albrecht, 
2010). 
 
Figure 1-1: Suprachiasmatic Nucleus. The SCN is a group of brain cells located in the 
Hypothalamus which has been related to the control of circadian cycles of physiological and 
behavioural rhythms. Taken from; 
http://operativeneurosurgery.com/doku.phpidsuprachiasmatic. 
Nowadays, after numerous studies, it has become clear that, at a molecular level, 
this endogenous rhythmicity in the SCN is actually generated by clock genes, 
forming a complex web of feedback loops (Wilsbacher and Takahashi, 1998; King 
and Takahashi, 2000); this will be further detailed in the following sections. 
The SCN can be synchronised by both photic (Nelson and Zucker, 1981; Meijer et. 
al, 1999; Yamazaki et. al, 1999) and non-photic cues (Reppert and Weaver, 2002). 
Because of the type neurons contained in the SCN, it can be divided in 2 parts: 1) a 
core with vasoactive intestinal peptide (VIP) (Abrahamson and Moore, 2001); and 
2) a shell with arginine vasopressin peptide (AVP) (Silver and Moore, 1998). 
Furthermore, all neurons in the SCN contain GABA (Moore & Speh, 1993).  
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There are approximately 35 different inputs to the SCN from other areas of the 
brain, (summarised in table 1-1 ) (Krout et al., 2002). However, the three most 
important inputs to the SCN are: 1) The core of the SCN receives photic input from 
the retino-hypothalamic tract (RHT) (Moore and Lenn, 1972), which results in the 
induction of various genes (Kornhauser et al., 1990) and chromatin remodelling 
(Crosio et al., 2000); 2) non-photic input is received from projections from the 
intergeniculate leaflet (Hastings et al., 1998); and 3) non-photic inputs from the 
median raphe nucleus (Meyer-Bernstein and Morin, 1996; Morin, 1999). 
Table 1-1: Brain regions projecting directly to the rat SCN.  Table from Krout et. al, 2002. 
 
Moreover, the SCN also has three important projections (Watts and Swanson, 
1987): 1) to the periventricular hypothalamic nuclei (Watts and Swanson, 1987; 
Abrahamson and Moore, 2001; Aston-Jones et al., 2001); 2) to the septum and 
anterior paraventricular thalamus (Watts and Swanson, 1987; Moore, Speh and 
Leak, 2002); and 3) to the bed nucleus of stria terminalis (Watts, Swanson and 
Sanchez-Watts, 1987; Morin et al., 1994). Additionally, a projection to the 
amygdala (Morin et al., 1994) and to the intergeniculate leaflet (Card and Moore, 
1989) has been described. 
Therefore, the SCN is a very complex “central clock” which is essential for the 
circadian timing in mammals. Additionally, the molecular basis of how this clock 
works relies on genetic mechanisms and a complete circadian clockwork.  
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1.3.2 Peripheral oscillators and rhythms 
Although the SCN is commonly known as the “master clock”, many other regions 
in the brain and body tissue display circadian rhythms (Oishi et al., 1998; 
McNamara et al., 2001; Reick et al., 2001).  
The idea of the SCN as the unique time keeper changed when several studies 
showed that most cells in other different types of tissue had the ability to oscillate 
even when cultured in vitro (Balsalobre et al., 2000; Le Minh et al., 2001; 
Kamphuis et al., 2009). 
Furthermore, the idea that peripheral clocks were controlled (entrained) through 
hormonal and neuronal cues provided by the SCN was dismissed when different 
studies using food availability (Damiola et al., 2000), temperature cycles (Brown 
et al., 2002) and hormone signals (Balsalobre et al., 2000) showed that rhythms in 
peripheral oscillators could be sustained by these conditions.  
Nowadays, the idea of the SCN as a central pacemaker has changed, proposing  this 
nucleus as  the central coordinator of all other peripheral clocks (Dibner, Schibler 
and Albrecht, 2010). Moreover, both the SCN and the peripheral oscillators seem 
to have a very similar molecular mechanism (Kamphuis et al., 2005; Liu et al., 
2007). This mechanism consists of two transcriptional/post-translational feedback 
loops involving clock genes, as described in the next section.  
1.3.3 Molecular circadian clockwork (gene network) 
In 1990,  a study done in Drosophila proposed that circadian rhythms were 
generated by an intracellular mechanism of autoregulatory 
transcriptional/translational feedback loops which involved clock genes (Hardin, 
Hall and Rosbash, 1990). After this, a myriad of research was carried out on these 
“clock genes” and today, a number of essential mammalian “clock genes”, 
necessary for the maintenance of the circadian rhythm, have been identified (Table 
1-2).
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Table 1-2: Main clock genes in mammals. Taken from (Cermakian and Boivin, 2003). 




The molecular mechanism driving rhythmic gene expression consists of two 
positive and negative transcriptional/translational feedback loops (Figure 1-2). The 
core feedback loop includes two transcriptional activators, the ‘‘circadian loco-
motor output cycle kaput’’ (CLOCK) and ‘‘brain-muscle-arntl-like protein 1’’ 
(BMAL1), and two transcriptional repressors, Period genes (PERs: PER1, PER2 
and PER3) and Cryptochromes (CRYs: CRY1 and CRY2). PER and CRY are 
translated into their proteins which translocate from the cytoplasm to the nucleus to 
inhibit their own gene expression and their target genes CLOCK and BMAL1 
(Gekakis et al., 1998; Bunger et al., 2000). The secondary loop is BMAL1 
transcription being regulated by the clock-controlled nuclear receptors, retinoic acid 
receptor-related orphan nuclear receptors RORs and REV-ERBs. Additionally, 
CLOCK-BMAL1 controls the expression of  REV-ERBs, and then RORs and REV-
ERBs induce (RoRalpha) or repress (REV-ERBalpha/beta) BMAL1, contributing 
to rhythmic gene transcription and stabilizing the clockwork mechanism (Sato et 
al., 2004; Guillaumond et al., 2005).  
 
Figure 1-2: Molecular circadian clockwork. The molecular mechanisms of circadian rhythms 
depend of two transcriptional/translational feedback loops. CLOCK and BMAL1 induce 
transcription of PERs and CRYs. Then, PER and CRY repress CLOCK and BMAL1. 
Additionally, CLOCK and BMAL1 control transcription of ROR and REV-ERB which modulate 
BMAL1 levels.  Taken from (Chung, Son and Kim, 2011b). 
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This brief description of the molecular mechanism of circadian rhythms 
demonstrates the complexity of the clockwork. Interestingly, this mechanism has 
become of great relevance when studying circadian clock-related diseases, such as 
sleep disorders, psychiatric disorders and metabolic disorders, which epidemiology 
researchers have linked to circadian abnormalities. 
1.3.4 Circadian rhythms in health and disease 
As described above, all organisms depend largely on the circadian system to adapt 
and survive effectively in a moving world. Hence, when organisms do not have a 
functional circadian system, their adaptation and survival is at risk, and the 
development of pathology becomes a common consequence (Litinski, Scheer and 
Shea, 2009). 
A substantial area of chronobiology has studied the negative impact of a 
dysfunctional circadian system and its relationship with behavioural (Saper, 
Scammell and Lu, 2005; Krystal, Benca and Kilduff, 2013), physiological (Swaab, 
Fliers and Partiman, 1985; Schernhammer et al., 2001), metabolic (Turek et al., 
2005; Garaulet and Madrid, 2010; Reiter et al., 2012) and even psychiatric diseases 
(Desan et al., 2000; Harvey, Mullin and Hinshaw, 2006; Walker and Lawrence, 
2017). 
One of the major endocrine circuits that has been related to circadian alterations 
and disorders, and which is of primary interest in our study, is the HPA axis. HPA 
axis activity is under circadian regulation by the SCN (Buijs and Kalsbeek, 2001). 
However, this circadian regulation seems to be bidirectional given the participation 
of glucocorticoids (GC), the endpoint of the HPA axis, in several physiological 
processes (Buckingham, 2006), their capacity to reset peripheral oscillators 
(Stratmann and Schibler, 2006), and their ability to promote accumulation of clock 
genes (Balsalobre et al., 2000) and stimulate cyclic expression of target genes 
independently of the molecular circadian system (Oishi et al., 2005). Therefore, the 
influence of the HPA axis over the circadian system, and vice versa, establishes a 
deep connection between abnormal rhythms of GC and the presence of pathology 
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(Naylor et al., 2000; Liu et al., 2006; Lamia, Storch and Weitz, 2008; Mukherjee et 
al., 2010). 
Of special relevance to our study too is the fact that abnormal HPA axis activity has 
been associated with depression and anxiety disorders (Morin, 1999; Pompili et al., 
2010). The bidirectional connection between GC and the circadian system seems to 
be of fundamental importance in this idea as it appears that GC may influence 
specific central functions by controlling/resetting rhythms (Lamont et al., 2005; 
Hood et al., 2010). Moreover, GCs appear to drive the accumulation of tph mRNA 
(rate limiting enzyme in the biosynthesis of serotonin) in the raphe nucleus (central 
nucleus of serotonin biosynthesis), and hence influencing the biosynthesis and 
neurotransmission of serotonin (Malek et al., 2007), which is of major significance 
in the aetiology of depression and other psychiatric disorders (Murphy et al., 1998; 
Owens and Nemeroff, 1998; Naughton, Mulrooney and Leonard, 2000a).  
Thus, altered HPA axis circadian activity and malfunctioning of the serotonin 
system, and their relationship with depressive disorders, has been established. 
However, the molecular mechanisms of this association are still unknown.  
1.4 The HPA axis 
According to the World Health Organisation, the term stress-related disorders 
specifically relates to problems such as post-traumatic stress disorder (PTSD), acute 
stress reaction and bereavement reactions that require an exposure to a defined 
stressor as a precursor. There are numerous other stress-related disorders and 
problems such as depression, behavioural disorders, alcohol/substance use 
problems, self-harm/suicide, medically-unexplained somatic complaints, but these 
are not specifically related to stress (i.e. they may also occur in the absence of 
identifiable stressful life events) (World Health Organisation, 2013). But what is 
stress?  And how does our body deal with stress?  
All living organisms maintain a complex dynamic equilibrium or homeostasis 
(Cannon, 1929). This equilibrium is repetitively challenged by intrinsic or extrinsic 
changes, called stressors; these stressors can be physical or emotional (Chrousos 
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and Gold, 1992).  In the 1930s, Hans Selye used the term “stress” (from physics) to 
define the psychological and physiological events occurring in ill patients as a 
consequence of prolonged adaptational responses; “Stress syndrome” (Selye, 
1936). 
When homeostasis is challenged by stressors with certain severity or stressors 
exceed a temporal threshold, the organism activates compensatory responses 
(Chrousos, Loriaux and Gold, 1988). The major endocrine system which relates to 
the compensatory responses to stress, is the HPA axis (Tsigos and Chrousos, 2002). 
1.4.1 Structure, physiology and function of the HPA axis  
The HPA axis is the major endocrine system which provides a rapid response 
against stress (Charmandari, Tsigos and Chrousos, 2005). Moreover, this system 
displays circadian activity and its abnormal activity and/or dysfunction of its 
elements are strongly associated with many pathologies (Anagnostis et al., 2009; 
Frodl and O’Keane, 2013; Bailey and Silver, 2014; Checkley, SL and WS, 2015; 
Peeters et al., 2015). 
The HPA axis endpoint is the secretion of GC hormones (Szabó, 2014), which 
regulate many biological functions such as metabolism glucose (Cherrington, 
1999), protein (Clarke et al., 2007) and fat metabolism (Macfarlane, Forbes and 
Walker, 2008; Peckett, Wright and Riddell, 2011), cardiovascular functions (Carey, 
2010) and immune functions (Rosenberg et al., 2002). 
In normal conditions, the HPA axis displays a circadian activity and an underlying 
ultradian rhythm (of around 60-90 minutes) of GC hormones (Deuschle, Schweiger, 
Weber, Gotthardt, Körner, et al., 1997; Lightman et al., 2000; Jamie J. Walker, 
Terry and Lightman, 2010; Lightman and Conway-Campbell, 2010). On top of this 
basal HPA rhythmicity, GC secretion increases when the organism perceives and 
responds to stress (Tsigos and Chrousos, 2002; Lightman, 2008; Sarabdjitsingh, 
Joëls and de Kloet, 2012). 
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The normal circadian activity of the HPA axis and the intensified stress response 
given by this system can be described by the following path (Figure 1-3): when the 
organism receives external cues (circadian information) or perceives stress, a 
response is initiated by afferent neural pathways from limbic, brain-stem structures 
and areas such as the SCN, the nucleus of the solitary tract  (NTS), the posterior 
hypothalamus and the bed nucleus of the stria terminalis (BTS) (Engeland and 
Arnhold, 2005; Ulrich-Lai and Herman, 2009; Herman et al., 2016), which induces 
the release of corticotropin-releasing hormone (CRH) and arginine vasopressin 
(AVP) from the parvocellular neurons of the paraventricular  nucleus (PVN) of the 
hypothalamus (Rivier and Vale, 1983; Whitnall, Mezey and Gainer, 1985; Childs, 
1992; Scott ’ and Dinan, 1998). CRH and AVP are released at the level of the 
median eminence and, via the portal circulation, they reach the anterioir pituitrary 
where they bind to their receptors, the CRH receptor 1 (CRHR1) (Chalmers, 
Lovenberg and De Souza, 1995; Pozzoli et al., 1996) and AVP 1B receptor 
(AVP1BR) (Antoni et al., 1984; Scott and Dinan, 1998), and stimulate corticotroph 
cells to release adrenocorticotropic hormone (ACTH) into the circulation (Aguilera, 
1994; Watts, Tanimura and Sanchez-Watts, 2004). Next, ACTH stimulates the 
adrenal gland to produce and secrete GC hormones (DALLMAN et al., 1987; 
Herman et al., 2003; Spiga, Waite, et al., 2011) which, when released into the 
circulation, access target tissue, such as liver and brain, inducing metabolic effects 
and eliciting changes in brain function (de Kloet, 1991; De Kloet, 2004; 
Sarabdjitsingh, Joëls and de Kloet, 2012). Additionally, HPA axis activity, 
including GC production, is regulated through a feedback mechanism by which 
GCs inhibit  ACTH release (pituitary level) and CRH and AVP release (PVN level) 
(Aston-Jones et al., 2001)(Jones, Hillhouse and Burden, 1977; Keller-Wood and 
Dallman, 1984; Atkinson et al., 2008; Tasker and Herman, 2011).  




Figure 1-3: HPA axis. The hypothalamic paraventricular nucleus (PVN) responds to signals 
from the SCN and from stress inputs from the brainstem. The PVN projects to the median 
eminence and releases corticotrophin-releasing hormone (CRH) and arginine vasopressin 
(AVP). CRH/AVP reach the anterior pituitary which responds with the release of 
adrenocorticotropic hormone (ACTH). ACTH arrives at the adrenal cortex where it triggers 
the synthesis and secretion of glucocorticoid hormones. Reproduced with permission from 
Lightman and Conway-Campbell, 2010 (Lightman and Conway-Campbell, 2010). 
1.4.2 Glucocorticoids 
It is well established that GCs play an important role in the stress response since 
they are the ultimate product of the activation of the HPA axis. They are also 
important for many physiological processes and act as major mediators in the 
maintenance of the organization of the circadian timing system and the systemic 
homeostasis (Herbert et al., 2006; Dickmeis, 2009; Dibner, Schibler and Albrecht, 
2010). 
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1.4.2.1 Endogenous Glucocorticoids 
GCs are synthesized in the adrenal cortex. The adrenal cortex consists of three 
zones; the zona glomerulosa, zona fasciculata and zona reticularis. GCs (cortisol in 
humans, corticosterone [CORT] in rodents) are synthesized in the zona fasciculata 
(middle zone). GC production and secretion is regulated by ACTH which has pulses 
occurring every 30-120 minutes and the amplitude of these pulses lead to the 
circadian rhythm of GCs production (Dallman et. al, 1987).  
The substrate of GCs is cholesterol. When cholesterol is mobilized from the outer 
to the inner mitochondrial membrane by the steroidogenic acute regulatory (StAR) 
protein, it is converted to pregnenolone. ACTH regulation of StAR protein is the 
rate-limiting step in adrenal production of GCs (Wurtman and Axelrod, 1965; Arlt 
and Stewart, 2005; Gupta and Bhatia, 2008). 
1.4.2.2 Synthetic Glucocorticoids 
Synthetic glucocorticoids (sGCs) are widely used in clinic in physiological doses 
or as pharmacological therapies for their anti-inflammatory and 
immunosuppressive properties  (Axelrod, 1976; Van Der Velden, 1998; Gupta and 
Bhatia, 2008). Nowadays, in the UK, sGCs or so called corticosteroids, are used 
frequently by 1% of the adult population (Van Staa et al., 2001). However, the use 
of GCs in high doses suppresses the HPA axis activity by central suppression or 
adrenal gland atrophy (Krasner, 1999; Buchman, 2001; Arlt and Allolio, 2003) and 
can cause significant side effects such as adrenal insufficiency, diabetes, 
osteoporosis, and glaucoma (Schäcke, Döcke and Asadullah, 2002; Vandewalle et 
al., 2018). 
Since the use of GCs in the treatment of rheumatoid arthritis in 1949 (Hench and 
Kendall, 1949), a substantial amount of research in science and industry has been 
done to elaborate synthetic compounds with GC activity to maximize their benefits 
and minimize the side effects of GCs.  
There are many sGCs today, and the difference between these compounds is given 
by structural alterations which can affect their bioavailability (absorption, half-life, 
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administration route, metabolism, affinity to their receptor target, concentration in 
target tissue) (Schäcke, Döcke and Asadullah, 2002). Whilst endogenous GCs exert 
their effects by binding to two nuclear receptors, the glucocorticoid receptor (GR) 
and mineralocorticoid receptor (MR) (discussed in detail below), modern sGCs 
trigger their effects by binding specifically to the GR (Chrousos, Pavlaki and 
Magiakou, 2000; Paragliola et al., 2017). 
Adverse side effects of sGCs are observed when higher doses are given over long 
periods of time. These side effects have been profoundly researched and described, 
and include effects on metabolism resulting in diabetes, increased body weight, 
(Huscher et al., 2009), Cushing’s Syndrome (Mazziotti, Gazzaruso and Giustina, 
2011), bone demineralisation (Iwamoto, Takeda and Ichimura, 2002), myopathy 
(Waddell et al., 2008), problems in cardiovascular systems (Radhakutty et al., 
2016), problems in gastrointestinal system (Buttgereit and Scheffold, 2002) and risk 
of infections (Hench and Kendall, 1949). However, the neuropsychiatric side 
effects, which are of particular interest for our study, have been less researched and 
are likely to be of great relevance since research indicates that 23% of patients using 
sGCs report mania during early treatment (Naber, Sand and Heigl, 1996),  and 
shows that depression is reported in 28% of patients (Sirois, 2003) and anxiety in 
60% of patients during chronic treatment (Bolanos et al., 2004). 
1.4.3 Glucocorticoid and Mineralocorticoid Receptors  
Endogenous GCs trigger their effects by binding to two specific intracellular 
receptors expressed in target cells, the glucocorticoid receptor (GR) and the 
mineralocorticoid receptor (MR). GR and MR are nuclear receptors, which act as 
latent transcription factors (Mangelsdorf et al., 1995). These receptors share three 
major characteristics; a DNA binding domain (DBD), a ligand binding domain 
(LBD) and a N-terminal domain (NTD) (Kumar and Thompson, 1999). 
MR bind GCs with higher affinity than GR. However, GR is expressed in almost 
all cell types and MR is specific to epithelial cells in kidney, colon and salivary 
glands, and non-epithelial cells in the brain and heart (Reichardt and Schütz, 1998). 
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MR is activated at low concentrations of GC, whereas GR is only activated at higher 
concentrations (Mifsud and Reul, 2016). 
Moreover, because MR is active under basal conditions it is thought to play a 
different role in stress in comparison to GR that  functions as a response to and 
recovery from stress (De Kloet and Reul, 1987), MR sets the threshold for stress 
responsiveness (Joëls et al., 2008). Additionally, both receptors act as ligand-
activated transcription factors exerting both genomic and non-genomic responses, 
which will be discussed in the next section.  
In the brain, GR is expressed in almost all types of cells and tissues in the body. 
GRs in the brain are found with particularly high density in the hippocampus, the 
medial prefrontal cortex (mPFC) and in parvocellular neurons of the PVN. It has 
also been found in cerebellar and olfactory cortex, thalamus and hypothalamus (J 
M H M Reul and De Kloet, 1985). In contrast, MR is restricted to the hippocampus, 
prefrontal cortex, and amygdala (Arriza et al., 1988) and it has high levels  of 
expression in kidney and adipose tissue (Edwards et al., 1988) 
Considering only the GR, its structure is designed by; 1) the NTD which has a 
transactivation domain (AF1) and has been shown to be very important for gene 
regulation (Hollenberg et al., 1987), 2) the (DBD) which has two zinc-finger motifs 
that interact with specific DNA sequences known as glucocorticoid response 
elements (GREs) (Freedman et al., 1988), and 3) the C-terminal LBD which 
provides a ligand-specific binding site and contains the ligand-dependent activation 
function 2 (AF2) (Nagpal et al., 1993). 
Additionally, in the interest of this study, the GR is the product of a single gene 
(Nr3c1), but multiple variants exist (5 variants [GRα, GRβ, GRγ, GR-A, and GR-P]. 
Forty distinct isoforms are generated through alternative splicing and alternate 
translation (Lu and Cidlowski, 2005). 
Two variants, GRα and GRβ, have had special attention given their relative 
abundance (Miller and Auchus, 2011). GRα is expressed more than GRβ in healthy 
individuals, however a higher expression of GRβ compared with GRα has been 
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correlated with glucocorticoid resistance (Honda et al., 2000; Chikanza, 2002; 
Rhen and Cidlowski, 2005).  
1.4.4 Mechanism of action; ligand-receptor complex 
As described above, GCs and sGCs exert their effects by binding to GR. 
Additionally, GR receptor acts as a ligand-activated transcription factor. After GCs 
binds to GR, this ligand-receptor complex translocates to the nucleus and causes 
genomic and non-genomic responses. After numerous studies, genomic effects 
have been well described. However, non-genomic responses are still being 
investigated. 
When GCs are absent, GR is mainly localised in the cytoplasm in a multiprotein 
complex containing chaperone molecules (p23, Src) (Almawi and Melemedjian, 
2002), different heat shock proteins (hsp90, hsp70, hsp56 or hsp40) (Pratt et al., 
2006), immunophilins (Hutchison et al., 1993) and kinases (MAPK) (Wikström, 
2003), which stabilize and prevent its degradation. When GCs are at high levels, 
they bind to the GR causing it to experience a conformational change where it 
dissociates from the chaperone complex and translocates to the nucleus (Kitchener 
et al., 2004). Within the nucleus, GR functions as a transcription factor, hence 
interacting with the DNA or other proteins, to modulate genomic responses via 
activating or repressing transcription of target genes (J M H M Reul and De Kloet, 
1985; J. M.H.M. Reul and De Kloet, 1985; Conway-Campbell et al., 2007).  
1.4.4.1 Genomic effects 
To modulate genomic responses (slow effects (within hours)), three main 
mechanisms can be described for the GC-GR complex.  
1. Transactivation; the GR translocates to the nucleus where it binds to a 
glucocorticoid response element (GRE) (Truss and Beato, 1993) and 
enhances target gene expression. GRs can even bind to degenerated GRE 
sequences (Starick et al., 2015) and GRE sequences can affect GR 
conformation, which in turn leads to different levels of GR affinity (Watson 
et al., 2013). 
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2. Gene activation or repression: GR binds to another transcription factor (TF) 
and this complex binds to its “composite elements” on the DNA. Hence, 
this specific GR binding contains half GRE and half of another response 
element of another TF. Therefore, this binding can lead to gene activation 
or repression (Ramamoorthy and Cidlowski, 2016). 
3. Transrepression; GR can also bind to a negative GRE which can lead to 
repression of gene transcription (Strömstedt et al., 1991). Moreover, there 
can also be tethering of GR with another TF; GR can physically interact 
with another TF without having contact with DNA to influence the TF 
activity (Ratman et al., 2013). 
1.4.4.2 Non-genomic effects  
It is clear that a stressful situation requires a rapid response. However, these rapid 
GC effects are far from clear. Researchers in this area have proposed from two to 
five different non-genomic mechanisms, independently of gene expression and 
protein synthesis, that result in the immediate action of GCs. Hypotheses suggest 
that: 1) GCs interact with plasma and mitochondrial membranes influencing the 
activity of their associated proteins (Buttgereit and Scheffold, 2002), 2) binding of 
GCs with the GR multiprotein complex causes disassociation of some of the 
complex molecules, which in turn activate other cellular processes (Pratt et al., 
2006), 3) there exists a protein-protein interaction between GCs and GC 
transporters (Haller, Mikics and Makara, 2008) and 4) non-genomic responses 
could be mediated by a GR variant which is membrane-bound and has already been 
described (Gametchu, Watson and Wu, 1993). 
1.4.5 Circadian and ultradian rhythms of glucocorticoids  
GCs are the archetypal example of a hormone regulated in a circadian manner by 
the central clock in the SCN (Abe et al, 1979; Moore and Eichler, 1972; Stephan 
and Zucker, 1972). The SCN regulates the GC circadian rhythm: 1) centrally by 
modulating CRH release into the hypophyseal portal vessels (Watts, Tanimura and 
Sanchez-Watts, 2004); and 2) peripherally through a neural pathway that extends 
from the PVN through the intermedium-lateral column of the spinal cord to the 
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adrenal glands (Teclemariam-mesbah et al., 1999). In addition, regardless of the 
control of the SCN, the PVN, pituitary and adrenal cortex express circadian clock 
genes, which also appear to play a role in the circadian rhythm of GCs (Ishida et 
al., 2005; Oster et al., 2006). 
One of the principal characteristics of GCs is that they are released in a pulsatile 
manner and the pulse amplitude is modulated over a 24-hour period to establish a 
circadian GC rhythm (Figure 1-4) (Veldhuis et al., 1989; Spiga et al., 2007). This 
rhythm exhibits remarkable plasticity and can be modified by physiological 
parameters such as: age and gender (Lightman et al., 2000), susceptibility to disease 
(Windle et al., 1998, 2001), early life programming (Shanks et al., 2000); 
pathophysiological conditions in early life (Meaney et al., 1989) and by chronic 
stress (Young, Abelson and Lightman, 2004)and constant light exposure (Waite et 
al., 2012; Park et al., 2013a). 
 
Figure 1-4:  Circadian and Ultradian rhythm of plasma corticosterone. Circadian (grey line) 
and ultradian rhythm (black line) of corticosterone concentration in plasma of rodents in a 24 
hr period. Reproduced with permission from (Spiga, Waite, et al., 2011). 
However, the ultradian rhythm of GCs (Veldhuis et al., 1989; Windle et al., 1998) 
is still not fully understood, but it has been shown that it does not require input from 
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the SCN (Waite et al., 2012). A strong hypothesis has been developed where a 
balance between positive feed-forward and negative feedback causes ultradian 
oscillations in ACTH and GC secretion (Jamie J Walker, Terry and Lightman, 
2010; Park et al., 2013a; F. Spiga et al., 2017; Francesca Spiga et al., 2017).  
These rhythms in GCs are very important as it has been shown that the pulsatile 
secretion of GCs has an important implication in the rapid and non-rapid mediated 
actions of GR and MnR (de Kloet and Sarabdjitsingh, 2008) and that this pulsatility 
changes in disease (Windle et al., 1998; Holsboer, 2000a). Therefore, these rhythms 
appear to set an optimal functional system which provides the organism with the 
appropriate neuroendocrine and behavioural responses to deal with stress, maintain 
homeostasis, secure adaptation and help other neuroendocrine systems maintain 
their circadian activity in time with other bodily processes.  
1.4.6 Glucocorticoid rhythms in health and disease 
Rhythms are essential structures of life. The GC rhythms have been established as 
fundamental characteristics for the correct functionality of the HPA axis, and hence 
a healthy organism. Furthermore, alterations in GC rhythms have been related to 
numerous pathophysiological conditions which are found in many human diseases 
(Young, Abelson and Lightman, 2004; Chung, Son and Kim, 2011b). 
As mentioned above, dysregulation of circadian and/or ultradian GC rhythms have 
been reported in many diseases such as Cushing’s syndrome (Van Aken et al., 
2005), obstructive sleep apnoea (Henley et al., 2009), Parkinson’s disease 
(Hartmann et al., 1997), Huntington’s disease  (Aziz et al., 2009), and even 
Alzheimer’s disease (Ferrari et al., 2001) . However, for the particular interest of 
this study, we will focus on the poorly understood relation between GC altered 
rhythms and psychiatric disorders, such as depression and anxiety (Pariante, 
Nemeroff and Miller, 1995; Daban et al., 2005; Graeff, 2007). A GC-target brain 
region which has not been fully explored in this context is the serotonergic system 
within the dorsal raphe complex. This system has also been involved in regulating 
physiological (Ursin, 2002; Solarewicz et al., 2015) and behavioural functions 
(Kepser & Homberg, 2015; Kiser, Steemers, Branchi, & Homberg, 2012) and it’s 
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altered functionality has been studied in  psychiatric disorders (Owens and 
Nemeroff, 1998; Lowry et al., 2005a; Oquendo et al., 2007). Moreover, a 
relationship between GC rhythms, serotonin and these types of condition has been 
established (Chaouloff, 1993; Pompili et al., 2010), but not fully explained. 
1.5 Serotonergic systems 
Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter. 
Approximately 95% of the total body’s serotonin is produced in the digestive tract 
(Gershon, 2004), because serotonin cannot cross the blood-brain barrier, the central 
and peripheral serotonergic systems are functionally separated and in this study, the 
focus will only be on the serotonergic system found in the central nervous system 
(CNS).  
The brain’s serotonergic system is the biggest monoaminergic system in the brain 
(broad projections within the brain). It is well established that brain 5-HT has a 
rhythmic, circadian release and is involved in several physiological and behavioural 
functions, including locomotor activity (Geyer, 1995), sleep (Portas, Bjorvatn and 
Ursin, 2000) and  feeding behaviour (Voigt and Fink, 2015). Nevertheless, in this 
section, the discussion of brain serotonin will be focussed only on the physiological 
and behavioural functions of 5-HT when related to glucocorticoids and psychiatric 
disorders. 
The vast majority of serotonin synthesis and serotonergic neurons are located in the 
dorsal (DR) and median raphe (MnR) nuclei situated in the brainstem (J. Abrams 
et al., 2004; Pollak Dorocic et al., 2014) therefore, these areas will be the main 
focus. Moreover, the neurotransmitter system formed by the raphe complex (DR 
and MnR) extends out to most of the CNS (Vertes, Fortin and Crane, 1999a; 
Waselus, Valentino and Van Bockstaele, 2011). 
Alterations in the serotonergic system, including altered expression of tph gene, the 
rate-limiting enzyme for brain serotonin synthesis (Walther and Bader, 2003; 
Walther et al., 2003; Patel, Pontrello and Burke, 2004; Zhang et al., 2004), have 
been related to several psychiatric disorders, such as depression (Owens and 
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Nemeroff, 1998; Arango, Underwood and Mann, 2002; Gao et al., 2012), anxiety 
(Lowry et al., 2005a, 2008a; Ottenhof et al., 2018), bipolar disorders (Mcelroy et 
al., 2006; Oquendo et al., 2007; Serretti et al., 2011) among others (Naughton, 
Mulrooney and Leonard, 2000b; Ottenhof et al., 2018). Significantly regarding this 
study, it has also been shown that tph depends on the circadian nature of circulating 
GC as adrenalectomy abolishes the pattern of tph and corticosterone administration 
enhances tph2 expression in the inactive phase (Malek et al., 2007; Donner, 
Johnson, et al., 2012a).  
1.5.1 Serotonin; biosynthesis, transporters, receptors and 
degradation 
Serotonin is synthesized from the essential amino acid tryptophan. The initial and 
rate limiting step is the conversion of L-Tryptophan to 5-hydroxy-L-tryptophan (5-
HTP) and then the second step is the conversion of 5-HTP to serotonin by L-amino 
acid decarboxylase as shown in Figure 1-5. 




Figure 1-5: Biosynthesis of serotonin. 
The rate-limiting enzyme of serotonin, i.e. the conversion of L-tryptophan to 5-
HTP,  is set by tryptophan 5-hydroxylase (Tph) (Fitzpatrick, 1999) which has two 
identified isoforms tph1 and tph2 (López-Narváez et al., 2015; Tidemand et al., 
2017).    
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1.5.1.1 Tph isoforms  
The tph enzyme belongs to the aromatic amino acid hydroxylases superfamily 
(AAAH), which also includes phenylalanine (PAH) and tyrosine hydroxylase (TH) 
(Hufton, Jennings and Cotton, 1995). To date, tph-cDNAs has been cloned for 
rabbit (Grenett et al., 1987), mouse (Stoll, Kozak and Goldman, 1990), rat (Darmon 
et al., 1988) and human (Boularand, Darmon and Mallet, 1995).  
Initial studies from Walther et al, which were evaluating the physiological effects 
of the loss of 5-HT using tph1 knockout mice showed that 5-HT remained 
unchanged in the hippocampus and frontal cortex but not in the periphery. They 
also found that tph1 deficient mice had no significant change in behaviour, which 
suggested the presence of  a tph isoform (Walther and Bader, 2003). After its 
discovery, in post-mortem studies, Zill et. al, showed that tph2 gene is specific to 
the brain, whereas tph1 is responsible for the peripheral serotonergic effects (Figure 
1-6) (Peter Zill et al., 2004). 
1.4.1.1.1 Tph1 
Tph1 gene has since been identified and is mostly localized in the enterochromaffin 
cells of the digestive tract (Gershon and Tack, 2007). However, it is also found in 
small quantities in enteric neurons (Fiorica-Howells, Maroteaux and Gershon, 
2000) and mast cells (Finocchiaro et al., 1988). Tph1 is also localized in the pineal 
gland (Patel, Pontrello and Burke, 2004; Huang et al., 2008) and in the brainstem, 
but in this area it is expressed in a ratio of 1:15 compared to tph2 ;  the contribution 
of this gene on brain 5-HT is unknown (Walther et al., 2003). 
1.4.1.1.2 Tph2  
The human tph2 gene is located in chromosome 12 showing a 72% sequence 
homology to tph1 (Walther et al., 2003). Tph2 is primarily found in central and 
enteric neurons and total tph2 mRNA is expressed 150 times more than tph1 mRNA 
(Yu et al., 1999; Walther and Bader, 2003). Whilst tph2 gene can be found in frontal 
cortex, thalamus, hippocampus, hypothalamus and amygdala (Peter Zill et al., 
2004), it is mainly expressed in the raphe complex (Hamon M., Bourgom S., Artaud 
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F, 1981). Because tph2 is the gene in charge of brain serotonin, this particular 
isoform has been implicated in the pathogenesis of many psychiatric disorders, and 
in the behavioural traits of these disorders (Bailly et al., 1993; Moffitt et al., 1998). 
In the interest of this dissertation, mRNA for tph2, is expressed selectively in the 
brain and exists as orthologs in mice, rats and humans. Tph2 maps to synthetic 
regions in chromosome 7 in rats. Moreover, there are two splice variants in Tph2 of 
rat, but only one transcript (according to ENSEMBL), because the difference between both 
variants is in the 3’ UTR (one is longer than the other by 276 bp) and not in the coding 
sequence. The two tph2 mRNA splice variants have been found to be expressed in 
the rat DR and the MnR (Patel, Pontrello and Burke, 2004). TPH2b (with a short 
3’-UTR) is the predominant variant in the DRN, whereas TPH2a (with a longer 3’-
UTR) shows a low abundance in this nucleus (Abumaria et al., 2008). 
Tph2 is the major transcript of TPH protein in the raphe cells and the pattern of 
expression in individual raphe cells is at least as great as tph1 on pineal cells 
(Haycock et al., 2002). Early studies suggesting that TPH has a short functional 
half-life (Hasegawa et al., 1995) could imply that a high transcriptional activity is 
needed to maintain TPH activity, hence, tph2 expression should be somewhat 
stable.  
Furthermore, not all tph2 mRNA synthesis seems to be made in local cell bodies as 
detection of tph2 mRNA in the prefrontal cortex suggests that a substantial amount 
of tph2 transcripts synthesized in the raphe nuclei is transported to the nerve 
terminal and allows local serotonin synthesis at the synapses (Perroud et al., 2010; 
Carkaci-Salli et al., 2011). Alternatively, these observations might suggest local 
synthesis of tph2 by another serotonergic neurons.  
 Moreover, rat tph2 gene expression seems to be modulated by different 
environmental stressors. For example, exposing rats to a repeated forced swim test 
resulted in elevated tph2 expression in the midbrain (Shishkina, Kalinina and 
Dygalo, 2008), while early-life experience and social defeat changed tph2 mRNA 
expression in the raphe (Katherine L. Gardner et al., 2009a). Moreover, over-
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expression or knockdown of tph2 in the rat brain altered anxiety-like behaviour 
dependant of their estrogen status (Hiroi et al., 2011). 
 
Figure 1-6: Schematic representation of tph1 and tph2 associated functions. Taken from 
Walther and Bader (2003). 
1.5.1.2 Serotonergic transporters 
Once serotonin is produced it is transported into vesicles though a vesicular 
monoamine transporter (VMAT). There are also two isoforms of VMAT, 1 (found 
in neuroendocrine cells) and 2 (neuronal) (Erickson et al., 1996). Serotonin is 
released into the synaptic cleft where it binds to serotonin receptors, which can 
either be pre- or post-synaptic (Hannon and Hoyer, 2008). Serotonin reuptake 
transporter (SERT) is necessary to reuptake serotonin and avoid desensitising 5-HT 
receptors (Fuller & Wong, 1990). 
1.5.1.3 Serotonergic receptors  
Seven families of serotonin receptors have now been recognized (Table 1-3) (5-
HT1 to 5-HT7). Furthermore, these receptors are not limited to the brain but those 
that are, are expressed in a cell-type-specific fashion (Berger, Gray and Roth, 2009). 
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Table 1-3: Families of 5-HT receptors. 
 
5-HT receptors can act as metabotropic or ionotropic receptors. The 5-HT3 family 
is the only family of receptors which has been described to act in an ionotropic way 
(ligand-gated ion channel); these receptors are characterized by a low affinity for 
serotonin and rapid activation (Thompson and Lummis, 2006). The other 5-HT 
receptor families are metabotropic receptors which act through a G protein 
activation and second messenger and display high affinity for serotonin and slow 
activation. (Bockaert et al., 2006). 
The seven families of 5-HT receptors have different sub-types of receptors which 
have different functional properties described below;  
• 5-HT1 includes 1A, 1B, 1D, 1E and 1F sub-types; functional receptors 
include 1A, 1 B and 1D (Hoyer and Martin, 1997). The 5-HT1A sub-type is 
the most distributed serotonin receptor in the brain. These have high 
expression in cerebral cortex, hippocampus, septum, amygdala and raphe 
nucleus (el Mestikawy et al., 1991), but can also be found in small quantities 
in other areas of the brain such as, basal ganglia and thalamus. This family 
of receptors is linked to anxiety (Klemenhagen et al., 2006). Additionally, 
the 1B subtype can be found in many areas of the brain and its function 
depends on its location. However, in general, its function has an inhibitory 





Fig. 1. Synthesis of serotonin from tryptophan (the hydroxylation of tryptophan trough tryptophanhydroxylase is a speed limiting step 
in the serotonin production). Source: own figure 
 
 
Table 1. Families of 5-HT receptors. 
 
Family Potential Type Mechanism of action 
5-HT1 Inhibitory Gi/G0-protein coupled Decreasing intracellular concentration of cAMP 
5-HT2 Excitatory Gq11-protein coupled 
Increasing intracellular concentration of IP3 and 
DAG 
5-HT3 Excitatory Ligand-gated Na
+/K+ channel Depolarization of cell plasma membrane 
5-HT4 Excitatory Gs-protein coupled Increasing intracellular concentration of cAMP 
5-HT5 Inhibitory Gi/G0-protein coupled Decreasing intracellular concentration of cAMP 
5-HT6 Excitatory Gs-protein coupled Increasing intracellular concentration of cAMP 
5-HT7 Excitatory Gs-protein coupled Increasing intracellular concentration of cAMP 
 




 At least 20 subpopulations of 5-HT receptors 
have been cloned, yet (Table 2).  
 
5-HT1 receptors 
 This group consists of five receptor subtypes  
(5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F), which are 
structurally identical in humans to 40-63 %. There is no 
5-HT1C receptor, as it was reclassified as the 5-HT2C 
receptor. They are mostly (but not exclusively) associated 
with Gi/G0 proteins and inhibit prod ction o  cAMP. 
Fully functional 5-HT1A, 5-HT1B and 5-HT1D receptors 
have been found in many tissues of various species 
(Hoyer and Martin 1997). 
 The 5-HT1A receptor is the most extensively 
distributed of all the 5-HT receptors. In the central 
nervous system, 5-HT1A receptors are present in high 
density in the cerebral cortex, hippocampus, septum, 
amygdala, and raphe nucelus, but they were proven in 
small amounts in the basal ganglia and thalamus as well 
(el Mestikawy et al. 1993). However, they can be found 
also in myentericus plexus and whole gastrointestinal 
tract. In the brain, 5-HT1A receptors act as autoreceptors 
as well as postsynaptic receptors. They are involved in 
the inhibition of "discharge" of neurons, regulation of the 
production of ACTH (but not prolactin), and regulation of 
behavior and eating (Wang et al. 2009). They play 
probably an important role in the emergence of anxiety. 
This observation was confirmed by studies with knockout 
gene for this subtype of 5-HT1 receptor in mice. The 
animals showed increased fear in many experimental 
conditions (Klemenhagen et al. 2006). Moreover, 5-HT1A 
antagonists (buspiron, gepiron) are used or developed for 
the treatment of anxiety and depression. Antagonists of  
5-HT1A receptor and β-blocker pindolol improve the 
effectiveness of selective serotonin reuptake inhibitors – 
SSRIs in treatment of depression (Artigas et al. 2006). 
The antianxiety actions of 5-HT1A (partial) agonists may 
provide primarily presynaptic somatodendritic 5-HT1A 
receptors (leading to reduced release of 5-HT in terminal 
areas), whereas the antidepressant action of 5-HT1A 
agents may primarily provide postsynaptic 5-HT1A 
receptors (De Vry 1995). Certain 5-HT1A agents display 
antiaggressive behavior, and measurement of the density 
of 5-HT1A receptors in frontal cortex of suicide victims 
reveals that nonviolent suicide victims had a significantly 
higher Bmax, compared with controls and violent 
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role (Jin et al., 1992). The 1D has a low expression compared to 1B and can 
be found in the dorsal raphe nuclei, where they modulate the release of 
serotonin (Pullar et al., 2004).  
 
Additionally, these family of receptors, particularly 1A and 1B expressed in 
all, but not limited to, serotonergic neurons of the DR (Day et al., 2004)(Day 
et al., 2004). Moreover, the distribution of 5-HT1A and IB mirror 
expression of Tph2 with peak expression in the ventromedial DR and mid-
rostral levels (Clark, McDevitt and Neumaier, 2006).  
 
Furthermore, these types of receptors appear to be GC sensitive as several 
studies have shown that these receptors are negatively regulated by GC 
especially in the limbic system (Lanfumey et al., 2008). Moreover, different 
research groups have shown that GC via GR and MR are involved in 
negative regulation of 5-HT1A gene expression (Mendelson and McEwen, 
1992; Meijer and de Kloet, 1994; Meijer et al., 1997).  
 
Finally, molecular data has shown the inhibitory effect of GCs on 5HT 
receptor gene transcription as chronic stress, hence, increased levels of 
CORT, have shown to reduce the activation of 5-HT receptors (Mendelson 
and McEwen, 1991; Laaris et al., 1999; Lanfumey et al., 1999). In the other 
hand, electrophysiological studies have demonstrated that exposure to 
elevated GC levels attenuated 5-HT auto receptor function in the DR in rats 
(Man, Young and McAllister-Williams, 2002; Fairchild, Leitch and Ingram, 
2003; Judge, Ingram and Gartside, 2004). 
 
• 5-HT2 includes 2A, 2B and 2C. This particular family of receptors have been 
shown to be the main excitatory serotonin receptors (Hannon and Hoyer, 
2002). The 2A subtype is expressed in central and peripheral tissue; in the 
brain, these receptors can be found mainly in the basal ganglia (Cook  Jr. et 
al., 1994). The 2B subtype is associated with smooth muscle and can be 
found in cerebellum, hypothalamus and medial part of the amygdala 
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(Schmuck et al., 1994). The 2C subtype has a strong link to psychiatric 
disorders since it is a good, effective target of antidepressant action 
(Goodwin et al., 2009). 
 
• 5-HT3 only has 3A and 3B. These receptors are the only ionotropic serotonin 
receptors. They have 5 subunits arrange around an ion channel. These 
receptors are excitatory and can be found in central and peripheral tissue 
(Gyermek, 1995). 
 
• 5-HT4 has 4A, 4B, 4C, 4D, 4E, 4F, 4G and 4H.  The complete family is 
linked to adenylyl cyclase activity (Hoyer, Hannon and Martin, 2002). 
These receptors are found in high density in the nucleus accumbens and may 
be involved in memory, learning and the reward system (Reynolds et al., 
1995). 
 
• 5-HT5 includes 5A and 5B. The activity of these specific  receptors is largely 
unknown; however, given their localization within the brain, they have been 
related to motor control, anxiety, depression, learning and memory 
consolidation (Thomas, 2006). 
 
• 5-HT6 has 6A and 6B. This family is located in limbic areas such as caudate 
and substantia nigra, but its functions are still unknown (Kohen et al., 1996). 
 
•  5-HT7 has 7A, 7B, 7C, 7E and 7D. These are found in thalamus, 
hypothalamus, cerebral cortex, amygdala and dorsal raphe (Bonaventure et 
al., 2004). These receptors have been related to depression, anxiety, 
cognitive disturbances, migraine and schizophrenia (Thomas and Hagan, 
2004). 
1.5.1.4 Serotonin degradation 
After SERT reuptakes serotonin, the neurotransmitter degradation is completed 
mainly by monoamino oxidase which includes two isoforms; MAOA and MAOB, 
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with MAOA being the main isoform of degradation in the brain (Shih, Wu and Chen, 
2011). Serotonin gets broken up into 5-hydroxyindoleacetic acid (5-HIAA) or can 
be metabolized into N-methyl, N.N-dimethyl or O-methyl tryptamine to then be 
synthesized to melatonin (Stahl, 1998). 
1.5.2 Brain serotonergic system anatomy and functional correlates 
As mentioned above, the majority of brain serotonin biosynthesis and release is in 
the raphe complex, which comprises the dorsal raphe nucleus (DR) and the medium 
raphe nucleus (MnR) (Imai et al., 1986); we will therefore focus on this complex. 
The raphe complex is a collection of neurons which extend rostral-caudally in the 
brainstem in animals and humans (Taber, Brodal and Walberg, 1960), where in rats 
goes from -7.328 to -8.672 mm bregma (Paxinos and Watson, 2005). They contain 
different types of neurons with different morphologies, projections and chemical 
characteristics (Dahlström and K. Fuxe, 1964). However, these neurons are 
topographically organized according to their anatomical structure/location and their 
functional properties, indicating a possible connection between function and 
structure (cluster of neurons) (Baker, Halliday and Törk, 1990) (Figure 1-7).  
Most of the afferent projections to the raphe complex originate from forebrain 
structures that belong to the limbic systems (Peyron et al., 1997a); this will be fully 
discussed in the sections below. 
The raphe complex can be divided into a rostral and caudal group given the neuron 
distribution and main projections. The rostral group has major projections to 
specific forebrain structures and the caudal group to other forebrain structures as 
well as a few projections to the caudal brainstem and spinal cord (Ding et al., 2003).  
Projections from the rostral group to specific structures are different from the 
projections of the caudal group to other structures; hence, specificity of projections 
is present (Imai et al., 1986; Villar et al., 1988), suggesting again a link between 
unique function (behavioural associations) of target structures (projections of 
serotonergic neurons to specific forebrain structures) and specific clusters of  
serotonergic neurons (subregions of the raphe complex). 




Figure 1-7: Line drawings and stereotaxic schematics of coronal sections of the rat brain. Representation of all subdivisions of the DR and MnR used for this study. Taken 
and modified with permission from Hale and Lowry, 2011 and The rat brain atlas from Paxinos and Watson 2005 (Paxinos and Watson, 2005; Hale and Lowry, 2011).
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The functional anatomy of the DR complex has been described through different 
methodological techniques and by different research groups. To mention a few, 
studies of single unit recordings were used to investigate behavioural correlates 
(Fornal et al., 1996; Sakai and Crochet, 2001) In vitro electrophysiology in brain 
slices to describe unique electrophysiologic properties (Crawford, Craige and Beck, 
2010). Immunohistochemical detection of c-Fos as markers of neuronal activity 
(Hale et al., 2010). Injections of retrograde tracers into the DR for topography of 
serotonergic systems (Baratta et al., 2009). Microinjection of drugs into the Raphe 
complex to mimic behavioural outcomes (Hammack et al., 2002). Microdissection 
techniques with liquid chromatography to describe functional topography (Evans, 
Heerkens and Lowry, 2009) and in situ hybridization to measure changes in gene 
expression (Malek, 2007; Donner, Montoya, et al., 2012).  
The following section corresponds to a brief summary of the findings of the 
anatomy and functional correlates of the Raphe complex. 
1.5.2.1 Dorsal raphe (DR) 
The dorsal raphe nucleus has been divided in several subregions based on the 
projections and function of its serotonergic neurons; these areas are the dorsal part 
of the dorsal raphe (DRD), the ventral part of the dorsal raphe (DRV), the 
intrafascicular part of the dorsal raphe (DRI), the ventro-lateral part of the dorsal 
raphe (DRVL/VLPAG), and the caudal part of the dorsal raphe (DRC) (Baker, 
Halliday and Tork, 1990) (for summary see table 1-4). 
1.5.2.1.1 Dorsal Raphe nucleus, caudal part (DRC) 
This area accepts afferents from medial prefrontal cortex, preoptic area, arcuate 
nucleus and perifornical and lateral hypothalamic areas, and midbrain and 
brainstem regions including the IPN, laterodorsal tegmental area, and area postrema 
(H. H. S. Lee et al., 2003). 
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 The DRC projects to subfornical and subcomisural organ (Lind, 1986) the ventral 
hippocampus, amygdala, locus coeruleus , and midline and thalamic nuclei (Imai et 
al., 1986; Krout, Belzer and Loewy, 2002). 
Hence, the DRC seems to be related to stress and anxiety circuits. Moreover, 
because of its common afferents to brain structures which are implicated to  anxiety-
related states and a specific subpopulation of serotonergic neurons,  this area seems 
to have a special interaction with the DRD (Hale and Lowry, 2011; Hale, Shekhar 
and Lowry, 2012). 
1.5.2.1.2 Dorsal Raphe nucleus, interfascicular part (DRI) 
The DRI has not been completely detailed. However, studies have shown that the 
DRI receives projections from the median preoptic area, and lateral parabrachial 
nucleus (H. H. S. Lee et al., 2003; Holstege, Mouton and Gerrits, 2003). 
The DRI projects to dorsal and ventral hippocampus, medial septum, entorhinal 
cortex, cortical areas and barrel field cortex (Azmitia and Segal, 1978a; Köhler, 
Chan‐Palay and Steinbusch, 1982; Waterhouse et al., 1986; Kirifides et al., 2001). 
Therefore, the DRI may play an important role in cognitive and emotional processes 
and seems to have a strong interaction with DRVL/VLPAG area (Lowry et al., 
2007; Hale, Shekhar and Lowry, 2012). 
1.5.2.1.3 Dorsal Raphe nucleus, dorsal part (DRD) 
The DRD receives afferents from the lateral and ventral orbitofrontal and 
infralimbic cortices, central nucleus of the amygdala, BNST, and the dorsal, 
dorsomedial, lateral, and posterior hypothalamic nuclei (Peyron et al., 1997a). 
The DRD shows projections to the basolateral (Hale et al., 2008) and central nuclei 
of the amygdala, dorsal hypothalamic area (Commons, Connolley and Valentino, 
2003), nucleus accumbens, and medial prefrontal cortex (Van Bockstaele, Biswas 
and Pickel, 1993). Moreover, it projects to hippocampus, entorhinal cortex, septum, 
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locus coeruleus and prefrontal cortex (Köhler and Steinbusch, 1982a; Imai et al., 
1986). 
The DRD seems to be important for the regulation of emotional behaviour 
associated with stress- and anxiety-related physiologic and behavioural responses 
(Commons et. al, 2003; Lowry et. al, 2008, 2005). An increase in tph2 in the  DRD 
has also been related to an antidepressant-like effect (Donner and Handa, 2009). 
However, high levels of tph2 in the DRD were found depressed patients (H Bach-
Mizrachi et al., 2006).  
1.5.2.1.4 Dorsal Raphe nucleus, ventral part (DRV) 
The DRV shows the highest expression of tph2 of all the DR subregions (Clark, 
McDevitt and Neumaier, 2006). This area receives afferents from the dorsomedial 
and ventromedial hypothalamus, central nucleus of the amygdala, cingulate cortex, 
and lateral orbital cortex (Peyron et al., 1997a). 
Additionally, the DRV projects to caudate putamen (Steinbusch, 1981), 
sensorimotor cortex, ventrolateral orbital, frontal cortex, motor cortex, visual and 
barrel field cortex (Waterhouse et al., 1986; Coffield, Bowen and Miletic, 1992; 
Kirifides et al., 2001). 
It has been shown that the DRV plays a role in motor function and cognitive tasks 
(Hale and Lowry, 2011; Hale, Shekhar and Lowry, 2012).  
1.5.2.1.5 Dorsal raphe nucleus, ventrolateral/ventrolateral periaqueductal 
grey (DRVL/VLPAG) 
The DRVL/VLPAG accepts afferents from the parabrachial nucleus (H. H. S. Lee 
et al., 2003), the solitary tract (Herbert, 1992), infralimbic cortex (Hurley et al., 
1991), BNTS, central amygdala (Gray and Magnuson, 1992), preoptic nucleus, 
median preoptic nucleus (Watts and Swanson, 1987), lateral and perifornical 
hypothalamic nuclei (H. H. S. Lee et al., 2003) and  from the retina (Fite et al., 
1999). 
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Additionally, DRVL/VLPAG projects to lateral hypothalamus (Ljubic-Thibal et 
al., 1999), rostro-ventrolateral medulla (Bago, Marson and Dean, 2002), 
dorsolateral periaqueductal grey (Stezhka and Lovick, 1997), lateral geniculate 
body, lateral posterior nucleus of the thalamus, superior colliculus, the retina (Villar 
et al., 1988) ventral posterior medial thalamus (Kirifides et al., 2001)and 
parafascicular thalamic nucleus (Chen et al., 1992). 
DRVL/VLPAG subregions appear to be involved in the control of autonomic 
function and emotional behaviour. They are also involved in panic behaviours 
where fight-or-flight is suppressed and freezing behaviours are increased (Bandler 
et al., 2000; K. L. Gardner et al., 2009). 
1.5.2.2 Median Raphe nucleus (MnR) 
The median raphe nucleus (MnR) is a cluster of neurons consisting of 80% 
serotonergic neurons (Baker, Halliday and Törk, 1990). 
The MnR is innervated by medial hypothalamic structures such as the preoptic area, 
the perifonical, dorsomedial and lateral hypothalamic areas and mammillary and 
supramammilary nuclei. It also receives projections from the medial prefrontal 
cortex, anterior cingulate cortex and the ventral lateral preoptic area (Vertes, Fortin 
and Crane, 1999). Moreover, the MnR receives projections from the DR (Tischler 
and Morin, 2003). 
The MnR projects to the posterior hypothalamus, medial mammillary nucleus, 
medial supramammillary nucleus, tuberomammillary nucleus, ventrolateral 
dorsomedial hypothalamus and perifornical region, and anterior hypothalamic 
nucleus. 
The MnR has been implicated in resistance, tolerance and adaptation to chronic 
psychosocial stress (Deakin, 1996; Graeff et al., 1996). It has been implicated in 
ingestive behaviour (Bendotti and Samanin, 1986; Wirtshafter and Krebs, 1990) 
and in circadian rhythmicity given that the MnR projects directly to the SCN (Moga 
and Moore, 1997; Morin, 1999). 
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All these clusters of neurons have been shown to receive afferents from different 
areas and send projections to distinct forebrain areas, providing a functional 
correlation with behaviour. Two strong schemes have thereby been proposed; a 
DRC/DRD “anxiety-facilitating” system, and a DRVL/VLPAG/DRI 
“antidepressant-like” system (Hale, Shekhar and Lowry, 2011, 2012), which 
implicates an important role for the serotonergic system in psychiatric disorder. 
1.5.2.3 Interactions within the Raphe Complex 
As mention by experts in the area, it is important to study the fact that serotonergic 
neurons from specific subdivisions within the Raphe complex give rise to 
distributed, but related targets (Hale and Lowry, 2011). This is important because 
it might be the key to understand the neural functions of this areas and perhaps to 
develop strategies to modulate these specific neural functions. 
A different approach to understand this complex system has been to study not only 
the related targets of serotonergic neurons but also the intra-connections within the 
Raphe complex. Different research groups have suggested intra-connections 
between the subdivisions of the Raphe complex and functional interconnections 
within it. Here a list of the findings; 
• MnR- DR: The MnR receives projections from the DR (Tischler and Morin, 
2003). Moreover, a functional interaction between the DR and MnR was 
shown by the fact that inhibition of the MnR prevented the increase of 
serotonin release in the prefrontal cortex following stimulation of the DR 
(Forster et al., 2008) . 
 
• The DRD-DRC; These structures have been related to an anxiety-related 
neuronal circuit (Lowry et al., 2008b). Various anxiogenic drugs selectively 
increase c-Fos expression in the DRD and DRC (Abrams et al., 2005). 
Moreover, chronic injection of estrogen-receptor-beta agonist increases 
tph2 expression in DRD and DRC only (Donner and Handa, 2009).   
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• The DRV-DRD; Both structures receive afferents from similar set of 
hypothalamic, limbic and cortical regions (H. S. Lee et al., 2003) and 
injections of tracer that label fibres in the DRV also label fibres in the DRD 
and DRVL/VLPAG (Peyron et al., 1997a). 
 
• DRVL/VLPAG-DRV; Neurons within DRVL/VLPAG project to the DRV 
and selective lesions of the DRVL/VLPAG results in an increase of tph2 
gene expression in the DRV, hence DRVL.VLPAG might have an 
inhibitory role of the DRV (Peyron et al., 1997b).  
 
• DRVL/VLPAG-DRD; When serotonergic neurons in the DRVL/VLPAG 
are activated, neurons in the DRD are inactive, and when DRD neurons are 
active DRVL/VLPAG neurons are not, hence, a hypothesized relationship 
has been established, but not fully studied ((Staub, Spiga and Lowry, 2005; 
Hollis et al., 2006; Bouwknecht et al., 2007a) 
  
• DRI-MnR; Evidence has shown that serotonergic neurons in the caudal part 
of the DRI are closely related to the MnR than to other subdivisions of the 
DR (Jacobs and Azmitia, 1992). 
 
• DRI-DVL/VLPAG; Both subdivisions receive projections from the median 
preoptic (Holstege, Meiners and Tan, 1985) are and the lateral parabrachial 
nucleus (Saper and Loewy, 1980). Furthermore, serotonergic neurons 
within this subdivisions are co-activated following injections with LPS 
(Hollis et al., 2006),  after peripheral immune stimulation with saprophytic 
bacterium (Lowry et al., 2007) and following exposure to warm ambient 
temperature (Hale et al., unpublished data).  
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Table 1-4; Summary of Afferent and efferent connections of all subdivisions studied from the DR complex. 
Subdivision of 
Raphe complex 
Afferents Efferents Functional topography 
DRC • Medial Prefrontal cortex. 
• Hypothalamic regions, preoptic area, 
arcuate nucleus, perifornical and lateral 
areas. 
• IPN, laterodorsal tegmental area and area 
postrema.  
 
(H. H. S. Lee et al., 2003) 
• Subfornical organ (Lind, 1986). 
• Subcommissural organ (Mikkelsen, Hay-
Schmidt and Larsen, 1997). 
• Circumventricular organs, ependymal lining 
and cerebral ventricles (Simpson et al., 1998). 
• Ventral hippocampus, amygdala 
• Locus coeruleus (Imai et al., 1986). 
• Midline thalamic nuclei; paratenial, 
paraventricular and lateral parafascicular 
thalamic nuclei (Krout et al., 2002). 
• Stress and anxiety-related neuronal 
circuit (Lowry et al., 2005a). 
DRI • Median preoptic area (Holstege, Meiners 
and Tan, 1985). 
• Lateral parachial nucleus (H. H. S. Lee et 
al., 2003). 
• LC (Kim et al., 2004). 
• Dorsal and ventral hippocampus (Azmitia 
and Segal, 1978b; Amaral and Cowan, 1980). 
• Medial septum (Köhler and Steinbusch, 
1982a). 
• Entorhinal cortex (Köhler and Steinbusch, 
1982b). 
• Barrel field cortex (Kirifides et al., 2001). 
• Frontal pole, dorsolateral prefrontal cortex,  
Medial orbital cortex, Inferior convexity and 
Anterior cingulate cortex (Porrino and 
Goldman‐Rakic, 1982). 
• Mediodorsal thalamus (Groenewegen, 1988). 
• Antidepressant like-behavioural effects 
(Lowry et al., 2007). 
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DRD • Rostral DR- Samee as mid-rostralcaudal 
DR. 
• Lateral and ventrolateral orbitoforintal and 
infralimbic cortices. 
• Central nucleus of the amygdala. 
• BNTS  
• Dorsal, dorsomedial, latera and posterior 
hypothalamic nuclei.  
 
(Peyron et al., 1997a) 
• Caudate putamen and substantia nigra, Locus 
coeruleus, vemtral hippocampus (Imai, 
Steindler and Kitai, 1986). 
• Subthalamic nucleus (Canteras et al., 1990). 
• Substantia innominate (Grove, 1988). 
• Motor cortex (Waterhouse et al., 1986). 
• Basolateral and central nuclei of the 
amygdala (Commons, Connolley and 
Valentino, 2003; Hale et al., 2008). 
• Nucleus accumbens,  medial prefrontal cortex 
and prefrontal cortex (Van Bockstaele, Biswas 
and Pickel, 1993). 
• Hippocampus and entorhinal cortex, Septum 
(Köhler and Steinbusch, 1982a). 
• Activation of stress and anxiety related 
circuits(Commons, Connolley and 
Valentino, 2003; Lowry et al., 2008c).  
 
Such as; social defeat (Gardner et al., 
2005), Uncontrollable stress (Amat et al., 
2005)and Open-field arena (restricted to 
the rostral part of the DRD (Bouwknecht 
et al., 2007b). 
DRV • Dorsomedial and ventromedial 
hypothalamus. 
• Central nucleus of the amygdala. 
• Cingulate cortex. 
• Lateral and orbital cortex. 
 
(Peyron et al., 1997b; H. H. S. Lee et al., 
2003) 
• Caudate putamen (Steinbusch et al., 1980). 
• Sensoriomotor cortex (Waterhouse et al., 
1986). 
• Ventrolateral orbital cortex (Coffield, Bowen 
and Miletic, 1992). 
• Frontal cortex (Kazakov et al., 1992). 
• Motor cortex, Visual cortex and Barrel field 
cortex (Kirifides et al., 2001). 
• Motor function  
• Complex cognitive tasks  
 
(Greenwood et al., 2005a) 
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DRVL/VLPAG • Lateral parabrachial nucleus (H. H. S. Lee 
et al., 2003). 
• Medial part of the nucleus of the solitary 
tract (Herbert, 1992). 
• Viscerosensory glossopharyngeal and 
vagal nerves(Herbert and Saper, 1992). 
• Infralimbic cortex (Hurley et al., 1991) 
• BNTS, central amygdaloid nucleus (Gray 
and Magnuson, 1992). 
• Median preoptic nucleus (Simerly and 
Swanson, 1986). 
• Lateral and perifornical hypothalamic 
nuclei (Saper, Swanson and Cowan, 1979). 
• Retina (Kawano, Decker and Reuss, 
1996a). 
• Lateral hypothalamus (Ljubic-Thibal et al., 
1999). 
• Rostroventrolateral medulla (Bago, Marson 
and Dean, 2002). 
• Dorsolateral periaqueductal gray, Dorsal and 
ventral parts of the lateral geniculate body, 
Lateral posterior nucleus of the thalamus  (Fite 
et al., 1999). 
• Superior colliculus (Villar, Vitale and Parisi, 
1987). 
• Retina (Waterhouse et al., 1993). 
• Trigeminal nerve and Ventral posterior 
medial Thalamus (Kirifides et al., 2001). 
• Parafascicular thalami nucleus (Chen et al., 
1992). 
•Supressing Panic-like symptoms       
(Johnson et al., 2005). 
MnR •Medial hypothalamic structures (preoptic 
area, perifornial dorsomedial and lateral 
hypothalamic areas, and mammillary and 
supramammillary nuclei). 
•Medial prefrontal cortex (medial angraular 
(frontal cortex, anterior cingulate cortex 
and PL). 
•Agranular insular cortex. 
•Ventral lateral preoptic area. 
 
(Vertes and Linley, 2008) 
•Septohippocampla system. 
•Posterior hypothalamus. 
•Medial mammillary nucleus, Medial 
supramammillary nucleus and Tueromamillary 
nucleus. 
•Ventrolateral dorsomedial hypothalamus and 
perofornical region. 
•Anteriour hypothalamic nucleus 
•Suprachiasmatic nucleus. 
(Moga and Moore, 1997; Vertes and Linley, 
2008) 
•Implicated in inhibitory control of 
ingestive behaviour (Wirtshafter and 
Krebs, 1990). 
•Circadian rhythmicity (Lowry, 2002; 
Yamakawa and Antle, 2010). 
•Regulation of hippocampal theta rhythm 
(Vertes et al., 1994). 
•Anxety-related behaviour (Mansur et 
al., 2011). 
•Locomotor hyperactivity (Adams, 
Kusljic and van den Buuse, 2008). 
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1.5.3 Brain serotonergic system and circadian rhythms 
Serotonin has its highest peak of release in periods of activity, thus correlating it to 
arousal and locomotor activity (Dudley, DiNardo and Glass, 1998). Furthermore, a 
major input to the SCN is given by serotonergic projections arising from the raphe 
complex. These serotonergic neurons connecting to the SCN are mainly from the 
MnR (Hay-Schmidt et al., 2003) and secondly from the DR (Kawano, Decker and 
Reuss, 1996b); thus, a link between the circadian timing system and serotonin 
system has been  established. 
To my knowledge, only one other study has shown that tph2 mRNA expression 
displays a circadian pattern (Malek et al., 2005). However, this data was obtained 
under a different protocol which did not include anatomical detail (i.e. did not cover 
all rostro-caudal gradient and all the subdivisions of the DR and the MnR nucleus). 
1.5.4 Brain serotonergic systems in health and disease  
To this point, it is clear that the serotonin system is a very complicated area of study 
for; 1) its robust structure, 2) its circadian pattern, 3) its extensive afferents and 
efferents to many forebrain structures and 4) its association with many 
physiological and behavioural correlates. Moreover, this system has also been 
correlated with great significance to pathological conditions. 
Psychiatric disorders such as depression and anxiety have been linked to 
abnormalities in serotonin neurotransmission (Domínguez-López, Howell and 
Gobbi, 2012). This relationship has been established at all levels of the system, 
from abnormalities in serotonin transporter (SERT) (Meyer, 2007), to abnormalities 
in  5-HT receptors (Savitz, Lucki and Drevets, 2009) and even in abnormal tph2 
mRNA expression (Jahanshahi et al., 2011). 
Many studies in this area have known connections between the serotonergic system 
and classical behavioural symptoms of the mentioned disorders. For example; 
lower levels of serotonin have been found in suicide victims (Mann et al., 1989; 
Arango et al., 2003), patients with anxiety and depression have been shown to have 
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an elevated serotonin turnover compared to healthy individuals (Esler et al., 2007; 
Barton et al., 2008), patients with panic disorders have also been shown to have 
reduce 5-HT1A receptor binding (Neumeister, 2004), depressed suicide patients 
show elevated tph2 mRNA (Helene Bach-Mizrachi et al., 2006) and tph2 knock out 
mice have shown an increased aggression and depression-like behaviour (Lesch et 
al., 2012). Additionally, in recent years, several studies have establish that tph2 
variants may be genetic predictors of depression (P Zill et al., 2004) as well as 
predictors  for antidepressant treatment responsiveness (Peters et al., 2004). 
Therefore, interventions in the 5-HT system play an important role in 
pharmacological therapies of mental disorders such as depression, anxiety, bipolar 
disorders and obsessive compulsive disorders (Andrade et al., 2010).  
Therefore, with all the aforementioned, a clear relationship between all levels of the 
serotonergic system and mental disorders is well recognised. Nevertheless, the 
mechanisms involved in connecting the serotonergic system to these disorders are 
not fully understood. 
1.6 Relating systems in health and disease 
When trying to uncover the underlying mechanisms of psychiatric disorders, an 
altered circadian rhythm of GCs and an abnormal functionality of the serotonergic 
system at all levels come to mind, but is there any relationship between them? Could 
this altered rhythm in GCs be caused by an abnormal serotonergic system, 
promoting psychiatric symptoms? Or is an abnormal serotonergic system caused 
by the altered circadian rhythms of GCs? 
GCs have a circadian rhythm, which is known to be under control of the SCN (Buijs 
et al., 1993a; Herman et al., 2016). Moreover, GCs seem to influence the correct 
rhythmicity of the SCN and other brain functions. The serotonergic system has 
direct projections to the SCN; therefore, it could be mediating the daily GC rhythm 
in an indirect way.  
Furthermore, it is known that GCs influences tph2 mRNA accumulation in the 
raphe complex, contributing to its rhythmic release (Nexon et al., 2009). 
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Additionally, GC seem to up-regulate tph2 gene expression in rats (Malek, 2007) 
and decrease raphe expression in mice (Clark et al., 2008), suggesting a species-
dependent effect of GC on tph2 gene expression.  
Serotonin also plays a role in locomotor activity, arousal, sleep and feeding, all of 
which demonstrate a circadian activity which in turn is mediated by the SCN, which 
in turn is regulated also by GCs. Therefore, it is fair to say that interactions between 
GCs and serotonin are diverse; however, the mechanisms of these interactions are 
not understood.  
Circadian rhythms are essential for life. These rhythms when altered can cause 
many pathological conditions. Psychiatric disorders have been described with 
important alterations in circadian rhythms of GCs and serotonin; hence, abnormal 
functionality of both systems appears to be related to these disorders. However, as 
the fundamental mechanisms are not well understood, the need to study this 
relationship is of great importance because a better described mechanism could 
elucidate potential therapeutic targets to then benefit patients with these specific 
disorders.  
1.7 Hypothesis and Aims 
Stress-related psychiatric disorders such as depression and anxiety, have a common 
trait, the dysregulated circadian rhythm of the HPA axis and the dysfunctional 
activity of the serotonergic system. The link between these two important 
neurobiological systems has long been suggested, but not fully understood. Hence, 
the main focus of my PhD was to investigate this relationship by characterizing 
how the HPA axis activity is related/connected to the serotonergic system’s activity, 
to gain a better understanding of the underlying mechanisms of psychiatric 
disorders. 
1.7.1 Hypothesis 
Across the 24 hour period, there is a distinctive rhythmic variation in the 
expression levels of Tph2 mRNA, which encodes TPH2 the rate-limiting enzyme 
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in serotonin biosynthesis in the dorsal and median raphe nuclei. There is also a 
distinctive daily variation in circulating CORT levels, with a similar pattern to the 
Tph2 mRNA expression pattern. Therefore, I hypothesize the two phenomenon 
are related, and specifically that the changes in Tph2 mRNA expression over the 24 
hour period is dependent upon the changes in circulating CORT levels. The daily 
variation in circulating CORT has been proposed to be important for maintaining a 
variety of physiological and homeostatic processes, including mood and behaviour, 
and is also known to become dysregulated during chronic stress, chronic illness, 
and during treatment with synthetic glucocorticoids, along with consequent effects 
on mood and affective behavioural state of the individual. I hypothesise that the 
documented impact on mood and behavioural is due to dysregulation of the 'normal' 
pattern of Tph2 mRNA expression. I therefore plan to test models that 
induce dysregulation of glucocorticoid secretory dynamics and assess whether the 
daily rhythm of Tph2 mRNA expression in the dorsal and median raphe nuclei is 
affected.  
1.7.2 Aims  
In my PhD studies, I aimed to assess the regulation of the neuroendocrine responses 
to altered GC rhythms and its relationship to the serotonergic system at the level of 
tph2 mRNA. Therefore, the following aims were established; 
 
Aim 1: To characterize the natural circadian rhythm of the HPA axis and the normal 
circadian rhythm of tph2 mRNA expression. 
 
a) To describe the natural circadian rhythm of CORT and the normal rhythm 
of tph2 mRNA expression in all subregions of the DR (DRC, DRI, DRD, 
DRV, DRVL/VLPAG) and Median Raphe Nucleus (MnR) at 5 different 
time points across a 24-hour period. 
b) To analyze the full level-by-level dataset using a Linear Mixed Model to 
determine where the changes occur within the rostro-caudal gradient of each 
DR subregion and the MnR. 
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Aim 2: To manipulate the HPA axis rhythm by sub-chronic administration of the 
long-acting sGC methylprednisolone (MPL), which is known to cause prolonged 
GR activation throughout the brain, characterize the resulting CORT rhythm, 
characterize the resulting tph2 mRNA expression profile and compare it to its 
natural circadian rhythmicity. 
 
a)  To assess the effect of MPL on the rhythm of tph2 mRNA expression profile 
in all the subregions of the dorsal raphe (DR; DRC, DRI, DRD, DRV, 
DRVL/VLPAG) and Median Raphe Nucleus (DR and MnR). 
b) To analyze the full level-by-level dataset using a Linear Mixed Model to 
determine where the changes occur within the rostro-caudal gradient of each 
DR subregion and the MnR. 
 
Aim 3: To disrupt the circadian rhythm of the HPA axis with five weeks constant 
light, characterize the resulting CORT rhythm, characterize the resulting tph2 
mRNA expression profile and compare it to its natural circadian rhythmicity. 
 
a)  To assess the effects of a disrupted HPA axis activity on the circadian 
rhythm of CORT and the rhythm of tph2 mRNA expression profile in all 
the subregions of the dorsal raphe (DR; DRC, DRI, DRD, DRV, 
DRVL/VLPAG) and Median Raphe Nucleus (DR and MnR). 
b) To analyze the full level-by-level dataset using a Linear Mixed Model to 
determine where the changes occur within the rostro-caudal gradient of each 
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Chapter 2 General Methods and Materials 
2.1 Animal experiments  
 
2.2 Sample collection  
2.2.1 Plasma sample collection  
2.2.2 Brain and pituitary collection  
 
2.3 Plasma sample analysis: Corticosterone radioimmunoassay (CORT 
RIA)  
2.3.1 Diluting samples  
2.3.2 Adding tracer and antibody  
2.3.3 Adding charcoal solution for counting  
 
2.4 Cryosectioning of the Dorsal and Median Raphe nuclei  
2.4.1 Mounting the brain 
2.4.2 Slicing of the brain and collection of brain sections 
 
2.5 In situ hybridization histochemistry (ISHH)  
2.5.1 Riboprobes 
2.5.2 Transcription of sense and antisense DNA 
2.5.3 Prehybridization  
2.5.4 Hybridization  
2.5.5 Riboprobe washing  
2.5.6 ISHH solutions  
2.5.7 Film exposure  
 
2.6 Image quantification 
2.6.1 Acquiring images  
2.6.2 Cataloguing images by rostro-caudal level  
2.6.3 Using image J  
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2.7 Statistical analysis  
2.7.1 Statistical analyses of circulating CORT levels  
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2.1 Animal experiments 
All experiments were performed using adult male Sprague-Dawley (SD) rats 
weighing 250-300g (Harlan Laboratories, Inc., Blackthorn, UK). All animal 
procedures were approved by the University of Bristol Ethical Group and were 
conducted in accordance with Home Office guidelines and the UK Animals 
(Scientific Procedures) Act, 1986.  
Animals used to investigate the natural rhythm of tph2 mRNA expression and the 
altered rhythm of expression after MPL treatment were given 7 days of habituation 
period before the start of the experiment and maintained under a 12/12 light-dark 
cycle (lights at 0700 h). Rats used for the third experiment arrived as p21 and were 
kept in specially designed chambers with 200 lux constant light (LL) over the 24-
hour day for 6 weeks. All rats were housed four per cage (polycarbonate cages; 45 
cm L x 25.2 cm W x 14.7 cm D) with bedding changed every two days. All animals 
had ad libitum access to food and water and were kept in an environmentally 
controlled, highly specialised animal facility at the University of Bristol.  
All experiments were performed solely by the candidate, including animal 
experiments, sample collection, radio immunoassays for CORT, in situ 
hybridization for tph2 mRNA and statistical analysis. 
2.2 Sample collection  
2.2.1 Plasma sample collection 
Once rats were euthanized and decapitated, trunk bloods (approx. 10 ml) were 
collected and maintained in ice-cold tubes containing 75 µl of EDTA (0.5 M; pH 
7.4) (the volume of EDTA was taken from other experiments from our group 
showing that 75 µl serves as anti-coagulant in large volumes of trunk blood, exact 
EDTA volume is not critical)  until the experiment in the animal facility had ended. 
Plasma was separated by centrifugation at 4oC (15 min 10000xg, Sigma 4-16KS 
centrifuge), and stored at -20o C until radio immunoassay for CORT was performed. 
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2.2.2 Brain and pituitary collection  
Rapidly after euthanizing and decapitation, brains and pituitaries were quickly 
collected. When extracting the brain, the entire brainstem and part of the spinal cord 
was also collected to ensure the DR and MnR would not be damaged. Brains and 
pituitaries were carefully frozen dorsal side down on a piece of aluminium foil that 
was cooled down on a flat piece of dry ice.  
After the experiment in the animal facility had ended, samples were stored at -80oC 
until cryosectioning of the DR and MnR nucleus for further in situ hybridization 
histochemistry (ISHH) experiments.  
2.3 Plasma sample analysis: Corticosterone 
radioimmunoassay (CORT RIA) 
Total circulating corticosterone was measured in the collected plasma samples by 
RIA as previously performed in our group (Walker et al., 2012). All samples were 
diluted (1:50) in citrate buffer (pH 3.0) to denature the binding globulin.  Antiserum 
was supplied by G Makara (Institute of Experimental Medicine, Budapest, 
Hungary), and 125I corticosterone isotope was purchased from IZOTOP (Institute 
of Isotopes Co. Ltd., Budapest, Hungary) with a specific activity of ≥ 600 GBq/mg 
and a radioactive concentration of ≥ 3700 MBq/ml. 
Each RIA included triplicates for each sample and all plasma samples were run 
three times in three different RIAs to prove consistency. Dilutions of 1:50 were kept 
exactly the same for experimental and control rats in the three assays.  
2.3.1 Diluting samples  
After defrosting samples, 10 µl of plasma sample in 490 µl of citrate buffer were 
mixed. From this diluted sample 300 µl were used to do the triplicates of each 
sample (100 µl for each). Samples were kept in ice-cold tubes during this step. 
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2.3.2 Adding tracer and antibody 
After the dilution of samples, 50 µl of radiolabelled antigen (hot tracer with around 
3000-4000 counts) and 50µl of antibody were added to each triplicated sample. 
Then, all samples were gently shaken/vortex for 10 seconds and left at -4o C 
overnight to incubate. 
Furthermore, a binding curve (standard curve with antibody and tracer) was used. 
Total (only radiolabelled antigen) and blank samples (citrate buffer with tracer and 
without antibody) and specific antigen quantity samples (QCs) were also used to 
assess consistency within the assays.  
2.3.3 Adding charcoal solution for counting 
In day 2 of the RIA, 500 µl of activated charcoal solution was added. All samples 
were then gently shaken/vortexed and then placed in a centrifuge (Sigma 4-16KS 
centrifuge, Rotor 11150-13215) for 15 minutes at 4, 000 rpm (3256 xg) to separate 
the unbound antigens from the bound antigens. 
Straightaway after this step, the supernatant was aspirated, and the remaining 
antigens were measured in the pellet by the Wizard gamma counter (Perkin Elmer 
2470 Automatic Gamma) with an energy range up to 1,000 keV.  Quantity of 
antigen in each sample was then derived from the standard curve and results 
obtained were saved to do statistical analysis.  
2.4 Cryosectioning of the Dorsal and Median Raphe nuclei  
All brains were sliced in a (Leica manual) microtome at -20o C with sharpened 
Leica blades. Brains were taken out one by one from a -80o C freezer and 
immediately put in the cryostat chamber to stand by for 15 minutes before slicing. 
2.4.1 Mounting the brain.  
Following the 15 min in the -20o C cryostat chamber the brain was cut using a sharp, 
warm (room temperature) razor blade into two pieces (Figure 2-1); forebrain and 
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hindbrain piece in coronal planes (at -1.000 mm and at -6.500 mm bregma)(Paxinos 
and Watson, 2005). Then, the forebrain piece of the brain was put back into the -
80o C and the hindbrain piece of the brain (after carefully trimming off the upper 
part of the cerebellum) was mounted onto a sample-chuck using Tissue-Tek 
embedding medium. The brain was positioned in order to section from caudal to 
rostral. 
 
Figure 2-1: Schematic representation of the sectioning of the Dorsal and Median Raphe nuclei. 
2.4.2 Slicing of the brain and collection of brain sections.  
All brains were sectioned in a coronal plane at 12 µm in series of two sets (A and 
B) of seven slides (1-7) with nine brain sections per slide; meaning that 
neighbouring sections on the same slide were neuroanatomically 84 µm “apart” 
from each other (12 µm x 7 = 84 µm).  Consequently, at the end of the collection 
of sections for each brain, seven different assemblages of sections would be 
obtained (which included the complete rostro-caudal levels of DR and MnR nuclei), 
this would allow us to do seven different ISHH experiments with each brain if 
needed. 
All brain sections were collected from -7.328 to -8.672 mm bregma area which 
contains the DR and MnR nuclei (Paxinos and Watson, 2005). When anatomical 
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characteristics of level -8.756 mm bregma were reached, all consecutive sections 
were collected and mounted into double coated gelatine microscope slides made in 
our lab. 
Brain section (from caudal to rostral), were collected in the following way;  
1) Brain section number one (around -8.756 mm bregma) was placed onto slide 
one from set A (1A). 
2) Brain section number two (around -8.744 mm bregma, 12 µm apart) was 
placed onto slide two from set A (2A). 
3) Brain section number three (around -8.732 mm bregma, 12 µm apart) was 
placed onto slide three from set A (3A). 
4) And so on, until section number 63 (around -8.000 mm bregma, 744 µm 
apart) was collected and placed in slide seven of set A (7A); meaning that 
by this point, each slide would be completed with 9 sections from different 
bregma levels of the DR and MnR nuclei. 
5) Then, set B followed with the exact same procedure, going from brain 
section 64 (around -8.012 mm bregma) in slide one (1B), to section 126 
(around -7.328 mm bregma) which was the 9th brain section placed in slide 
seven from set B (7B). 
Therefore, for each ISHH experiment run, two slides were used (one from each set) 
to have a suitable representation of the complete DR and MnR nuclei (all rostro-
caudal levels) (Figure 2-2). 




Figure 2-2: Collection of brain sections. Schematic of the seven different assemblages of the 
DR and MnR nuclei obtain from each animal. Each assemblage has a complete representation 
of the neuroanatomical extent (all rostro-caudal levels) of the DR and the MnR nuclei.  
Finally, after sectioning, all slides were appropriately labelled and returned to a -
80o C freezer until ISHH experiments. All brains, regardless of the experiment they 
belonged to, were cryosectioned in the same way as explained. 
2.5 In situ hybridization histochemistry (ISHH) 
All ISHH were done as reported in previous studies from our collaborators and from 
our group (Gardner et al., 2005; Donner, Johnson, et al., 2012b; Waite et al., 2012; 
Lukkes et al., 2013; Donner et al., 2018). This technique required a great number 
of optimizations to work for our specific interest. The following description 
includes all optimizations completed. 
2.5.1 Riboprobes 
As shown in Figure 2-3, 35S-UTP-labelled riboprobe was directed against tph2 
mRNA and was detected using a 462 base (1552-2013) antisense riboprobe 
complementary to the rat cDNA encoding tph2, the probe contained 23 bp of 
encoding sequence plus 438 bp of 3’ UTR  (i.e. tph2 , NCBI Reference Sequence: 
NC_005106.4 ) (K. L. Gardner et al., 2009).  




Figure 2-3: Plasmid map for tph2 riboprobe. 
The riboprobe that used for the analysis picked up both variants of tph2 gene, as it 
was designed for a 461 pb fragment of rat tph2, containing 23 bp of coding sequence 
plus 438 bp of 3’ UTR, which in turn is inside both variants of 3’ UTR (Figure 2-
4). 
 
Figure 2-4: Schematic map of tph2a and tph2b splice variants, plus riboprobe construct 
representation. Modified from Alternative Splicing and Extensive RNA Editing of Human tph2 
transcripts (Grohmann et al., 2010).  
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Important to mention, radiolabelled oligo probes were used with no success as no 
specific signal was seen on films after different exposure times and high 
background was observed throughout the film.  
2.5.1.1 Sense and antisense DNA 
Two different Eppendorf tubes were used for the digestion of the sense (ISHH 
control) and antisense DNA. These reactions were done by adding 10 µl ( 
approximately 4 µg) of plasmid DNA, 6 µl of sterile water, 2 µl of the appropriate 
reaction buffer R2 for sense (Invitrogen, Part no. Y90004, 2014) and R3 for 
antisense (Invitrogenm Part no. Y92500, 2014),  and 2 µl of the appropriate 
restriction enzyme; HINDI III for sense (Invitrogen, Cat. no. 15207-012, 2014) and 
EcoR I for antisense (Invitrogen, Cat. no. 152020-013, 2014). The two reactions 
were placed in a water bath at 37o C for 90 min for an optimal enzyme reaction. 
2.5.1.2 Purification of the cut DNA  
DNA clean-up was performed using a Min Elute Reaction Cleanup kit (Qiaqen cat 
no.28204) which involved 10 different steps of adding buffers, centrifuging, 
discarding supernatants, cleaning with ethanol and eluting the DNA to have a final 
volume of 10 µl of sense DNA and 10 µl of antisense DNA. These digested DNAs 
were stored at -20oC if they were going to be used further or at 4oC if the next stage 
of the ISHH was to follow. 
2.5.1.3 Verification of well-cut DNA by gel electrophoresis  
To verify if the digestion of our sense and antisense DNA was accurately done, a 
1% agarose gel was done. Carefully, 0.4 g Bioline agarose in 40 ml of 1xTBE were 
placed in a sterile conical flask and microwaved on high power for 1 min. Once the 
agarose was melted and cooled down a bit 2 µl of ethidium bromide was added and 
well mixed. Next, the gel was poured into the gel tank (GibcoBRL 41060, Horizon 
58), a comb of 8 channels was inserted and the gel was leaved to set for 20 min. 
The tank was flooded with 1xTBE, containing 5 µl of ethidium bromide per 100 
ml. 
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The digested sense and antisense DNA were prepared by adding 6 µl of sterile water 
and 2 µl of loading buffer to 2 µl of the sense or antisense. After carefully mixing 
by pipetting, the 10 µl were loaded into the gel.  Additionally, two samples (10 µl) 
of size markers were added to the gel to confirm that the DNA was the correct 
length.  The gel tank was connected to the power supply (Hoefer PS 2A200 power 
pack) and left to run at 80V until the markers were about 1/3 of the way down of 
the gel (between 25 to 30 min). 
Finally, after the gel was taken out of the tank it was placed onto clingfilm and into 
a GBox (Syngene). If DNA was well digested only one band would be visible in 
the lanes were the sense and antisense were placed, therefore the samples were then 
stored at -20o C to continue with transcription. If other bands were found, the cutting 
process would be repeated. 
2.5.2 Transcription of sense and antisense DNA. 
To perform the synthesis of the radiolabelled probe a SP6/T7 transcription kit 
(version 18 Roche) was used. First, the 35S- UTP (Perkin Elmer, 12.5 mCi/mL, i.e., 
27750000 dpm/g) was taken out of the freezer. UTP from the transcription kit was 
diluted (1:50) and MIX A (one for the sense and one for the antisense) was created 
with the following substances provided in the kit; 1.1 µl of ATP, 1.1 µl of CTP, 1.1 
µl of GTP, 1.1 µl of the diluted UTP, 2.2 µl of 10x transcription buffer and 0.22 of 
1M DTT. 
In one new Eppendorf tube, 2 µl of digested DNA (sense), 6.2 µl of Mix A, .9 µl of 
RNase inhibitor (from kit with 40 units), 0.9 µl of sterile water, 8 µl of 35S- UTP 
and 2 µl of T7 (RNA polymerase) were combined and carefully mixed together. 
Additionally, another tube was elaborated in the same way and with the same 
amount of substances, but antisense DNA was used instead of sense DNA and T3 
(RNA polymerase instead of T7. Both reaction tubes were placed in a water bath at 
37o C for exactly 60 min. 
While the last 10 min of the appointed hour went by, two Mix B (one for each tube) 
were developed with 1.5 µl of tRNA, 0.75 µl of RNase-free DNase 1 and 0.75 µl 
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of RNase inhibitor, to remove template DNA by reacting with the sense and 
antisense probes. After the 60 min were finished, 2.5 µl of Mix B were added to 
each tube, mixed and left to react again at 37o C for 15 min. 
Afterwards, tubes were heated at 65oC in a heating block for 5 min and quenched 
on ice for 2 min to denature the DNA template from the new synthesized 
radiolabelled RNA probe. Next, 77.5 µl of RNase free water were added to make a 
total of 100 µl and the clean-up of RNA followed. 
2.5.2.1 Clean up of RNA  
A MinElute Rneasy Cleanup kit (Qiaqen cat no. 74204) was used for this step. This 
procedure consisted in the adding of buffers, centrifugation and the use of ethanol 
to clean the radiolabelled RNA probe. At the end, 12 µl of radiolabelled probe were 
obtain (12 µl for each sense or anti sense probe) and the following step was to count 
how radioactive (cpm/µl) was the probe. 
2.5.2.2 Probe counts 
Counting how radioactive the probes were, allowed us to know if they were good 
enough to continue with further steps of the ISHH or if the transcription had to be 
done again. After several tests, 4,000 0000 cpm/µl were the minimum counts 
expected for a probe to work correctly, i.e. the signal of tph2 mRNA was optimum 
and the noise (background) was minimum in all the exposure times tested.  
To count, 0.5 µl of probe (sense or antisense) was diluted in 5 ml of liquid 
scintillation analyser (universal LSC-cocktail, Ultima gold High Flash-Point) in a 
polyethylene vial (Packard bioscience) tube. After well shaken tubes were counted 
in a beta counter (Perkin Elmer). If cpm/µl were less than expected, transcription 
was performed again. If it was hot enough, the probe was frozen at -80o C until 
hybridization step. All probes used in all the experiments of this study were used 
within 3 days of making. 
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2.5.3 Prehybridization  
For this step, corresponding slides which included 32 slides per ISHH (ten for 
CTRL animals, ten for MPL treated animals, ten for LL treated animals and two 
slides for sense [control ISHH]) were taken from the -80o C freezer and placed on 
foil to warm up for 10 minutes before their fixation. 
2.5.3.1 Fixation 
Sections were fixed in 4% fresh-cold paraformaldehyde for 15 minutes. Then, they 
were rinsed 2 times in 1x PBS. They were acetylated in a triethanolamine 
(TEA)/acetic anhydride (AA) mix for 10 min. Afterwards, all slides were 
dehydrated through several graded alcohols; 70% ethanol for 1 minute, 80% ethanol 
for 1 minute, 95% ethanol for 1 minute, 100% ethanol for 1 minute, chloroform for 
5 minutes, 100% ethanol for 1 minute and 95% ethanol for 1 minute. And finally, 
all slides were allowed to dry (around 20 minutes). 
2.5.4 Hybridization  
For the hybridization process each slide needed a minimum of 1,000 000 cpm/slide, 
therefore, depending on how hot the probe was, we used around 1.5 µl to 3.5 µl of 
antisense probe (35 slides) and 0.2 µl to 0.8 µl of the sense probe (3 slides) per 
performed ISHH. Probes were mixed separately with 2 µl of nucleic acid mix (per 
slide), heated to 65o C for 5 minutes and quenched on ice for 2 minutes. 
Next, 1 µl of 5M DTT (per slide) and 0.5 µl of 10% SDS (per slide) were added to 
the probe and mixed with 120 µl of hybridization buffer (per slide). After the mix 
was done, 120 µl of the mix was taken to the betta counter to assure the counts 
(cpm/slide) were acceptable. If the counts were lower than expected the mix had to 
be repeated. 
Once the mix had the correct amount of counts, 120 µl of mix was applied to each 
slide and covered with a cover slip (VWR international, Borosilicate glass; 22x60 
mm). As each slide was covered, it was placed in a plastic container. After all slides 
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were placed correctly in the container and the container was humid enough, this 
was arranged in a water bath at 55o C and slides were incubated overnight. 
2.5.5 Riboprobe washing 
Three different water baths were used for washing (two at 50o C and one at 37o C). 
Five different sterilized glass containers with 1x SCC/ 50% formamide were 
distributed in the two 50o C water baths. Additionally, three glass containers were 
allocated in the 37o C water bath; one had a ribonuclease solution (250 µl RNaseA 
[40mg/ml] in 500 ml of RNase buffer) and the two others had only 1x SCC. Six 
more glass containers were set up with 1x SCC and one more with sterile water at 
room temperature. 
The first step consisted in removing the cover slip of each slide through a wash in 
1x SSC and placing it in a specialized slide holder positioned in a glass container 
with fresh 1x SCC at room temperature while the other slides had the cover slip 
removed. The sense slides were washed first to avoid contamination. 
After all slides were free of their cover slip, all slides in two different holders were 
taken through 3 washes in fresh 1x SCC at room temperature. Then, two more 
washes in 1x SCC/ 50% formamide at 50o C were performed for 15 minutes each.  
Next, slides were only dip in 1x SCC at 37o C and taken to the next wash which 
consisted in 30 min under ribonuclease solution at 37o C. Afterwards, slides were 
again dipped in fresh 1x SSC at 37o C and immediately taken through three more 
washes in 1x SCC/ 50% formamide at 50o C (15 minutes each).  Then, slides were 
given two more washes in fresh 1x SCC at room temperature and finally, slides 
were passed quickly through sterile water and allow to dry after this last dip. After 
drying, slides were ready to be exposed to an autoradiography film. 
2.5.6 ISHH solutions 
• 20 x SSC (saline sodium citrate): Dissolve 175.3g of NaCL and 88.2g 
trisodium citrate in 800ml of distilled water. Adjust to pH 7 and make up to 
1 litre. Autoclave. 
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• 10 x PBS (phosphate buffered saline): Dissolve 90g NaCl, 1.65g 
potassium dihydrogen orthophosphate (KH2PO4) and 19.53g disodium 
hydrogen orthophosphate dodecahydrate (Na2HPO4:l2H2O) in 800ml 
distilled water. Adjust to pH 7.4. Autoclave. 
• 4% formaldehyde in l x PBS: Add 50ml 40% formaldehyde to 450ml l x 
PBS. 
• (TEA)/acetic anhydride (AA) mix: Add 3.5 ml of TEA and 0.625 ml of 
AA in 250 ml of sterile saline. 
• Dithlothreitol (DTT): For 1 M DTT dissolve 154.2mg/ml DTT in 0.01M 
sodium acetate (pH 5.2). Filter through a 0.2µm filter into a sterile container. 
Store as 20 µl aliquots at -20 °C. 
• 10mM Tris-HCL-EDTA buffer (TE) pH 7.6: Take 1ml of 1M Tris pH 8 
and add 0.036g (1mM) EDTA. Add 80ml water, pH to 7.6, make up to 
100ml and autoclave. 
• 4M NaCl: Dissolve 23.36g NaCl in 100ml water. Autoclave. 
• Hybridization Buffer (40 ml): Store at -20°C. Use 950 µl M Tris, pH 7.4, 
190 µl 0.25M EDTA, pH 8.0, 357 µl 4M NaCl, 23800 µl 50% Deionized 
formamide. Sigma F9037, 100ml, 9520 µl 50% Dextran Sulphate solution 
(50,000 MWt), 950 µl 50 X Denhardts and 1000 µl sterile water. 
• Nucleic acid Mix: Use 250 µl single stranded salmon sperm DNA. Defrost 
1ml, heat to 90C on heating block (to ensure single stranded). Quench on ice 
for 2 mins before adding, 250 µl tRNA, 500 µl sterile water. Freeze in small 
aliquots. 
• 5 RNase buffer: Use 25ml 1M tris pH 7.5, 25ml 0.5M EDTA pH 8.0, 
(ethylenediaminetetra-acetic acid, disodium salt, needs about 15g of NaOH 
pellets for pH 8.0) and 73.05g NaCl. Make up to 500ml and autoclave. 
2.5.7 Film exposure  
Different exposure times were tested in all the ISHH performed (e.g.;1 day, 2, days 
3 days, 5 days, 7 days, 10 days), the tph2 probe we used was confirmed to have an 
optimal exposure time in autoradiography films (Fujifilm super RX) of 3 days. A 
standard curve of C14 (carbon 14, ARC-146C, ARC Inc.) was included in each film. 
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Additionally, all films were developed in the automatic film processor (Kodak, ) to 
avoid another variability source.  
2.5.7.1 Set up of autoradiography films  
Considering the need of consistency through this study and the high variability that 
can be found when assessing so many brain sections in so many slides, a scheme of 
exposure was developed, where in each film the three experiments (control, MPL 
and LL) and all the time points considered (3 am, 9 am, 3 pm, 6 pm and 9 pm) were 
included (Figure 2-4). This idea was to minimize variability and increase uniformity 
within comparisons that would be made in further analysis. Therefore, considering 
that for the three experiment of this study a total of 120 animals were needed (5 
time points, with 8 animals/per time point), eight different ISHH to complete the n 
number for each time point/group from each experiment were performed. 
 
Figure 2-5: Schematic representation of autoradiography film set up for all the ISHH 
experiments done for this study. 
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2.6 Image quantification 
All image analysis of ISHH were performed similarly to the method used by our 
collaborators (Katherine L. Gardner et al., 2009a; Donner, Montoya, et al., 2012; 
Lukkes et al., 2013) and with the publicly available NIH-developed image analysis 
software ImageJ (https://imagej.nih.gov/ij/). However, some fluctuations were 
expected given the specifics of our study, .i.e, camera used to take the pictures, 
bregma levels considered, differences in produced atlas and calibration of each film 
corresponding to the C14 standard.   
2.6.1 Acquiring images  
All images were obtained using Scion Image version 1.63 in a power Mac 64 with 
a Leica MZ6 camera and the help of a light box (Wolverson) turned at all times. 
Additionally, a lens of 1.0 x was used with an adjusted magnification of 2.5 (Leica 
MOB-149). The grey scale option was chosen, and measurements of area and mean 
density were selected in Scion Image. 
After the starting set up, to begin capturing images the “live” option was selected 
to visualize the correct positioning of the film. Next, the “stacks” + “capture 
frames” options were selected, and 16 to 18 different pictures of each brain were 
captured. Additionally, a montage was made out of those 16-18 pictures to produce 
a picture atlas of each of the brain assessed (Figure 2-5). 
Fifteen different brains were exposed in each film; hence, fifteen different montages 
were obtained from each film (this meant 270 pictures per film for further analysis). 
A montage of the sense and standard curve (C14) were also taken for completeness. 
Once all pictures were acquired for the eight ISHH films, all images were saved for 
image quantification analysis. 




Figure 2-6: Montage of pictures taken of rat tph2 mRNA expression in the Raphe complex. 
Displayed (from top left to bottom right) are 17 coronal bregma levels used to measure tph2 
mRNA expression in all the subregions of the DR and MnR nuclei from caudal to rostral. Scale 
bar 1 mm.  
2.6.2 Cataloguing images by rostro-caudal level.  
Before acquiring measurements of all DR and MnR nuclei images different 
arrangements were done for all images in the interest of uniformity for further 
assessment. 
2.6.2.1 Analysis atlas of the DR and MnR nuclei 
A rostro-caudal analysis atlas for tph2 mRNA expression in the DR and MnR was 
generated by comparing the images obtained from the tissue sections with the brain 
atlas of Paxinos and Watson (Paxinos and Watson, 2005) and the landscape 
proposed by Gardner et al. (Gardner et al., 2009b). Therefore, 17 different rostro-
caudal levels were taken into consideration for this particular study. 
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Additionally, according to previous studies (Abrams et al., 2004; Gardner et al., 
2009b) each rostro-caudal level was further divided into subregions of the DR; thus, 
5 different subdivision in the DR plus the MnR nuclei where acknowledged for this 
study (Figure 2-6). These areas consisted of; the dorsal raphe nucleus, caudal part 
(DRC), –8.336 mm to –8.672 mm from bregma; dorsal raphe nucleus, 
interfascicular part (DRI), –8.420 mm to –8.672 mm from bregma dorsal raphe 
nucleus, dorsal part (DRD), –7.328 mm to –8.252 mm from bregma; dorsal raphe 
nucleus, ventral part (DRV), –7.328 mm to –8.204 mm from bregma; left and right 
dorsal raphe nucleus, ventrolateral part/ventrolateral periaqueductal grey region 
(left and right DRVL/VLPAG), –7.748 mm to –8.336 mm from bregma; and the 
median raphe nucleus (MnR), –7.496 mm to –8.672 mm from bregma. 
 
Figure 2-7: Schematic of rostro-caudal levels (including level code) DR subregions and MnR 
nucleus used in this study. 
2.6.2.2 Rostro-Caudal level code for this study 
To avoid confusion of all the possible rostro-caudal bregma levels, a level code for 
this study was implemented, where going from rostro level 7-328 to caudal level -
8.672 mm from bregma, was coded as going from level 1 to level 17 (Table 2-1). 
 




Table 2-1: Level code of the rostro-caudal level used in this study in comparison with mm 
bregma levels given by Paxinos and Watson (Paxinos and Watson, 2005). 
 
2.6.2.3 Reorganization of images 
To finish cataloguing the images, after the development of the rostro-caudal 
analysis atlas used for this study, all images from each animal were reorganized by 
rostro-caudal level, i.e., all images from one animal (15-18 pictures) were studied, 
separated and placed in a rostro-caudal level folder independently of to which 
animal it belonged to, hence, 17 different rostro-caudal level folders were created, 
in which every single one of them included ≤ 40 images (8 per time point) of the 
same rostro-caudal level. This categorization would make the analysis easier by 
taking all the measurements of a single level for the forty animals used in each 
experiment, thus, the assessment of each bregma level was blinded. This 
categorization was done for the three different experiment. 




Figure 2-8: Diagram of reorganization of pictures. Level pictures of all brains went to the same 
17 rostro-caudal level folders, therefore, each level folder contained 40 images.  
2.6.3 Using image J 
After having all the images organized by rostro-caudal level, measurements also 
needed to have a systematic method to keep reliability through all the 2160 images 
taken, therefore, different approaches were considered. 
2.6.3.1 Setting the scale 
When taking all the images, an extra image was taken from a ruler showing the 
length of one mm with the same lens and magnification used for all other images. 
Once Image J was open, this image of the ruler was set in the screen and with the 
straight-line tool, a line was drawn in that one mm shown. Then, the set scale 
window was opened, leaving the “distance in pixels” as it was, which showed the 
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was added as the “unit of length”. The “global” function was also selected, so this 
new scale setting would apply in every measurement taken. This setting was saved 
and used for all images across all experiments.   
2.6.3.2 Matrix for the DR and MnR nuclei atlas 
Again, to keep regularity through the different measurements of all images, 
matrices in the shape of the respective DR subregions and the MnR nucleus were 
created and overlaid with the real image. Therefore, for all images of the same 
rostro-caudal level, measurements were taken by the same matrix with the same 
area size. This matrix was done taking in consideration the rostro-caudal level 
analysis atlas done for this study (Figure 2-8). 
With image J we created the matrix by using the “macros” and the “record” options. 
Once the drawn matrices where finished for each DR subregion and MnR we would 
click the “create” and “save as” options. Afterwards, to pull up any macro, the 
“plugins” + “macros” + “run” command was clicked.




Figure 2-9: Matrix created and used for the expression of tph2 mRNA quantification at each rostro-caudal level. Displayed (from top left to bottom right) are 17 coronal 
bregma levels (from -7.328 to -8.672 bregma) used to measure tph2 mRNA expression in all the subregions of the Raphe complex. Scale bar 1 mm.
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2.6.3.3 Units of measure and definitive measurements    
For this study the unit “grey value” was used. Additionally, a constant threshold 
function was applied through the entire analysis and only the area (pixels) above 
the threshold signal would be considered. Therefore, when taking into consideration 
the threshold function were all pixels with a grey density below threshold were 
automatically excluded, and the measurements were only the area above-threshold 
signal given within each matrix, the ending measurement given by this specific 
method was “mean grey value x mean area”. However, because an individual 
background measurement was taken for each image to correct the real signal of tph2 
mRNA expression, the “mean grey value x mean area” was background-corrected, 
giving the ultimate unit as: “Corrected mean grey value x mean area” (CMGV x 
MA). 
Additionally, as mentioned before, multiple film exposures were performed to 
ensure that the measurements taken were within the response range and not 
saturated only because of a long exposure time. All measurements were taken from 
films exposed for 3 days.  
2.6.3.4 Acquiring measurements 
After the images were organized and the matrix was finished, to begin 
measurements, all images from level 1 were opened in Image J. Then, the macros 
were pulled up to the screen and were placed over the brain region of interest by 
clicking “CTRL+m” a measurement would be added to a new window of Image J. 
Next all measurements were copied and saved in an excel file for further statistical 
analysis. This was done for all the rostro-caudal levels. 
2.7 Statistical analysis 
All statistical analyses for CORT RIAs and ISHHs were conducted using the 
software package IBM Statistical Package for the Social Sciences (version 24.0, 
SPSS Inc., Chicago, IL, USA). Additionally, Sigma Plot (Version 13.0) was used 
to create all graphs presented in this thesis. Statistical analyses were based on 
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analyses previously reported for our group and collaborators ( Gardner et al., 2009a; 
Spiga, Knight, et al., 2011; Spiga, Waite, et al., 2011; Donner, Johnson, et al., 
2012b). 
2.7.1 Statistical analyses of circulating CORT levels  
All data of circulating CORT was presented as MEAN ± SEM of CORT (ng/ml). 
Statistical analyses assessing the circadian rhythm of CORT in control, MPL treated 
animals or LL treated animals were done with a one-way ANOVA followed by 
various post hoc tests but because of the need to use a time point as control, we 
used the Dunnett’s two-tailed test output, since all groups (time points) were 
compared to the 9 am time point. Statistical significance was set at P < 0.05.   
Two-way ANOVA’s were performed to compare between groups (control vs MPL 
treatment or control vs LL treatment). Statistical significance was set at P < 0.05.  
Afterwards, if the two-way ANOVA’s was significant, then multiple comparisons 
were done by a Tukey HSD test. Statistical significance was set at P < 0.05.  
2.7.2 Statistical analyses of the DR and MnR nuclei 
After obtaining all measurements of all images in Image J, values were saved and 
arranged in three different excel files (CTRL, MPL and LL files). All data was 
presented as MEAN ± SEM of tph2 mRNA expression (CMGVxMA) for each 
rostro-caudal level of each DR subdivision and MnR for each rat. Statistical 
analysis of the DR and MnR nuclei were done in several stages. 
2.7.2.1 Grubbs test 
The first stage of the analysis was to identify extreme outliers in the each of the 
three excel files (CTRL, MPL or LL). Therefore, Grubbs’ test for single outliers 
using two-sided α = 0.05  (Grubbs, 1969). The percentage of outlier observations 
per treatment group were as follows: Control=1.3%, MPL=1.8%, LL=.89%. 
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2.7.2.2 Wide statistical analysis of the tph2 mRNA expression in DR and 
MnR nuclei. 
After removing outliers of each excel file, a wide statistical analysis was done for 
all data of each of the experiments (CTRL, MPL and LL) and also to compare 
between experiments (CTRL vs MPL and CTRL vs LL) at all time points assessed. 
2.7.2.2.1 Tph2 mRNA expression in the DR complex: overall effect of time 
and treatment 
Thus, the second stage was collapsing all subregions and rostro-caudal level into a 
single Mean ± SEM value for each of the 5 different time points assessed for a 
given treatment (CTRL, MPL and LL, separately). Hence, the overall effect of time 
and treatment in tph2 mRNA expression in the whole DR complex (DR and MnR 
nuclei) was assessed. 
A one-way ANOVA followed by a Dunnett’s two-tailed test output (all groups were 
compared to the 9 am group) was performed to compare the effect of time in each 
experiment separately (CTRL, MPL and LL). Statistical significance was set at P < 
0.05.  
Two-way ANOVA’s were also performed to compare between groups (control vs 
MPL treatment or control vs LL treatment) and the overall effect of treatment in 
tph2 mRNA expression in the whole DR complex. Statistical significance was set 
at P < 0.05.  
Next, if the two-way ANOVA was significant, then multiple comparisons were 
done by a Tukey HSD test. Statistical significance was set at P < 0.05. 
2.7.2.2.2 Tph2 mRNA expression in each DR subregions and MnR nucleus; 
overall effect of time and treatment 
Then, the third stage of the statistical analysis of tph2 mRNA expression in the DR 
and MnR nuclei consisted in collapsing again all rostro-caudal levels into a single 
Mean ± SEM value for each of the 5 different time points assessed for a given 
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treatment (CTRL, MPL and LL, separately) but for these analyses we would assess 
the effect of time and treatment in each of the DR subregions and the MnR 
separately. This intended to assess the overall effect of time and treatment in tph2 
mRNA expression in each of the subregions of the DR (DRC, DRI, DRD, DRV, 
DRVL/VLPAG) and MnR nucleus. Moreover, because all of the subregions were 
divided into rostral-caudal sections, statistical analyses were performed for the 
whole, rostral and caudal area of each subregion separately. 
One-way ANOVAs were performed to compare the effect of time in each of the 
subregions of the DR and MnR (whole, rostral, caudal) of all the experiments 
(CTRL, MPL and LL). These one-way ANOVA’s were followed by a Fisher’s 
Least Significant Difference test (LSD). Statistical significance was set at P < 0.05.  
Two-way ANOVA’s were also performed to compare between groups (control vs 
MPL treatment or control vs LL treatment) and the overall effect of treatment in 
tph2 mRNA expression in each of the DR subregions and MnR. Statistical 
significance was set at P < 0.05.  
Next, if the two-way ANOVA output was significant, then multiple comparisons 
were done by an LSD test. Statistical significance was set at P < 0.05. 
2.7.2.3 Linear Mixed Models  
Finally, the fourth stage of the tph2 mRNA expression statistical analysis was 
performed. This analysis intended to evaluate the effects of time and treatment in 
all the subregions of the DR and MnR nuclei through their complete rostro-caudal 
extent. Therefore, because of the quantity and variability of the data (e.g. missing 
rostro-caudal levels, missing time points, technical outliers, statistical outliers, large 
amount of comparisons) these specific analyses were performed using Linear 
Mixed effects Models (LMM). These types of analyses are highly flexible and can 
accommodate a wide range of real-world data using more general covariance 
structures, i.e. these different covariance structures make different assumptions or 
no assumptions at all about the pattern of errors within subjects.  Moreover, these 
analyses incorporate fixed and random effects and allow us to save degrees of 
   Chapter 2 
75 
 
freedom compared to running standard linear models (for more information on 
LMM see appendix 1). These analyses were performed based on previous statistical 
methodological studies (Duricki, Soleman and Moon, 2016a, 2016b). 
More specifically, these analyses modelled tph2 mRNA expression (CMGVxMA) 
by experiment (CTRL, MPL or LL) or treatment (CTRL vs MPL or CTRL vs LL) 
in five different time point (3am, 9 am, 3 pm, 6 pm and 9 pm) within 5 different 
subregions of the DR (DRC, DRI, DRD, DRV, DRVL/VLPAG) plus the MnR 
nuclei at each rostro-caudal level (mm from bregma: −7.328, −7.412, −7.496, 
−7.580, −7.664, −7.748, −7.832, −7.916, −8.000, −8.084, −8.168, −8.252, −8.336, 
−8.420, −8.588, −8.672), hence, the need of LMMs. Additionally, some of the 
simple comparisons were taken back to simple ANOVAs to confirm that the LMMs 
were working correctly. All analyses were consistent.  
2.7.2.3.1 Global methodology  
Each of these analyses was run with 16 different covariate structures which 
included; ARMA (1,1), Compound Symmetry, Correlation Compound Symmetry, 
Diagonal, First-order Analytic, First-order Ante-dependence, First-order 
Autoregressive, First-order Factor Analytic, Heterogeneous Compound Symmetry, 
Heterogeneous First-order Autoregressive, Heterogeneous Toeplitz, Huynh-Feldt, 
Identity, Toeplitz, Unstructured, and Unstructured Correlations (for more 
information on covariance structures for LMM see appendix A) . 
Moreover, all these models included a series of diagnostics to confirm that the 
assumptions made for each fitted model were not violated. These diagnostics 
included; descriptives, normality test, error variances and a file of analysis of 
predicted and residual values of the fitted model (for more information on 
diagnostics for LMM see appendix A).  
These files were studied carefully to confirm if the assumptions of the model were 
not violated and the model was well fitted. If the assumptions were violated, then 
another covariate type was chosen. This situation never happened with any of the 
LMMs performed. 




Figure 2-10: Flow chart of the LMM analysis procedure.  
2.7.2.3.2 Overall Models  
With these considerations, two overall models (higher level models) were run for 
two different conditions; 1) to assess the overall effect of time in tph2 mRNA 
expression, for the CTRL, MPL and LL experiments, within each subregion of the 
DR and MnR nucleus throughout all their rostro-caudal extent across the 5 different 
time points measured and 2) to assess the effect of time and treatment, for CTRL 
vs MPL  and CTRL vs LL comparisons, within each subregion of the DR and MnR 
nucleus throughout all their rostro-caudal extent across the 5 different time points 
measured.  
As mentioned before these overall methods were run with 16 different covariates 
structures, therefore, to determine the best fitted model, the 16 different output 
models were compared with their Akaike information criterion (AIC) score and the 
one which had the lowest, was the best fitted model for the data.  Following these 
overall analyses, if a main effect or interaction between a main effect and any other 
factor reached p < 0.05, secondary LMM were run for each individual subregion of 
the DR and the MnR nucleus (for more information on LMM see appendix A). 
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2.7.2.3.3 Secondary LMM models  
Taken in consideration the overall models run in the previous stage, secondary 
models (lower level models) were run, all these models again were run with 16 
different covariates structures and included all the diagnostic files. 
These models intended to assess 2 different conditions; 1) the effect of time, for the 
CTRL, MPL and LL experiments, in each DR subregion and MnR nucleus 
separately, throughout all their rostro-caudal extent across the 5 different time 
points measured and 2) the effect of time and treatment, for CTRL vs MPL  and 
CTRL vs LL comparisons in each DR subregion and MnR nucleus separately 
throughout all their rostro-caudal extent across the 5 different time points measured.  
Additionally, the secondary lower level models for the second condition were done 
assessing each timepoint separately, thus, for example CTRL vs MPL in the DRC, 
at 3 am in one LMM analysis, CTRL vs MPL in the DRC at 9 am in another LMM 
CTRL vs MPL in the DRC at 3 pm in a third model, and so on for the 5 time points 
were assessed. However, these analyses only corresponded to the DRC, so the same 
number of LMM analysis for the DRI, DRD, DRV, DRVL/VLPAG and MnR were 
performed.  
For the last stage of this analysis, to determine the best fitted model the covariance 
structures were compared to the AIC score. The model with the lowest score was 
the best fitted model. Following these secondary analyses, if a main effect or 
interaction between a main effect and any other factor reached p < 0.05, post hoc 
pairwise comparisons were made with Fisher’s LSD test.  
Finally, important to clarify three different conditions had to be accomplished in 
order to performed post hoc analyses; 1) if a main effect or interaction between a 
main effect and any other factor reached p < 0.05, 2) if both the overall and 
secondary LMM reach significance in interaction or a main effect and 3) if the 
sample sizes was not below 50% of the full sample size models (for more 
information on LMM see appendix A). 
 
   Chapter 3 
78 
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3.1 Introduction  
An important characteristic of GC secretion is that it has a pulsatile pattern of 
release from the adrenal glands, and that the pulse amplitude is modulated over a 
24-hour period establishing the natural circadian rhythm of GCs (Windle et al., 
2001) According to previous studies, this rhythm follows a specific pattern which 
displays its highest peak at the onset of the active phase and its nadir at the onset of 
the inactive phase (Keller-Wood and Dallman, 1984). 
Various studies have shown that serotonin also has a circadian rhythmic release 
(Barassin et al., 2002). Moreover, rhythmic mRNA expression of tph2 , the rate 
limiting enzyme in serotonin biosynthesis, appears to depend on the circadian 
pattern of circulating GC (Malek, Pévet and Raison, 2004; Donner, Montoya, et al., 
2012). However, the circadian pattern of tph2 mRNA expression has not been well 
described in all of the subregions of the Dorsal Raphe (DR) and, even less so, in the 
Median Raphe (MnR) nucleus.  
Therefore, and considering the above, my first results chapter is focused on 
confirming whether there is a circadian rhythm in the tph2 mRNA expression 
profile in the DR. I also expand upon the current knowledge in the field, by 
performing a thorough characterization of tph2 mRNA expression throughout the 
full rostro-caudal gradient of subregions of the DR and the MnR. Finally, I compare 
the circadian CORT profile to the pattern of tph2 mRNA expression and discuss 
whether there is any type of relationship between the circadian rhythm of plasma 
CORT levels and the tph2 mRNA expression profile. 
3.2 Methods 
3.2.1 Study design to assess the natural rhythm of CORT and tph2 
mRNA expression. 
After arrival, 40 adult male SD rats (weighing between 250-300 g) were separated 
into five groups and housed four per cage in sound proof rooms for 7 days to 
habituate to the facility. All animals were maintained under a 12/12 light-dark cycle 
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(lights on at 0700 h) with food and water ad libitum. From day 3 to day 7, all animals 
were handled for 10 minutes at different times of day to avoid stress on the day of 
the experiment. 
After the week of habituation, in order to collect samples, all animals were 
euthanized with an overdose of isoflurane (schedule 1 procedure) and decapitated 
with a guillotine at defined timepoints across the 24-hour cycle; 9 am, 3 pm, 6 pm, 
9 pm and 3 am (n= 8 per time point). Animals were killed starting 25 minutes before 
the appointed hour and finishing 25 minutes past the hour. Trunk blood and whole 
brains were collected. 
 
Figure 3-1: Experimental design for the assessment of the natural rhythm of CORT and tph2 
mRNA expression. 
3.2.2 Statistical analysis  
1. One-way ANOVA was performed for the CORT data to assess the natural 
circadian rhythm. When an effect of time was found, Dunnet’s post-test was 
used to compare each time point to the 9am nadir. 
 
2. When analysing the whole Raphe complex, the same statistical tests used for 
the CORT analysis were used to enable a direct comparison between the 
rhythm of tph2 mRNA expression and the rhythm of CORT. A one-way 
ANOVA with a Dunnett’s (2-sided) post-test was also performed to compare 
each timepoint to the 9 am nadir. 
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3.  Finally, in all the more detailed (subregional and rostro-caudal analysis) an 
overall and subregional LMMs were performed, followed by Fisher’s Least 
Significant Difference (LSD) multiple comparison post-tests when a time 
effect was found. 
3.3 Results 
3.3.1 Circadian rhythm of circulating corticosterone 
The levels of circulating CORT in all of our control animals resemble previous 
studies from our group (Atkinson et al., 2008; Lightman and Conway-Campbell, 
2010; Walker et al., 2012). These results confirm that CORT plasma levels are 
following the natural circadian rhythm of adrenal CORT secretion in our control 
groups, with levels rising at 3pm and reaching a peak at 6pm, just prior to the onset 
of the dark phase (the active phase for rodents). 
To analyse the data from CORT RIA in this control group (Figure 3-2), a one-way 
ANOVA was performed to determine if there were any differences between time 
points; 3 am, 9 am, 3 pm, 6 pm and 9 pm (n=8/timepoint). A significant effect of 
time was detected; F(4, 35) = 29.85, p< 0.001, therefore further comparisons were 
made by a Dunnett’s post hoc test which compared the mean of every group against 
the 9 am group. I considered the 9 am group be our control comparison group 
because, as seen in previous studies, it clearly has the lowest level of circulating 
CORT (Kitchener et al., 2004; Atkinson et al., 2008; Waite et al., 2012). 
Statistically significant differences were found when comparing 9 am to 3 pm 
(p<0.001), 6 pm (p<0.001) and 9 pm (p<0.05). 




Figure 3-2: Circadian changes in circulating CORT of control animals. CORT levels were 
measured in plasma obtained from trunk blood of control animals at 5 different timepoints; 
3am, 9 am, 3 pm, 6 pm and 9 pm (n=8/group/timepoint). CORT levels are expressed as ng/ml. 
Data is presented as Mean ± SEM of CORT. One-way ANOVA was performed to assess effect 
of time; (F(4, 35) =29.85) p< 0.001. Additionally, Dunnett’s (2-sided) post hoc test was 
performed; *** p< 0.001 at 3 pm and at 6 pm when compared to the 9 am group; *p< 0.05 at 
9 pm when compared to the 9 am group. 
3.3.2 Circadian rhythmicity of tph2 mRNA expression in the 
Raphe complex.  
The Raphe complex contains the MnR nucleus (Brodal, Walberg and Taber, 1960) 
and 5 different nuclei (subregions) within the DR. These are the DRC, dorsal raphe 
nucleus, caudal part; DRI, dorsal raphe nucleus, interfascicular part; DRD, dorsal 
raphe nucleus, dorsal part; DRV, dorsal raphe nucleus, ventral part and 
DRVL/VLPAG, dorsal raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal grey). These nuclei are a collection of neurons with weakly defined 
cytoarchitectonic limits, and the majority of these neurons are serotonergic 
(Dahlström and K. Fuxe, 1964). 




Figure 3-3: Raphe complex. Representative pictures of all DR subdivisions within three 
different bregma levels (-8.00, -8.336 and -8.672 bregma). Scale bar 1mm.  
Although we understand and appreciate that the different nuclei within the Raphe 
complex are anatomically and functionally distinct (Lowry, 2002), we first wanted 
to very simply assess tph2 mRNA expression in the whole Raphe complex. To do 
this, I averaged the tph2 mRNA expression data of all the rostro-caudal levels of all 
the subregions. Interestingly, even in this ‘global’ analysis of the entire Raphe 
complex, I could detect time-dependent variation in tph2 mRNA expression over 
the 24-hour period. 
This analysis showed that tph2 mRNA expression exhibited a pronounced circadian 
rhythm (Figure 3-3) which was confirmed as a significant effect of time by one-
way ANOVA; F (4, 2020) = 29.85, p< 0.001. I then performed a Dunnett’s post hoc 
test to compare the mean of every group against the 9 am group, as it showed the 
lowest level of tph2 mRNA expression. Statistically significant differences were 
found at 3 pm (p<0.001), 6 pm (p<0.05), 9 pm (p<0.05) and 3 am (p<0.05). 




Figure 3-4: Circadian variation in Tph2 mRNA expression in the DR and MnR complex of 
control animals. All measurements of tph2 mRNA expression of all levels of the DR and MnR 
complex were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA 
expression for each group/timepoint (n=8/group). One-way ANOVA was performed to assess 
effect of time; (F (4, 2020) =5.814) p< 0.001. Additionally, Dunnett’s (2-sided) post hoc test was 
performed; *** p< 0.001 at 3 pm when compared to the 9 am group; ** p< 0.01 at 6 pm when 
compared to the 9 am group: *p< 0.05 at 3 am and 9 pm when compared to the 9 am group. 
3.3.3 Circadian changes in tph2 mRNA expression in subregions of 
the Dorsal Raphe and the MnR nucleus. 
As mentioned in the previous section, the Raphe complex has different anatomical 
and functional properties. In the last few years a large amount of research has been 
committed to describe and define the distinct properties of each subregion of the 
DR (DRC, DRI, DRD, DRV, DRVL/VLPAG) and the MnR nucleus. Following 
this line of research, in order to assess the overall effects of time (consistent with a 
circadian rhythm) on tph2 mRNA expression in each of the subregions of the DR 
and the MnR nucleus, I have analysed the overall tph2 mRNA expression across 
the whole rostro-caudal gradient for each subregion. 
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In the case of subregions that span across an extended rostro-caudal gradient, such 
as the DRD, DRV, DRVL/VLPAG and the MnR, further rostral and caudal analysis 
was performed. This was important to include in the analysis because most of the 
literature in this research area uses an allocation of antero-posterior division of the 
Raphe complex. Two different populations are recognized based on how the 
serotonergic clusters are distributed and also by their main projections. Two groups 
are well defined; the rostral group (projecting to the forebrain) and the caudal group 
(projecting to the brainstem) (Ding et al., 2003). Furthermore, this rostral and 
caudal group have been shown to have different anatomical and functional 
properties (Jacobs and Fornal, 1991; Mitchell, Lowe and Fields, 1998; Mason, 
1999; Horikawa et al., 2000). Hence, we decided to use this antero-posterior 
division of the Raphe complex in order to assess whether there was an overall effect 
of time (consistent with a circadian rhythm) on tph2 mRNA expression in the rostral 
group and the caudal parts of the three subregions of the DR which have this 
division (DRD, DRV, DRVL/VLPAG) and also in the MnR nucleus. Therefore, we 
analysed the overall MEAN ± SEM of tph2 mRNA expression including either the 
rostral levels or the caudal levels for each subregion separately. 
Interestingly, these analyses were able to detect circadian variation in tph2 mRNA 
expression in some but not all of the DR subregions, as well as in the MnR nucleus, 
with further striking antero-posterior differences in some cases. The results for each 
subregion will now be described in detail in the following sections. 
3.3.3.1 Dorsal Raphe nucleus, caudal part (DRC).  
To assess the presence of a circadian variation in tph2 mRNA expression 
throughout a 24-hour period in the DRC a one-way ANOVA was performed to 
determine if there was a significant effect of time. 
The DRC showed a small trend for a 9 am nadir (Figure 3-5), however, no 
statistically significant effect of time was revealed by the one-way ANOVA; F (4, 
118) =0.948, p> 0.05. Therefore, tph2 mRNA expression within the DRC does not 
appear to exhibit any significant circadian variation. 




Figure 3-5: Circadian variation in tph2 mRNA expression in the DRC of control animals. 
Measurements of tph2 mRNA expression of the five levels of the DRC (-8.336 to -8.672 mm 
bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA 
expression in the DRC for each group/timepoint (n 8/group [  8 animals x 5 levels =  40 
values]). One-way ANOVA was performed to assess effect of time; (F (4, 118) =0.948) p> 0.05. 
3.3.3.2 Dorsal Raphe nucleus, interfascicular part (DRI).  
Similar to the DRC, the one-way ANOVA was performed to assess the circadian 
variation of tph2 mRNA expression over a 24-hour period in the DRI (Figure 3-5).  
Again, a small trend can be observed for a 9 am nadir and a peak in expression at 6 
pm, however the one-way ANOVA did not detect a significant effect of time; F (4,77) 
=0.395, p> 0.05. Therefore, it appears that in the DRI there is a lack of circadian 
variation in tph2 mRNA expression. 




Figure 3-6: Circadian variation in tph2 mRNA expression in the DRI of control animals. 
Measurements of Tph2 mRNA expression of the four levels of the DRI (-8.420 to -8.672 mm 
bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 expression in 
the DRI for each group/timepoint (n 8/group [  8 animals x 4 levels =  32 values]). One-
way ANOVA was performed to assess effect of time; (F (4,77) =0.395) p> 0.05. 
3.3.3.3 Dorsal Raphe nucleus, dorsal part (DRD) 
For the DRD, which spans rostro-caudally through levels -7.328 to -8.252 mm 
bregma, three separate one-way ANOVA’s were performed assessing the whole, 
rostral and caudal DRD (Figure 3-6).  
An interesting rhythm was detected in the DRD subregion. With respect to the 
whole DRD (Figure 3-6A), the circadian variation in tph2 mRNA expression 
appeared with a well-defined nadir at 9 am and a peak in expression at 3 pm and 6 
pm. A significant effect of time was detected by one-way ANOVA; (F (4, 446) =3.045, 
p< 0.01). Therefore, further multiple comparisons were made by a Fisher’s LSD 
test and revealed that the 9 am nadir is significantly different when compared to the 
peak in expression at 6 pm (p<0.01) and 3 pm (p<0.01). 
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Moreover, the circadian pattern found in the whole DRV was also present in the 
rostral DRD (Figure 3-6B), however, within the rostral levels an even more 
profound nadir at 9 am was observed. This observation was supported by the one-
way ANOVA, which revealed a significant effect of time; (F (4, 299) =2.205, p< 0.05). 
Additionally, Fisher’s LSD post-tests detected a significant difference of the 9 am 
nadir when compared to tph2 mRNA expression levels at 3 am (p<0.05), 3 pm 
(p<0.05) and the peak in expression at 6 pm (p<0.01). 
Finally, when considering the caudal DRD (Figure 3-6C) no circadian variation was 
displayed, which was also supported by the one-way ANOVA, which revealed no 
significant effect of time; (F (4, 180) =1.857, p> 0.05). Therefore, it appeared that tph2 
mRNA expression within the DRD displays a circadian variation under natural 
conditions and that this variation is only seen in the rostral part of this area. 
 
Figure 3-7: Circadian variation in tph2 mRNA expression in the DRD of control animals. For 
each timepoint; 3am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements of tph2 mRNA 
expression (y axis) were averaged; (A) twelve levels (-7.328 to -8.252 mm bregma) for the 
whole DRD, (B) eight levels (-7.328 to -7.916 mm bregma) for the rostral DRD and (C) 5 levels 
(-7.916 to -8.252 mm bregma) for the caudal DRD. Tph2 mRNA quantification is expressed as 
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Calibrated Mean Grey Value multiplied by its own Measured Area. Data points correspond to 
overall MEAN ± SEM of tph2 mRNA expression of the whole/rostral/caudal DRD for each 
group/timepoint (n 8/group [  8 animals x  12/8/5 levels =  96/64/40 values]). One-way 
ANOVAs were performed to assess effect of time : (A) (F (4, 446) =3.045) p< 0.01  ** p<0.01 for 
9 am vs 3 pm and for 9 am vs 6 pm with Fisher’s Least Significant Difference test; (B) (F (4, 299) 
=2.205) p< 0.05: **p< 0.05 for 9 am vs 6 pm, *p< 0.05 for 3am vs 9 am and for 9 am vs 3 pm 
with Fisher’s Least Significant Difference test; (C) (F (4, 180) =1.857) p> 0.05. 
3.3.3.4 Dorsal Raphe nucleus, ventral part (DRV).  
Similar to what I found in the DRD, a comparable circadian variation pattern was 
found within the DRV subregion. However, the circadian pattern in the DRV 
appears to be localised to the caudal bregma levels in the DRV, in contrast to the 
rostral-localised effects in the DRD (Figure 3-7).  
Tph2 mRNA expression within the whole DRV (Figure 3-7A) also displayed a 
circadian pattern. However, in this area the peak in expression was reached at 3 pm 
and the nadir was maintained at 9 am. This circadian variation was detected by the 
one-way ANOVA, which revealed a significant effect of time; (F (4, 524) =2.113, p< 
0.05). Furthermore, Fisher’s LSD post-test showed that the peak in expression at 3 
pm is statistically different from the nadir at 9 am (p<0.01) and the next low level 
of expression at 9 pm (p<0.05). Moreover, as mentioned before, the circadian 
variation in this area appears to depend primarily on the caudal levels of the area. 
Therefore, no circadian variation in the rostral DRV was found (Figure 3-7B) and 
the one-way ANOVA confirmed this observation; F (4, 302) =0.688, p> 0.05. 
Finally, a more pronounced circadian variation pattern was observed in the caudal 
DRV (Figure 3-7C), which was supported by a significant effect of time in the One-
way ANOVA; (F (4, 256) =3.700, p< 0.01). Significant differences were found when 
comparing the 3 pm peak to the 9 am nadir (p<0.001), and the low levels of 3 am 
(p<0.05) and 9 pm (p<0.05).   




Figure 3-8: Circadian variation in Tph2 mRNA expression profile of the DRV of control 
animals. For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements of Tph2 
mRNA expression (y axis) were averaged; (A) fourteen levels (-7.328 to -8.420 mm bregma) 
for the whole DRV, (B) eight levels (-7.328 to -7.916 mm bregma) and (C) seven levels (-7.916 
to -8.420 mm bregma) for the caudal DRV. Tph2 mRNA quantification is expressed as 
Calibrated Mean Grey Value multiplied by its own Measured Area. Data points correspond to 
the overall MEAN ± SEM of th2 expression of the whole/rostral/caudal DRV for each 
group/timepoint (n 8/group [ 8 animals x 14/8/7 levels =  112/64/56 values]). One-way 
ANOVAs were performed to assess effect of time ; (A) (F (4, 524) =2.113) p< 0.05: ** p< 0.01 
for 9 am vs 3 pm and * p< 0.05 for 3pm vs 9 pm with Fisher’s Least Significant Difference test; 
(B) (F (4, 302) =0.688) p> 0.05; (C) (F (4, 256) =3.700) p< 0.01: ***p< 0.001 for 9 am vs 3 pm, 
*p< 0.05 for 3am vs 3 pm and for 3 pm vs 9 pm with Fisher’s Least Significant Difference test. 
3.3.3.5 Dorsal raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal grey (DRVL/VLPAG) 
The DRVL/VLPAG also displayed a strong circadian variation in tph2 mRNA 
expression, which also seemed to be primarily dependent on the caudal bregma 
levels of the area (Figure 3-8). This circadian variation in expression was found to 
be very similar to the pattern found in the DRV, where the nadir is at 9 am and the 
peak in expression at 3 pm.  
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This circadian variation pattern in tph2 mRNA expression appears to be maintained 
in the whole (Figure 3-8A) and caudal DRVL/VLPAG (Figure 3-8C) which were 
confirmed by the One-way ANOVAS; (F (4, 297) =2.26, p< 0.050) and (F (4, 219) =2.67, 
p< 0.05), respectively. However, no circadian variation was seen in the rostral 
DRVL/VLPAG (Figure 3-8B), with no effect of time detected by the one-way 
ANOVA; F (4, 112) =0.880), p> 0.05.  Further post-tests for the whole and rostral 
DRVL/VLPAG revealed a significant difference (p<0.01) between the nadir at 9 
am and the peak at 3 pm for both the whole and caudal DRVL/VLPAG. 
Additionally, another significant difference was found between the peak in 
expression at 3 pm and the low levels of tph2 mRNA expression at 9 pm in the 
whole (p<0.05) and the caudal DRVL/VLPAG (p<0.001). 
 
Figure 3-9: Circadian variation in Tph2 mRNA expression profile of the DRVL/VLPAG of 
control animals. For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements 
of Tph2 mRNA expression ( y axis) were averaged; (A) eight levels (-7.748 to -8.336 mm 
bregma) for the whole DRVL/VLPAG, (B) three levels (-7.748 to -7.916 mm bregma) for the 
rostral DRVL/VLPAG and (C) six levels (-7.916 to -8.336 mm bregma) for the caudal 
DRVL/VLPAG.Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value 
multiplied by its own Measured Area. Data points correspond to the overall MEAN ± SEM of 
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tph2 mRNA expression of the whole/rostral/caudal DRVL/VLPAG for each group/timepoint (n 
8/group [  8 animals x 8/3/6 levels =  64/24/48 values]). One-way ANOVAs were performed 
to assess effect of time ; (A) (F (4, 297) =2.26) p< 0.050: ** p< 0.01 for 9 am vs 3 pm, *p< 0.05 
for 3pm vs 9 pm with Fisher’s Least Significant Difference test; (B) (F (4, 112) =0.880) p> 0.05; 
(C) (F (4, 219) =2.67) p< 0.05: ***p< 0.001 for 3 pm vs 9 pm, **p< 0.01 for 9 am vs 3 pm with 
Fisher’s Least Significant Difference test. 
3.3.3.6 Median Raphe nucleus (MnR). 
Comparable to the DRV and DRVL/VLPAG, the MnR shows a strong circadian 
variation pattern in tph2 mRNA expression, which appears to be primarily 
dependent on the caudal levels of the subregion (Figure 3-9). Moreover, this pattern 
behaves in the same way as the other subregions mentioned before with a nadir at 
9 am and a peak in expression at 3 pm. 
Tph2 mRNA expression pattern in the whole (Figure 3-9A) and caudal MnR 
(Figure 3-9C) displayed a pronounced circadian pattern, confirmed by the 
significant effect of time found in the one-way ANOVAs; F (4, 493) =2.649, p < 0.05 
and F (4, 302) =4.261, p< 0.01, respectively. No significant effect of time was found 
for the rostral MnR (Figure 3-9B); F (4, 225) =0.435, p> 0.05. 
Further multiple comparisons in the whole MnR revealed that the peak in 
expression at 3 pm was statistically different from the 9 am nadir (p< 0.01) and the 
9 pm (p< 0.05) low levels of expression. Additionally, because the 9am nadir shows 
very low levels of expression, a statistically significant difference is found when 
compared to 3 am (p< 0.05) and 6 pm (p< 0.05). Similar findings appeared in the 
caudal MnR where changes in expression levels between the peak and nadir were 
very robust, hence the 3 pm peak was statistically different from the 9 am nadir (p< 
0.001), 6 pm (p< 0.05) and 9 pm (p< 0.01), plus an additional difference was found 
between the 9 am nadir and the 3 am (p< 0.05) tph2 mRNA expression levels. 




Figure 3-10: Circadian variation in Tph2 mRNA expression profile of the whole MnR of control 
animals. For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements of Tph2 
mRNA expression (y axis) were averaged; (A) fifteen levels (-7.496 to -8.672 mm bregma) for 
the whole MnR, (B) six levels (-7.494 to -7.916 mm bregma) for the rostral MnR and (C) 10 
levels (-7.916 to 8.672 mm bregma) for the caudal MnR. Tph2 mRNA quantification is 
expressed as Calibrated Mean Grey Value multiplied by its own Measured Area. Data points 
correspond to the overall MEAN ± SEM of tph2 mRNA expression of the whole/rostral/caudal 
MnR for each group/timepoint (n 8/group [  8 animals x 15/6/10 levels =  120/48/80 
values]). One-way ANOVAs were performed to assess effect of time ; (A) (F (4, 493) =2.649) p < 
0.05: ** p< 0.01 for 9 am vs 3 pm, *p< 0.05 for 3am vs 9 pm, for 9 am vs 6 pm and for 3 pm 
vs 9 pm with Fisher’s Least Significant Difference test; (B) (F (4, 225) =0.435) p> 0.05; (C) (F 
(4, 302) =4.261) p< 0.01; ***p< 0.001 for 9 am vs 3 pm, ** p< 0.01 for 3 pm vs 9 pm, *p< 0.05 
for 3 am vs 9 am and for 3 pm vs 6 pm with Fisher’s Least Significant Difference test. 
3.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR 
subregions and MnR nucleus; analysis across the full rostro-
caudal gradient. 
The DR subregions and the MnR nucleus are highly specialized areas that have 
been revealed to have specific anatomical and functional properties (Lowry, 2002; 
Hornung, 2003; J. Abrams et al., 2004). Nevertheless, experts in the area have 
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hypothesized that even throughout the rostro-caudal gradient of these particular 
subregions there are variations which can also have a meaningful functional output 
(Kirby, Rice and Valentino, 2000; Lowry et al., 2000; J. Abrams et al., 2004; 
Ruddick et al., 2006; Price and Drevets, 2012), for example; the majority of  
serotonergic neurons show decreased firing rates during inactivity, but a small 
population of these neurons located in the caudal pat of the DR and MnR do not 
show this decline in firing rate (Peyron et al., 1997a). Following this idea, and in 
order to assess the effects of time throughout the rostro-caudal gradient of the DR 
subregions and the MnR nucleus, LMM analyses were completed as described in 
Chapter 2 General Methods.  All LMM analyses were methodically finalized, and 
only when significant differences in any main factor or interaction were found, 
Fisher’s LSD post-tests followed according to previously described analyses in the 
Raphe (Stamper et al., 2015, 2017). Finally, as data was excluded during the Grubbs 
analysis, results of statistical tests were deemed valid only when the remaining 
sample size was greater than four (half the original sample size for each timepoint 
at each rostro-caudal level). 
Analysis of tph2 mRNA expression using LMM analysis (Table 3-1) revealed a 
rostro-caudal level x time point interaction (F (4, 247.606) = 10.793, p<.0. 000), a 
rostro-caudal level (raphe subregion) interaction (F(36, 134.754) = 40.036, p< 0.000), a 
main effect of rostro-caudal level (F (16, 111.562) = 205.278, p < 0.000), a main effect 
of raphe subregion (F(5, 127.176) = 254.618, p< 0.000) and a main effect of time point 
(F(4, 247.606) = 10.793, p< 0.000). 
Based on this overall LMM analysis, secondary LMMs were used to determine 
changes over time in tph2 mRNA expression at each rostro-caudal level of all the 
subregions of the DR and in the MnR nucleus separately (Table 3-1). Additionally, 
changes across the rostro-caudal gradient at each time point were assessed, but for 
simplicity, these changes are not represented in the Figures. 
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Table 3-1: Linear mixed model analysis results for tph2 mRNA expression in Control SD male 
animals. 
 
Model Test statistic p-value 
Overall analysis for Controls    
First-Order Ante-Dependence covariance structure 
Akaike’s information Criterion (AIC): 7944.574 
  
 Rostrocaudal level1 (1-17) F(16, 111.562) = 205.278 .000 *** 
 
Raphe subregion2 (DRC, DRI, DRD, DRV, 
DRVL/VLPAG, MnR) F(5, 127.176) = 254.618 
.000 *** 
 Time point3 (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 247.606) = 10.793 .000 *** 
 Rostrocaudal level * Time point F(63, 140.564)= 1.577 .014 * 
 Raphe subregion * Time point F(20,  139.185)= 1.102 .354 
 Rostrocaudal level (Raphe subregion) F(36, 134.754) = 40.036 .000 *** 
 
Rostrocaudal level * Time point (Raphe 
subregion) 







Unstructured covariance structure 
Akaike’s Information Criterion (AIC): 416.066 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 399.263)= 1.054 .379 
 Rostrocaudal level (13-17) F(4, 79.290)= 2.541 .046 * 
  Time point * Rostrocaudal level F(15, 78.086)= 1.825 .046 * 
DRI 
Unstructured Correlations covariance structure 
Akaike’s Information Criterion (AIC): 261.911 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 9.629)= 1.725 .223 
 Rostrocaudal level (14-17) F(3, 4.083)= 205.708 .000 *** 
  Time point * Rostrocaudal level F(11, 5.114)= .552 .809 
DRD 
First-Order Autoregressive covariance structure 
Akaike’s Information Criterion (AIC): 1818.946   
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 104.957)= 2.754 .032* 
 Rostrocaudal level (1-12) F(11, 252.511)= 28.027 .000 *** 
  Time point * Rostrocaudal level F(44, 253.888)= 1.062 .376 
DRV 
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Akaike’s Information Criterion (AIC): 2274.114 
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 78.918)= 3.723 .008** 
 Rostrocaudal level (1-14) F(13, 78.612)= 113.743 .000 *** 
  Time point * Rostrocaudal level F(52, 81.330)= .751 .865 
DRVL/VLPAG 
First-Order Ante-Dependence covariance structure 
Akaike’s Information Criterion (AIC): 1280.871 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 52.840) = 3.859 .008 ** 
 Rostrocaudal level (6-13) F(7, 45.730)= 73.566 .000 *** 
  Time point * Rostrocaudal level F(28, 45.723)= 1.250 .247 
MnR 
Unstructured covariance structure 
Akaike’s Information Criterion (AIC): 1427.028 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 293.819)= 3.081 .015 * 
 Rostrocaudal level (3-17) F(14, 66.643)= 64.654 .000 *** 
  Time point * Rostrocaudal level F(55, 52.645)= 3.463 .000 *** 
Rostrocaudal levels were well-defined from bregma levels given in the atlas; where 
most rostral level was -7.328 mm bregma (1 according to level code) progressing to 
the most caudal level at –8.672 mm bregma (17 according to level code). Within this 
brain section 17 different and representative coronal sections of 12 µm were used to 
measure tph2 mRNA of the dorsal raphe nucleus and the median raphe nucleus. 2The 
Raphe subregions used in this research were the following: DRC, dorsal raphe 
nucleus, caudal part; DRI, dorsal raphe nucleus, interfascicular part; DRD, dorsal 
raphe nucleus, dorsal part; DRV, dorsal raphe nucleus, ventral part and 
DRVL/VLPAG, dorsal raphe nucleus, ventrolateral part/ventrolateral periaqueductal 
grey. MnR, median raphe nucleus was also included and considered as a subregion of 
the Raphe complex.3 The five different time points (3 am, 9 am, 3 pm, 6 pm, 9 pm) 
used in this study were considered as a suitable description of the circadian rhythm of 
tph2 mRNA expression. They were chosen to fit in parallel with the measured 
circadian rhythm of plasma CORT. *p<0.05. **p<0.01. ***p<0.001. 
3.3.4.1 Dorsal Raphe nucleus (DRC) 
First, and consistent with my earlier findings that total tph2 mRNA content in the 
DRC was not sensitive to time of day (Figure 3-4), there was no obvious time-
dependent variation detected across any rostro-caudal levels of the DRC (Figure 3-
10).  However, the secondary LMM analysis of the DRC (Table 3-1) did reveal a 
timepoint * rostro-caudal level interaction (F(15, 78.086)= 1.825, p<0.05) and a main 
effect of rostro-caudal level (F(4, 79.290)= 2.541, p <0.05). Based on detecting a 
significant interaction, I further interrogated the dataset with Fisher’s LSD post-
tests, which detected some significant differences in tph2 mRNA expression across 
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rostro-caudal levels. However, every significant difference found was excluded due 
to the aforementioned minimum sample size criteria. Therefore, no significant 
differences between any of the time points were detected at any rostro-caudal level 
of the DRC. 
 
Figure 3-11: Rostro-caudal level variation of tph2 mRNA expression profile in the DRC of 
control animals. Tph2 mRNA expression in the DRC was measured in five different rostro-
caudal levels presented in the x (-8.336 to -8.672 mm bregma). Five different timepoints; 3 am, 
9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-caudal level (time course). Tph2 mRNA 
quantification is expressed as Calibrated Mean Grey Value multiplied by its own Measured 
Area. Top data points are associated to the right y-axis which represent the post-Grubb’s test 
sample size at each rostro-caudal level. Bottom data points are linked to the left y-axis which 
correspond to the MEAN ± SEM of tph2 mRNA expression of each group/timepoint (n 
8/group) at each rostro-caudal level. Fisher’s Least Significant difference test showed no 
significant differences. 
3.3.4.2 Dorsal Raphe nucleus, interfascicular part (DRI) 
Again, consistent with my earlier findings that total tph2 mRNA content in the DRI 
did not vary with time of day (Figure 3-5), there was no obvious time-dependent 
variation detected across any rostro-caudal level of the DRI (Figure 3-11). In 
support of this apparent lack of circadian variation within the DRI, the secondary 
LMM analysis revealed only a main effect of rostro-caudal level (F(3, 4.083)= 
205.708, p< 0.05), no main effect of time (F(4, 9.629)= 1.725, p >0.05) and no 
interaction (F(11, 5.114)= .552, p >0.05) (Table 3-1). Post-hoc tests to further 
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interrogate differences between time points at each rostro-caudal level of the DRI 
were therefore not performed.  
 
Figure 3-12: Rostro-caudal level variation of tph2 mRNA expression profile in the DRI of 
control animals. Tph2 mRNA expression in the DRI was measured in four different rostro-
caudal levels presented in the x axis (-8.420 to -8.672 mm bregma). Five different timepoints; 
3 am, 9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-caudal level (time course). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the post-
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for each 
group/timepoint (n 8/group) at each rostro-caudal level. Fisher’s Least Significant difference 
test showed no significant differences.   
3.3.4.3 Dorsal Raphe nucleus, dorsal part (DRD). 
Secondary LMM analysis within the DRD revealed a main effect of rostro-caudal 
level (F(11, 252.511)= 28.027, p< 0.000) and a main effect of time  (F (4, 104.957)= 2.754, 
p< 0.05), however, no significant interaction was found (F (44, 253.888)= 1.062, p> 
0.05) (Table 3-1).  Furthermore, post tests showed that tph2 mRNA expression 
varied significantly over time at multiple rostro-caudal levels of the DRD (Figure 
3-12); tph2 mRNA expression at level 3 (-7.496 mm bregma) was increased at 9 
am when compare to 6 pm; at level 4 (-7.580 mm bregma) 3 am tph2 mRNA 
expression was higher when compared to 9 am, 3 pm or 9 pm; at level 6 (-7.748 
mm bregma) tph2 mRNA at 9 am was lower compared to its expression at 3 am 
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and; at level 8 (-7.916 mm bregma) tph2 mRNA expression was also lower at 9 am 
compared to the 3 pm time point; and finally, at level 12 (-8.252 mm bregma)  this 
low tph2 mRNA expression at 9 am was maintained compared to 3 pm. 
 
Figure 3-13: Rostro-caudal level variation of tph2 mRNA expression profile in the DRD of 
control animals. Tph2 mRNA expression in the DRD was measured in fourteen different rostro-
caudal levels presented in the x axis (-7.328 to -8.252 mm bregma). Five different timepoints; 
(a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-caudal level. The 
left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value multiplied by its own 
Measured Area). Upper segmented area is associated to the right y-axis that represents the 
post-Grubb’s test sample size at each rostro-caudal level. Fisher’s Least Significant difference 
test results are indicated on graph and are annotated by a to e for each time point as shown in 
the plot key. Additionally, double letters indicate p<0.01 and simple letters for p<0.05.  Here, 
(aabb) indicates a significant difference for 3 am vs 9 am, (ac) for 3 am vs 3 pm, (ae) for 3 am 
vs 9 pm, (bc) for 9 am vs 3 pm, (bd) for 9 am vs 6 pm and (be) for 9 am vs 9 pm. 
3.3.4.4 Dorsal Raphe nucleus, ventral part (DRV). 
Secondary LMM analysis was also performed within the DRV and it showed a main 
effect in rostro-caudal level (F (13, 78.612)= 113.743, p< 0.000), a main effect of time 
(F (4, 78.918)= 3.723, Figure 3-13, post tests revealed significant differences in tph2 
mRNA expression between 9 am and 3pm, across five bregma levels (-7.916, -
8.084, -8.168, 8.252, -8.336 mm bregma).  




Figure 3-14: Rostro-caudal level variation of tph2 mRNA expression profile in the DRV of 
control animals. Tph2 mRNA expression in the DRV was measured in fourteen different rostro-
caudal levels presented in the x axis (-7.328 to -8.420 mm bregma). Five different timepoints; 
(a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-caudal level. The 
left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value multiplied by its own 
Measured Area). Upper segmented area is associated to the right y-axis that represents the 
post Grubb’s test sample size at each rostro-caudal level. Fisher’s Least Significant difference 
test results are indicated on graph and are annotated by a to e for each time point as shown in 
the plot key. Additionally, simple letters indicate p<0.05. Here (bc) indicates a significant 
difference for 9 am vs 3 pm.  
3.3.4.5 Dorsal Raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal grey (DRVL/VLPAG). 
Secondary LMM analysis within the DRVL/VLPAG revealed two main effects in 
time point (F (4, 52.840) = 3.859, p<0.01) and rostro-caudal level (F(7, 45.730)= 
73.566, p<0.001), with no interaction (F(28, 45.723)= 1.250, p>0.05) (Table 3-1). 
Post tests revealed significant differences in tph2 mRNA expression across six 
rostro-caudal levels (-7.748, -7.832, -7.916, -8.000, -8.168, 8.252) as indicated in 
the graph in Figure 3-14. Notably, tph2 mRNA expression was significantly lower 
at 9 am than 3 pm at rostro-caudal levels 7, 11 and 12 (-7.832, -8.168, 8.252 mm 
bregma), and significantly lower at 9am and 3am compared to 9pm at level 6 (-
7.748 mm bregma).  




Figure 3-15; Rostro-caudal level variation of tph2 mRNA expression profile in the 
DRVL/VLPAG of control animals. Tph2 mRNA expression in the DRVL/VLPAG was measured 
in eight different rostro-caudal levels presented in the x axis (-7.748 to -8.336 mm bregma). 
Five different timepoints; (a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for 
each rostro-caudal level. The left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey 
Value multiplied by its own Measured Area). Upper segmented area is associated to the right 
y-axis that represents the post Grubb’s test sample size at each rostro-caudal level. Fisher’s 
Least Significant difference test results are indicated on graph and are annotated by a to e for 
each time point as shown in the plot key. Additionally, double letters indicate p<0.01 and simple 
letters p<0.05. Here (bbee) indicates a significant difference for 9 am vs 9 pm, (ac) for 3 am vs 
3 pm (ae) for 3 am vs 9 pm, (bc) for 9 am vs 3 pm and (ce) p< 0.05 for 3 pm vs 9 pm. 
3.3.4.6 Median Raphe nucleus (MnR).  
To finalize the study of the natural circadian rhythm of tph2 mRNA expression, a 
Secondary LMM analysis within the MnR was performed. This analysis revealed a 
time point * rostro-caudal level interaction (F(55, 52.645)= 3.463, p< 0.001) and two 
main effects in time point (F(4, 950445,357)= 3.081, p< 0.05) and rostro-caudal level 
(F(14, 2489.673)= 64.654, p< 0.001) (Table 3-1). Post tests revealed significant 
differences in tph2 mRNA expression in six different rostro-caudal levels (-7.496, 
-8.168, -8.252, -8.336, -8.420, -8.504). Interestingly tph2 mRNA expression 
appeared lower at 9 am when compared to 3pm from level 7 to level 14, but the 
difference was only significant at level 12 and 14.  Notably, the 3 pm timepoint was 
significantly higher than 3 am, 9 am, 6 pm and 9 pm, albeit only at defined points 
from level 11 to level 15, as indicated on the graph in Figure 3-15.  




Figure 3-16: Rostro-caudal level variation of tph2 mRNA expression profile in the MnR of 
control animals. Tph2 mRNA expression in the MnR was measured in fifteen different rostro-
caudal levels presented in the x axis (-7.496 to -8.672 mm bregma). Five different timepoints; 
(a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-caudal level. The 
left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value multiplied by its own 
Measured Area). Upper segmented area is associated to the right y-axis that represents the 
post Grubb’s test sample size at each rostro-caudal level. Fisher’s Least Significant difference 
test results are indicated on graph and are annotated by a to e for each time point as shown in 
the plot key. Additionally, double letters indicate p<0.01 and simple letters p<0.05. Here (aacc) 
indicates a significant difference for 3 am vs 3 pm, (bbcc) for 9 am vs 3 pm, (ccdd) for 3 pm vs 
6 pm, (ab) for 3 am vs 9 am, (bc) for 9 am vs 3 pm, (cd) for 3 pm vs 6 pm and (ce) for 3 pm vs 
9 pm. 
Overall the LMM analysis of the Tph2 mRNA expression data, level by level 
throughout the rostro-caudal gradient of each subdivision, was reassuringly 
consistent with the total tph2 mRNA expression values for each subdivision. This 
data also extended the analysis to allow a more thorough appreciation of the way 
tph2 mRNA expression changed over the rostro-caudal gradient and with time.  
3.3.5 Summary of results 
The following table is a summary of the key findings on this chapter.  
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Table 3-2: Table 3-3: Key findings on the circadian expression of tph2 mRNA.by subdivision of the Raphe complex and by bregma level. Differences found by statistical 
analysis form ANOVA’s and Linear Mixed Model analysis.  
 
  Nadir Peak Complete Subdivisions LMM analysis Figures 
DR complex 9:00 AM 3:00 PM 
↑ expression at 3 am, 6 pm and 9 pm when 
compared to nadir 
NA 
 Figure 3-4  
DRC No significant changes 
 Figure 3-5 
Figure 3-11 
DRI No significant changes 
Figure 3-6 
Figure 3-12 
DRD 9:00 AM 6:00 PM 
↑ expression at 3 am, 3 pm and 6 pm when 
compared to nadir. Specific to rostral bregma 
levels.  
Changes at level 2,  4, 6, 8 and 12.  Figure 3-7 
Figure 3-13 
DRV 9:00 AM 3:00 PM 
↓ expression at 3 am, 9 am and 9 pm when 
compared to peak. Specific to caudal bregma 
levels.  
Changes at level 4, 8 and from 10 
to 13. All  changes were 
comparing nadir to peak.   
Figure 3-8 
Figure 3-14 
DRVL/VLPAG 9:00 AM 3:00 PM 
↓ expression at 9 am and 9 pm when compared 
to peak. Specific to caudal bregma levels.  
Changes detected from level 6 to 
level 12 with exception of level 
10. Most changes here comparing 
nadir to peak.   
Figure 3-9 
Figure 3-15 
MnR 9:00 AM 3:00 PM 
↓ expression at 9 am, 6 pm and 9 pm when 
compared to peak. Specific to caudal bregma 
levels.  
Changes at level 3 and from 11 to 
15. Most changes were comparing 
9 am to 3 pm or 9 pm.  Figure 3-10 
Figure 3-16 
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3.4 Discussion  
According to the results described in this chapter we have determined that CORT 
levels in this control group (Figure 3-2) entirely correspond to the natural circadian 
rhythm of circulating CORT as shown in previous studies. Consequently, I can 
conclude with reasonable confidence that the control group used in my studies, 
represents “true” basal (non-stressed) experimental conditions given that levels of 
circulating CORT at each time studied were consistent with other previous studies 
from the Lightman group and others (Windle et al., 1998; Spiga, Waite, et al., 2011; 
Waite et al., 2012; Park et al., 2013). 
Regarding the average tph2 mRNA expression across the whole Raphe complex 
(Figure 3-4), the data showed a significant circadian variation in tph2 mRNA 
expression, with the lowest levels of expression at 9 am, which matches to the nadir 
of circulating CORT. The highest level of tph2 mRNA expression occurs at 3 pm, 
which coincides with the initial rise in circulating CORT. This finding is consistent 
with a rapid induction of tph2 mRNA in line with rising CORT levels. The levels 
of tph2 mRNA remain significantly elevated at 6 pm, relative to 9 am nadir levels, 
then decrease to baseline over the time course. 
Considering the mean tph2 mRNA expression in the DR subregions and the MnR 
nucleus we can confirm the presence of a circadian variation in the DRD (Figure 3-
7), DRV(Figure 3-8), DRVL/VLPAG (Figure 3-9) and MnR (Figure 3-10)  which 
appears to be specific of the caudal part for each area with the exclusion of the DRD 
which seems to be specific of the rostral part.  In all of the areas with the presence 
of a circadian variation, the lowest point of tph2 mRNA expression matches the 
nadir of circulating CORT levels at 9 am. Interestingly, in the DRV, 
DRVL/VLPAG and MnR the highest peak of expression is at 3 pm, moreover, in 
these areas the increase in tph2 mRNA is quite transient with levels decreasing back 
to baseline by 9 pm. The exception to this again is the DRD where a prolonged 
elevation of tph2 mRNA is evident from 3 pm to 9 pm, decreasing again from 9 pm 
onwards. No significant differences were found in DRC (Figure 3-5) or DRI (Figure 
3-6). 
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Considering the rostral-caudal gradient of each of the subregions of the DR and the 
MnR nucleus, overall analyses showed that tph2 mRNA expression profile changes 
across this gradient in all of the areas of the Raphe complex (Figure 3-11 to 3-16). 
This finding is consisted to previous studies (Malek et al., 2004; 2005) and 
represents functionally important neuroanatomical aspects of the raphe nuclei, 
which will be further discussed. Additionally, the data shows a circadian variation 
throughout the rostral-caudal levels of the DRD (Figure 3-13), DRV (Figure 3-14),  
DRVL/VLPAG (Figure 3-15) and MNR (Figure 3-16), and even though these 
changes are only statistically significant for some levels of each area, a general 
trend in the data can be observed.  
Finally, all this data confirms the existence of a natural variation of tph2 mRNA 
expression over a 24-hour period, but how is this related to the circadian expression 
of CORT? Is there a relationship between circulating CORT levels and tph2 mRNA 
expression levels? Can circulating CORT levels modify tph2 mRNA expression 
levels in all the Raphe complex? If we modify the natural circadian activity of 
circulating CORT, will tph2 mRNA expression circadian activity change too? In 
the following chapters, I will present data from experiment models where I have 
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Chapter 4 Effect of the long-acting synthetic 
glucocorticoid Methylprednisolone on the circadian 
expression profile of tph2 mRNA expression in the Dorsal 
and Median Raphe nuclei. 
4.1 Introduction  
 
4.2 Methods: Experimental Design  
4.2.1 Study design to assess the rhythm of CORT and tph2 mRNA expression 
after methylprednisolone (MPL) treatment.  
4.2.2 Statistical analysis  
 
4.3 Results  
4.3.1 Circadian rhythm of circulating Corticosterone after MPL treatment.  
4.3.2 Circadian rhythmicity of tph2 mRNA expression in the Raphe complex 
after MPL treatment.  
4.3.3 Circadian changes in tph2 mRNA expression in subregions of the Dorsal 
Raphe and the MnR nucleus after MPL treatment.  
4.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR subregions and 
MnR nucleus; analysis across the full rostro-caudal gradient.  
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4.1 Introduction  
Synthetic glucocorticoids (sGCs) are widely used in clinical practice for the 
treatment of inflammatory and immune diseases. In fact, 1% of the adult UK 
population are currently being prescribed oral glucocorticoid treatment (Van Staa 
et al., 2001). Although GCs are a strong therapeutic option because of their potent 
anti-inflammatory and immunosuppressant properties (Keller-Wood and Dallman, 
1984; Gupta and Bhatia, 2008; Paragliola et al., 2017), their long-term use has been 
associated with numerous side effects (Brown and Chandler, 2001). While the 
adverse metabolic side effects of long-term GC use have been widely researched, a 
current area of research, that is of and of crucial interest to this study, is the less 
well-understood neuropsychiatric side effects. In particular, 23% of patients report 
mania during early treatment (Naber, Sand and Heigl, 1996), while depression is 
reported by 28% of patients during chronic treatment (Sirois, 2003). Anxiety is 
reported in 60% of patients (Bolanos et al., 2004), while suicidal ideation is less 
common but still reported in 17.3% of patients (Bräunig, Bleistein and Rao, 1989). 
Notably for my research interests, the sGC methylprednisolone (MPL) is far more 
long-acting than endogenous GCs. In vivo, MPL half-life is 2 to 4 hrs (Uhl et al., 
2002) which is considerably longer than cortisol (half-life of 60 min) (Weitzman et 
al., 1971) or corticosterone (half-life of 15 min) (Sainio, Lehtola and Roininen, 
1988). At higher doses, MPL can gain access to the brain (Earl et al., 2017; Stubbs 
et al., 2018) by saturating the MDR efflux transporter p-glycoprotein (Meijer et al., 
2001). Then, MPL distributes into target cells where it binds and activates the 
intracellular glucocorticoid receptor (GR). Furthermore, MPL causes prolonged GR 
activation in cell lines (Stavreva et al., 2009) and in-vivo (Earl et al., 2017). 
A relationship between altered activity of GCs and mood disorders has long been 
suggested. As early as 1952, Brody proposed that psychiatric disorders are an 
extreme response to stress (Brody, 1952). Plotsky et. al, showed that patients with 
depression have high levels of stress hormone (Plotsky, Owens and Nemeroff, 
1998), and an abnormal pulsatility of cortisol has been described in these patients 
(Deuschle, Schweiger, Weber, Gotthardt, K??rner, et al., 1997; Young, Carlson and 
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Brown, 2001). Depression and anxiety disorders also have a strong relationship 
with the dysfunction of serotonergic systems (Owens and Nemeroff, 1994; Lowry 
et al., 2008c). Moreover, recent studies suggest that tph2 may be a genetic predictor 
for depression or anxiety (P Zill et al., 2004; Peters et al., 2004; Haghighi et al., 
2008). Tph2 genetic variations have also been associated with major depression 
(Van Den Bogaert et al., 2006), further to this, tph2 variations in regulatory regions 
have been shown to modulate transcriptionally and post-transcriptionally gene 
expression, while variations in coding regions change amino acid sequence, hence 
function of gene product (Knight, 2005; Wang et al., 2005; Pastinen, Ge and 
Hudson, 2006; Chen and Miller, 2008). Finally, intronic variations may also affect 
mRNA splicing and gene expression (Chen and Miller, 2012).  
Moreover, a relationship between GC activity and the tph2 mRNA expression 
profile has been suggested. Many studies have demonstrated that the tph2 mRNA 
expression profile is modulated by GCs and tph2 expression changes after stressful 
events (McEwen, 1998; Brown, Henderson and Keay, 2006; Katherine L. Gardner 
et al., 2009). Notably, the removal of circulating GCs by surgical adrenalectomy, 
produces a disrupted tph2 mRNA expression profile (Clark and Russo, 1997; 
Malek, 2007; Donner, Montoya, et al., 2012). Clearly, a lot of research has focused 
on the understanding of serotonergic systems and their involvement in psychiatric 
disorders in one part, and GCs and psychiatric disorders in the other. However, the 
possible association between GCs, tph2 gene (as an important modulator of 5-HT 
(Brommage et al., 2015), hence, of pathophysiological and pharmacological 
relevance) and psychiatric disorders as a common triad has not been well described. 
Therefore, in this study, we have tested whether sub-chronic treatment with the 
long-acting sGC MPL dysregulates the circadian expression profile of tph2 mRNA 
in the DR and MnR, providing a potential mechanism underlying neuropsychiatric 
side effects reported by patients. 
The experimental model used is a sub-chronic treatment regime of four days with 
1mg/mL MPL provided ad libitum in drinking water, which acts to effectively 1) 
suppress endogenous CORT, and 2) replace the endogenous circadian and ultradian 
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pattern of circulating CORT with the long-acting sGC MPL. The model will be 
used to assess the changes in the tph2 mRNA expression profile in the complete 
Raphe complex, in each subregion of the DR and the MnR nucleus and throughout 
the extended rostro-caudal gradient of each subregion of the DR and the MnR 
nucleus. 
4.2 Methods: Experimental Design  
4.2.1 Study design to assess the rhythm of CORT and tph2 mRNA 
expression after methylprednisolone (MPL) treatment.  
After arrival, 40 adult male Sprague Dawley (SD) rats (weighing between 250-300 
g) were separated into 5 groups and housed 4 per cage in sound proof rooms for 7 
days to habituate to the facility. All animals were maintained under a 12/12 light-
dark cycle (lights on at 0700 h) with food and water ad libitum. From day 3 to day 
7, all animals were handled for 10 minutes at different times of day to avoid stress 
on the day of the experiment. 
From day 5 to day 8, all animals were submitted to 4 days of MPL treatment in their 
drinking water (1g/L), a dose which was previously shown to be the minimum dose 
to suppress CORT secretion (Spiga, Waite, et al., 2011) as well as activate GRs 
within the brain (Earl et al., 2017). During the fourth day of treatment, all animals 
were euthanized with an overdose of isoflurane (schedule 1 procedure) and 
decapitated with a guillotine at defined time points over the 24-hour cycle; 3 am, 9 
am, 3 pm, 6 pm, 9 pm (n= 8 per time point) in order to collect samples. Animals 
were killed starting 25 minutes before the appointed hour and finishing 25 minutes 
past the hour. Trunk blood and whole brains were collected. 




Figure 4-1: Experimental design for the assessment of the altered rhythm of CORT and tph2 
mRNA expression after MPL treatment.  
4.2.2 Statistical analysis  
1. One-way ANOVA was performed for the CORT data to assess for an effect 
of time after MPL treatment. When an effect of time was 
found, Dunnet’s post-test was used to compare each time point to the 9am 
nadir. Furthermore, a two-way ANOVA with a Tukey HSD post-test was 
performed to compare between controls and MPL treated groups.  
 
2. When analysing the whole Raphe complex, the same statistical tests used for 
the CORT analysis were used to enable a direct comparison between the 
rhythm of tph2 mRNA expression and the rhythm of CORT. A one-way 
ANOVA with a Dunnett’s (2-sided) post-test was also performed, however 
3 am (nadir) was here considered as the control group. Additionally, a two-
way ANOVA with a Tukey HSD post-test was performed to compare 
between treatment groups. This fitted with previous statistical tests 
performed in chapter 3. 
 
3. Finally, in all the more detailed (subregional and rostro-caudal analysis) 
overall and secondary LMMs were performed as in chapter 3 and 4, followed 
by Fisher’s Least Significant Difference (LSD) multiple comparison post-
tests when a time effect was found. Two different overall LLMs were 
performed to 1) assess the effect of time in the rostro-caudal gradient of each 
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subregion and 2) the effect of MPL treatment in the rostro-caudal gradient 
of each subregion.  
 
4. The CTRL vs MPL comparisons made throughout this chapter were done 
with the data of our control groups from chapter 3. All the MPL experimental 
groups were independent from our control groups. This is further discussed 
in limitations.  
4.3 Results 
4.3.1 Circadian rhythm of circulating Corticosterone after MPL 
treatment.  
The circulating CORT profile of animals after 4 days of 1g/L MPL treatment in 
drinking water is shown in Figure 4 -2. All time points showed particularly low 
levels of CORT. This dose has previously been shown to suppress CORT secretion 
in SD rats (Spiga, et. al, 2011) therefore the data obtained from the MPL treated 
group showed the treatment worked as expected. 
 




Figure 4-2: Circadian suppression of circulating CORT of MPL treated animals. CORT levels 
were measured in plasma obtained from trunk blood of control animals at 5 different 
timepoints; 3 am, 9 am, 3 pm, 6 pm and 9 pm (n=8/group/timepoint). CORT levels are 
expressed as ng/ml. Data is presented as Mean ± SEM of CORT. One-way ANOVA was 
performed to assess effect of time; F (4, 35) = 0.537, p> 0.05.  
A one-way ANOVA was performed to determine if there was a significant effect 
of time after MPL treatment. There was no statistically significant difference 
between groups, F (4, 35) = 0.537, p> 0.05, indicating that the circadian rhythm of 
circulating CORT was ablated (Figure 4-2). 
When comparing the control group with the MPL treated group (Figure 4 - 3), a 
two-way ANOVA was performed to additionally determine that there was a 
significant interaction between timepoint and treatment (F (4, 70) =26.752) p< 0.001, 
which was assessed further with a Tukey HSD test. As expected, no significant 
differences were found at 3 am or 9 am, which may have been expected given that 
endogenous CORT levels of the control animals are low during those time points. 
However, at the circadian CORT peak times of 3 pm, 6 pm and 9 pm, the MPL 
treated group had significant lower CORT levels than control animals. Again, this 
is consistent with adrenal CORT suppression, indicating the loss of circadian and 
ultradian HPA axis activity. 




Figure 4-3: Circadian changes in circulating CORT of Control versus MPL treated animals. 
CORT levels were measured in plasma obtained from trunk blood of two different groups 
(Control or MPL treated animals) at 5 different timepoints; 3 am, 9 am, 3 pm, 6 pm and 9 pm 
(n=8/group/timepoint). CORT levels are expressed as ng/ml in the y axis. Data is presented as 
MEAN ± SEM of CORT for each group. Two-way ANOVA was performed to assess effect of 
treatment; (F (4, 70) =26.752) p< 0.001. Additionally, a Tukey HSD test was included; *** p< 
0.001 when comparing CTRL vs MPL at 3 pm and 6 pm; ** p<.01 when comparing CTRL vs 
MPL at 9 pm.   
4.3.2 Circadian rhythmicity of tph2 mRNA expression in the 
Raphe complex after MPL treatment.  
As mentioned in the introduction, this study consisted of evaluating the effect of 
the sGC MPL on 1) the activity pattern of tph2 mRNA expression in all the 
subregions of the DR and the MnR nucleus throughout a 24-hour period and 2) the 
changes (if any) in this activity pattern when compared to the natural variation of 
expression.  
First, in order to assess if there was a circadian pattern of tph2 mRNA expression 
after MPL treatment, I analysed the overall averaged tph2 mRNA expression across 
all rostro-caudal levels and all subregions together (Figure 4- 4). This analysis 
showed that tph2 mRNA expression no longer exhibited the natural pronounced 
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circadian rhythm, appearing fairly ‘flattened’ after MPL treatment.  However, there 
was a statistically significant effect of time of day F (4, 2024) =5.881, p< 0.001) by 
one-way ANOVA. Therefore, the Dunnett’s post hoc test was performed to 
compare the mean of every group against the new observed nadir (3 am group.  A 
significant difference was found when comparing to 9 am (p<0.05), 9 pm (p<0.05) 
and to the new 6 pm peak (p<0.001) in expression.  
 
Figure 4-4: Circadian variation in Tph2 mRNA expression in the DR and MnR complex of MPL 
treated animals. All measurements of tph2 mRNA expression of all levels of the DR and MnR 
complex were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA 
expression for each group/timepoint (n=8/group). One-way ANOVA was performed to assess 
effect of time; (F(4, 2024)=5.881, p< 0.001). Additionally, Dunnett’s (2-sided) post hoc test was 
performed; *** p< 0.001 at 6pm, *p< 0.05 at 9 am and *p< 0.05 at 9 pm when compared to 
the 9 am group. 
I next assessed the circadian tph2 mRNA expression pattern after MPL treatment 
compared to the control dataset (Figure 4-5). This analysis showed clear 
modifications in the pattern of tph2 mRNA expression after MPL treatment. 
Notable differences were seen after the MPL treatment, as the peak expression of 
tph2 mRNA changed from 3 pm to 6 pm and the nadir from 9 am to 3 am. 
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The visual observations were supported by two-way ANOVA, which showed a 
significant interaction between timepoint and treatment reported F(4, 3901)=6.572, p< 
0.001. Tukey HSD test showed that the MPL group had a significant reduction in 
tph2 mRNA expression at 3 am and 3 pm compared to the control group, p< 0.05, 
p<0.01 respectively, and a significant increase at 9 am, p<0.01.  
 
Figure 4-5: Circadian variation in Tph2 mRNA expression in the DR and MnR complex of 
control vs MPL treated animals. All measurements of tph2 mRNA expression of all levels of the 
DR and MnR complex were averaged for each timepoint of each group; 3 am, 9 am, 3 pm, 6 
pm and 9 pm (x axis). Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value 
multiplied by its own Measured Area (y axis). Data points correspond to overall MEAN ± SEM 
of tph2 mRNA expression for each group/timepoint (n=8/group). A two-way ANOVA was 
performed to assess effect of treatment; (F(4, 3901)=6.572, p< 0.001).  Additionally, a Tukey HSD 
post hoc test was performed; **p< 0.01 at 9 am ad 3 pm when comparing CTRL vs MPL and 
*p< 0.05 at 3 am when comparing CTRL vs MPL. 
4.3.3 Circadian changes in tph2 mRNA expression in subregions of 
the Dorsal Raphe and the MnR nucleus after MPL 
treatment.  
As in the previous chapter, in order to assess the overall effects of time (circadian 
pattern) in tph2 mRNA in each of the anatomical and functional distinct subregions 
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of the DR and the MnR nucleus after MPL treatment, I analysed the averaged 
mRNA expression across all the rostro-caudal levels for each subregion separately. 
I also separately evaluated the two well defined antero-posterior divisions of the 
Raphe complex. Thus, rostral and caudal levels were assessed for the three 
subregions of the DR which span rostro-caudally (DRD, DRV and DRVL/VLPAG) 
as well as the MnR.  
Additionally, in order to describe the overall effect of MPL treatment and the 
changes in the circadian pattern of tph2 mRNA expression I compared the global 
MEAN ± SEM of tph2 mRNA expression from the control group (natural 
conditions) versus the MPL group for each of the distinct subregions of the DR and 
the MnR nucleus, including the two well-defined rostral and caudal groups of the 
DRD, DRV, DRVL/VLPAG and the MnR nucleus.   
Circadian variations in tph2 mRNA expression could be detected in some, but not 
all, of the DR subregions and the MnR over a 24-hour period during sub-chronic 
MPL treatment. These variations were predominantly localized to the caudal part 
of each of the subregions. Moreover, MPL treatment changed the circadian pattern 
of tph2 mRNA expression, compared to controls, in many of the regions analysed. 
4.3.3.1 Dorsal Raphe nucleus, caudal part (DRC).  
A one-way ANOVA was performed to determine if there were any variation across 
the times 3 am, 9 am, 3 pm, 6 pm and 9 pm, which would indicate a circadian 
variation of tph2 mRNA expression in the DRC after MPL treatment (Figure 4 - 6). 
Despite a trend towards a peak at 6pm and a nadir at 3am, there was no statistically 
significant effect of time (F (4, 135) =1.727) p> 0.05. Therefore, tph2 mRNA 
expression within the DRC does not appear to display a significant circadian 
variation. 




Figure 4-6: Circadian variation in tph2 mRNA expression in the DRC of MPL treated animals. 
Measurements of tph2 mRNA expression of the five levels of the DRC (-8.336 to -8.672 mm 
bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA 
expression in the DRC for each group/timepoint (n 8/ group [  8 animals x 5 levels =  40 
values]). One-way ANOVA was performed to assess effect of time; (F (4, 135) =1.727) p> 0.05. 
Furthermore, a two-way ANOVA was performed to determine that there was no 
significant interaction between timepoint and treatment in the DRC (Figure 4 - 7); 
(F (4, 253) =1.192) p> 0.05.  This result might have been expected based upon the 
lack of circadian variation in the control group. 




Figure 4-7: Changes in circadian variation of tph2 mRNA expression in the DRC of Control 
versus MPL treated animals. Measurements of tph2 mRNA expression of the five levels of the 
DRC (-8.336 to -8.672 mm bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm 
and 9 pm (x axis) for each group separately (CTRL or MPL). Tph2 mRNA quantification is 
expressed as Calibrated Mean Grey Value multiplied by its own Measured Area (y axis). Data 
points correspond to overall MEAN ± SEM of tph2 mRNA expression in the DRC for each 
group/timepoint (CTRL or MPL [n 8/ group [  8 animals x 5 levels =  40 values]). Two-
way ANOVA was performed to assess effect of treatment: (F (4, 253) =1.192) p> 0.05. 
4.3.3.2 Dorsal Raphe nucleus, interfascicular part (DRI). 
A one-way ANOVA was performed to determine if there were any differences 
between timepoints; 3 am, 9 am, 3 pm, 6 pm and 9 pm, which would indicate a 
circadian variation of tph2 mRNA expression in the DRI (Figure 4 - 8). However, 
there was no statistically significant effect of time (F (4,97) =0.667) p> 0.05, 
indicating a lack of significant circadian variation in tph2 mRNA expression in the 
DRI after MPL treatment.  
 




Figure 4-8: Circadian variation in tph2 mRNA expression in DRI of MPL treated animals. 
Measurements of tph2 mRNA expression of the four levels of the DRI (-8.420 to -8.672 mm 
bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA in the 
DRI for each group/timepoint (n 8/ group [  8 animals x 4 levels =  32 values]). One-way 
ANOVA was performed to assess effect of time; (F (4,97) =0.667) p> 0.05. 
Additionally, tph2 mRNA expression after MPL treatment behaved very similarly 
to the control groups throughout the 5 time points (Figure 4 - 9). A two-way 
ANOVA showed no significant interaction between timepoint and treatment in the 
DRI; (F (4, 174) =.162) p> 0.05. Therefore, tph2 mRNA did not appear to exhibit a 
significant circadian pattern within the DRI subregion under natural conditions nor 
after MPL treatment. 
  





Figure 4-9: Changes in circadian variation of tph2 mRNA expression in the DRI of Control 
versus MPL treated animals. Measurements of Tph2 mRNA expression of the four levels of the 
DRI (-8.420 to -8.672 mm bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm 
and 9 pm (x axis) for each group separately (CTRL or MPL). Tph2 mRNA quantification is 
expressed as Calibrated Mean Grey Value multiplied by its own Measured Area (y axis). Data 
points correspond to overall MEAN ± SEM of tph2 mRNA expression in the DRI for each 
group/timepoint (CTRL or MPL [n 8/ group [  8 animals x 4 levels =  32 values]).  A Two-
way ANOVA was performed to assess effect of treatment: (F (4, 174) =.162) p> 0.05. 
4.3.3.3 Dorsal Raphe nucleus, dorsal part (DRD) 
For the DRD, to determine if there is a circadian variation of tph2 mRNA 
expression after MPL treatment throughout the 24-hour period, three different one-
way ANOVA’s were completed for the whole, rostral and caudal DRD which 
compared between timepoints/groups; 3 am, 9 am, 3 pm, 6 pm and 9 pm. 
For the whole DRD (Figure 4 - 10A), there was a statistically significant effect of 
treatment; (F (4, 414) =3.132), p< 0.01. LSD post-tests were performed showing 
various statistically significant differences. The highest tph2 mRNA expression was 
found at 6 pm which was significantly increased when compared to the 3 am (p< 
0.01), 3 pm (p< 0.05), and 9 pm (p< 0.05) groups. Considering that 3 am had the 
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lowest tph2 mRNA expression, 9 am was also significantly different from this time 
point, p < 0.05. 
There was a distinct lack of circadian rhythm visible in the rostral DRD (Figure 4 - 
10B), and no significant effect of time detected by one-way ANOVA, F (4, 272) 
=1.426) p> 0.05. However, there was a robust circadian pattern in the caudal DRD 
(Figure 4 -10C), and a significant effect of time detected by one-way ANOVA (F 
(4, 174) =3.428), p< 0.01. Again, several significant differences were found with the 
Fishers LSD post-tests. Interestingly, exactly the same differences were found as in 
the whole DRI (the highest tph2 mRNA expression was found at 6 pm) and this 6 
pm time point had statistically increased tph2 mRNA expression when compared 
to the 3 am (p< 0.01), 3 pm (p< 0.05), and 9 pm (p< 0.05). Likewise, when 
considering the nadir of tph2 mRNA expression at 3 am, this was significantly 
different from the 9 am time point, p< 0.05. Therefore, it appears that tph2 mRNA 
expression within the DRD displays a circadian variation after MPL treatment. 
Further, the variation is localised to the caudal bregma levels of this area. 
 
 




Figure 4-10: Circadian variation in tph2 mRNA expression in the DRD of MPL treated animals.  
For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements of tph2 mRNA 
expression (y axis) were averaged; (A) twelve levels (-7.328 to -8.252 mm bregma) for the 
whole DRD, (B) eight levels (-7.328 to -7.916 mm bregma) for the rostral DRD and (C) 5 levels 
(-7.916 to -8.252 mm bregma) for the caudal DRD. Tph2 mRNA quantification is expressed as 
Calibrated Mean Grey Value multiplied by its own Measured Area. Data points correspond to 
overall MEAN ± SEM of tph2 expression of the whole/rostral/caudal DRD for each 
group/timepoint (n 8/group [  8 animals x  12/8/5 levels =  96/64/40 values]). One-way 
ANOVAs were performed to assess effect of time: (A) (F (4, 414) =3.132) p< 0.01; ** p< 0.01 for 
3 am vs 6 pm, * p< 0.05 for 3 am vs 9 am, for 3 pm vs 6 pm and for 6 pm vs 9 pm; (B) F (4, 272) 
=1.426) p> 0.05; (C) (F (4, 174) =3.428) p< 0.01; **p< 0.01 for 3 am vs 6 pm, *p< 0.05 for 3 
am vs 9 am, for 3 pm vs 6 pm  and for 6 pm vs 9 pm with Fisher’s Least Significant Difference 
test.  
Next, I assessed the tph2 mRNA expression pattern within the whole DRD 
compared to the control pattern (Figure 4 - 11A).  The peak in expression is seen at 
6pm in both controls and treated. However, the 9am nadir appears to be elevated in 
the MPL group. A significant interaction between timepoint and treatment was 
detected (F (4, 860) =2.799) p< 0.05, so post-tests were run. Interestingly, the only 
statistically significant difference was found at 9 am, where the MPL group was 
significantly elevated compared to the control group, p< 0.05.  
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Similarly, for the rostral DRD (Figure 4 - 11B) there was an elevation at 9am in the 
MPL group compared to controls. As a significant interaction detected (F (4, 571) 
=2.236) p< 0.05, post-tests were performed to show that the increased tph2 mRNA 
expression in the MPL group at 9am was statistically significant, p< 0.05.  
For the caudal DRD (Figure 4 -11C), the two-way ANOVA again showed a 
significant interaction; (F (4, 354) =2.890) p< 0.01. Like in the rostral DRD, a 
significantly higher tph2 mRNA expression was found at 9 am in the MPL group 
compared to the control group, p< 0.05. Interestingly, there was also a significantly 
increased tph2 mRNA expression at 6 pm in the MPL group compared to the control 
group, p< 0.05.  
Therefore, it appears that the tph2 mRNA expression profile within the DRD 
subregion is significantly altered with MPL treatment, with an increase in 9 am 
nadir levels throughout the whole DRD. However, the apparent MPL-dependent 
‘shift’ in peak expression from 3pm to 6pm is localised to the caudal DRD.  
 
 




Figure 4-11:  Changes in circadian variation of tph2 mRNA expression in the DRD of Control 
vs MPL treated animals.  For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or MPL); (A) twelve levels (-7.328 to -8.252 mm bregma) for the whole DRD, (B) eight 
levels (-7.328 to -7.916 mm bregma) for the rostral DRD and (C) 5 levels (-7.916 to -8.252 mm 
bregma) for the caudal DRD. Tph2 mRNA quantification is expressed as Calibrated Mean Grey 
Value multiplied by its own Measured Area. Data points correspond to overall MEAN ± SEM 
of tph2 mRNA expression of the whole/rostral/caudal DRD for each group/timepoint (CTRL vs 
MPL [n 8/group [  8 animals x  12/8/5 levels =  96/64/40 values]). Two-way ANOVAs 
were performed to assess effect of treatment; (A) (F (4, 860) =2.799) p< 0.05; * p< 0.05 when 
comparing CTRL vs MPL at 9 am;  (B) (F (4, 571) =2.236) p< 0.05; * p< 0.05 when comparing 
CTRL vs MPL at 9 am; (C) (F (4, 354) =2.890) p< 0.01;*p< 0.05 when comparing CTRL vs MPL 
at 9 am and 6 pm with Fisher’s Least Significant Difference test. 
4.3.3.4 Dorsal Raphe nucleus, ventral part (DRV).  
Tph2 mRNA expression within the DRV subregion appears to exhibit very little 
circadian variation across the 24-hour period after MPL treatment (Figure 4-12). 
There was no significant effect of time detected by one-way ANOVA in the whole 
DRV (Figure 4-12A); (F (4, 485) =1.2862) p> 0.05, the rostral DRV (Figure 4-12B), 
(F (4, 272) =0.555) p> 0.05 or the caudal DRV (Figure 4-12C), F (4, 244) =2.178) p> 
0.05. 




Figure 4-12: Circadian variation in tph2 mRNA expression in the DRV of MPL treated animals. 
For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements of tph2 mRNA 
expression (y axis) were averaged; (A) fourteen levels (-7.328 to -8.420 mm bregma) for the 
whole DRV, (B) eight levels (-7.328 to -7.916 mm bregma) and (C) seven levels (-7.916 to -
8.420 mm bregma) for the caudal DRV. Tph2 mRNA quantification is expressed as Calibrated 
Mean Grey Value multiplied by its own Measured Area. Data points correspond to the overall 
MEAN ± SEM of th2 expression of the whole/rostral/caudal DRV for each group/timepoint (n 
8/group [ 8 animals x 14/8/7 levels =  112/64/56 values]). One-way ANOVAs were 
performed to assess effect of time; (A) (F (4, 485) =1.2862) p> 0.05; (B) (F (4, 272) =0.555) p> 
0.05; (C) (F (4, 244) =2.178) p> 0.05. 
Additionally, to visualise how the modified pattern in tph2 mRNA expression after 
MPL treatment compared to the control pattern, the data was plotted together 
(Figure 4-13). Again, the differences were more pronounced in the caudal DRV 
(Figure 4-13C), where it appears that the lack of circadian rhythm in the MPL group 
is due to elevated expression at the 9am nadir, and decreased expression at the 3pm 
peak. These differences are less pronounced in the whole DRV (Figure 4-13A), and 
minimal in the rostral DRV (Figure 4-13B).  
For the whole and rostral regions of the DRV, two-way ANOVAs showed no 
interaction; (F (4, 1009) =1.635) p> 0.05 and (F (4, 574) =.240) p> 0.05 respectively. A 
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significant interaction between timepoint and treatment was found for the caudal 
DRV; F (4, 500) =4.393) p< 0.01 so post tests were then used to detect significant 
differences between MPL and control at 9 am p<0.05, and at 3 pm p< 0.001.  
Thus, MPL treatment has quite profoundly changed the circadian variation in tph2 
mRNA expression profile. Furthermore, these changes seem to be specific to the 
caudal levels, where a convincing decrease in expression at 3 pm and an increase 
at 9 am results in a loss of circadian rhythmicity. 
 
Figure 4-13: Changes in circadian variation of tph2 mRNA expression in the DRV of Control 
vs MPL treated animals. For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or MPL); (A) fourteen levels (-7.328 to -8.420 mm bregma) for the whole DRV, (B) eight 
levels (-7.328 to -7.916 mm bregma) and (C) seven levels (-7.916 to -8.420 mm bregma) for the 
caudal DRV.  Tph2 mRNA quantification is expressed as Corrected Mean Grey Value 
multiplied by its own Measured Area (y axis). Data points correspond to the overall MEAN ± 
SEM of th2 expression of the whole/rostral/caudal DRV for each group/timepoint (CTRL vs 
MPL [n 8/group [ 8 animals x 14/8/7 levels =  112/64/56 values]). Two-way ANOVAs were 
performed to assess effect of treatment; (A) (F (4, 1009) =1.635) p> 0.05; (B) (F (4, 574) =.240) p> 
0.05; (C) (F (4, 500) =4.393) p< 0.01; **p< 0.01 when comparing CTRL vs MPL at 3 pm and 
*p<0.05 when comparing CTRL vs MPL at 9 am with Fisher’s Least Significant Difference 
test. 
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4.3.3.5 Dorsal raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal grey (DRVL/VLPAG) 
The DRVL/VLPAG has an interesting tph2 mRNA expression profile after MPL 
treatment, with a nadir at 3 am and two peaks at 9 am and 6 pm (Figure 4-14). This 
pattern appears to be maintained across both the rostral (Figure 4-14B) and caudal 
(Figure 4-14C) DRVL/VLPAG. One-way ANOVAs revealed a statistically 
significant effect of time for the whole DRVL/VLPAG (F (4, 282) =2.582) p< 0.05), 
as well as for the rostral (F (4, 105) =2.547) p< 0.01) and caudal (F (4, 209) =4.174) p< 
0.01) subregions. Post tests revealed that the difference between the nadir at 3 am 
and the peak at 9 am was significant (p<0.01) in the whole, rostral and caudal 
DRVL/VLPAG. The difference between the nadir at 3 am and the peak at 6 pm was 
also found to be significant in the whole (p<0.01), rostral (p<0.05) and caudal 
(p<0.01) parts of the DRVL/VLPAG.  
 
Figure 4-14: Circadian variation in tph2 mRNA expression profile in the DRVL/VLPAG of 
MPL treated animals. For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) 
measurements of Tph2 mRNA expression ( y axis) were averaged; (A) eight levels (-7.748 to -
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8.336 mm bregma) for the whole DRVL/VLPAG, (B) three levels (-7.748 to -7.916 mm bregma) 
for the rostral DRVL/VLPAG and (C) six levels (-7.916 to -8.336 mm bregma) for the caudal 
DRVL/VLPAG.Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value 
multiplied by its own Measured Area. Data points correspond to the overall MEAN ± SEM of 
tph2 expression of the whole/rostral/caudal DRVL/VLPAG for each group/timepoint (n 
8/group [  8 animals x 8/3/6 levels =  64/24/48 values]). One-way ANOVAs were performed 
to assess effect of time; (A) (F (4, 282) =2.582) p< 0.05; **p< 0.01 for 3 am vs 9 am and for 3 
am vs 6 pm; (B)  (F (4, 105) =2.547) p< 0.01; **p< 0.01 for 3 am vs 9 am and *p< 0.05 for 3am 
vs 6 pm; (C) (F (4, 209) =4.174) p< 0.01; **p< 0.001 for 3 am vs 9 am and for 3 am vs 6 pm with 
Fisher’s Least Significant Difference test. 
Next, I plotted the data from Figure 4 - 14 together with the control data from whole, 
rostral and caudal DRVL/VLPAG to assess how the pattern of DRVL/VLPAG tph2 
mRNA expression has changed after MPL treatment compared to the natural 
circadian rhythm (Figure 4-15).  
Figure 4-15A shows how the temporal tph2 mRNA expression pattern in the whole 
DRVL/VLPAG has changed from the characteristic circadian pattern in the control 
dataset, with nadir at 9 am and peak at 3 pm, to a dysregulated profile with nadir at 
3am and peaks at 9 am and 6 pm. A significant interaction between timepoint and 
treatment was observed (F (4, 579) =3.347) p< 0.01, and post-tests show that the 
significant differences were found at 9 am when control levels were low and MPL 
treated levels were high (p< 0.05) and 3 pm when control levels were high and MPL 
levels were low (p< 0.05). 
For the rostral DRVL/VLPAG (Figure 4 - 15B), MPL treatment resulted in a 
relative reduction of tph2 mRNA across all timepoints except for the 9 am, when 
the control levels are at a natural nadir. The visual observation was supported by 
two-way ANOVA, which detected a significant interaction (F (4, 217) =2.890) p< 
0.05. Further, post tests revealed significant differences at 3 am (p<0.01) and 3 pm 
(p< 0.01).  
Interestingly, the caudal DRVL/VLPAG (Figure 4-15C) followed a very similar 
pattern to the whole DRVL/VLPAG, with a distinctive temporal dysregulation 
observed. Supporting the observed change with MPL treatment, a significant 
interaction was detected by two-way ANOVA (F (4, 428) =4.809) p< 0.01. Similar to 
the whole DRVL/VLPAG, the higher tph2 mRNA expression for the MPL treated 
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group 9 am, was significantly different (p <0.01). Additionally, in this caudal 
analysis, the small difference found at 3 am is significant (p< 0.05). 
 
Figure 4-15: Changes in circadian variation of tph2 mRNA expression in the DRVL/VLPAG of 
Control vs MPL treated animals.  For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or MPL); (A) eight levels (-7.748 to -8.336 mm bregma) for the whole DRVL/VLPAG, 
(B) three levels (-7.748 to -7.916 mm bregma) for the rostral DRVL/VLPAG and (C) six levels 
(-7.916 to -8.336 mm bregma) for the caudal DRVL/VLPAG. Tph2 mRNA quantification is 
expressed as Calibrated Mean Grey Value multiplied by its own Measured Area. Data points 
correspond to the overall MEAN ± SEM of tph2 mRNA expression of the whole/rostral/caudal 
DRVL/VLPAG for each group/timepoint (CTRL vs MPL [n 8/group [  8 animals x 8/3/6 
levels =  64/24/48 values]).Two-way ANOVAs were performed to assess effect of treatment; 
(A) (F (4, 579) =3.347) p< 0.01; * p< 0.05 when comparing CTRL vs MPL at 9 am and 3 pm;  
(B) (F (4, 217) =2.890) p< 0.05; ** p< 0.01 when comparing CTRL vs MPL at 3 am and 3 pm; 
(C) (F (4, 428) =4.809) p< 0.01;**p< 0.01 when comparing CTRL vs MPL at 9 am and  *p< 0.05 
when comping CTRL vs MPL at 3 am with Fisher’s Least Significant Difference test. 
4.3.3.6 Median Raphe nucleus (MnR). 
The MnR tph2 mRNA expression profile exhibited a strong circadian variation 
during MPL treatment (Figure 4 - 16). One-way ANOVAs revealed a statistically 
significant effect of time for the whole (F (4, 492) = 3.224) p< 0.05), rostral (F (4, 213) 
   Chapter 4 
130 
 
=3.369) p< 0.05) and caudal (F (4, 311) =2.768) p< 0.05) MnR.  A robust peak at 6 
pm was seen in the whole MnR, where it was significantly different to the relatively 
flat levels at 3 am, 9 am and 3 pm as indicated in Figure 4-16A. The 6pm peak was 
also significantly different to 9 am and 3 pm in the rostral MnR as indicated in 
Figure 4-16B, and to the nadir times of 3 am and 3 pm in the caudal MnR as 
indicated in Figure 4-16C.  Interestingly, the 9 am nadir was only seen in the rostral 
MnR.  In the caudal MnR by contrast, the 9 am tph2 mRNA expression was nearly 
as high as 6 pm. 
 
Figure 4-16: Circadian variation in tph2 mRNA expression in the MnR of MPL treated animals.  
For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) measurements of tph2 mRNA 
expression (y axis) were averaged; (A) fifteen levels (-7.496 to -8.672 mm bregma) for the whole 
MnR, (B) six levels (-7.494 to -7.916 mm bregma) for the rostral MnR and (C) 10 levels (-7.916 
to 8.672 mm bregma) for the caudal MnR. Tph2 mRNA quantification is expressed as 
Calibrated Mean Grey Value multiplied by its own Measured Area. Data points correspond to 
the overall MEAN ± SEM of tph2 expression of the whole/rostral/caudal MnR for each 
group/timepoint (n 8/group [  8 animals x 15/6/10 levels =  120/48/80 values]). One-way 
ANOVAs were performed to assess effect of time; (A) (F (4, 492) =3.224) p< 0.05; **p< 0.01 for 
3 am vs 6 pm, and for 3 pm vs 6 pm, *p< 0.05 for 9 am vs 6 pm; (B (F (4, 213) =3.369) p< 0.05; 
**p< 0.01 for 9 am vs 6 pm, *p< 0.05 for 3 am vs 9 am, for 9 am vs 9 pm and for 3 pm vs 6 
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pm; (C) (F (4, 311) =2.768) p< 0.05; ** p< 0.01 for 3 am vs 6 pm and for 3 pm vs 6 pm with 
Fisher’s Least Significant Difference test. 
Then, in Figure 4-17, I assessed whether MPL treatment altered the circadian tph2 
mRNA expression profile in the whole, rostral and caudal MnR. A striking 
difference was seen in the whole MnR with MPL treatment, with an apparent shift 
in the peak expression time from 3 pm to 6 pm (Figure 4-17A). A significant 
interaction between treatment and time was detected by two-way ANOVA; (F (4, 
985) =3.252) p< 0.05 and post-tests showed a significant difference with MPL 
treatment at 3 pm, p< 0.01. The rostral MnR (Figure 4-17B), did not show a 
significant effect of time (F (4, 438) = 0.923) p> 0.05. However, a trend of high levels 
of tph2 mRNA expression after MPL Treatment can be seen at 3 am, 6 pm and 9 
pm. Lastly, and very interesting, the caudal MnR (Figure 4-17C) displayed a 
similar, yet stronger, pattern to that observed for the whole MnR. This pattern has 
a contrasting temporal difference within treatment group which is supported by a 
significant interaction reported by two-way ANOVA; F (4, 613) =5.553) p< 0.01.  Post 
test revealed that the lower levels of tph2 mRNA expression found in the MPL 
groups at 3 am and 6 pm are statistically different to their corresponding control 
groups, p<0.01 and p<0.001, respectively.  




Figure 4-17: Changes in circadian variation of tph2 mRNA expression in the MnR of Control 
vs MPL treated animals.  For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or MPL; (A) fifteen levels (-7.496 to -8.672 mm bregma) for the whole MnR, (B) six 
levels (-7.494 to -7.916 mm bregma) for the rostral MnR and (C) 10 levels (-7.916 to 8.672 mm 
bregma) for the caudal MnR. Tph2 mRNA quantification is expressed as Calibrated Mean Grey 
Value multiplied by its own Measured Area. Data points correspond to the overall MEAN ± 
SEM of tph2 mRNA expression of the whole/rostral/caudal MnR for each group/timepoint (n 
8/group [  8 animals x 15/6/10 levels =  120/48/80 values]). Two-way ANOVAs were 
performed to assess effect of treatment; (A) (F (4, 985) =3.252) p< 0.05; ** p< 0.01 when 
comparing CTRL vs MPL at 3 pm;  (B) (F (4, 438) = 0.923) p> 0.05; (C) (F (4, 613) =5.553) p< 
0.01; *** p< 0.001 when comparing CTRL vs MPL at 3 pm, ** p< 0.01 when comparing CTRL 
vs MPL at 3 am with Fisher’s Least Significant Difference test. 
4.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR 
subregions and MnR nucleus; analysis across the full rostro-
caudal gradient. 
In order to assess the effects of MPL treatment in the circadian activity of tph2 
mRNA expression throughout the rostro-caudal gradient of the DR subregions and 
the MnR nucleus, Linear Mixed Model (LMM) analyses were completed as 
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described in the methods chapter. Additionally, different LMM analysis were 
performed to compare the changes throughout the rostro-caudal gradient of the DR 
subregions and the MnR nucleus under natural conditions and after the MPL 
treatment. 
All LMM analyses were methodically finalized and only if there were significant 
differences in any main factor or interaction, then, Fisher’s Least Significant 
Difference test post hoc tests followed. All statistical tests were considered only if 
the sample size was above four animals (half the original sample size for each 
timepoint at each rostro-caudal level). 
Overall, we can again see in the full rostro-caudal gradient plots (Figures 4 -18 to 
4-29) that tph2 mRNA expression levels changed in a highly characteristic manner 
across the anterior to posterior axis of the DR and MnR. Furthermore, in these 
detailed analyses, we can start to readily visualise where the time-dependent and 
treatment-dependent changes are localised within each subregion, if at all. 
Analysis of the circadian tph2 mRNA expression profile after MPL treatment using 
the LMM analysis (Table 4 - 1), revealed a rostro-caudal level * time point 
interaction (F (63, 193.802)= 1.936, p<.0. 000), a rostro-caudal level (raphe subregion) 
interaction (F (36, 217.175) = 29.372, p< 0.000), a main effect of rostro-caudal level (F 
(16, 174.634) = 66.544, p < 0.000), a main effect of raphe subregion (F (5, 116,289) = 
78.887, p< 0.000) and a main effect of time point (F (4, 147.582) = 3.891, p< 0.000). 
Based on this first overall LMM analysis, secondary LMMs were used to determine 
changes in the circadian activity of tph2 mRNA expression after MPL treatment at 
each rostro-caudal level of all the subregions of the DR and in the MnR nucleus 
separately (Table 4 - 1). Additionally, changes across the rostro-caudal gradient at 
each time point were assessed, but for simplicity reasons, these changes are not 
represented in the Figures. 
 
 
   Chapter 4 
134 
 





Test statistic p-value 
Overall analysis for MPL   
Heterogeneous toeplitz covariance structure  
Akaike’s Information Criterion (AIC): 8076.794 
  
 Rostrocaudal level1 (1-17) F(16, 174.634) = 66.544 .000 *** 
 
Raphe subregion2 (DRC, DRI, DRD, DRV, 
DRVL/VLPAG, MnR) F(5, 116,289) = 78.887 
 
.000 *** 
 Time point3 (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 147.582) = 3.891 .005 ** 
 Rostrocaudal level * Time point F(63, 193.802)= 1.936 .000*** 
 Raphe subregion * Time point F(20, 116.431)= .349 .996 
 Rostrocaudal level (Raphe subregion) F(36, 217.175) = 29.372 .000 *** 
 
Rostrocaudal level * Time point (Raphe 
subregion) 







ARMA (1.1) covariance structure 
Akaike’s Information Criterion (AIC): 584.683 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 39.358)= .689 .604 
 Rostrocaudal level (13-17) F(4, 71.002)= 7.420 .000 *** 
  Time point * Rostrocaudal level F(16, 68.002)= .661 .821 
DRI 
Heterogeneous Compound Symmetry covariance 
structure 
Akaike’s Information Criterion (AIC): 387.937 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 23.121)= .706 .596 
 Rostrocaudal level (14-17) F(3, 14.873)= 64.337 .000 *** 
  Time point * Rostrocaudal level F(12, 15.469)= .848 .608 
DRD 
Unstructured covariance structure 
Akaike’s Information Criterion (AIC): 1747.826   
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 33.913)= 1.390 .258 
 Rostrocaudal level (1-12) F(11, 29.175)= 34.444 .000 *** 
  Time point * Rostrocaudal level F(43, 31.1000)= 1.766 .050* 
DRV 
Heterogeneous Toeplitz covariance structure 
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Akaike’s Information Criterion (AIC): 2203.095 
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 41.958)= 1.170 .338 
 Rostrocaudal level (1-14) F(13, 85.806)= 45.589 .000 *** 
  Time point * Rostrocaudal level F(51, 80.401)= 1.176 .254 
DRVL/VLPAG 
Heterogeneous toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 1227.890 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 23.978 )= 1.943 .136 
 Rostrocaudal level (6-13) F(7, 50.969)= 46.764 .000 *** 
  Time point * Rostrocaudal level F(28, 55.769)= 1.642 .050 * 
MnR 
Heterogeneous toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 1489.291 
 
  
  Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 31.202)= 1.429 .248 
 Rostrocaudal level (3-17) F(14, 59.923)= 18.527 .000 *** 
  Time point * Rostrocaudal level F(56, 61.674)= 1.730 .018 * 
1Rostrocaudal levels were well-defined from bregma levels given in the atlas; where most rostral 
level was -7.328 mm bregma (1 according to level code) progressing to the most caudal level at –
8.672 mm bregma (17 according to level code). Within this brain section 17 different and 
representative coronal sections of 12 µm were used to measure tph2 mRNA of the dorsal raphe 
nucleus and the median raphe nucleus. 2The Raphe subregions used in this research were the 
following: DRC, dorsal raphe nucleus, caudal part; DRI, dorsal raphe nucleus, interfascicular part; 
DRD, dorsal raphe nucleus, dorsal part; DRV, dorsal raphe nucleus, ventral part and 
DRVL/VLPAG, dorsal raphe nucleus, ventrolateral part/ventrolateral periaqueductal grey. MnR, 
median raphe nucleus was also included and considered as a subregion of the raphe complex. 3 The 
five different time points (3 am, 9 am, 3 pm, 6 pm, 9 pm) used in this study were considered as a 
suitable description of the circadian rhythm of tph2 mRNA expression. They were chosen to fit in 
parallel with the measured circadian rhythm of plasma CORT after MPL treatment. *p<0.05. 
**p<0.01. ***p<0.001. 
Another overall LMM analysis was performed to assess the changes in tph2 mRNA 
expression profile under natural conditions and after MPL treatment (Table 4.2). 
The analysis revealed a treatment * timepoint interaction (F (4, 409.745)  = 4.732, p< 
0.001), a treatment * rostro-caudal level interaction (F (16, 300.823)  = 5.733, p <0.000), 
a timepoint* rostro-caudal level interaction (F (64, 290.087)  = 2.022, p< 0.000), a 
rostro-caudal level * raphe subregion interaction (F (36, 338.936)  = 55.640, p< 0.000),  
a treatment * time point * rostro-caudal level interaction (F (62, 321.711)  = 1.618, 
p<0.004) a treatment *rostro-caudal level (raphe subregion interaction) (F (36, 341.576)  
= 1.653, p < 0.013), a main effect in timepoint (F (4, 356.439) = 6.124, p < 0.000), a 
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main effect in rostro-caudal level (F (16, 283.275)  = 215.876, p < 0.000) and a main 
effect in raphe subregion (F (5, 232.201)  = 302.652, p< 0.000). 
Based on the findings of this second overall LMM analysis, secondary LMMs were 
used to determine changes in the circadian activity of tph2 mRNA expression 
between control animals and MPL treated animals at each rostro-caudal level of all 
the subregions of the DR and in the MnR nucleus separately (Table 4.2). 
Additionally, changes across the rostro-caudal gradient at each time point were also 
assessed, but for simplicity reasons, these changes are not represented in the 
Figures. 
Table 4-2: Linear mixed model analysis results for tph2 mRNA expression in Control vs MPL 
treated SD male rats. 
Model  Test statistic p-value 
Overall analysis for Controls vs MPL    
First Order Ante-dependence covariance 
structure 
Akaike’s Information Criterion (AIC): 16068.671   
 Treatment1 (CTRL vs MPL) F(1, 351.113)= .537 .464 
  
Time point2 (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 356.439) = 6.124 .000 *** 
  Rostrocaudal level3 (1-17) F(16, 283.275)  = 215.876 .000 *** 
  
Raphe subregion4 (DRC, DRI, DRD, 
DRV, DRVL/VLPAG, MnR) F(5, 232.201)  = 302.652 .000 *** 
 Treatment * Time point  F(4, 409.745)  = 4.732 .001 ** 
 Treatment * Rostrocaudal level F(16, 300.823)  = 5.733 .000 *** 
 Treatment * Raphe subregion F(5, 232.913)  = .651 .661 
  Time point * Rostrocaudal level F(64, 290.087)  = 2.022 .000 *** 
 Time point * Raphe subregion F(20, 238.828)  = .506 .963 
 Rostrocaudal level * Raphe subregion F(36, 338.936)  = 55.640 .000 *** 
 
Treatment * Time point * Raphe 
subregion 
F(20, 255.376)  = .597 .913 
 
Treatment * Time point * Rostrocaudal 
level 
F(62, 321.711)  = 1.618 .004 ** 
 
Treatment * Rostrocaudal level (Raphe 
subregion) 
F(36, 341.576)  = 1.653 .013 * 
 Time point * Rostrocaudal level (Raphe 
subregion) 
F(144, 349.080)  = 1.082 .280 
 
Treatment * Time point * Rostrocaudal 
level (Raphe subregion) 
 
F(140, 394.304)  = .863 .847 
Subregional analyses    
DRC    
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First-Order Factor Analytic (Heterogeneous 
Diagonal Offset) covariance structure 
Akaike’s Information Criterion (AIC): 1034.172 
  Treatment (CTRL vs. MPL) F(1, 61.455) = .516 .475 
 
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 60.141) = .784 .540 
  Rostrocaudal level (13-17) F(4, 25.611) = 12.056 .000 *** 
 Treatment * Timepoint F(4, 63.833)= .852 .498 
  Treatment * Rostrocaudal level F(4, 26.066)= .995 .428 
 Timepoint * Rostrocaudal level F(16, 26.414) = .810 .664 
 
Treatment * Time point * Rostrocaudal 
level  F(15, 31.158) = .978 .499 
DRI 
Heterogeneous Compound Symmetry covariance 
structure 
Akaike’s Information Criterion (AIC): 649.113    
  Treatment (CTRL vs. MPL) F(1, 109.619)= 2.239 .137 
 
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 105.220)= 1.453 .222 
  Rostrocaudal level (14-17) F(3, 60.618)= 131.772 .000 *** 
 Treatment * Timepoint F(4, 108.435)= .374 .827 
  Treatment * Rostrocaudal level F(3, 61.606) = 1.572 .205 
 Timepoint * Rostrocaudal level F(12, 69.887)= 1.433 .172 
 
Treatment * Time point * Rostrocaudal 
level  F(11, 72.481)= .445  .930 
DRD 
Heterogeneous Toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 3464.719   
  Treatment (CTRL vs. MPL) F(, 75.932)= .239 .626 
 
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 75.890)= 1.544 .198 
  Rostrocaudal level (1-12) F(11, 160.823)= 79.774 .000 *** 
 Treatment * Timepoint F(4, 76.287)= 2.143 .084 
  Treatment * Rostrocaudal level F(11, 161.877)= 5.716 .000 *** 
 Timepoint * Rostrocaudal level F(44, 164.029)= 1.755 .006 ** 
 
Treatment * Time point * Rostrocaudal 
level  F(43,  161.864)= 1.260 .154 
DRV 
First Order Ante-Dependence covariance 
structure 
Akaike’s Information Criterion (AIC): 4452.248    
  Treatment (CTRL vs. MPL) F(1, 128.354)= .226 .635 
 
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 127.897)= 1.646 .167 
  Rostrocaudal level (1-14) F(13, 118.533)= 142.081 .000 *** 
 Treatment * Timepoint F(4, 127.790)= 2.715 .033* 
  Treatment * Rostrocaudal level F(13, 116.938)= 2.020 .025*  
 Timepoint * Rostrocaudal level F(52, 120.436)= 1.433 .055 
 
Treatment * Time point * Rostrocaudal 
level  F(51, 117.394)= 1.165 .249 




Heterogeneous Toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 2514.414    
  Treatment (CTRL vs. MPL) F(1, 69.248) = .186 .668 
 
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 69.241)= 1.216 .312 
  Rostrocaudal level (6-13) F(7, 129.116)= 98.770 .000 *** 
 Treatment * Timepoint F(4, 69.241)= 3.003 .024 * 
  Treatment * Rostrocaudal level F(7, 129.116)= 11.427 .000 *** 
 Timepoint * Rostrocaudal level F(28, 133.506) = 1.128 .317 
 
Treatment * Time point * Rostrocaudal 
level  F(28, 133.506) = 1.523 .060 
MnR 
Unstructured covariance structure 
Akaike’s Information Criterion (AIC): 2894.013    
  Treatment (CTRL vs. MPL) F(1, 68.239)= .293 .590 
 
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 68.682)= 1.460 .224 
  Rostrocaudal level (3-17) F(12, 63.075)= 66.963 .000 *** 
 Treatment * Timepoint F(4, 67.977)= 1.570 .192 
  Treatment * Rostrocaudal level F(12, 64.094)= 3.315 .001 ** 
 Timepoint * Rostrocaudal level F(48, 65.953)= 2.810 .000 *** 
 
Treatment * Time point * Rostrocaudal 
level  F (47, 66.745) = 2.425 .000 *** 
1Two different treatment groups (n40/group) were considered in this study; Controls and MPL 
treated SD male rats.2The five different time points (3 am, 9 am, 3 pm, 6 pm, 9 pm) used in this 
study were considered as a suitable description of the circadian rhythm of tph2 mRNA expression. 
They were chosen to fit in parallel with the measured circadian rhythm of plasma CORT. 
3Rostrocaudal levels were well-defined from bregma levels given in the atlas; where most rostral 
level was -7.328 mm bregma (1 according to level code) progressing to the most caudal level at –
8.672 mm bregma (17 according to level code). Within this brain section 17 different and 
representative coronal sections of 12 µm were used to measure tph2 mRNA of the dorsal raphe 
nucleus and the median raphe nucleus. 4The Raphe subregions used in this research were the 
following: DRC, dorsal raphe nucleus, caudal part; DRI, dorsal raphe nucleus, interfascicular part; 
DRD, dorsal raphe nucleus, dorsal part; DRV, dorsal raphe nucleus, ventral part and 
DRVL/VLPAG, dorsal raphe nucleus, ventrolateral part/ventrolateral periaqueductal grey. MnR, 
median raphe nucleus was also included and considered as a subregion of the Raphe complex. 
*p<0.05. **p<0.01. ***p<0.001. 
4.3.4.1 Dorsal Raphe nucleus (DRC) 
Secondary LMM analysis within the DRC revealed a main effect of rostro-caudal 
level (F (4, 71.002)= 7.420, p <0.000), but no effect of time (F (4, 39.358) = .689, p>0.05) 
or interaction (F (16, 68.002)= .661, p>0.05) was found (Table 4-1) (Figure 4 -18). 
Therefore, no circadian variation in tph2 expression was detected in the DRC after 
MPL treatment, even with this full rostro-caudal gradient analysis.  




Figure 4-18: Rostro-caudal level variation of tph2 mRNA expression profile in the DRC of MPL 
treated animals. Tph2 mRNA expression in the DRC was measured in five different rostro-
caudal levels presented in the x axis (-8.336 to -8.672 mm bregma). Five different timepoints; 
(a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-caudal level. The 
left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value multiplied by its own 
Measured Area). Upper segmented area is associated to the right y-axis that represents the 
post Grubb’s test sample size at each rostro-caudal level.  Fisher’s Least Significant difference 
test were not performed. 
An additional secondary LMM analysis was performed for the DRC, which 
evaluated the changes between control and MPL groups (Table 4-2). This analysis 
revealed only a significant difference in rostro-caudal level (F(4, 25.611) = 12.056, p< 
0.000) and no other main effect or interaction so further post tests were not 
performed for this region.  
As shown in Figure 4-19 the DRC, appeared to have no significant changes in tph2 
mRNA expression at any timepoint or rostro-caudal level as a result of MPL 
treatment. 




Figure 4-19: Circadian changes in tph2 mRNA expression at each rostro-caudal level in the 
DRC of Controls versus MPL treated animals. Tph2 mRNA expression in the DRC was 
measured in five different rostro-caudal levels presented in the x axis (-8.336 to -8.672 mm 
bregma) at five different time points; (A) 3 am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. 
Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL 
or MPL [n 8/each group]) at each of the five rostro-caudal levels of the DRC. Fisher’s Least 
Significant Difference were not performed.  
4.3.4.2 Dorsal Raphe nucleus, interfascicular part (DRI) 
Secondary LMM analysis within the DRI revealed a significant main effect of 
rostro-caudal level (F(3, 14.873)= 64.337, p <0.000), but no effect of time (F(4, 23.121)= .706, 
p> 0.05) or interaction (F(12, 15.469)= .848, p> 0.05) (Table 4-1). Thus, as observed in 
Figure 4-20, it appeared that no circadian variation in tph2 mRNA expression in the 
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DRI during MPL treatment can be detected, even when examining the full rostro-
caudal gradient. 
 
Figure 4-20: Rostro-caudal level variation of tph2 mRNA expression profile in the DRI of MPL 
treated animals. Tph2 mRNA expression in the DRI was measured in four different rostro-
caudal levels presented in the x axis (-8.420 to -8.672 mm bregma). Five different timepoints; 
(a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-caudal level. The 
left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value multiplied by its own 
Measured Area). Upper segmented area is associated to the right y-axis that represents the 
post Grubb’s test sample size at each rostro-caudal level. Fisher’s Least Significant difference 
test were not performed. 
An additional secondary LMM analysis was performed for the DRI to determine if 
there was any effect of MPL treatment compared to controls at any of the time 
points assessed. This analysis again revealed only a significant effect in rostro-
caudal level (F(3, 60.618)= 131.772, p< 0.000) with no other main effect or interaction 
(Table 4-2). Therefore, no post-tests were performed. The DRI appeared to be 
insensitive to change over the circadian period or with MPL treatment, even when 
analysed throughout the full rostro-caudal gradient, as can be observed in Figure 4-
21.  




Figure 4-21: Circadian changes in tph2 mRNA expression at each rostro-caudal level in the 
DRI of Controls versus MPL treated animals. Tph2 mRNA expression in the DRI was measured 
in four different rostro-caudal levels presented in the x axis (-8.420 to -8.672mm bregma) at 
five different time points; (A) 3 am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. Tph2 mRNA 
quantification is expressed as Calibrated Mean Grey Value multiplied by its own Measured 
Area. Top data points are associated to the right y-axis which represent the after Grubb’s test 
sample size at each rostro-caudal level. Bottom data points are linked to the left y-axis which 
correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL or MPL [n 
8/each group]) at each of the four rostro-caudal level of the DRI. Fisher’s Least Significant 
Difference post hoc test were not performed.  
4.3.4.3 Dorsal Raphe nucleus, dorsal part (DRD). 
Secondary LMM analysis within the DRD revealed a significant main effect of 
rostro-caudal level (F(11, 29.175)= 34.444, p<0.000) but no main effect of time (F(4, 
33.913)= 1.390, p>0.05). However, a significant interaction between rostro-caudal 
level and time was detected (F(43, 31.1000)= 1.766, p= 0.050) (Table 4-1). Subsequent 
post tests revealed a few notable significant differences in tph2 mRNA expression 
between time points, at defined rostro-caudal levels as shown in Figure 4-22.  




Figure 4-22: Rostro-caudal level variation of tph2 mRNA expression profile in the DRD of 
MPL treated animals. Tph2 mRNA expression in the DRD was measured in twelve different 
rostro-caudal levels presented in the x axis (-7.328 to -8.252 mm bregma). Five different 
timepoints; (a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-
caudal level. The left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value 
multiplied by its own Measured Area). Upper segmented area is associated to the right y-axis 
that represents the post Grubb’s test sample size at each rostro-caudal level. Fisher’s Least 
Significant difference test results are indicated on graph and are annotated by a to e for each 
time point as shown in the plot key. Additionally, double letters indicate p<0.01 and simple 
letters p<0.05. Here (ddee) indicates a significant difference for 6 pm vs 9 pm, (ad) for 3 am vs 
6 pm, (ae) for 3 am vs 9 pm, (be) for 9 am vs 9 pm, (de) 6 pm vs 9 pm.  
A further secondary LMM analysis was performed to additionally assess the effect 
of MPL treatment compared to controls (Table 4-2). This analysis revealed a 
treatment * rostro-caudal level interaction (F (11, 161.877)= 5.716, p< 0.000), a 
timepoint * rostro-caudal level interaction (F (44, 164.029)= 1.755, p< 0.06) as well as 
a main effect in rostro-caudal level (F (11, 160.823) = 79.774, p< 0.000) (Table 4-2). 
Multiple comparisons post-tests found significant differences between MPL and 
controls at all time points except for 9 pm, as indicated on the graphs (Figure 4 - 
23). Despite the observed increase at 9 am in the MPL treated group across nearly 
all levels (Figure 4 - 23B), a decrease at 3 pm with MPL across levels 3-9 (Figure 
4 - 23C), and an increase with MPL at 6 pm at levels 8, 10, 11 and12 (Figure 4 - 
23D), many of these changes were only significant at one or two bregma levels, as 
indicated on the graphs. Taken together however, these findings are fundamentally 
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consistent with our initial observation for the DRD (Figure 4 - 11) with an elevated 
nadir at the 9 am point and a loss of peak expression at the 3 pm point with MPL 
treatment.  
 
Figure 4-23: Circadian changes in tph2 mRNA expression at each rostro-caudal level in the 
DRD of Controls vs MPL treated animals. Tph2 mRNA expression in the DRD was measured 
in twelve different rostro-caudal levels presented in the x axis (-7.328 to -8.252 mm bregma) at 
five different time point: (A) 3am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. Tph2 mRNA 
quantification is expressed as Calibrated Mean Grey Value multiplied by its own Measured 
Area. Top data points are associated to the right y-axis which represent the after Grubb’s test 
sample size at each rostro-caudal level. Bottom data points are linked to the left y-axis which 
correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL or MPL [n 
8/each group]) at each of the twelve rostro-caudal level of the DRD. Fisher’s Least Significant 
Difference post hoc test showed the following significant differences; (A) *p< 0.05 for CTRL 
vs MPL in level 4 and 9 at 3 am; (B) *p< 0.05 for CTRL vs MPL in level 10 at 9 am; (C) 
**p<0.01 for CTRL vs MPL in level 9 and *p< 0.05 in level 8 at 3 pm; (D) **p< 0.01 for CTRL 
vs MPL in level 9 and 11, and *p< 0.05 in level 10 and 12 at 6 pm; (E) ns at 9 pm. 
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4.3.4.4 Dorsal Raphe nucleus, ventral part (DRV). 
Secondary LMM analysis was also performed within the DRV and it showed only 
a main effect in rostro-caudal level (F (13, 85.806)= 45.589, p< 0.000), without effect of 
time (F (4, 41.958)= 1.170, p> 0.05) or interaction (F (51, 80.401)= 1.176, p> 0.05 ) (Table 4 - 
1). Therefore, as no circadian variation in tph2 mRNA expression was detected, no 
post-tests were performed for the DRV time course data (Figure 4 - 24). 
Interestingly this lack of circadian variation during MPL treatment, within the full 
rostro-caudal gradient of the DRV, was consistent with the lack of circadian 
variation noted in the averaged data from the whole, rostral and caudal DRV 
(Figures 4 - 12,). 
 
Figure 4-24: Rostro-caudal level variation of tph2 mRNA expression profile in the DRV of MPL 
treated animals. Tph2 mRNA expression in the DRV was measured in fourteen different rostro-
caudal levels presented in the x axis (-7.328 to -8.420 mm bregma). Five different timepoints; 
(a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-caudal level. The 
left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value multiplied by its own 
Measured Area). Upper segmented area is associated to the right y-axis that represents the 
post Grubb’s test sample size at each rostro-caudal level. Fisher’s Least Significant difference 
test showed no significant differences. 
An additional secondary LMM analysis was performed for the DRV to interrogate 
whether there was a significant effect of MPL treatment compared to controls.  This 
analysis revealed a main effect in rostro-caudal level (F (13, 118.533)= 142.081, p< 0.000), 
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a treatment * timepoint interaction (F (4, 127.790)= 2.715, p< 0.05) and a treatment * 
rostro-caudal level interaction (F (13, 116.938)= 2.020, p< 0.05) (Table 4-2). Subsequent 
post-tests confirmed that the differences observed (Figure 4-25) between MPL and 
controls at each time point were significant in at least one bregma level.  Notably, 
a higher tph2 mRNA expression in the MPL group was observed (Figure 4-25B) at 
9 am, albeit only significant at rostro-caudal level 10 (p< 0.01). A lower tph2 
mRNA expression was observed in the MPL group at 3 pm, significantly at level 9 
(p < 0.01) and level 11 (p < 0.01). A higher tph2 mRNA expression was observed 
at 6pm in the MPL group, significantly at level 10 (p< 0.01). Taken together, these 
data are consistent with MPL treatment inducing a raised nadir in tph2 mRNA 
expression in the caudal DRV at 9 am, and a loss of the 3 pm peak, also 
demonstrated in the mean data analysis shown in Figure 4.13. 
 




Figure 4-25: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRV of Controls vs MPL treated animals. Tph2 mRNA expression in the DRV 
was measured in fourteen different rostro-caudal levels presented in the x axis (-7.328 to -8.420 
mm bregma) at five different time point: (A) 3 am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. 
Tph2 mRNA quantification is expressed as Calibrated Mean Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL 
or MPL [n 8/each group]) at each of the fourteen rostro-caudal level of the DRV. Fisher’s 
Least Significant Difference post hoc test showed the following significant differences; (A) ns 
at 3 am; (B) **p< 0.01 for CTRL vs MPL in level 10 at 9 am; (C) **p< 0.01 for CTRL vs MPL 
in level 9 and 11 at 3 pm; (D) **p<0.01 for CTRL vs MPL in level 10 at 6 pm; (E) ns at 9 pm.  
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4.3.4.5 Dorsal Raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal grey (DRVL/VLPAG). 
Secondary LMM analysis within the DRVL/VLPAG revealed a time point * rostro-
caudal interaction (F (28, 55.769)= 1.642, p< 0.050) and a main effect in rostro-caudal 
level (F (7, 50.969)= 46.764, p<0.000) (Table 4-1). Fisher’s LSD post tests revealed 
many significant differences in tph2 mRNA expression between individual time 
points at each bregma level analysed, as indicated in Figure 4 - 26. Notably, 3am 
has the lowest expression across many of the levels assessed. Interestingly, 9 am 
had a higher tph2 mRNA expression than all other timepoints across levels 8-10, 
although this was only significant at level 8 and level 10, as indicated in the graph. 
Conversely, 6pm had higher expression than all other timepoints across levels 11-
13, although this was significant only at level 12 as indicated in the graph.  
Therefore, a significant circadian variation in tph2 mRNA expression was seen 
across the rostro-caudal gradient of the DRVL/VLPAG in the MPL treated animals, 
with a nadir at 3 am and a peak at 9am in the rostral levels, and a peak at 6pm in 
the caudal levels.  
 
Figure 4-26: Rostro-caudal level variation of tph2 mRNA expression profile in the 
DRVL/VLPAG of MPL treated animals. Tph2 mRNA expression in the DRVL/VLPAG was 
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measured in eight different rostro-caudal levels presented in the x axis (-7.748 to -8.336 mm 
bregma). Five different timepoints; (a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are 
shown for each rostro-caudal level. The left y-axis shows Tph2 mRNA expression (Calibrated 
Mean Grey Value multiplied by its own Measured Area). Upper segmented area is associated 
to the right y-axis that represents the post Grubb’s test sample size at each rostro-caudal level. 
Fisher’s Least Significant difference test results are indicated on graph and are annotated by 
a to e for each time point as shown in the plot key. Additionally, triple letters indicate p<0.001, 
double letters p<0.01 and simple letters p<0.05. Here, (aaabbb) indicates a significant 
difference for 3 am vs 9 am, (aadd) for 3 am vs 6 pm, (ab) for 3 am vs 9 am, (bc) for 9 am vs 3 
pm, (be) for 9 am vs 9 pm, (de) for 6 pm vs 9 pm.  
Additional secondary LMM analysis for DRVL/VLPAG was performed to assess 
for MPL treatment effects compared to controls. Analysis revealed a treatment * 
time point interaction (F (4, 76.287) = 2.143, p<0.024), a treatment * rostro-caudal interaction (F 
(7, 129.116)= 11.427, p<0.000) as well as the main effect in rostro-caudal level (F (7, 129.116)= 
98.770, p< 0.000) (Table 4 - 2). Interestingly, further Fisher’s LSD tests (Figure 4 - 
27) showed that changes after MPL treatment area observed across all timepoints 
and across the entire rostro-caudal gradient, which is consistent with data shown in 
the above (Figure 4-26). Additionally, a very interesting phenomenon is happening 
as a lower tph2 mRNA expression was observed after MPL at 3 am and 3 pm in its 
rostral levels (Figure 4-27A, 4-27C) and changes in MnR caudal levels are observed 
at 9 am and 6 pm (Figure 4-27B, 4-27D). Although not all levels reach statistical 
significance, there is a strong trend in the data that follows the given observation. 
Moreover, this observation is consistent with the observed effect in Figure 4-15 as 
it strongly coincides with the low time points of expression (3 am and 3 pm) and 
with the peak times at 9 am and 6 pm. 
Consequently, a change in the circadian variation of tph2 mRNA expression as a 
result of MPL treatment can be confidently concluded here for the DRVL/VLPAG. 
These changes are characterised by the recurring theme of elevated tph2 mRNA 
expression at 9 am, and loss of peak expression at 3 pm with MPL treatment, 
although there is an increased complexity as we observe how these alterations are 
localised within the rostro-caudal levels of the DRVL/VLPAG. 




Figure 4-27: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRVL/VLPAG of Controls vs MPL treated animals. Tph2 mRNA expression 
in the DRVL/VLPAG was measured in eight different rostro-caudal levels presented in the x 
axis (-7.748 to -8.336 mm bregma) at five different time point: (A) 3am, (B) 9 am, (C) 3 pm, 
(D) 6 pm and (E) 9 pm. Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value 
multiplied by its own Measured Area. Top data points are associated to the right y-axis which 
represent the after Grubb’s test sample size at each rostro-caudal level. Bottom data points are 
linked to the left y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for 
each group (CTRL or MPL [n 8/each group]) at each of the eight rostro-caudal level of the 
DRVL/VLPAG. Fisher’s Least Significant Difference post hoc test showed the following 
significant differences; (A)***p< 0.001 for CTRL vs MPL in level 8 and *p< 0.05 in level 9 at 
3 am; (B) ***p< 0.001 for CTRL vs MPL in level 10 and *p< 0.05  in level 11  at 9 am; (C) 
***p< 0.001 for CTRL vs MPL in level 9 and *p< 0.05 in level 7 and 8 at 3 pm; (D) ***p< 
0.001 for CTRL vs MPL in level 11, **p<0.01 in level 9, 10 and 12, and *p< 0.05 in level 6 at 
6 pm; (E) **p<0.01 for CTRL vs MPL in level 10 at 9 pm.   
   Chapter 4 
151 
 
4.3.4.6 Median Raphe nucleus (MnR).  
To complete the study of the natural circadian rhythm of tph2 mRNA expression 
after MPL treatment a final secondary LMM analysis within the MnR was 
performed. This analysis revealed a time point * rostro-caudal level interaction (F 
(56, 61.674) = 1.730, p< 0.018) and a main effect in rostro-caudal level (F (14, 59.923) = 
18.527, p< 0.001) (Table 4-1). Fisher’s LSD post-tests revealed several significant 
differences in tph2 mRNA expression between timepoints. Tph2 mRNA expression 
after MPL treatment changed in five different rostro-caudal levels, as indicated in 
Figure 4-28. These observed changes are mainly related to the peak in expression 
at 6 pm and the 9 am nadir. Interestingly, this peak in expression also seemed to be 
different from the 3 pm point which showed low levels of expression in different 
levels of the MnR. Strangely, only in one single level (-8.000 mm bregma) the 3 
am point was increased when compared the other time points, however, one isolated 
point like this is more likely to be related to a technical issue and therefore less 
likely to be of functional significance. Thus, a circadian variation in tph2 mRNA 
expression across the rostro-caudal gradient can be clearly observed in the MnR 
nucleus as a result of MPL treatment. 
 
Figure 4-28: Rostro-caudal level variation of tph2 mRNA expression profile in the MnR of MPL 
treated animals. Tph2 mRNA expression in the MnR was measured in fifteen different rostro-
caudal levels presented in the x axis (-7.496 to -8.672 mm bregma). Five different timepoints; 
(a) 3 am, (b) 9 am, (c) 3 pm, (d) 6 pm and (e) 9 pm are shown for each rostro-caudal level. The 
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left y-axis shows Tph2 mRNA expression (Calibrated Mean Grey Value multiplied by its own 
Measured Area). Upper segmented area is associated to the right y-axis that represents the 
post Grubb’s test sample size at each rostro-caudal level. Fisher’s Least Significant difference 
test results are indicated on graph and are annotated by a to e for each time point as shown in 
the plot key. Additionally, double letters indicate p<0.01 and simple letters p<0.05. Here (aacc) 
indicates a significant difference for 3 am vs 3 pm, (ab) for 3 am vs 9 am, (ad) for 3 am vs 6 
pm, (bd) for 9 am vs 6 pm, (cd) for 3 pm vs 6 pm.  
Lastly, to complete the study intended to assess changes in circadian activity of 
tph2 mRNA expression under natural conditions and during MPL treatment, a final 
secondary LMM analysis for MnR was performed. These analyses revealed a 
treatment * rostro-caudal level interaction (F (12, 64.094)= 3.315, p<0.001), a time 
point * rostro-caudal interaction (F (48, 65.953)= 2.810, p<0.000) and a main effect in 
rostro-caudal level (F (12, 63.075)= 66.963, p< 0.000). Multiple comparisons with 
Fisher’s LSD post tests revealed many significant differences in tph2 mRNA 
expression between MPL and controls, at all timepoints except for 9pm, and at 
multiple rostro-caudal levels as shown in Figure 4 - 29.  
Notable effects of MPL in the MnR included: a pronounced decrease at 3am at 
levels 11, 12 and 13, which were all significant (p<0.05 or p<0.001 as indicated in 
Figure 4-29A), a pronounced elevation in tph2 mRNA at 9am across levels 10, 11 
and 12, which was significant only at level 10 (p<0.05 as indicated in Figure 4-
29B); a pronounced decrease at 3pm at levels 10, 12, 13 and 14, which were all 
significant (p<0.05 or p<0.001 as indicated in Figure 4-29C; and an elevation at 
6pm at levels 7, 8, 10, 11 and 12, significant only at level 8 (p<0.05 as indicated in 
Figure 4-29D. There is also a single point with a significant decrease at level 9 
(Figure 4-29D), which is potentially very interesting. However, in cases like this, I 
cannot rule out the possibility that one isolated point that does not follow the general 
‘data trend’ of the surrounding points may be related to a technical issue. 
Overall, the full rostro-caudal dataset in the MnR revealed a highly localised and 
significant circadian dysregulation of tph2 mRNA expression after MPL treatment. 
Interestingly, in this case, the MPL induced changes are primarily characterised by 
a large and significant decrease in tph2 mRNA expression at 3pm, with an increase 
in expression at 6pm, relative to controls.  This data is consistent with the overall 
averaged tph2 mRNA analysis, shown in Figures 4-16 and Figure 4-17, which 
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together indicate that MPL treatment resulted in a shift in the circadian tph2 mRNA 
peak from 3pm to 6pm. 
 
Figure 4-29: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the MnR of Controls vs MPL treated animals. Tph2 mRNA expression in the MnR 
was measured in fifteen different rostro-caudal levels presented in the x axis (-7.496 to -8.672 
mm bregma) at five different time point: (A) 3am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. 
Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL 
or MPL [n 8/each group]) at each of the fifteen rostro-caudal level of the MnR. Fisher’s Least 
Significant Difference post hoc test showed the following significant differences; (A)***p< 
0.001 for CTRL vs MPL in level 12, **p<0.01 in level 5 and *p< 0.05 in level 11 and 13 at 3 
am; (B) for CTRL vs MPL *p< 0.05  in level 10  at 9 am; (C) **p< 0.01 for CTRL vs MPL in 
level 14 and *p< 0.05 in level 9, 12 and 13  at 3 pm; (D) *p< 0.05 for CTRL vs MPL in level 9 
and 9  at 6 pm; (E) ns at 9 pm. 
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4.3.5 Summary of results 
The following table is a summary of the key findings on this chapter. 
Table 4-3: Key findings of the circadian expression of tph2 mRNA after MPL treatment. Data shown by subdivision of the Raphe complex and by bregma level. Differences 
found by statistical analysis form ANOVA’s and Linear Mixed Model analysis. 








Complete Subdivisions after MPL tx LMM analysis after MPL tx Figures 
DR complex 3:00 AM 6:00 PM 
↑ expression at 9 am ↓ expression at 3 am 
and 3 pm when compared to ctrls 
NA 
 (Figure 4-5) 
DRC No significant changes 
 (Figure 4-7) 
(Figure 4-19) 
DRI No significant changes 
 (Figure 4-9) 
(Figure 4-21) 
DRD 3:00 AM 6:00 PM 
↑ expression at 9 am in rostral and caudal 
bregma levels and ↑ at 6 pm in caudal levels  
when compared to ctrls. 
Changes at level 8, 9, 10, 11 when 
compared to Ctrls. Most differences 
were found at 6 pm. 
 (Figure 4-11) 
(Figure 4-23) 
DRV No differences detected  
↑ expression at 9 am and ↓ expression at 3 
pm only in caudal bregma levels when 
compared to ctrls. 
Changes at level 9, 10, and 11 when 
compared to Ctrls.  
 (Figure 4-13) 
(Figure 4-25) 
DRVL/VLPAG 3:00 AM 6:00 PM 
↑ expression at 9 am and ↓ expression at 3 
am and 3 pm when compared to ctrls. 
Changes at level 6, 7, 8, 9, 10, 11 and 
12 when compared to Ctrls. Most 
changes were found at 6 pm.   (Figure 4-15) 
(Figure 4-27) 
MnR 
3:00 AM/ 09:00 
AM 
6:00 PM 
↓ expression at 3 am and 3 pm specific to 
caudal bregma levels  when compared to 
ctrls. 
Changes at level 5, 8, 9, 10, 12, 13 and 
14 when compared to Ctrls 
 (Figure 4-17) 
(Figure 4-29) 
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4.4 Discussion  
According to the results described in this chapter we can determine that CORT 
levels in our MPL group (Figure 4-2)  entirely correspond to the suppressed 
secretion of endogenous corticosteroids as shown in previous studies from our 
group (Spiga et al, 2011). Moreover, with these results we can hypothesize that 
MPL has replaced the circadian and ultradian rhythm of circulating CORT by 
inducing a prolonged activation of GRs.   
About, tph2 mRNA expression in the whole Raphe complex after MPL (Figure 4-
4), the data shows the presence of a flattened but significant circadian variation in 
tph2 mRNA expression, with the highest expression at 6 pm and the lowest at 3 am. 
When compared to the pattern of activity under natural conditions, tph2 mRNA 
expression after MPL treatment  (Figure 4-5) seems to have changed considerably 
at 9 am and 3pm; the nadir of expression changed from 9 am to 3 am, while the 
peak of expression changed from 3 pm to 6 pm/ This change in the peak expression 
can be presumed as an effect of the long-acting of MPL compared to CORT and 
the connection between rhythms of GCs and tph2 mRNA expression (Donner et. 
al, 2011; Malek et. al, 2007). 
 
Figure 4-30 Representative image of tph2 mRNA expression of Ctrl (left) vs MPL (right). Image 
of bregma level 10 (-8.00 bregma level) from of a single brain section from a A) Control animal 
vs a single brain section of a B) LL treated animal from the 6 pm time point (peak expression 
after MPL tx).Scale bar 1 mm.  
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Regarding the assessment of the DR subregions and the MnR nucleus, there is an 
existent circadian rhythm in the DRD (Figure 4-10), DRVL/VLPAG (Figure 4-14) 
and MnR (Figure 4-16). No rhythm was found in the DRV (Figure 4-12), which was 
interesting as there was a circadian rhythm under in the controls. Hence, MPL 
treatment eliminates the circadian variation in tph2 mRNA expression. As 
expected, no circadian variation was found in the DRC (Figure 4-6) or DRI (Figure 
4-8), but this could be explained because no circadian variation was found under 
normal condition. Moreover, this circadian variation of expression after MPL 
treatment, in the DRD, DRVL/VLPAG and MnR did not appeared to be specific of 
the caudal part of each area since we also found significant differences in their 
rostral part. These conditions could have functional and behavioural consequences, 
which will be discussed further in chapter 6.  Additionally, In the DRD and the 
MnR, the peak of tph2 mRNA expression matches with the peak of circulating 
CORT, but this does not happen with the DRVL/VLPAG since the peak was at 9 
am. 
Continuing with the DR subregions and the MnR nucleus analysis, when compared 
to the natural circadian activity, as expected nothing was found for the DRC (Figure 
4-7) or DRI (Figure 4-9). However, at 9 am the whole and rostral DRD (Figure 4-
11) show an increase in expression, which is maintained in the caudal DRD at 9 am 
and 6 pm. The caudal DRV (Figure 4-13) shows an unusual change when compared 
to control conditions; increasing tph2 mRNA expression at 9 am and significantly 
reducing it at 3 pm, when it was supposed to be high (peak of expression under 
natural conditions). Changes are found in the whole, rostral and caudal 
DRVL/VLPAG (Figure 4-15) with MPL treatment changing the peak expression 
from 3 pm to 9 am and the nadir of expression from 9am to 3 am. This could 
implicate a “inversed shifted” circadian rhythm of tph2 mRNA.  Finally, a decrease 
in tph2 mRNA expression at 3 pm for the whole and caudal MnR (Figure 4-17) can 
be seen when compared to the natural activity pattern, but this could mean also a 
shifted circadian rhythm, since the peak expression has gone from 3 pm to 6 pm.  
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Now, bearing in mind the rostro-caudal gradient of each of the subregions of the 
DR and the MnR nucleus after MPL, LMM analyses showed that tph2 mRNA 
expression profile changes across this gradient in all of the areas of the Raphe 
complex. Additionally, data shows few circadian variations throughout the rostro-
caudal levels of the DRD (Figure 4-22), DRV (Figure 4-24), DRVL/VLPAG (Figure 4-
26) and MNR (Figure 4-28). These changes are specific to only some levels of each 
area and are specific to 9 pm in the DRD, to 6 pm in the DRV, to 3 am in the 
DRVL/VLPAG and to 9 am and 6 pm in the MnR. These changes might have 
functional implications as hypothesized by others. These will be further discussed 
in chapter 6.  
Additionally, when considering the rostro-caudal gradient and the comparison 
between the natural tph2 mRNA activity and the changed pattern after MPL 
treatment the overall LMM analyses and secondary LMM analysis revealed that 
tph2 mRNA expression profile changed across this gradient in all of the areas of 
the Raphe complex. Moreover, there is an effect of treatment and time point across 
the rostro-caudal level in the DRD (Figure 4-23), DRV (Figure 4-25), 
DRVL/VLPAG (Figure 4-27) and MnR (Figure 4-29); for the DRD, only the changes 
found in the cauda levels at 6 pm appear to be of great importance, however, 
changes at 3 am, 9 am and 3 pm were also found; for the DRV very precise changes 
were found so no assumption can be given about the effect of MPL treatment; the 
DRVL/VLPAG is the most interesting area since the changes found are detected 
across all the 24-hour period, therefore an overall effect of MPL treatment can 
further be discussed as a functional or behavioural implication can be assumed; for 
the MnR, changes can be considered  at 3 am and 3 pm. 
This data confirms the existence of a flattened circadian variation of tph2 mRNA 
expression in a 24-hour period after MPL in 3 subregions of the DR and the MnR. 
Moreover, this circadian variation seems to have changed when compared to the 
circadian variation under natural conditions, and these changes might involve a 
shifted circadian rhythm. Therefore, these changes can presume a relationship 
between an altered HPA axis activity because of a prolonged GR activation by the 
long-acting of MPL and an altered tph2 mRNA expression.  
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Although this data and the LMM’s analysis done in this study simply describe with 
more precision the intricacy of the Raphe complex and the changes that tph2 gene 
expression exhibit after a manipulation of the GC circadian rhythm, we can surely 
say that this findings could support the idea of a strong relationship between the 
circadian expression of tph2 mRNA and the activity of HPA-axis. Moreover, it can 
contribute to the basic knowledge of why sGCs have solid neuropsychiatric side 
effects by proposing a novel mechanism of the connection between altered activity 
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Chapter 5 Circadian changes in the rhythm of tph2 mRNA 
expression in the Dorsal and Median Raphe nuclei 
following chronodisruption by five weeks of constant light 
exposure. 
5.1 Introduction  
 
5.2 Methods: Experimental design  
5.2.1 Study design to assess the circadian rhythm of CORT and tph2 mRNA 
expression after constant light exposure for five weeks  
5.2.2 Statistical analysis  
 
5.3 Results  
5.3.1 Circadian rhythm of circulating Corticosterone after constant light (LL) 
treatment  
5.3.2 Circadian rhythmicity of tph2 mRNA expression in the Raphe complex 
after LL treatment 
5.3.3 Circadian changes on tph2 mRNA expression in subregions of the Dorsal 
Raphe and the MnR nucleus after LL treatment 
5.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR subregions and 
MnR nucleus after LL treatment; analysis across the full rostro-caudal 
gradient.  
 




   Chapter 5 
161 
 
5.1 Introduction  
Daily rhythms in behaviour and physiology are present in all organisms, including, 
plants, animals, fungi and cyanobacteria.  These rhythmic responses are coordinated 
by an internal central pacemaker (biological clock) in the suprachiasmatic nucleus 
(SCN) of the anterior hypothalamus (Moore and Eichler, 1972a; Inouye and 
Kawamura, 1979; Gillette and Prosser, 1988). The SCN drives the circadian 
rhythmic activity of many physiological and behavioural processes (Buijs et al., 
1993a, 2003). 
An important characteristic of the SCN is that the ventrolateral part of this nucleus 
receives projections from the retina, obtaining information of the day/night 
(light/dark) cycle. This important information synchronises the SCN which in turn, 
coordinates behavioural and physiological responses to adapt and respond 
efficiently to the daily demands (Moore MD, 1997). Hence, light has an important 
contribution in synchronizing the SCN. 
Since the discovery of the “internal clock” studies of the circadian biological 
rhythms have acquired great attention. Moreover, in recent years, many of the 
studies in this area of research have focused on the circadian disruption and the 
potential negative consequences. It has been well established that disruption of 
circadian rhythms is related to mood disorders, such as anxiety and depression 
(Kjellman et al., 1985; Stetler, Dickerson and Miller, 2004; Goodman et al., 2005; 
Germain and Kupfer, 2008; Monteleone et al., 2011).   
The adverse effects of disrupted circadian rhythms are most notably seen in shift 
workers or associated with the “jet lag” of transmeridian travel. Recent evidence 
has indicated that long periods of light, mixed with arousal and activity, can send 
unpredictable signals to the biological clock and lead to circadian disruption 
(Navara and Nelson, 2007), which in turn can cause fatigue, irritability, depression 
and anxiety (Haus and Smolensky, 2006; Gorwood et al., 2007). 
With respect to this, the model of constant light in rodents has been shown to cause 
altered circadian rhythms, and specifically the loss of the circadian CORT nadir 
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(Waite et al., 2012). Moreover, depressive-like symptoms, anxiety and anhedonia 
have been well characterized in animals subjected to this model (Prendergast and 
Kay, 2008; Fonken et al., 2010; Fonken and Nelson, 2011). Therefore, it appeared 
to be good experimental paradigm to study mechanisms of depression and anxiety. 
Important to mention is that exposure to constant light can induce a disrupted 24 hr 
locomotor activity (Ma et al., 2007) with a significant change on the temporal 
distribution of activity rather than the average amount of activity or the maximum 
levels of activity in the 24 hr period (Cassone, 1992). 
There is a strong circadian regulation of HPA axis activity, closely controlled by 
the SCN (Cascio, Shinsako and Dallman, 1987; Buijs et al., 1993a; Buijs, 1999). 
Several studies have shown that lesioning the SCN in animal models results in a 
loss of the circadian nadir in CORT secretion (Abe, Kroning, Greer, & Critchlow, 
1979; Moore & Eichler, 1972). The same loss of nadir is also observed in animals 
exposed to long periods of constant light (Scheving and Pauly, 1966; Honma and 
Hiroshige, 1978; Waite et al., 2012). Importantly, despite the striking loss of 
circadian variation in CORT secretion, ultradian pulsatility remains intact.  
Therefore, consequence of the loss of circadian nadir results in the appearance of 
high amplitude CORT pulses over the full 24-hour period, characteristic of a 
hyperactive HPA axis. Interestingly, patients with depression exhibit high levels of 
GCs (Plotsky, Owens and Nemeroff, 1998). Abnormal cortisol pulsatility has also 
been described in depressed patients (Deuschle, Schweiger, Weber, Gotthardt, et 
al., 1997). Based upon these observations, an important HPA axis dysfunction 
theory has been proposed to explain the pathophysiology of depressive and anxious 
states (Dinan, 1994; Pariante & Lightman, 2008). 
Furthermore, depression and anxiety disorders also have a well characterised and 
strong relationship with serotonergic systems (Owens and Nemeroff, 1994; Lowry 
et al., 2008a). In fact, the dysfunction of serotonergic systems in depressed patients 
is arguably the most accepted neurochemical hypothesis (Mann et al., 1989; 
Axelson et al., 1993; Naughton, Mulrooney and Leonard, 2000; You et al., 2005; 
Zill et al., 2007). However,  reports that the circadian rhythmicity of important 
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physiological and biochemical processes are dysregulated in depression (McClung, 
2007) also deserves attention when considering the full picture.  
Despite all the current knowledge outlined here, the exact mechanisms underlying 
the connection between depression/anxiety disorders and circadian rhythms 
remains uncertain. Therefore, the aim of this study was to determine whether 
chronic exposure to constant light, which is already well established to induce a 
hyperactive CORT profile due to circadian disruption of CORT secretion, could 
also affect the pattern of tph2 mRNA expression, consequently suggesting a novel 
mechanism explaining why patients with disrupted circadian activity in the HPA 
axis exhibit a high vulnerability for depression and anxiety. 
Thus, we assessed 1) if the pattern of circulating CORT over a 24-hour period after 
five weeks LL treatment was disrupted and 2) if LL treatment altered the activity 
of tph2 mRNA expression profile in the complete Raphe complex, in each of the 
subregions of the DR and the MnR and throughout the rostro-caudal gradient of 
each of the subregions of the DR and the MnR nucleus and finally 3) if tph2 mRNA 
expression after LL treatment was different from the natural activity pattern of tph2 
mRNA expression, demonstrating a relationship between this altered activity and 
the altered circulating CORT.   
5.2 Methods: Experimental design 
5.2.1 Study design to assess the circadian rhythm of CORT and 
tph2 mRNA expression after constant light exposure for five 
weeks.   
On day one, forty SD rats (p21) were separated into different groups and housed 
four per cage in environmentally controlled chambers (Waite et al., 2012). These 
chambers had space for 4 rat cages and had controlled light (with the possibility of 
changing the brightness, however it was always kept in 200lux), temperature and 
humidity. All animals were maintained under bright constant light (200 lux) for a 
period of five weeks.  All animals had food and water ad libitum. From day 30 to 
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day 35, all animals were handled for 10 min at different times of day to avoid stress 
on the day of the experiment. 
At the beginning of the sixth week, in order to collect samples, all animals (now 
weighing 250 to 300g) were euthanized with an overdose of isoflurane (schedule 1 
procedure) and decapitated with a guillotine at defined time points over the 24-hour 
cycle; 3 am, 9 am, 3 pm, 6 pm, 9 pm (n= 8 per time point). Animals were killed 
starting 20 minutes before the appointed hour and finishing 20 minutes past the 
hour. Trunk blood and whole brains were collected.  
 
Figure 5-1: Experimental design for the assessment of the altered rhythm of CORT and tph2 
mRNA expression after five weeks of constant light (LL). 
5.2.2 Statistical analysis  
1. One-way ANOVA was performed for the CORT data to assess for an effect 
of time after five weeks of LL. When an effect of time was 
found, Dunnet’s post-test was used to compare each time point to the 9am 
nadir. Furthermore, a two-way ANOVA with a Tukey HSD post-test was 
performed to compare between controls and LL treated groups. 
 
2. When analysing the whole Raphe complex, the same statistical tests used for 
the CORT analysis were used to enable a direct comparison between the 
rhythm of tph2 mRNA expression and the rhythm of CORT. A one-way 
ANOVA with a Dunnett’s (2-sided) post-test was also performed, however 
3 pm (nadir) was here considered as the control group. Additionally, a two-
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way ANOVA with a Tukey HSD post-test was performed to compare 
between treatment groups. This fitted with previous statistical tests 
performed in chapter 3 and 4. 
 
3. Finally, in all the more detailed (subregional and rostro-caudal analysis) 
overall and secondary LMMs were performed as in chapter 3 and 4, followed 
by Fisher’s Least Significant Difference (LSD) multiple comparison post-
tests when a time effect was found. Two different overall LLMs were 
performed to 1) assess the effect of time in the rostro-caudal gradient of each 
subregion and 2) effect of treatment in the rostro-caudal gradient of each 
subregion.  
 
4. The CTRL vs LL comparisons made throughout this chapter were done with 
the data of our control groups from chapter 3. All the LL experimental groups 




5.3.1 Circadian rhythm of circulating Corticosterone after 
constant light (LL) treatment. 
Animals submitted to five weeks of LL showed high levels of circulating CORT 
across the 24-hour period (Figure 5-2).  The results obtained suggest the loss of the 
normal circadian activity of CORT, which was expected as it has been shown before 
by several research groups (Claustrat, Valatx, Harth, et al., 2008; Waite et al., 
2012). The results, showing the lack of a circadian nadir in CORT levels, thus 
confirm that the experimental paradigm used in my study successfully disrupted 
circadian HPA axis activity. A one-way ANOVA was performed to determine if 
there were any differences between time points after LL treatment, and no 
statistically significant difference was found; F (4, 35) = 0.875, p> 0.05, supporting 
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the statement that there was no detectable circadian rhythm of circulating CORT 
remaining after five weeks of constant light exposure. 
 
Figure 5-2: Circulating CORT of LL treated animals in a 24-hour period. CORT levels were 
measured in plasma obtained from trunk blood of control animals at 5 different timepoints; 
3am, 9 am, 3 pm, 6 pm and 9 pm (n=8/group/timepoint). CORT levels are expressed as ng/ml. 
Data is presented as Mean ± SEM of CORT. One-way ANOVA was performed to assess effect 
of time; F (4, 35) = 0.875, p> 0.05. 
When comparing our control group with our LL group (Figure 5 - 3), a two-way 
ANOVA was performed to determine if there was a significant interaction between 
treatment and time; (F (4, 70) =5.566), p< 0.001. A Tukey HSD test was performed 
and revealed that, when CORT is at low levels in the normal circadian rhythm at 3 
am and at 9 am (nadir), the LL group showed a significant increase of CORT with 
p values of <0.01 and p<0.001, respectively. No significant difference was found 
at the natural peak of CORT (6 pm), as both groups had equally high levels at this 
time. However, at 3 pm and 9 pm, again, high levels of CORT were found in the 
LL group (p<0.05) demonstrating the maintenance of high levels throughout the 
24-hour period. 




Figure 5-3: Circadian changes in circulating CORT of Control versus LL treated animals. 
CORT levels were measured in plasma obtained from trunk blood of two different groups 
(Control or LL treated animals) at 5 different timepoints; 3am, 9 am, 3 pm, 6 pm and 9 pm 
(n=8/group/timepoint) presented in the x axis. CORT levels are expressed as ng/ml in the y 
axis. Data is presented as MEAN ± SEM of CORT for each group. Two-way ANOVA was 
performed to assess interaction between treatment and time; (F (4, 70) = 5.566) p< 0.01. 
Additionally, a Tukey HSD test was included; *** p< 0.001 when comparing CTRL vs LL at 9 
am; **p <0.01 when comparing CTRL vs LL at 3 am and * p< 0.05 when comparing CTRL vs 
LL at 3 pm and 9 pm.    
5.3.2 Circadian rhythmicity of tph2 mRNA expression in the 
Raphe complex after LL treatment.  
This part of the study consisted of evaluating the effect of five weeks of LL on 1) 
the activity of tph2 mRNA expression in all the subregions of the DR and the MnR 
nucleus throughout a 24-hour period and 2) the possible changes of this activity 
pattern when compared to the natural variation of expression of tph2 mRNA. 
First, in order to describe the overall effect of five weeks of LL in the circadian 
pattern of tph2 mRNA expression, I analysed the global averaged tph2 mRNA 
expression across all rostro-caudal levels of all subregions together. This analysis 
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circadian activity with a continued nadir from 9 am to 6 pm and a peak from 9 pm 
to 3 am (Figure 5 - 4).  These changes were supported by the statistically significant 
effect of time found by the one-way ANOVA; (F (4, 2044) =8.044, p< 0.001). A 
Dunnett’s post hoc test was then performed to compare the mean of every group 
against the 3 pm group, since it was the observed nadir for this data base. The test 
revealed that the high levels of expression found at 3 am and 9 pm were statistically 
different to 3 pm with p values of p<0.05 and p< 0.01, respectively.  
 
Figure 5-4: Circadian variation in Tph2 mRNA expression in the DR and MnR complex of LL 
treated animals. All measurements of tph2 mRNA expression of all levels of the DR and MnR 
complex were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA 
expression for each group/timepoint (n=8/group). One-way ANOVA was performed to assess 
effect of time; (F(4, 2044) = 8.044, p< 0.001). Additionally, Dunnett’s (2-sided) post hoc test was 
performed; **p <0.01 at 9 pm when compared to the 3 pm group and *p< 0.05 at 3 am when 
compared to the 3 pm group. 
Next, I evaluated the tph2 mRNA expression pattern after LL treatment compared 
to the control dataset (Figure 5-5).  This analysis showed that across the 24-hour 
period, all time points assessed showed strong changes in the expression of tph2 
mRNA.  Moreover, the peak expression of tph2 mRNA expression after LL 
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treatment changed to 9 pm followed narrowly by the 3 am group, while the nadir 
occurred at 3 pm followed very closely by the 6 pm group.  
These findings were supported by the significant interaction between treatment and 
time found by two-way ANOVA; (F (4, 4004) =9.966, p< 0.001). Tukey HSD test 
revealed that after five weeks of constant light there was a significant reduction of 
tph2 mRNA expression at times when it was supposed to be high (3 pm [p<0.001] 
and 6 pm [p<0.05] in LL vs control comparison), and a significantly increase in 
expression at times when it was supposed to be low (3 am [p<0.05], 9 am [p<0.05] 
and 9 pm [p<0.001 in LL vs control comparison]). 
 
Figure 5-5: Circadian variation in tph2 mRNA expression in the DR and MnR complex of 
control vs LL treated animals. All measurements of tph2 mRNA expression of all levels of the 
DR and MnR complex were averaged for each timepoint of each group; 3 am, 9 am, 3 pm, 6 
pm and 9 pm (x axis). Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value 
multiplied by its own Measured Area (y axis). Data points correspond to overall MEAN ± SEM 
of tph2 mRNA expression for each group/timepoint (n=8/group). A two-way ANOVA was 
performed to assess the interaction between treatment and time; (F(4, 4004) = 9.966, p< 0.001).  
Additionally, a Tukey HSD post hoc test was performed; ***p < 0.001 at 9 pm when comparing 
CTRL vs LL at 9 pm, **p< 0.01 at 3 pm when comparing CTRL vs LL and *p <0.05 at 3 am, 9 
am and 6 pm when comparing CTRL vs LL. 
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5.3.3 Circadian changes on tph2 mRNA expression in subregions 
of the Dorsal Raphe and the MnR nucleus after LL 
treatment. 
In order to assess the overall effects of time (the circadian pattern) on tph2 mRNA 
expression in each of the anatomical and functional distinct subregions of the DR 
and the MnR nucleus after LL treatment, I analysed the averaged tph2 mRNA 
expression of all the rostro-caudal levels for each subregion separately.  As with the 
MPL analysis, I also assessed the two well defined antero-posterior division of the 
Raphe complex. Thus, I evaluated the rostral and caudal levels for the three 
subregions of the DR which extend rostro-caudally (DRD, DRV, DRVL/VLPAG) 
as well as the MnR. 
As for the MPL study, in order to describe the overall changes in the circadian 
pattern of tph2 mRNA expression after LL treatment I compared the global MEAN 
± SEM of tph2 mRNA expression from the control group (natural conditions) 
versus the LL group for each of the distinct subregions of the DR and the MnR 
nucleus, including also the antero-posterior division for the DRD, DRV, 
DRVL/VLPAG and the MnR nucleus. 
These analyses showed circadian variations in tph2 mRNA expression in four DR 
subregions and in the MnR nucleus throughout a 24-hour period after treatment. 
Moreover, variations were revealed after LL treatment when compared to the 
natural rhythm of tph2 mRNA expression in most of the regions analysed. Again, 
all of these variations found seemed to be primarily localised to the caudal part of 
the subregions with the notable exception of the DRD. 
5.3.3.1 Dorsal Raphe nucleus, caudal part (DRC).  
Five weeks of LL had a strong effect on tph2 mRNA expression in the DRC 
throughout the 24-hour period (Figure 5-6). This statement was supported by the 
significant effect of time found in the one-way ANOVA; (F (49, 154) =4.766) p<.001. 
Multiple comparisons with Fisher’s LSD post tests showed that tph2 mRNA 
expression at 9 pm was significantly different (p<0.01) to the nadir expression 
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levels at 9 am, 3 pm and 6 pm. Moreover, 3 am also showed a high level of tph2 
mRNA expression, which was significantly different (p<0.05) when compared to 9 
am, 3 pm and 6 pm.  Interestingly, a flattened profile in of tph2 mRNA was present 
from 9 am to 6 pm.  
 
Figure 5-6: Circadian variation in tph2 mRNA expression in the DRC of LL treated animals. 
Measurements of tph2 mRNA expression of the five levels of the DRC (-8.336 to -8.672 mm 
bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA 
expression in the DRC for each group/timepoint (n 8/ group [  8 animals x 5 levels =  40 
values]). One-way ANOVA was performed to assess effect of time; (F (4, 154) =4.766) p<.001: 
** p< 0.01 for 9 am vs 9 pm, 3 pm vs 9 pm and 6 pm vs 9 pm; * p< 0.05 for 3 am vs 9 am, for 
3 am vs 3 pm and for 3 am vs 6 pm with Fisher’s Least Significant Difference test.  
 
Next, a two-way ANOVA was performed to determine that there was no significant 












Figure 5-7: Changes in circadian variation of tph2 mRNA expression in the DRC of Control 
versus LL treated animals. Measurements of tph2 mRNA expression of the five levels of the 
DRC (-8.336 to -8.672 mm bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm 
and 9 pm (x axis) for each group separately (CTRL or LL ). Tph2 mRNA quantification is 
expressed as Calibrated Mean Grey Value multiplied by its own Measured Area (y axis). Data 
points correspond to overall MEAN ± SEM of tph2 mRNA expression in the DRC for each 
group/timepoint (CTRL or LL [n 8/ group [  8 animals x 5 levels =  40 values]). Two-way 
ANOVA was performed to assess the interaction between treatment and time: (F (4, 272) = 2.093) 
p> 0.05. 
5.3.3.2 Dorsal Raphe nucleus, interfascicular part (DRI). 
Within the DRI, a one-way ANOVA showed no significant effect of time; F (4,116) 
=0.663) p> 0.05, demonstrating the lack of circadian rhythm in tph2 mRNA 
expression in the DRI after five weeks of LL (Figure 5-8). 
 




Figure 5-8: Circadian variation in tph2 mRNA expression in DRI of LL treated animals. 
Measurements of tph2 mRNA expression of the four levels of the DRI (-8.420 to -8.672 mm 
bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area (y axis). Data points correspond to overall MEAN ± SEM of tph2 mRNA in the 
DRI for each group/timepoint (n 8/ group [  8 animals x 4 levels =  32 values]). One-way 
ANOVA was performed to assess effect of time; (F (4,116) =0.663) p> 0.05.  
Additionally, tph2 mRNA expression after five weeks of LL behaved similarly to 
the control groups across the 24-hour period (Figure 5-9). The two-way ANOVA 
determined no interaction between treatment and time in the DRI; (F (4, 193) =.121) 
p> 0.05.  Therefore, tph2 mRNA expression didn’t appear to exhibit a circadian 
pattern within the DRI subregion under natural conditions nor after five weeks of 
LL. 




Figure 5-9:  Changes in circadian variation of tph2 mRNA expression in the DRI of Control 
versus LL treated animals. Measurements of Tph2 mRNA expression of the four levels of the 
DRI (-8.420 to -8.672 mm bregma) were averaged for each timepoint; 3 am, 9 am, 3 pm, 6 pm 
and 9 pm (x axis) for each group separately (CTRL or LL). Tph2 mRNA quantification is 
expressed as Calibrated Mean Grey Value multiplied by its own Measured Area (y axis). Data 
points correspond to overall MEAN ± SEM of tph2 mRNA expression in the DRI for each 
group/timepoint (CTRL or LL [n 8/ group [  8 animals x 4 levels =  32 values]).  A Two-
way ANOVA was performed to assess interaction between treatment and time: (F (4, 193) =.121) 
p> 0.05. 
5.3.3.3 Dorsal Raphe nucleus, dorsal part (DRD). 
To determine if the DRD presented a circadian variation in tph2 mRNA expression 
after five weeks of LL throughout the 24-hour period, one-way ANOVAs were 
completed for the whole, rostral and caudal DRD separately, which compared 
between timepoints; 3 am, 9 am, 3 pm, 6 pm and 9 pm. 
For the whole DRD (Figure 5-10A) an effect of time was found; (F (4, 417) =4.135) 
p< 0.01. Hence, LSD post-tests were run and revealed that both 3 am and 9pm peak 
levels were significant when compared to the nadir levels of 9 am (p<0.05), 3 pm 
(p<0.05) and 6 pm (p<0.01).  
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With respect to the rostral DRD (Figure 5-10B), there was also a visible time-
dependent variation over the 24 hour period, supported by a significant effect of 
time by one-way ANOVA; (F (4, 273) =2.23) p< 0.05. The peak expression was again 
seen at 3 am and 9 pm, which both had a statistically increased tph2 mRNA 
expression when compared to 6 pm (p<0.05), although only 3 am had a statistically 
higher expression when compared to the 9 am group (p<0.05). 
Finally, for the caudal DRD (Figure 5-10C), there was also a statistically significant 
effect of time; (F (4, 178) =7.495) p< 0.001. Similar to the whole and rostral DRD, 
the peak of tph2 mRNA expression was seen at 9 pm and 3 am. The 9 pm peak was 
statistically increased when compared to the 9 am (p< 0.05), 3 pm (p< 0.001), and 
6 pm group (p< 0.001). Likewise, the 3 am was statistically increased when 
compared to 9 am (p< 0.05), 3 pm (p< 0.001) and 6 pm (p< 0.01). An additional 
significant difference was found when comparing the low levels of expression at 3 
pm with the 9 am group (p<0.05). 
 
 




Figure 5-10: Circadian variation in tph2 mRNA expression in the DRD of LL treated animals.  
For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) measurements of tph2 mRNA 
expression (y axis) were averaged; (A) twelve levels (-7.328 to -8.252 mm bregma) for the 
whole DRD, (B) eight levels (-7.328 to -7.916 mm bregma) for the rostral DRD and (C) 5 levels 
(-7.916 to -8.252 mm bregma) for the caudal DRD. Tph2 mRNA quantification is expressed as 
Calibrated Mean Grey Value multiplied by its own Measured Area. Data points correspond to 
overall MEAN ± SEM of tph2 expression of the whole/rostral/caudal DRD for each 
group/timepoint (n 8/group [  8 animals x  12/8/5 levels =  96/64/40 values]). One-way 
ANOVAs were performed to assess effect of time: (A) (F (4, 417) =4.135) p< 0.01; ** p< 0.01 for 
3 am vs 6 pm and for 6 pm vs 9 pm; * p< 0.05 for 3 am vs 9 am, for 3 am vs 3 pm, for 9 am vs 
9 pm and for 3 pm vs 9 pm; (B) (F (4, 273) =2.23) p< 0.05;  *p < 0.05 for 3 am vs 9 am, for 3 am 
vs 6 pm and for 6 pm vs 9 pm;  (C) (F (4, 178) =7.495) p< 0.001; ***p< 0.001 for 3 am vs 3 pm, 
for 3 pm vs 9pm and for 6 pm vs 9 pm: **p< 0.01 for 3am vs 6 pm: *p< 0.05 for 3 am vs 9 am, 
for 9 am vs 3 pm and for 9 am vs 9 pm with Fisher’s Least Significant Difference test.  
Next, I assessed changes between the natural circadian rhythm in tph2 mRNA 
expression and the modified pattern after LL treatment in the whole DRD (Figure 
5-11A).  A significant interaction between treatment and time was revealed by the 
two-way ANOVA; (F (4, 863) = 4.769) p< 0.01. Thus, Fisher’s LSD post-tests were 
run and revealed that the tph2 mRNA expression profile after LL treatment 
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appeared to have changed with a significant reduction at 6 pm (p<0.01) and a 
significant increase at 3 am (p<0.05) and 9pm (p<0.05). 
Interestingly, for the rostral DRD (Figure 5-11B), a marked reduction at 6 pm was 
observed after LL treatment. A significant interaction was found; (F (4, 572) = 2.901) 
p< 0.05 and Fisher’s LSD post-test revealed that the reduction at 6 pm was 
significantly different between LL and control, p< 0.01. LL treatment had no effect 
at any of the other timepoints. 
With respect to the caudal DRD (Figure 5-11C), a striking contrast was observed 
between the LL and control groups, supported by a significant interaction in two-
way ANOVA; (F (4, 358) = 7.996) p< 0.01. The peak in expression of tph2 mRNA 
after LL treatment was again seen at 9 pm and 3 am, both with statistically higher 
levels of expression, p<0.001 when compared to their time matched control groups. 
Also, a significant increase was revealed at 9 am, p<0.05. At 3 pm, when tph2 
mRNA expression reached its peak in control rats, the LL treated rats were at their 
nadir in tph2 mRNA expression, representing a significant reduction, p<0.05. The 
highly dysregulated pattern induced by LL appeared to be a complete inversion of 
the control pattern in circadian tph2 mRNA expression, with exaggerated peak 
levels at the ‘wrong time of day’. 
Therefore, it appeared that the tph2 mRNA expression profile within the DRD 
subregion was significantly altered after five weeks of LL treatment, with the most 
striking dysregulation in the caudal DRD. 




Figure 5-11: Changes in circadian variation of tph2 mRNA expression in the DRD of Control 
vs LL treated animals.  For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or LL); (A) twelve levels (-7.328 to -8.252 mm bregma) for the whole DRD, (B) eight 
levels (-7.328 to -7.916 mm bregma) for the rostral DRD and (C) 5 levels (-7.916 to -8.252 mm 
bregma) for the caudal DRD. Tph2 mRNA quantification is expressed as Calibrated Mean Grey 
Value multiplied by its own Measured Area. Data points correspond to overall MEAN ± SEM 
of tph2 mRNA expression of the whole/rostral/caudal DRD for each group/timepoint (CTRL vs 
LL [n 8/group [  8 animals x  12/8/5 levels =  96/64/40 values]). Two-way ANOVAs were 
performed to assess interaction between treatment and time:  (A) (F (4, 863) = 4.769) p< 0.01; 
** p< 0.01 when comparing CTRL vs LL at 6 pm; *p< 0.05 when comparing CTRL vs LL at 3 
am and 9 pm; (B) (F (4, 572) = 2.901) p< 0.05; ** p< 0.01 when comparing CTRL vs LL at 6 pm; 
(C) (F(4, 358) = 7.996) p< 0.01; ***p< 0.001 when comparing CTRL vs LL at 3 am and 9 pm; 
*p< 0.05 when comparing CTRL vs LL at 9 am and 3 pm. 
5.3.3.4 Dorsal Raphe nucleus, ventral part (DRV).  
The whole DRV subregion showed very little circadian variation after five weeks 
of constant light (Figure 5-12), and no significant effect of time was detected by the 
one-way ANOVA (Figure 5-12A); (F (4, 494) =1.271) p> 0.05. Similarly, there was 
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no significant circadian variation detected in the rostral DRV (Figure 5-12B); F (4, 
272) =0.445) p> 0.05. 
Fascinatingly for this area, when I took away the rostral levels a strong circadian 
pattern of tph2 mRNA expression was exposed. This indicates that the circadian 
rhythm of tph2 mRNA expression during constant light exposure is localised within 
the caudal DRV (Figure 5-12C). Accordingly, the one-way ANOVA showed a 
statistically significant effect of time; (F (4, 256) =5.394) p< 0.001. Similar to what 
was found in the caudal DRD, the peak of tph2 mRNA expression was seen at 9 pm 
and 3am. Then, expression levels decreased to an apparent extended nadir between 
9 am and 6 pm. Therefore, the Fisher’s LSD post-tests revealed that 9 pm is 
statistically increased when compared to 9 am (p<0.05), 3 pm (p<0.001) and 6 pm 
(p<0.01).  Similarly, at 3 am high levels were significantly higher than 9 am 
(p<0.05), 3 pm (p<0.01) and 6 pm (p<0.01). 
 
Figure 5-12: Circadian variation in tph2 mRNA expression in the DRV of LL treated animals. 
For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements of tph2 mRNA 
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expression (y axis) were averaged; (A) fourteen levels (-7.328 to -8.420 mm bregma) for the 
whole DRV, (B) eight levels (-7.328 to -7.916 mm bregma) and (C) seven levels (-7.916 to -
8.420 mm bregma) for the caudal DRV. Tph2 mRNA quantification is expressed as Calibrated 
Mean Grey Value multiplied by its own Measured Area. Data points correspond to the overall 
MEAN ± SEM of th2 expression of the whole/rostral/caudal DRV for each group/timepoint (n 
8/group [ 8 animals x 14/8/7 levels =  112/64/56 values]). One-way ANOVAs were 
performed to assess effect of time; (A) (F(4, 494) =1.271) p> 0.05; (B) F (4, 272) =0.445) p> 0.05; 
(C) (F (4, 256) =5.394) p< 0.001; ***p< 0.001 for 3 pm vs 9 pm; **p< 0.01  for 3 am vs 3 pm, 
for 3 am vs 6 pm and for 6 pm vs 9 pm; *p< 0.05 for 3am vs 9 am  and for 9 am vs 9 pm with 
Fisher’s Least Significant Difference test. 
Then, to assess changes between the natural circadian rhythm and the altered pattern 
in tph2 mRNA expression in the DRV after five weeks of LL, I plotted the data 
together (Figure 5-13). No interaction between treatment and time was found for 
either the whole DRV (Figure 5-13A); F(4, 1018) =2.006) p> 0.05, or the rostral DRV 
(Figure 5-13B); F (4, 574) =.055) p> 0.05. However, for the caudal DRV (Figure 5-
13C), the two-way ANOVA detected a significant interaction; (F (4, 512) =6.479) p< 
0.01. Fisher’s LSD post-tests further revealed that the observed differences in the 
caudal DRV between the LL and control groups were both statistically significant 
at both 9 pm and 3 pm (p<0.01).  
It therefore appeared that five weeks of constant light resulted in a fairly strong 
modification to the circadian rhythm of tph2 mRNA expression in the DRV. This 
alteration seemed to be specific to the caudal levels of the DRV and characterised 
by high levels of expression at 9 pm and 3 am and decreased expression at 3 pm, 
resulting in a striking dysregulation of the caudal DRV tph2 mRNA circadian 
rhythm that had been seen in control animals.  




Figure 5-13: Changes in circadian variation of tph2 mRNA expression in the DRV of Control 
vs LL treated animals. For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or LL); (A) fourteen levels (-7.328 to -8.420 mm bregma) for the whole DRV, (B) eight 
levels (-7.328 to -7.916 mm bregma) and (C) seven levels (-7.916 to -8.420 mm bregma) for the 
caudal DRV.  Tph2 mRNA quantification is expressed as Corrected Mean Grey Value 
multiplied by its own Measured Area (y axis). Data points correspond to the overall MEAN ± 
SEM of th2 expression of the whole/rostral/caudal DRV for each group/timepoint (CTRL vs LL 
[n 8/group [ 8 animals x 14/8/7 levels =  112/64/56 values]). Two-way ANOVAs were 
performed to assess interaction between treatment and time ; (A) (F (4, 1018) =2.006) p> 0.05; 
(B) (F (4, 574) =.055) p> 0.05; (C) (F (4, 512) =6.479) p< 0.01; **p< .01 when comparing CTRL 
vs LL at 3 pm and 9 pm with Fisher’s Least Significant Difference test. 
5.3.3.5 Dorsal raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal grey (DRVL/VLPAG). 
The DRVL/VLPAG subregion showed a similar circadian pattern of tph2 mRNA 
expression after LL treatment to that found in the DRD and caudal DRV (Figure 5-
14).  Interestingly, tph2 mRNA displayed high levels of expression at 3 am and 9 
pm and low levels at 3 pm and 6 pm in the whole (Figure 5-14A) and the caudal 
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DRVL/VLPAG (Figure 5-14C). No circadian pattern was observed in the rostral 
DRVL/VLPAG (Figure 5-14B). These observations were supported by one-way 
ANOVA which revealed a significant effect of time for the whole (F (4, 295) =3.976) 
p< 0.01) and caudal DRVL/VLPAG (F (4, 218) =4.218) p< 0.001), but no effect for 
the rostral DRVL/VLPAG (F (4, 111) =.171) p> 0.05).  
 
Further multiple comparisons within the whole DRVL/VLPAG with Fisher’s LSD 
post-tests showed that the peak of expression at 3 am and 9pm were both 
statistically increased when compared to 3 pm (p<0.01) and 6 pm (p<0.01). 
Comparable to the whole DRVL/VLPAG, the caudal levels of this subregion 
exhibited an even more pronounced rhythm in tph2 mRNA expression over the 24-
hour period. Again, tph2 mRNA expression appeared to maintain at peak levels 
from 9pm to 3am, with statistical differences found between 9 pm and the lower 
expression times of 9 am (p<0.05), 3 pm (p<0.001) and 6 pm (p<0.001). Similarly, 
for 3 am significant differences are found when compared to 9 am (p<0.05), 3 pm 
(p<0.001) and 6 pm (p<0.01). Therefore, this circadian pattern appeared to be 
characterised primarily by the high expression of tph2 mRNA at 3 am and 9 pm. 
 




Figure 5-14: Circadian variation in tph2 mRNA expression profile in the DRVL/VLPAG of LL 
treated animals. For each timepoint; 3 am, 9 am, 3 pm, 6 pm and 9 pm (x axis) measurements 
of Tph2 mRNA expression ( y axis) were averaged; (A) eight levels (-7.748 to -8.336 mm 
bregma) for the whole DRVL/VLPAG, (B) three levels (-7.748 to -7.916 mm bregma) for the 
rostral DRVL/VLPAG and (C) six levels (-7.916 to -8.336 mm bregma) for the caudal 
DRVL/VLPAG.Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value 
multiplied by its own Measured Area. Data points correspond to the overall MEAN ± SEM of 
tph2 expression of the whole/rostral/caudal DRVL/VLPAG for each group/timepoint (n 
8/group [  8 animals x 8/3/6 levels =  64/24/48 values]). One-way ANOVAs were performed 
to assess effect of time; (A) (F (4, 295) =3.976) p< 0.01; **p< 0.01 for 3 am vs 3 pm, for 3 am vs 
6 pm, for 3 pm vs 9 pm and for 6 pm vs 9 pm; (B) (F (4, 111) =.171) p> 0.05; (C) (F (4, 218) =4.218) 
p< 0.001; ***p< 0.001 for 3 pm vs 3 pm, for 3 pm vs 9 pm and for 6 pm vs 9 pm; **p< 0.01 
for 3 am vs 6 pm; *p< 0.05 for 3am vs 9 am and for 9 am vs 9 pm with Fisher’s Least Significant 
Difference test. 
Next, to assess changes resulting from treatment, I again plotted the data used in 
Figure 5-14 with the control data for the whole, rostral and caudal DRVL/VLPAG. 
In the whole DRVL/VLPAG (Figure 5-15A) five weeks of LL appeared to change 
the pattern of tph2 mRNA expression. Again, as in the DRD and caudal DRV, the 
pattern appeared to be almost reversed to the one observed under normal conditions. 
This observation was supported by a two-way ANOVA, which revealed a 
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significant interaction between treatment and time; F (4, 592) =4.905) p< 0.001. 
Again, Fisher’s LSD post-tests revealed that LL treatment triggered significantly 
higher levels of tph2 mRNA expression at 3 am (p<0.05) and 9 pm (p<0.01) 
compared to controls, and that a significant decrease at 3 pm was detected after LL 
treatment (p<0.05).  
No significant interaction; (F (4, 223) = 0.641 p> 0.05 was detected in the rostral 
DRVL/VLPAG after five weeks of LL (Figure 5-15B). However, when I assessed 
only the caudal levels of the DRVL/VLPAG, the striking inverted pattern, also 
found in the whole DRVL/VLPAG after five weeks of LL, appeared even more 
pronounced (Figure 5-15C). Accordingly, a significant interaction was reported by  
two-way ANOVA; (F (4, 437) = 7.374) p< 0.001. Post tests showed that the increased 
tph2 mRNA expression found at 3 am and 9 pm in the LL group were significantly 
different to their time matched controls, p< 0.001 at 9 pm and p< 0.01 at 3 am.  A 
significant increase was also detected in the LL group at 9 am (p<0.05). Moreover, 
the decrease found at 3 pm in the LL group, the nadir of this circadian dysregulated 
pattern, was also statistically different to the time matched control group (p<0.05). 
 
 




Figure 5-15: Changes in circadian variation of tph2 mRNA expression in the DRVL/VLPAG of 
Control vs LL treated animals.  For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or LL); (A) eight levels (-7.748 to -8.336 mm bregma) for the whole DRVL/VLPAG, (B) 
three levels (-7.748 to -7.916 mm bregma) for the rostral DRVL/VLPAG and (C) six levels (-
7.916 to -8.336 mm bregma) for the caudal DRVL/VLPAG. Tph2 mRNA quantification is 
expressed as Calibrated Mean Grey Value multiplied by its own Measured Area. Data points 
correspond to the overall MEAN ± SEM of tph2 mRNA expression of the whole/rostral/caudal 
DRVL/VLPAG for each group/timepoint (CTRL vs LL [n 8/group [  8 animals x 8/3/6 levels 
=  64/24/48 values]). Two-way ANOVAs were performed to assess interaction between 
treatment and time; (A) (F (4, 592) =4.905) p< 0.001; **p< 0.01 when comparing CTRL vs LL 
at 9 pm; * p< 0.05 when comparing CTRL vs LL at 3 am and 3 pm; (B) (F (4, 223) = 0.641 p> 
0.05; (C) (F (4, 437) = 7.374) p< 0.001; *** p< 0.001 when comparing CTRL vs LL at 9 pm; ** 
p< 0.01 when comparing CTRL vs LL at 3 am; *p< 0.05 when comparing CTRL vs LL at 9 am 
and 3 pm with Fisher’s Least Significant Difference test. 
5.3.3.6 Median Raphe nucleus (MnR). 
To determine if the MnR showed a circadian variation in tph2 mRNA expression 
after five weeks of constant light, one-way ANOVAs were completed for the whole, 
rostral and caudal MnR separately. 
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The MnR showed a fairly similar pattern to those found in the DRD, DRV and the 
DRVL/VLPAG, (Figure 5-16).  This pattern was somewhat ‘blunted’ in the whole 
MnR (Figure 5-16A), although a significant effect of time was still found by one-
way ANOVA; (F (4, 523) =2.573) p< 0.05. The observed peak in tph2 mRNA 
expression at 9 pm was statistically significant when compared to 6 pm (p<0.05), 3 
pm (p<0.01) and 9 am (p<0.05). The pattern was virtually non-existent in the rostral 
MnR (Figure 5-16B), the lack of circadian pattern was confirmed by one-way 
ANOVA with no significant effect of time; (F (4, 221) =2.186) p> 0.05. When the 
rostral levels were taken out, the caudal MnR exhibited a far more pronounced 
pattern (Figure 5-16C), and a significant effect of time was detected by one-way 
ANOVA; F (4, 336) =7.409) p< 0.001. Further multiple comparisons post-tests 
confirmed that the peak in tph2 mRNA expression at 9 pm was statistically different 
from 9 am (p<0.001), 3 pm (p<0.001) and 6 pm (p<0.001). Additionally, high levels 
of tph2 mRNA expression at 3 am also showed significant differences when 
compared to 9 am (p<0.05), 3 pm (p<0.05) and 6 pm (p<0.05). 
 




Figure 5-16: Circadian variation in tph2 mRNA expression in the MnR of LL treated animals.  
For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) measurements of tph2 mRNA 
expression (y axis) were averaged; (A) fifteen levels (-7.496 to -8.672 mm bregma) for the whole 
MnR, (B) six levels (-7.494 to -7.916 mm bregma) for the rostral MnR and (C) 10 levels (-7.916 
to 8.672 mm bregma) for the caudal MnR. Tph2 mRNA quantification is expressed as 
Calibrated Mean Grey Value multiplied by its own Measured Area. Data points correspond to 
the overall MEAN ± SEM of tph2 expression of the whole/rostral/caudal MnR for each 
group/timepoint (n 8/group [  8 animals x 15/6/10 levels =  120/48/80 values]). One-way 
ANOVAs were performed to assess effect of time; (A) (F (4, 523) =2.573) p< 0.05; **p< 0.01 for 
3 pm vs 9 pm: *p< 0.05 for 9 am vs 9 pm and for 6 pm vs 9 pm; (B) ((F (4, 221) =2.186) p> 0.05; 
(C) (F (4, 336) =7.409) p< 0.001; ***p< 0.001 for 9 am vs 9 pm, for 3 pm vs 9 pm and for 6 pm 
vs 9 pm; * p< 0.05 for 3 am vs 9 am, for 3 am vs 3 pm and for 3 am vs 6 pm with Fisher’s Least 
Significant Difference test. 
Next, I again assessed the changes between the normal circadian rhythm and the 
modified pattern in tph2 mRNA expression after five weeks of LL in the whole, 
rostral and caudal MnR (Figure 5-17). 
The whole MnR (Figure 5-17A), showed an interesting change in tph2 mRNA 
expression after LL exposure, which was detected by two-way ANOVA as it 
revealed a significant interaction between treatment and time; (F (4, 1016) = 3.637) p< 
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0.01. Interestingly the largest differences, between LL treated rats and controls, 
occurred at 3 pm and 9 pm. Further multiple comparisons post-tests showed a 
statistically significant decrease in tph2 mRNA expression at 3 pm after LL 
treatment, the time corresponding to the peak tph2 mRNA expression of the 
controls. Moreover, the peak in expression changed to 9 pm after LL treatment, 
which was a significant increase in expression when compared to the controls. 
The two-way ANOVA for the rostral MnR (Figure 5-17B) did not show a 
significant interaction; (F (4, 446) = 1.298) p> 0.05. In contrast, for the caudal MnR 
(Figure 5-17C), similar findings were observed as for the whole MnR, however, 
these changes were more pronounced. These changes were detected by the two-way 
ANOVA with a significant interaction; (F (4, 638) = 7.257) p< 0.001. The observed 
differences in the LL rats included a marked decrease in tph2 mRNA expression at 
3 pm, which was actually the peak tph2 mRNA expression time in controls. 
Furthermore, the peak tph2 mRNA expression time was shifted to 9 pm and the 
nadir shifted to 6 pm. The Fisher’s LSD post-tests revealed these three key 
timepoints; 3 pm (p<0.001), 6 pm (p<0.01) and 9 pm (p<0.01) to be significantly 
different between LL and control rats. Therefore, in the caudal MnR, once again, 
LL treatment appeared to profoundly affect the normal circadian rhythm of tph2 
mRNA expression by increasing tph2 mRNA expression when it would ‘normally’ 
be low (9pm) and reducing its expression when it would ‘normally’ be high (3 pm 
and 6 pm). 




Figure 5-17: Changes in circadian variation of tph2 mRNA expression in the MnR of Control 
vs LL treated animals.  For each timepoint; 3am, 9am, 3pm, 6pm and 9pm (x axis) 
measurements of tph2 mRNA expression (y axis) were averaged for each group separately 
(CTRL or LL; (A) fifteen levels (-7.496 to -8.672 mm bregma) for the whole MnR, (B) six levels 
(-7.494 to -7.916 mm bregma) for the rostral MnR and (C) 10 levels (-7.916 to 8.672 mm 
bregma) for the caudal MnR. Tph2 mRNA quantification is expressed as Calibrated Mean Grey 
Value multiplied by its own Measured Area. Data points correspond to the overall MEAN ± 
SEM of tph2 mRNA expression of the whole/rostral/caudal MnR for each group/timepoint (n 
8/group [  8 animals x 15/6/10 levels =  120/48/80 values]). Two-way ANOVAs were 
performed to assess interaction between treatment and time; (A) (F (4, 1016) = 3.637) p< 0.01; * 
p< 0.05 when comparing CTRL vs LL at 6 pm and 9 pm; (B) (F (4, 446) = 1.298) p> 0.05; (C) (F 
(4, 638) = 7.257) p< 0.001; *** p< 0.001 when comparing CTRL vs LL at 3 pm; ** p< 0.01 when 
comparing CTRL vs LL at 6 pm and   9 pm with Fisher’s Least Significant Difference test. 
5.3.4 Circadian rhythmicity of tph2 mRNA expression in the DR 
subregions and MnR nucleus after LL treatment; analysis 
across the full rostro-caudal gradient. 
Now, for this last section of the chapter, the goal was to assess the effects of five 
weeks of LL in the circadian activity of tph2 mRNA expression throughout the 
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rostro-caudal gradient of the DR subregions and the MnR nucleus. To accomplish 
this, several Linear Mixed Model (LMM) analyses were completed as described in 
the general methods chapter. Furthermore, a second overall LMM analysis was 
used to compare the changes in tph2 mRNA expression caused by LL treatment 
when compared to natural conditions throughout the rostro-caudal gradient of the 
DR subregions and the MnR nucleus. 
As for chapter 3 and 4, all LMM analyses were finalized and only if there were 
significant differences in any main factor or interaction, then, Fisher’s LSD post-
tests followed. All statistical tests were considered only if the sample size was 
above four animals (half the original sample size for each timepoint at each rostro-
caudal level). 
In General, tph2 mRNA expression changed throughout the rostro-caudal gradient 
in the all the DR subregions and MnR nucleus. Moreover, tph2 mRNA expression 
also changed over time in the DRD, DRV, DRVL/VLPAG subregions and MnR 
nucleus (Table 5-1). Furthermore, when assessing changes in tph2 mRNA 
expression under natural conditions and after LL treatment no changes were found 
in the DRC or DRI. Nevertheless, differences were found throughout multiple 
rostro-caudal levels of DRD, DRV DRVL/VLPAG and MnR at specific key time 
points assessed over the 24-hour period (Table 5-2).  
Analysis of the circadian activity of tph2 mRNA expression profile after LL 
treatment using LMM analysis revealed a rostro-caudal level * time point 
interaction (F (64, 9.073)= 3.071, p<.0. 019), a rostro-caudal level (raphe subregion) 
interaction (F (36, 74.334) = 36.636, p< 0.000), a main effect of rostro-caudal level (F (16, 
9.292) = 126.423, p < 0.000), a main effect of raphe subregion (F (5, 5.746) = 102.657, p< 
0.000) and a main effect of time point (F (4, 5.847) = 8.512, p< 0.013) (Table 5-1).  
Based upon the significant main effects and interactions in this first overall LMM 
analysis, secondary LMMs were then performed to assess how tph2 mRNA 
expression - over the entire rostro-caudal gradient in every subregion of the DR and 
the MnR changed over a 24 hour period Additionally, variations in tph2 mRNA 
expression across the rostro-caudal gradient at each time point were also assessed 
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independently, but for simplicity reasons, these changes are not represented in the 
Figures. 





Test statistic p-value 
Overall analysis for LL   
Unstructured Correlations covariance structure 
Akaike’s Information Criterion (AIC): 8636.898 
  
 Rostrocaudal level1 (1-17) F(16, 9.292) = 126.423 .000 *** 
 
Raphe subregion2 (DRC, DRI, DRD, 




Time point3 (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 5.847) = 8.512 
.013 * 
 Rostrocaudal level * Time point F(64, 9.073)= 3.071 .019 * 
 Raphe subregion * Time point F(20, 5.469)= .756 .706 
 Rostrocaudal level (Raphe subregion) F(36, 74.334) = 36.636 .000 *** 
 
Rostrocaudal level * Time point (Raphe 
subregion) 







First-Order Ante-dependence covariance structure 




Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 41.467)= 2.201 .086 
 Rostrocaudal level (13-17) F(4, 33.510)= 5.362 .002 ** 
  Time point * Rostrocaudal level F(16, 33.878)= 1.326 .238 
DRI 
Heterogeneous First-Order Autoregressive 
covariance structure 




Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 30.737)= 1.178 .340 
 Rostrocaudal level (14-17) F(3, 31.567)= 59.167 .000 *** 
  Time point * Rostrocaudal level F(12, 32.994)= 1.522 .166 
DRD   
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Unstructured Correlations covariance structure 
Akaike’s Information Criterion (AIC): 1745.481 
 
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 34.643)= 4.007 .009** 
 Rostrocaudal level (1-12) F(11,30.222)= 316.301 .000*** 
 Time point * Rostrocaudal level F(44,32.025)= 3.360 .000*** 
DRV 
Heterogeneous Toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 2201.773   
  
Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 41.987)= 1.911 .126 
 Rostrocaudal level (1-14) F(13, 66.808)= 48.956 .000 *** 
  Time point * Rostrocaudal level F(52, 69.091)= 1.634 .028 * 
DRVL/VLPAG 
Heterogeneous Compound Symmetry covariance 
structure 




Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 37.547)= 3.984 .009 ** 
 Rostrocaudal level (1-17) F(7, 69.588)= 69.599 .000 *** 
  Time point * Rostrocaudal level F(28, 70.977)= 1.787 .026 * 
MnR 
Unstructured covariance structure 




Time point (3 am, 9 am, 3 pm, 6 pm, 9 
pm) F(4, 147.722) = 1.424 .229 
 Rostrocaudal level (1-17) F(14, 10.452)= 25.909 .000 *** 
  Time point * Rostrocaudal level F(56, 1586.409)= 6.723 .000 *** 
1Rostrocaudal levels were well-defined from bregma levels given in the atlas; where most rostral 
level was -7.328 mm bregma (1 according to level code) progressing to the most caudal level at –
8.672 mm bregma (17 according to level code). Within this brain section 17 different and 
representative coronal sections of 12 µm were used to measure tph2 mRNA of the dorsal raphe 
nucleus and the median raphe nucleus. 2The Raphe subregions used in this research were the 
following: DRC, dorsal raphe nucleus, caudal part; DRI, dorsal raphe nucleus, interfascicular part; 
DRD, dorsal raphe nucleus, dorsal part; DRV, dorsal raphe nucleus, ventral part and 
DRVL/VLPAG, dorsal raphe nucleus, ventrolateral part/ventrolateral periaqueductal grey. MnR, 
median raphe nucleus was also included and considered as a subregion of the raphe complex. 3 The 
five different time points (3 am, 9 am, 3 pm, 6 pm, 9 pm) used in this study were considered as a 
suitable description of the circadian rhythm of tph2 mRNA expression. They were chosen to fit in 
parallel with the measured circadian rhythm of plasma CORT after LL treatment. *p<0.05. 
**p<0.01. ***p<0.001. 
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A second overall LMM analysis was performed to evaluate now the effect of 
treatment (LL versus ‘normal’ LD conditions) at each time point, across all rostro-
caudal levels and in all Raphe subregions. This analysis revealed a treatment * 
timepoint interaction (F (4, 511.600)  = 13.180, p< 0.000), a treatment * rostro-caudal 
level interaction (F (16, 405.927)  = 5.132, p <0.000), a timepoint* rostro-caudal level 
interaction (F (64, 444.210)  = 2.147, p< 0.000), a rostro-caudal level * raphe subregion 
interaction (F (36, 448.004)  = 61.503, p< 0.000),  a treatment * time point * rostro-
caudal level interaction (F (63, 455.830)  = 2.944, p<0.004) a treatment *rostro-caudal 
level (raphe subregion interaction) ( F (36, 435.701)  = 1.794, p < 0.004), a main effect 
in rostro-caudal level (F (16, 410.952)  = 235.431, p < 0.000) and a main effect in raphe 
subregion (F (5, 386.026)  = 210.632, p<0.000) (Table 5-2). 
Considering all the significant main effects and interactions found in this overall 
LMM analysis, subregional LMMs were used to assess the effect of treatment (LL 
versus ‘normal’ LD conditions) at each time point, across the rostro-caudal gradient 
of each DR subregion and MnR nucleus separately (Table 5-2). Moreover, as 
explained previously, changes across the rostro-caudal gradient within each time 
point were also assessed, but for simplicity reasons, these changes are not 
represented in the Figures. 
Table 5-2: Linear mixed model analysis results for tph2 mRNA expression in Control vs LL 
treated SD male rats. 
 
Model  Test statistic p-value 
Overall analysis for Controls vs LL 
 
  
Heterogeneous Toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 16595.877   
 Treatment1 (CTRL vs LL) F(1, 508.120)= .171 .679 
  Time point2 (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 505.185) = .274 .895 
  Rostrocaudal level3 (1-17) F(16, 410.952)  = 235.431 .000 *** 
  
Raphe subregion4  (DRC, DRI, DRD, DRV, 
DRVL/VLPAG, MnR) F(5, 386.026)  = 210.632 .000 *** 
 Treatment * Time point  F(4, 511.600)  = 13.180 .000 *** 
 Treatment * Rostrocaudal level F(16, 405.927)  = 5.132 .000 *** 
 Treatment * Raphe subregion F(5, 384.611)  = 13.180 .785 
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  Time point * Rostrocaudal level F(64, 444.210)  = 2.147 .000 *** 
 Time point * Raphe subregion F(20, 387.148)  = .684 .843 
 Rostrocaudal level * Raphe subregion F(36, 448.004)  = 61.503 .000 *** 
 Treatment * Time point * Raphe subregion F(20, 388.360)  = .632 .889 
 Treatment * Time point * Rostrocaudal level F(63, 455.830)  = 2.944 .000 *** 
 
Treatment * Rostrocaudal level (Raphe 
subregion) 
F(36, 435.701)  = 1.794 .004 ** 
 Time point * Rostrocaudal level (Raphe 
subregion) 
F(144, 524.350)  = 1.058 .326 
 
Treatment * Time point * Rostrocaudal level 
(Raphe subregion) 





First-Order Autoregressive covariance structure 
Akaike’s Information Criterion (AIC): 1113.543 
 
  
  Treatment (CTRL vs LL) F(1, 106.215) = .028 .867 
 Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 98.741) = .280 .890 
  Rostrocaudal level (13-17) F(4, 183.051) = 4.389 .002 ** 
 Treatment * Timepoint F(4, 97.135)= 1. 977 .104 
  Treatment * Rostrocaudal level F(4, 183.138)= .375 .826 
 Timepoint * Rostrocaudal level F(16, 180.577) = 1.250 .234 
 Treatment * Time point * Rostrocaudal level  F(15, 179.008) = .629 .848 
DRI 
Unstructured Correlations covariance structure 
Akaike’s Information Criterion (AIC): 773.089 
 
  
  Treatment (CTRL vs LL) F(1, 43.119)= 2.394 .129 
 Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 43.157)= 1.872 .133 
  Rostrocaudal level (14-17) F(3, 33.719)= 133.870 .000 *** 
 Treatment * Timepoint F(4, 45.735)= .980 .428 
  Treatment * Rostrocaudal level F(3, 33.522) = 2.246 .101 
 Timepoint * Rostrocaudal level F(12, 33.798)= 1.611 .135 
 Treatment * Time point * Rostrocaudal level  F(11, 36.668)= 1.401  .214 
DRD 
Heterogeneous Toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 3510.182   
  Treatment (CTRL vs LL) F(1, 67.800)= .037 .848 
 Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 67.790)= .850 .498 
  Rostrocaudal level (1-12) F(11, 128.787)= 100.357 .000 *** 
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 Treatment * Timepoint F(4, 67.790)= 5.899 .000 *** 
  Treatment * Rostrocaudal level F(11, 128.787)= 5.701 .000 *** 
 Timepoint * Rostrocaudal level F(44, 140.805)= 1.395 .075 
 Treatment * Time point * Rostrocaudal level  F(44, 140.805)= 1.803 .005 ** 
DRV 
Heterogeneous Toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 4430.078 
 
  
  Treatment (CTRL vs LL) F(1, 87.798)= .031 .861 
 Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 87.766)= .472 .756 
  Rostrocaudal level (1-14) F(13, 124.997)= 121.636 .000 *** 
 Treatment * Timepoint F(4, 87.766)= 3.109    .019 * 
  Treatment * Rostrocaudal level F(13, 124.997)= 1.424 .157 
 Timepoint * Rostrocaudal level F(52, 127.943)= 1.503 .034 * 
 Treatment * Time point * Rostrocaudal level  F(52, 127.943)= 1.750 .006 ** 
DRVL/VLPAG 
Heterogeneous Toeplitz covariance structure 
Akaike’s Information Criterion (AIC): 2602.203 
 
  
  Treatment (CTRL vs LL) F(1, 76.607) = 2.723 .103 
 Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 76.570)= .985 .421 
  Rostrocaudal level (6-13) F(7, 114.074)= 116.452 .000 *** 
 Treatment * Timepoint F(4, 76.570)= 6.226 .000 *** 
  Treatment * Rostrocaudal level F(7, 114.074)= 7.358 .000 *** 
 Timepoint * Rostrocaudal level F(28, 114.112) = 1.295 .172 
 Treatment * Time point * Rostrocaudal level  F(28, 114.112) = 1.624 .040 * 
MnR 
First-Order Ante-dependence covariance structure 
Akaike’s Information Criterion (AIC): 3055.346 
 
  
  Treatment (CTRL vs LL) F(1, 117.985)= .437 .510 
 Time point (3 am, 9 am, 3 pm, 6 pm, 9 pm) F(4, 117.295)= .435 .783 
  Rostrocaudal level (3-17) F(13, 155.194)= 56.143 .000 *** 
 Treatment * Timepoint F(4, 118.402)= 2.539 .043 * 
  Treatment * Rostrocaudal level F(13, 152.320)= 4.234 .000 *** 
 Timepoint * Rostrocaudal level F(52, 164.365)= 2.772 .000 *** 
 Treatment * Time point * Rostrocaudal level  F (51, 154.449) = 3.667 .000 *** 
1Two different treatment groups (n40/group) were considered in this study; Controls and LL treated 
SD male rats.2The five different time points (3 am, 9 am, 3 pm, 6 pm, 9 pm) used in this study were 
considered as a suitable description of the circadian rhythm of tph2 mRNA expression. They were 
chosen to fit in parallel with the measured circadian rhythm of plasma CORT. 3Rostrocaudal levels 
were well-defined from bregma levels given in the atlas; where most rostral level was -7.328 mm 
bregma (1 according to level code) progressing to the most caudal level at –8.672 mm bregma (17 
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according to level code). Within this brain section 17 different and representative coronal sections 
of 12 µm were used to measure tph2 mRNA of the dorsal raphe nucleus and the median raphe 
nucleus. 4The Raphe subregions used in this research were the following: DRC, dorsal raphe 
nucleus, caudal part; DRI, dorsal raphe nucleus, interfascicular part; DRD, dorsal raphe nucleus, 
dorsal part; DRV, dorsal raphe nucleus, ventral part and DRVL/VLPAG, dorsal raphe nucleus, 
ventrolateral part/ventrolateral periaqueductal grey. MnR, median raphe nucleus was also included 
and considered as a subregion of the Raphe complex. *p<0.05. **p<0.01. ***p<0.001. 
5.3.4.1 Dorsal Raphe nucleus (DRC). 
The secondary LMM analysis to assess the circadian variation, within the DRC 
revealed only a main effect in the rostro-caudal level variable (F (4, 33.510)= 5.362, p 
<0.000) and no effect in time or interaction (Table 5-1) (Figure 5-18). Interestingly, 
the LMM was unable to detect a circadian variation in tph2 mRNA expression 
within the rostro-caudal extent of the DRC after LL treatment, which is inconsistent 
with the circadian variation found in the simpler (averaged data) analysis (Figure 
5-6).  This unexpected finding could be based in the fact that the sample size for 
each rostro-caudal level was not big enough while the averaged analysis had 
sufficient data to be statistically significant.  
 
Figure 5-18: Rostro-caudal level variation of tph2 mRNA expression profile in the DRC of LL 
treated animals. Tph2 mRNA expression in the DRC was measured in five different rostro-
caudal levels presented in the x axis (-8.336 to -8.672 mm bregma). Five different timepoints; 
3 am, 9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-caudal level (time course). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
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Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression of each group/timepoint 
(n 8/group) for each rostro-caudal level. Performed Fisher’s Least Significant difference test 
showed the following significant differences: (ad) p< 0.05 for 3 am vs 6 pm, (ce) p< 0.05 for 3 
pm vs 9 pm, (de) p< 0.05 for 6 pm vs 9 pm. 
Moreover, as observed in Figure 5-19, the subregional LMM analysis to assess the 
circadian variation between treatment groups, revealed only a rostro-caudal level 
effect (F (4, 183.051) = 4.389, p<0.01) and no effect of treatment (F (1, 508.120)= .171, 
p>0.05) or time point (F (4, 505.185) = .274, p>0.05), nor any other interaction (Table 
5-2) within this subregion of the DRC. Therefore, no post-tests were performed.  
 
Figure 5-19: Circadian changes in tph2 mRNA expression at each rostro-caudal level in the 
DRC of Controls versus LL treated animals. Tph2 mRNA expression in the DRC was measured 
in five different rostro-caudal levels presented in the x axis (-8.336 to -8.672 mm bregma) at 
five different time points; (A) 3 am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. Tph2 mRNA 
quantification is expressed as Calibrated Mean Grey Value multiplied by its own Measured 
Area. Top data points are associated to the right y-axis which represent the after Grubb’s test 
sample size at each rostro-caudal level. Bottom data points are linked to the left y-axis which 
correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL or LL [n 
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8/each group]) at each of the five rostro-caudal levels of the DRC. Fisher’s Least Significant 
Difference post hoc test showed no significant differences. 
Taking these LMM analyses into consideration, it seems that the DRC did not 
display a circadian variation within its rostro-caudal levels after five weeks of 
constant light. However, because even under normal conditions the DRC doesn’t 
exhibit a circadian variation and this analysis is inconsistent to the simpler analysis, 
the effect shown of LL treatment in this specific DR subregion cannot be taken into 
consideration for interpretation.  
5.3.4.2 Dorsal Raphe nucleus, interfascicular part (DRI). 
Secondary LMM analysis within the DRI revealed a significant main effect of 
rostro-caudal level (F (3, 31.567)= 59.167, p <0.000) and no effect of time or 
interaction (Table 5-1). Therefore, as shown in Figure 5-20, the rostro-caudal extent 
of the DRI does not exhibit a circadian pattern of tph2 mRNA expression after LL 
treatment.  
 
Figure 5-20: Rostro-caudal level variation of tph2 mRNA expression profile in the DRI of LL 
treated animals. Tph2 mRNA expression in the DRI was measured in four different rostro-
caudal levels presented in the x axis (-8.420 to -8.672 mm bregma). Five different timepoints; 
3 am, 9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-caudal level (time course). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
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Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN value ± SEM of tph2 mRNA expression for each 
group/timepoint (n 8/group) for each rostro-caudal level. Performed Fisher’s Least 
Significant difference test showed the following significant differences: (bc) p< 0.05 for 9 am 
vs 3 pm, (bd) p< 0.05 for 9 am vs 6 pm, (be) p< 0.05 for 9 am vs 9 pm. 
The subregional LMM analysis assessing the pattern of circadian variation after LL 
treatment when compared to controls, revealed only a significant difference in 
rostro-caudal level (F (3, 33.719)= 133.870, p< 0.000) (Table 5-2), therefore, no post 
tests were performed for this subregion (Figure 5.21). 
 
Figure 5-21: Circadian changes in tph2 mRNA expression at each rostro-caudal level in the 
DRI of Controls versus LL treated animals. Tph2 mRNA expression in the DRI was measured 
in four different rostro-caudal levels presented in the x axis (-8.420 to -8.672mm bregma) at 
five different time points; (A) 3am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. Tph2 mRNA 
quantification is expressed as Calibrated Mean Grey Value multiplied by its own Measured 
Area. Top data points are associated to the right y-axis which represent the after Grubb’s test 
sample size at each rostro-caudal level. Bottom data points are linked to the left y-axis which 
correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL or LL [n 
8/each group]) at each of the four rostro-caudal level of the DRI. Fisher’s Least Significant 
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Difference post hoc test showed the following significant differences; (B) *p< 0.05 for CTRL 
vs LL in level 14 at 9 am.  
5.3.4.3 Dorsal Raphe nucleus, dorsal part (DRD). 
Now, considering the subregional secondary LMM analysis performed for the DRD 
the resulting significant differences were revealed; a timepoint * rostro-caudal level 
interaction (F (44,32.025)= 3.360, p< 0.000), a main effect in time point (F (4, 34.643)= 
4.007, p <0.009) and a main effect of rostro-caudal level (F (11,30.222)= 
316.301p<0.000). Additionally, post-tests revealed various statistically significant 
differences, confirming a strong circadian variation in tph2 mRNA expression after 
five weeks of constant light within the DRD (Figure 5-22).  Significant differences 
throughout the rostro-caudal levels within each time point are not shown in the 
Figure. However, when looking at the effect in tph2 mRNA expression over time, 
six different levels of the DRD reached statistical significance. Interestingly, a 
strong effect of LL is observed in the caudal levels of the DRD (9 to 12) where the 
3am peak becomes significantly different when compared to 3pm and 6pm time 
points, which is consistent with the averaged analyses of the DRD caudal levels in 
the section above. This condition is observed even in the rostral level 5 and 7, where 
6 pm.  In general, a clear trend in the data can be seen where the 6 pm nadir is 
different from the 3 am and 9 am peak, however statistical differences are only 
reached in specific levels. 




Figure 5-22: Rostro-caudal level variation of tph2 mRNA expression profile in the DRD of LL 
treated animals. Tph2 mRNA expression in the DRD was measured in twelve different rostro-
caudal levels presented in the x axis (-7.328 to -8.252 mm bregma). Five different timepoints; 
3 am, 9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-caudal level (time course). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN value ± SEM of tph2 mRNA expression for each 
group/timepoint (n 8/group) for each rostro-caudal level. Performed Fisher’s Least 
Significant difference test showed the following significant differences:  (bbcc) p< 0.01 for 9 
am vs 3pm, (ccee) p< 0.01 for 3 pm vs 9 pm, (ddee) p< 0.01 for 6 pm vs 9 pm, (ac) p< 0.05 for 
3 am vs 3 pm, (ad) p< 0.05 for 3 am vs 6 pm, (bd) p< 0.05 for 9 am vs 6 pm, (ce) p< 0.05 for 3 
pm vs 9 pm, (de) p< 0.05 6 pm vs 9 pm. 
To evaluate changes in the circadian rhythm of tph2 mRNA expression after five 
weeks of LL when compared to controls, a secondary LMM analysis was performed 
for the DRD. This analysis revealed a treatment * timepoint interaction (F (4, 67.790)= 
5.899, p< 0.000), a treatment * rostro-caudal level interaction (F (11, 128.787)= 5.701, 
p <0.000), a treatment *timepoint * rostro-caudal level interaction (F (44, 140.805)= 
1.803, p< 0.005) and a main effect of rostro-caudal level (F (11, 128.787)= 100.357, 
p<0.000). Multiple comparisons showed an interesting pattern within the DRD 
(Figure 5-23) which strongly coincided with the simpler DRD analysis (section 
above) as higher expression of tph2 mRNA after LL treatment was seen at 3 am 
(Figure 5-23A), 9am (Figure 5-23B) and 9pm (Figure 5-23E) and lower expression 
was observed in the 3pm (Figure 5-23C) and 6 pm (Figure 5-23D) timepoints when 
   Chapter 5 
202 
 
compared to controls. Fascinatingly, higher tph2 mRNA expression was mainly 
specific to the caudal levels (10-12), whereas lower expression was seen in the 
rostral levels at least in the 6 pm timepoint, because at 3 pm, even when a trend in 
lower levels after LL treatment was observed in almost all the levels, no statistical 
difference was reached. 
 
Figure 5-23: Circadian changes in tph2 mRNA expression at each rostro-caudal level in the 
DRD of Controls vs LL treated animals. Tph2 mRNA expression in the DRD was measured in 
twelve different rostro-caudal levels presented in the x axis (-7.328 to -8.252 mm bregma) at 
five different time point: (A) 3am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. Tph2 mRNA 
quantification is expressed as Calibrated Mean Grey Value multiplied by its own Measured 
Area. Top data points are associated to the right y-axis which represent the after Grubb’s test 
sample size at each rostro-caudal level. Bottom data points are linked to the left y-axis which 
correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL or LL [n 
8/each group]) at each of the twelve rostro-caudal level of the DRD. Fisher’s Least Significant 
Difference post hoc test showed the following significant differences;  (A) **p< 0.01 for CTRL 
vs LL in level 10 and 11, and *p< 0.05 in level 4 and 12 at 3 am; (B) **p< 0.01 for CTRL vs 
LL in level 10 and *p< 0.05 L in level 101 and 12 at 9 am; (C) *p< 0.05 for CTRL vs LL in 
level 8 at 3 pm; (D) ***p< 0.001 for CTRL vs LL in level 5 and 9, **p< 0.01 in level 3 and 11, 
and *p< 0.05 in level 4 at 6 pm; (E) **p< 0.01 for CTRL vs LL in level10, 11 and 12 at 9 pm. 
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Accordingly, it appears that the DRD displayed a strong circadian variation across 
its 12 rostro-caudal levels after LL treatment, which seems to have a strong effect 
when compared to the natural rhythm of tph2 mRNA expression across the 24-hour 
period within this specific subregion.  
5.3.4.4 Dorsal Raphe nucleus, ventral part (DRV). 
For the DRV, the secondary LMM analysis which assessed only the circadian 
variation after LL, revealed a time point *rostro-caudal interaction (F (52, 69.091)= 
1.634, p<0.028) and a main effect in rostro-caudal level (F (13, 66.808)= 48.956, p< 
0.000) (Table 5-11). Fisher’s LL tests revealed various significant differences in 
tph2 mRNA expression throughout the rostro-caudal gradient within each time 
point, nonetheless, they are not shown in the Figure. However, post-tests also 
revealed differences over time at each rostro-caudal level which seemed to 
correspond almost entirely to the differences between the 3 am and 9 pm peak and 
the 3 pm and 6 pm nadir (Figure 5-24). Again, similar to the DRD subregion, these 
changes were primarily specific to the caudal levels of the DRV (10-14), which 
again agrees with the simpler subregion analysis.  




Figure 5-24: Rostro-caudal level variation of tph2 mRNA expression profile in the DRV of LL 
treated animals. Tph2 mRNA expression in the DRV was measured in fourteen different rostro-
caudal levels presented in the x axis (-7.328 to -8.420 mm bregma). Five different timepoints; 
3 am, 9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-caudal level (time course). Tph2 
mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN value ± SEM of tph2 mRNA expression for each 
group/timepoint (n 8/group) for each rostro-caudal level. Performed Fisher’s Least 
Significant difference test showed the following significant differences: (ccee) p< 0.01 for 3 pm 
vs 9 pm, (ac) p< 0.05 for 3 am vs 3 pm, (ad) p< 0.05 for 3 am vs 6 pm, (be) p< 0.05 for 9 am 
vs 9 pm, (cd) p< 0.05 for 3 pm vs 6 pm, (ce) p< 0.05 for 3 pm vs 9 pm, (de) p< 0.05 6 pm vs 9 
pm. 
The second  subregional  LMM analysis was performed for the DRV to additionally 
evaluate the effect of LL treatment in comparison to the ‘normal’ controls, and it 
revealed a treatment * timepoint interaction (F (4, 87.766)= 3.109, p< 0.019), a 
timepoint * rostro-caudal level interaction (F (52, 127.943)= 1.503, p< 0.034), a  
treatment * timepoint * rostro-caudal level interaction (F (52, 127.943)= 1.750, p< 
0.006) and a main effect in rostro-caudal level (F (13, 124.997)= 121.636, p<0.000) 
(Table 5-2). Post-multiple comparisons showed a treatment effect in all time points 
assessed within the DRV (Figure 5-25). However, even when statistical 
significance was reached only at specific rostro-caudal levels (with 3 pm as an 
exception) a robust trend was seen in the data from 3 am (Figure 5-25A) and 9 pm 
(Figure 5-25E) which showed higher expression levels after LL treatment. 
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Moreover, these high levels contrasted with the decreased expression observed in 
the caudal levels of the DRV at 3 pm (Figure 5-25C). 
 
Figure 5-25: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRV of Controls vs LL treated animals. Tph2 mRNA expression in the DRV 
was measured in fourteen different rostro-caudal levels presented in the x axis (-7.328 to -8.420 
mm bregma) at five different time point: (A) 3am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. 
Tph2 mRNA quantification is expressed as Calibrated Mean Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL 
or LL [n 8/each group]) at each of the fourteen rostro-caudal level of the DRV. Fisher’s Least 
Significant Difference post hoc test showed the following significant differences; (A) *p< 0.05 
for CTRL vs LL in level 12 at 3 am; (B) **p< 0.01 for CTRL vs LL in level 10 at 9 am; (C) 
**p< 0.01 for CTRL vs LL in level 13 and *p< 0.05 in level 8, 9, 10, 11, 14  at 3 pm; (D) 
***p<0.01 for CTRL vs LL in level 9 at 6 pm; *p< 0.05 in level 5 and 7 at 6pm; (E) **p< 0.01 
for CTRL vs LL in level 10 and *p< 0.05 in level 12. 
Once again, it looks like after LL treatment, the DRV displayed a strong circadian 
variation in tph2 mRNA expression across its extent of 14 rostro-caudal levels. 
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Furthermore, the five weeks of LL treatment seemed to have substantially changed 
tph2 mRNA expression across the 24-hour period when compared to controls 
within this specific DR subregion, this changed was predominantly observed in its 
caudal levels.  
5.3.4.5 Dorsal Raphe nucleus, ventrolateral part/ventrolateral 
periaqueductal grey (DRVL/VLPAG). 
For the DRVL/VLPAG, the secondary LMM analysis which assessed tph2 mRNA 
expression after LL treatment, revealed a time point *rostro-caudal interaction (F 
(28, 70.977)= 1.787, p<0.026),  a main effect in timepoint (F (4, 37.547)= 3.984, p<0.009) 
and a main effect in rostro-caudal level (F (7, 69.588)= 69.599, p< 0.000). Interestingly, 
LSD post-tests in the DRVL.VLPAG (Figure 5-26) showed a decreased tph2 
mRNA expression at 6pm and 3pm in almost all the caudal levels when compared 
to the 3am and 9 pm peak in expression. All these changes however, only reached 
statistical significance at level 11 (with other few statistical differences in level 9,10 
and 13), but a strong trend was observed from level 9 to 13.   
 
Figure 5-26: Rostro-caudal level variation of tph2 mRNA expression profile in the 
DRVL/VLPAG of LL treated animals. Tph2 mRNA expression in the DRVL/VLPAG was 
measured in eight different rostro-caudal levels presented in the x axis (-7.748 to -8.336 mm 
bregma). Five different timepoints; 3 am, 9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-
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caudal level (time course). Tph2 mRNA quantification is expressed as Calibrated Mean Grey 
Value multiplied by its own Measured Area. Top data points are associated to the right y-axis 
which represent the after Grubb’s test sample size at each rostro-caudal level. Bottom data 
points are linked to the left y-axis which correspond to the MEAN value ± SEM of tph2 mRNA 
expression for each group/timepoint (n 8/group) for each rostro-caudal level. Performed 
Fisher’s Least Significant difference test showed the following significant differences: (aacc) 
p< 0.01 for 3 am vs 3 pm, (ccee) p< 0.01 for 3 pm vs 9 pm, (ac) p< 0.05 for 3 am vs 3 pm, (ad) 
p< 0.05 for 3 am vs 6 pm, (ce) p< 0.05 for 3 pm vs 9 pm, (de) p< 0.05 for 6 pm vs 9 pm. 
Furthermore, the second subregional LMM analysis for DRVL/VLPAG was 
performed to further assess the effect of LL treatment compared to normal controls. 
Analysis revealed a treatment * time point interaction (F (4, 76.570)= 6.226, p<0.000), 
a treatment * rostro-caudal interaction (F (7, 114.074)= 7.358, p<0.000), a treatment * 
time point * rostro-caudal level interaction (F (28, 114.112) = 1.624, p< 0.040) and a 
main effect in rostro-caudal level (F (7, 114.074)= 116.452, p< 0.000). Furthermore, as 
observed in Figure 5-27, multiple comparisons showed a very fascinating pattern 
which concurred with the simpler subregion analysis shown in the section above 
for the DRVL/VLPAG. Interestingly, even when not all rostro-caudal levels were 
found statistically different, for the 3 am (Figure 5-27A), 9 am (Figure 5-27B) and 
9 pm (Figure 5-27E) a trend of very high tph2 mRNA expression after LL treatment 
was observed in the caudal levels, relative to controls and in contrast, low 
expression was shown in all the almost all the rostro-caudal levels at 3 pm (Figure 
5-27C) and just in specific levels at 6 pm (Figure 5-27D).  




Figure 5-27: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the DRVL/VLPAG of Controls vs LL treated animals. Tph2 mRNA expression in 
the DRVL/VLPAG was measured in eight different rostro-caudal levels presented in the x axis 
(-7.748 to -8.336 mm bregma) at five different time point: (A) 3am, (B) 9 am, (C) 3 pm, (D) 6 
pm and (E) 9 pm. Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value 
multiplied by its own Measured Area. Top data points are associated to the right y-axis which 
represent the after Grubb’s test sample size at each rostro-caudal level. Bottom data points are 
linked to the left y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for 
each group (CTRL or LL [n 8/each group]) at each of the eight rostro-caudal level of the 
DRVL/VLPAG. Fisher’s Least Significant Difference post hoc test showed the following 
significant differences; (A)***p< 0.001 for CTRL vs LL in level 11 and *p< 0.05 in level 10 
and 13 at 3 am; (B) **p< 0.01 for CTRL vs LL in level 10 and 11 at 9 am; (C) **p< 0.01 for 
CTRL vs LL in level 9 and *p< 0.05 in level 8, 12 and 13 at 3 pm; (D) ***p< 0.001 for CTRL 
vs LL in level 9, **p<0.01 in level 6 and *p< 0.05 in level 10  at 6 pm; (E) ***p< 0.001 for 
CTRL vs LL in level 10, **p<0.01 in level 6 and 11 and *p< 0.05 in level 9 at 9 pm.   
Consistent to the other DR subregions, it looked like the DRVL/VLPAG exhibited 
a strong circadian variation across its rostro-caudal gradient after five weeks of LL 
treatment, however, in this subregion, this pattern did not seem to be specific to the 
caudal levels. Additionally, the five weeks of LL treatment seem to have a strong 
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effect in tph2 mRNA expression across the 24-hour period when compared to 
normal conditions. This changed pattern, seemed to be more pronounced in the 3 
am and 9 pm time point, which was consistent with the described in previous 
sections. 
5.3.4.6 Median Raphe nucleus (MnR).  
Last, to complete this particular study two final subregional LMM analyses were 
performed for the MnR; the first aimed to assess how the tph2 mRNA expression 
changed over a 24-hour period after five weeks LL and the second to assess whether 
there was an additional effect of treatment (LL vs ‘normal’ controls) at any of the 
designated timepoints. 
The first analysis revealed a time point * rostro-caudal level interaction (F (56, 
1586.409) = 6.723, p< 0.000) and a main effect in rostro-caudal level (F (14, 10.452)= 
25.909, p< 0.000) (Table 5-1). Post-tests within the MnR revealed many numerous 
differences (Figure 5-28), however, the most noticeable condition to mention is that 
most of the statistically significant differences were seen between level 9 to level 
14, these differences seemed to depend fundamentally on the fact that in these 
levels, the 9 pm group exhibited the highest tph2 mRNA expression while the 6 pm 
groups presented the lowest expression with the exception of level 13 which 
displayed its lowest expression at 3 pm. Moreover, in levels 13 to 14 more 
differences were shown when compared to 3 pm, given that this time point also had 
a high expression of tph2 mRNA. Throughout the rostro-caudal gradient of this 
particular subregion, statistical significances went from strong to weak differences, 
demonstrating a particular circadian variation of tph2 mRNA expression across the 
span of the MnR. 




Figure 5-28: Rostro-caudal level variation of tph2 mRNA expression profile in the MnR of LL 
treated animals. Tph2 mRNA expression in the MnR was measured in fifteen different rostro-
caudal levels presented in the x axis (-7.496 to -8.672 mm bregma). Five different timepoints; 
3 am, 9 am, 3 pm, 6 pm and 9 pm are shown for each rostro-caudal level (time course). Tph2 
mRNA quantification is expressed as Corrected Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN value ± SEM of tph2 mRNA expression for each 
group/timepoint (n 8/group) for each rostro-caudal level. Performed Fisher’s Least 
Significant difference test showed the following significant differences:  (bbbeee) p< 0.001 for 
9 am vs 9 pm, (dddeee) p< 0.001 for 6 pm vs 9 pm, (aabb) p< 0.01 for 3 am vs 9 am, (aadd) 
p< 0.01 for 3 am vs 6 pm, (bbcc) p< 0.01 for 9 am vs 3 pm, (bbee)  p< 0.01 for 9 am vs 9 pm 
(ccee) p< 0.01 for 3 pm vs 9 pm, (ac) p< 0.05 for 3 am vs 3 pm, (ad) p< 0.05 for 3 am vs 6 pm, 
(be) p< 0.05 for 9 am vs 9 pm, (cd) p< 0.05 for 3 pm vs 6 pm, (ce) p< 0.05 for 3 pm vs 9 pm, 
(de) p< 0.05 for 6 pm vs 9 pm. 
Finally, the concluding secondary LMM analysis performed for the MnR revealed 
a treatment * time point interaction (F(4, 118.402)= 2.539, p<0.043), a treatment * 
rostro-caudal level interaction (F(13, 152.320)= 4.234, p<0.000), a time point * rostro-
caudal level interaction (F(52, 164.365)= 2.772, p<0.000), a treatment * time point * 
rostro-caudal level interaction (F (51, 154.449) = 3.667) and a main effect in rostro-
caudal level (F (13, 155.194)= 56.143, p< 0.000) (Table; 5-2). Multiple comparisons 
with Fisher’s LSD tests revealed many significant differences in tph2 mRNA 
expression throughout the rostro-caudal levels within each time point but these 
were not shown in the corresponding Figure. However, when considering 
differences between treatment groups in the MnR (Figure 5-29), multiple 
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comparisons showed that; 1) no differences whatsoever were observed at 3 am 
(Figure 5-29A) 2) at 9 am (Figure 5-29-B) higher tph2 mRNA expression was found 
from rostro-caudal level 3 to 10, but were only statistically significant for level 4,5 
and 7; 3) higher tph2 mRNA expression was observed from level 9 to 13  at 9 pm 
(Figure 5-29E) in the LL treatment group and 4) low tph2 mRNA expression 
appeared in levels 11 to 14 at 3 pm (Figure 5-29C) and 6 pm (Figure 5-29D). All 
these findings again correspond to what was observed in the simpler subregion 
analysis which showed a peak in expression at 9 pm, and the 9 am to 6 pm nadir.   
 
Figure 5-29: Circadian changes in tph2 mRNA expression at each rostro-caudal level 
expression in the MnR of Controls vs LL treated animals. Tph2 mRNA expression in the MnR 
was measured in fifteen different rostro-caudal levels presented in the x axis (-7.496 to -8.672 
mm bregma) at five different time point: (A) 3am, (B) 9 am, (C) 3 pm, (D) 6 pm and (E) 9 pm. 
Tph2 mRNA quantification is expressed as Calibrated Mean Grey Value multiplied by its own 
Measured Area. Top data points are associated to the right y-axis which represent the after 
Grubb’s test sample size at each rostro-caudal level. Bottom data points are linked to the left 
y-axis which correspond to the MEAN ± SEM of tph2 mRNA expression for each group (CTRL 
or LL [n 8/each group]) at each of the fifteen rostro-caudal level of the MnR. Fisher’s Least 
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Significant Difference post hoc test showed the following significant differences; (A) ns at 3 
am; (B) **p< 0.01 for CTRL vs LL in level 7 and 14, and *p< 0.05 in level 4, 5, and 13 at 9 
am; (C) ***p< 0.001 for CTRL vs LL in level 13, **p< 0.01 level 12 and *p< 0.05 in level 14 
at 3 pm; (D) ***p< 0.001 for CTRL vs LL in level 14, **p< 0.01 in level 13 and *p< 0.05 in 
level 8, 9 and 12 at 6 pm; (E) **p< 0.01 for CTRL vs LL in level 11 and 13 and *p< 0.05 in 
level 4, 10, 12 at 9 pm. 
All these changes observed in the MnR nucleus denotate a robust variation in tph2 
mRNA expression throughout its rostro-caudal levels and across a 24-hour period. 
Consistent to several subregions of the DR nucleus, the tph2 mRNA circadian 
activity also seemed to depend mainly in the caudal levels of the MnR. Moreover, 
a solid effect of five weeks of LL in this pattern of expression is observed in the 
complete time period, however, more changes can be appreciated principally at the 
late time points (6 pm and 9 pm).  
5.3.5 Summary of Results 
The following table is a summary of the key findings on this chap
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Table 5-3: Key findings of the circadian expression of tph2 mRNA after MPL treatment. Data shown by subdivision of the Raphe complex and by bregma level. Differences 
found by statistical analysis form ANOVA’s and Linear Mixed Model analysis.  
  Nadir after LL tx Peak after LL tx Complete Subdivisions after LL tx LMM analysis after LL tx Figures 
Raphe complex 
↓ expression from 
9 am to 6 pm 
↑ expression 
from 9 pm to 3 
am  
↑ expression at 3 am 9 am and 9 pm 
and ↓ expression at 3 pm and 6 pm 
when compared to ctrls 
NA 
 (Figure 5-5) 
DRC 
↓ expression from 
9 am to 6 pm 
↑ expression 
from 9 pm to 3 
am  
Changes appeared in the rhythm of 
expression, but no siginificant 
differences found when compared to 
ctrls. 
No changes detected   (Figure 5-7) 
(Figure 5-19) 
DRI No significant changes 
 (Figure 5-9) 
(Figure 5-21) 
DRD 
↓ expression from 
9 am to 6 pm 
↑ expression 
from 9 pm to 3 
am  
↑ expression at 3 am and 9 pm with ↓ 
expression at 3 pm when compared to 
controls 
Changes at level 3, 4, 5, 8, 9, 10, 11 
and 12. Most differences detected 
were found at 6 pm. 
 (Figure 5-5) 
(Figure 5-23) 
DRV 
↓ expression from 
9 am to 6 pm 
↑ expression 
from 9 pm to 3 
am  
↑ expression at 3 am, 9 am and 9 pm 
with ↓ expression at 3 pm specific to 
caudal bregma levels when compared to 
ctrls. 
Changes at level; 8, 9, 10, 11, 12, 13, 
and 14 when compared to Ctrls.  Most 
changes at 3 pm.  
 (Figure 5-5) 
(figure 5-25) 
DRVL/VLPAG 
↓ expression from 
9 am to 6 pm 
↑ expression 
from 9 pm to 3 
am  
↑ expression at 9 am and ↓ expression at 
3 am and 3 pm when compared to ctrls. 
Changes at level 6, 8, 9, 10, 11, 12 
and 13when compared to Ctrls.  Most 
changes were found at 3 pm and 9 
pm.  




expression from 3 
am to 6 pm 
9:00 PM 
↓ expression at 3 pm and  6 pm with  ↑ 
expression at 9 pm specific to caudal 
bregma levels when compared to ctrls. 
Changes at level 4, 5, 7, 8, and from  
9 to 14 when compared to Ctrls.  
Changes appeared in all time points 
except 3 am. 
 (Figure 5-17) 
(Figure 5-29) 
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5.4 Discussion  
According to the results described in this chapter we can conclude that CORT levels 
in our experimental group (five weeks of LL) (Figure 5-3) correspond to a disrupted 
circadian activity in CORT, displaying high levels of secretion across the 24-hour 
period. This was expected as it was shown before by various research groups 
(Claustrat, Valatx, Harth, et al., 2008; Waite et al., 2012). Nevertheless, we can 
confirm that all our animals that were submitted to our LL model had a disruption 
in their circadian rhythmicity.  
Considering the results of tph2 mRNA expression in the whole Raphe complex after 
five weeks of LL treatment, the data showed high levels of tph2 mRNA expression 
in the active phase but a flattened expression during the inactive phase (Figure 5-
4). However, and as mentioned before, exposing rodents to constant light leads to 
disruption of the sleep–wake temporal patterns, and a loss of circadian rhythmicity 
(De La Iglesia et al., 2004; Salgado-Delgado et al., 2008). Moreover, Malek’s 
group has shown that locomotor activity can also modulate tph2 mRNA 
expression(Malek et al., 2007). Therefore, is hard to talk about an active and 
inactive phase under this experimental model and to hypothesize if the changes in 
tph2 mRNA expression are given by GC changes or by the altered locomotor 
activity. 
Moreover, when compared to the pattern of activity under natural conditions, tph2 
mRNA expression after LL treatment (Figure 5-5) seemed to have changed 
considerably across the 24-hour period, displaying an almost inverted rhythm, with 
exception of the 9 am time point. This changed pattern included higher levels of 
expression at 3 am, 9 am and 9 pm, and decreased levels of tph2 mRNA expression 
at 3 pm and 6 pm. Thus, the overall effect of the circadian disruption in the HPA 








Figure 5-30: Representative image of tph2 mRNA expression of Ctrl (left) vs LL (right). Image 
of bregma level 10 (-8.00 bregma level) of a single brain section from a A) Control animal vs 
a single brain section of a B) LL treated animal from the 9 pm time point (peak expression after 
LL tx). Scale bar 1 mm. 
Regarding the evaluation of the DR subregions and the MnR nucleus, there was an 
important presence of a circadian rhythm in thp2 mRNA expression the DRC 
(Figure 5-6), the whole, rostral and caudal DRD (Figure 5-10), the caudal DRV (Figure 
5-12), the whole and caudal DRVL/VLPAG (Figure 5-14)  and the whole and caudal 
MnR (Figure 5-16). This rhythm seemed to be specific to the caudal subpopulations 
of the DRV, DRVL/VLPAG and MnR, but not for the DRD.  The presence of a 
circadian rhythm in almost all the areas of the Raphe complex might mean that the 
circadian disruption in the HPA axis activity was not strong enough to lose a 
circadian rhythm in tph2 mRNA expression, although it might modify it. 
However, and continuing with the DR subregions and the MnR nucleus analysis, 
when compared to the natural circadian activity changes in tph2 mRNA expression 
were found in all the DRD (Figure 5-11), DRV (Figure 5-13), DRVL.VLPAG (Figure 
5-15)  and MnR (Figure 5-17), yet nothing was found for the DRC (Figure 5-7) or DRI 
(Figure 5-9). As thought previously, tph2 mRNA expression changed considerably 
after LL treatment. In the DRD changes were observed, almost displaying an 
inverted rhythm in the caudal DRD. With the highest peak of tph2 mRNA changing 
from 3 pm in controls, to 3 am after LL. Moreover, higher levels of tph2 mRNA 
expression were found at almost all time points. The DRV, only displayed changes 
in the caudal area, where the peak of expression seemed to be shifted from 3 pm to 
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9 pm and continued to be high until 3 am. The changes in DRVL/VLPAG and MnR 
seemed to be specific of the caudal part too, where again the peak of expression 
shifted from 3 pm to 9 pm and maintained to be high until 3 am.  
Moreover, at 9 am the whole and rostral DRD showed a strong increase in 
expression, which was maintained in the caudal DRD at 9 am and 6 pm. The caudal 
DRV suddenly showed a change when compared to control conditions; increasing 
tph2 mRNA expression at 9 am and significantly reducing it at 3 pm, nothing 
happened when comparing whole or rostral DRV. Changes were found in the 
whole, rostral and caudal DRVL/VLPAG, where the biggest changes occurred in 
the rostral part, with MPL treatment reducing tph2 mRNA expression across all 
time points but being significant only at 3 am and 3 pm. Furthermore, higher tph2 
mRNA expression profiles in MPL groups were found at 9 am in the whole and 
caudal DRVL/VLPAG. Finally, a decrease in tph2 mRNA expression at 3 pm for 
the whole and caudal MnR were seen when compared to the natural activity pattern, 
additionally, a decrease was also found at 3 am in the caudal MnR. 
Considering the rostro-caudal gradient of each of the subregions of the DR and the 
MnR nucleus after five weeks of LL, LMM analyses showed that tph2 mRNA 
expression profile changed across this gradient in all of the areas of the Raphe 
complex, which was expected as anatomical variances (anatomical extent/size) are 
natural through the whole Raphe complex. Moreover, the LL analyses indicated 
changes across time for the all the subregions of the DR and the MnR nucleus. After 
LL treatment we saw changes across time but only in specific levels of all 
subregions, nevertheless, when looking at the DRD (Figure 5-22), DRV (Figure 5-24) 
and MnR (Figure 5-28) these changes were more specific of the caudal levels. 
Furthermore, these changes were not particularly consistent to a specific time point 
for all the areas or all the levels, so further discussion will be given in chapter 6 
when specific anatomical characteristics will be examined. 
Additionally, when considering the rostro-caudal gradient and the comparison 
between the natural tph2 mRNA activity and the changed pattern after LL treatment 
the overall LMM analyses and secondary LMM analysis revealed that tph2 mRNA 
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expression profile changed across this gradient in all of the areas of the Raphe 
complex (anatomical natural changes are confirmed). More interestingly, the LMM 
detected an effect of treatment and time point across the rostro-caudal level in the 
DRD(Figure 5-23), DRV (Figure 5-25), DRVL/VLPAG (Figure 5-27)  and MnR(Figure 
5-29)  which again, seemed to be more significant for the caudal levels of each area 
but not particular of time, indicating that these changes might be an overall effect 
of treatment across the 24-hour cycle. 
Finally, these data confirm the existence of a changed circadian pattern of tph2 
mRNA expression in a 24-hour period after the disruption of the circadian rhythm 
of the HPA axis. Moreover, this modified circadian variation seems to be different 
to the circadian rhythm under natural conditions, which again supports our premise 
that there is a relationship between disrupted rhythm of circulating CORT and the 
activity tph2 mRNA expression. This again indicates that tph2 mRNA rhythm 
dysregulation may be a possible mechanism underpinning high risk of, or 
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My PhD is based on the hypothesis that the serotonergic system’s activity, at the 
level of tph2 mRNA expression, has a strong temporal relationship with the 
circadian activity of the HPA axis, and that this specific link between them could 
be the underlying mechanism of stress-related psychiatric disorders, such as 
depression and anxiety.  
Many studies have shown that the brain serotonergic system has a strong 
relationship with HPA axis activity (Tsigos and Chrousos, 2002; Pompili et al., 
2010; Mahar et al., 2014; Checkley, SL and WS, 2015). Moreover, many studies 
have focused on the relationship  between tph2 mRNA expression and HPA axis 
activity (Malek et al., 2007; Waider et al., 2011; Donner, Montoya, et al., 2012; 
Lukkes et al., 2013; Donner et al., 2018). However, none of these studies fully 
characterized the link between the HPA axis circadian rhythm and the daily activity 
of tph2 mRNA in the five recognized subregions of the DR and MnR nuclei (Pollak 
Dorocic et al., 2014). Therefore, the importance of my PhD was set on this basis.  
But why study tph2 gene expression to assess the relationship between HPA-axis 
activity and the serotonergic system? Studies have shown that stressed-triggered 
induction of tph mRNA is related to the induction in TPH protein levels (F.M. et 
al., 2004; Helene Bach-Mizrachi et al., 2006) and to serotonin brain levels, as KO 
of tph2 show a substantial decrease of 5-HT (Brommage et al., 2015).  Moreover, 
studies have shown that tph2 gene expression is induced by antidepressant drugs 
(Matthes et al., 2010) and that it contributes to the antidepressant effects (Hanson, 
Owens and Nemeroff, 2011), thus, tph2 has become of great relevance for the 
understanding and development of strategies for psychiatric disorders and our 
interest was to describe its rhythmic activity under natural conditions and 
pathophysiological conditions.   
With the mentioned above, I consider that my PhD project provides strong evidence 
to support the premise that tph2 mRNA rhythmic expression, is linked to the HPA 
axis rhythm, therefore, suggesting that this relationship could be the molecular 
foundation of stress-related psychiatric disorders (Figure 6.1).  
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Figure 6-1: Schematic representation of the proposed relationships involved in stress-related 
psychiatric disorders. This model suggests that abnormal GC activity induces altered 
serotonergic system activity which can in turn be the underlying mechanism of psychiatric 
disorders.  
Ultimately, the evidence found in this project could lead to the expansion of 
therapeutic methods of treatment of psychiatric conditions with more consideration 
given to the timing of drug delivery. Additionally, it could set the basis for the 
development of new strategies for the control of specific subpopulations of 
serotonergic neurons which could result in the reduction of side effects of 
pharmacological therapies used nowadays. Based upon the data presented in this 
thesis, chronotherapy (drug administration at a time of day that works optimally 
with the body's natural rhythms) appears to be extremely important when targeting 
the serotonergic system in the treatment of neuropsychiatric disorders.  
6.2 Natural rhythm of tp2 mRNA Expression  
According to my findings presented in chapter 3, tph2 mRNA expression exhibits 
a significant natural circadian variation when assessed in the complete raphe 
complex (Figure 3-4); and more specifically, in three distinct subregions of the DR 
(DRD, DRV and DRVL/VLPAG) (Figure 3-7 to Figure 3-9) and MnR nucleus (Figure 
3-10). Importantly for my research question, my data shows that the natural 
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the natural circadian CORT rhythm (Figure 3-2), this had also been shown by other 
research groups (Malek et al., 2007; Donner, Montoya, et al., 2012), however, the 
neuroanatomical and circadian detail had not been assessed.  The nadir in tph2 
mRNA expression matches the nadir of CORT at 9 am, while the peak in tph2 
mRNA expression is reached at 3 pm, therefore closely following the initial rise of 
CORT that precedes the onset of the active phase. Hence, the dynamics that I have 
found indicate a rapid and transient induction of tph2 mRNA in many of the 
subregions of the Raphe complex, such as the DRV, DRVL/VLPAG and MnR 
nucleus. The one exception to this transient induction is the DRD, where the peak 
in tph2 mRNA expression is more prolonged, with elevated expression at both 3pm 
and 6pm, before reducing at 9pm. 
Overall, the results obtained in the DRD, DRV, DRVL/VLPAG and the MnR 
suggest that the circadian variation in tph2 mRNA expression is quite similar in 
most of the subregions of the Raphe complex, characterised by the 9 am nadir and 
3 pm peak in expression. The circadian tph2 mRNA nadir of 9 am that I found was 
consistent with, what is to my knowledge, the only previous study of the full 
circadian tph2 mRNA profile (Malek et al., 2007). However the peak in tph2 
mRNA expression that I found was different to the one reported by this group, 
where they observed the circadian tph2 mRNA peak at 5 pm (Malek et al., 2007). 
Nonetheless, despite not having the same time-matched data points in analysis, both 
studies do agree that the peak tph2 mRNA expression is reached prior to ‘lights 
off’, which is the start of the active phase for these nocturnal rodents. The data I 
present in this dissertation are novel as no study has ever assessed the tph2 mRNA 
circadian rhythm with the topographically organized details that I have used.  
Notably, I have found that the circadian variation in tph2 mRNA expression was 
predominantly localized to the caudal bregma levels of each subregion, with the 
exception of the DRD (Figure 3-7).  This caudal-dependent circadian variation in the 
DRV (Figure 3-8), DRVL/VLPAG (Figure 3-9) and MnR (Figure 3-10) is consistent 
with previous reports showing that serotonergic neurons in the mid-rostral caudal 
and caudal parts of the DR and the MnR nucleus are more responsive to stress and 
anxiety-related states (Singewald and Sharp, 2000). This suggests that the caudal 
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levels might also be more responsive to GCs. Consistent with this, I found that tph2 
mRNA expression increased with the early CORT rise that occurs prior to the onset 
of the active phase.  
I believe that with the exception of the DRD mentioned above, this also makes 
sense based upon previous studies, which showed that differential rostral or caudal 
activation in the DRD was dependent on the type of stress-related stimuli (Amat et 
al., 2005; Gardner et al., 2005), suggesting that the DRD can be differentially 
activated across its rostro-caudal extent, therefore displaying a robust circadian 
variation only in its rostral levels.  
As serotonergic neurons in these Raphe subregions are sensitive to regulation by 
stress-induced elevated GCs (Lowry et al., 2009) and they also express GC 
receptors (Morimoto et al., 1996) , then it also seems reasonable that they might be 
sensitive to regulation by rising and falling GC levels over the circadian phase. My 
data, showing circadian regulation of tph2 mRNA in defined caudal parts of the DR 
and the MnR, supports the prevailing hypothesis (proposed by Malek et al., 2007 
and Donner et al., 2012) for regulation of serotonergic neurons by GC-dependent 
transcriptional regulation of tph2 mRNA.  
Similar to how the circadian pattern of circulating GCs is known to be important 
for the maintenance and resetting of the circadian timing system in slave oscillators 
throughout the brain and the body  (Lamont et al., 2005; Hood et al., 2010), I can 
now also hypothesise that tph2 mRNA is under circadian regulation and that its 
circadian rhythm is at least partially dependent upon the natural circadian variation 
in GC levels.   
Furthermore, the serotonergic neurons that project to the hippocampus are located 
in the most caudal regions of the DR and the MnR (Steinbusch, 1981; Köhler and 
Steinbusch, 1982a; Abrams et al., 2005). Therefore, the GC dependent regulation 
of tph2 mRNA expression in these distinct populations could have important 
functional implications, for example by exerting serotonergic inhibitory influence 
on the HPA axis mediated via these raphe hippocampus interactions. Further, GC-
dependent regulation of tph2 mRNA expression in these distinct populations may 
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play an important role in the regulation of emotional responses to stress, as it is 
known that the hippocampus innervates the central autonomic and emotional 
control systems (Jacobson and Sapolsky, 1991).  
To look in more depth, I evaluated the complete rostral-caudal gradient of each 
subregion. Many experts in the Raphe field purport that tph2 mRNA expression 
changes in specific bregma levels across the raphe complex have specific and 
differential functional output (Price et al., 1998; Lowry et al., 2000). Many studies 
have shown that there is a robust difference in tph2 mRNA expression levels across 
the rostro-caudal gradient, and that these changes are largely defined by the 
anatomical structure of the subregion (J. K. Abrams et al., 2004; Lowry et al., 
2008a; Katherine L. Gardner et al., 2009). For example, the further rostral levels of 
the DRV are structurally smaller than the -8.000 mm caudal bregma level; 
therefore, more tph2 mRNA will be expressed in this particular level than in the 
rostral levels. However, no studies have shown if there is a circadian variation of 
tph2 mRNA expression within this full rostro-caudal gradient for each subregion of 
the DR and the MnR. 
Moreover, when studying the Raphe complex is important to take under 
consideration that the different subregions not only have anatomical (structure) 
differences, but also different afferent/efferent connections, differences in circuitry 
and differences in cells. For example; 1) in the DR different cell types can be 
identified, including small round neurones, medium-sized and fusiform or bipolar 
neurons, multipolar neurons, but until now, no functional properties have been 
based on morphology (Köhler and Steinbusch, 1982a), 2) differences in firing rates 
during periods of activity or inactivity can be observed in different populations of 
serotonergic neurons localised in specific regions of the raphe complex  (Peyron et 
al., 1997a) and 3) different serotonergic neurons respond differently in vivo (Price 
et al., 1998) and in vitro (Lowry et al., 2000). Hence, there are too many variables 
that must be considered when studying the serotonergic system.  
However, in this study, when considering the full rostro-caudal gradient of each 
subregion, we can visualise exactly where the time dependent changes in tph2 
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mRNA expression are localised within the DRD (Figure 3-13), DRV (Figure 3-14), 
DRVL/VLPAG (Figure 3-15) subregions and the MnR nucleus (Figure 3-16). 
These changes correspond well to previous reports, with significant changes seen 
in the rostral levels of the DRD, and the caudal levels of the DRV and MnR. 
Fascinatingly, in the DRVL/VLPAG, changes were seen across all the rostro-caudal 
extent of the subregion. Additionally, a common temporal theme of 9 am nadir and 
3pm peak was noted in all of the regions where significant circadian variation was 
detected. Therefore, I feel confident in concluding that tph2 mRNA has a clear 
circadian rhythm localised to specific levels within the rostro-caudal extent of the 
DRD, DRV, DRVL/VLPAG and the MnR nucleus.  
What might be the functional significance of this particular timing in tph2 mRNA 
expression? It seems logical that the circadian expression profile of tph2 mRNA - 
with its sharp and transient increase prior to the onset of the active phase, then 
reaching a nadir before the inactive phase - must exist for a biologically important 
reason. Circadian rhythms have been found to be important in many biological 
systems (Moore MD, 1997; Wilsbacher and Takahashi, 1998; Brown and Schibler, 
2001) and based on my results the serotonin system is clearly no exception. 
Furthermore, many circadian biological functions have been shown to be under the 
control of the serotonergic system, including but not limited to the sleep-wake cycle 
(Beersma and Gordijn, 2007), feeding behaviour (Voigt and Fink, 2015) and 
locomotor activity (Geyer, 1995). Therefore, the timing of serotonin synthesis will 
also potentially impact on these systems.  
Moreover, previous studies have shown that serotonin is involved in the 
synchronization of the SCN (Pickard et al., 1999; Glass, Dinardo and Ehlen, 2000; 
Malek, Pévet and Raison, 2004). As the SCN regulates many biological rhythms, 
including HPA axis activity (Buijs et al., 1993a) which in turn is involved in the 
rhythmic expression of tph2 mRNA (Malek et al., 2007), these systems are highly 
interdependent. In light of all this, it is unsurprising that disruption in the timing of 
any of these systems (circadian, HPA axis, or serotonergic) can lead to the 
development of affective disorders in susceptible individuals. 
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6.3 Effect of the long-acting synthetic GC MPL on rhythmic 
tph2 mRNA expression  
Synthetic glucocorticoids (sGCs) are widely used in clinic as a therapeutic 
treatment of inflammatory and immune diseases (Van Staa, Leufkens and Cooper, 
2002). Their mechanism of action in general, is to activate GRs and promote their 
activity, and thereby exert their corresponding anti-inflammatory functions (Van 
Der Velden, 1998). However, the importance of chapter four was not only set to 
address the idea that MPL treatment effectively and significantly alters the temporal 
dynamics of circulating GCs, but also by the fact that sGCs have well-documented 
adverse side effects (Buchman, 2001). Whilst the metabolic side-effects of sGCs 
have been extensively studied, neuropsychiatric symptoms associated with GC 
therapy (Brown and Chandler, 2001) have yet to be explained at the mechanistic 
level. Therefore, my data showing how MPL treatment significantly dysregulates 
tph2 mRNA expression in the Raphe complex now potentially provides a direct 
mechanism for how sGC treatment can impact the brain serotonergic system, 
leading to psychiatric disorders in susceptible individuals.  
The MPL dysregulation of circadian tph2 mRNA expression was characterised 
primarily by elevated expression at the 9am time point, and loss of the peak at 3pm. 
While significant variation over time was still found in many subregions of the DR 
and the MnR, the pattern exhibited an unusual bi-phasic expression profile, with 
two peaks in expression at 9am and 6pm. This altered pattern was observed in the 
complete raphe complex (Figure 4-5), in several subregions of the DR, and the MnR 
nucleus, and could be visualised at specific levels within the rostro-caudal gradient.  
How might MPL treatment be inducing this change in tph2 mRNA expression 
rhythm? As indicated by the RIA results, MPL suppressed endogenous CORT 
(Figure 4-3). Therefore, the normal circadian endogenous adrenal GC rhythm had 
been effectively replaced with the long-acting sGC MPL.  The impact of this on the 
circadian CORT rhythm may be expected to be twofold. First, the ‘anticipatory’ 
surge in rising CORT levels that occurs prior to the onset of the active phase will 
be ablated when endogenous adrenal CORT is suppressed by MPL (Spiga, Waite, 
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et al., 2011). As the MPL is delivered in drinking water in my experiments, thus 
modelling oral dosing in patients, the rise in circulating GC will be delayed until 
the onset of drinking behaviour at the early part of the dark phase (Kowanko et al., 
1982; Arvidson et al., 1997; Straub and Cutolo, 2007). Therefore, a phase shift in 
peak GC levels of approximately 4 hours would be expected with this type of oral 
dosing. In support of this, Stamper et al (Stamper et al., 2015) have shown, using a 
frequent blood sampling protocol, that CORT delivered in drinking water indeed 
does result in a 4 hour phase shift in the first peak in circulating CORT. In addition, 
Stamper et al reported that the phase delay in circulating CORT levels persisted 
throughout the dark phase, explaining that this was due to continued drinking 
throughout the active phase. Adrenal CORT secretion in contrast is known to be 
reduced during the late active phase (Spiga, Waite, et al., 2011).To further 
exaggerate the temporal dysregulation, MPL remains in the circulation (Uhl et al., 
2002)for far longer than the CORT used in the experiments of Stamper et al.  
Additionally, MPL has been shown to activate GRs for a prolonged period of time, 
replacing the normal circadian (Kitchener et al., 2004) and ultradian (Lightman et 
al., 2008; Conway-Campbell et al., 2010, 2012) GR activity with prolonged 
activation (Earl et al., 2017). While MPL has been demonstrated to induce 
prolonged GR activation (Earl et al., 2017), by definition, this can only apply to 
brain regions where GR is expressed. As GRs are highly expressed in the DR and 
MnR nuclei (Harfstrand et al., 1986; Morimoto et al., 1996), it is also possible that 
serotonergic neurons within the Raphe complex are subjected to this prolonged 
effect.  
Therefore, it seems likely that the observed alteration in tph2 mRNA expression 
pattern from the ‘normal’ 9am nadir and 3pm peak, to the highly dysregulated twin 
peak pattern (9am and 6pm) is due to this phase shift in circulating GCs over the 
24-hour period. The phase shift in the tph2 mRNA expression peak from 3pm to 
6pm represents a 3-hour shift rather than the hypothesised 4 hour shift, but this may 
be due to the (lack of) finer temporal resolution in my dataset as there were no time 
points assessed between 6pm and 9pm. The elevated tph2 mRNA expression at 9am 
is consistent with the prolonged duration of MPL in the circulation, as tph2 mRNA 
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levels decrease by 3pm. However, this simplistic view of prolonged MPL-
dependent increase in tph2 mRNA expression does not explain how or why the 
expression levels dip again at 9pm and 3am, rather than remaining constantly high 
from 6pm through to 9am. A potential explanation for this biphasic rhythm might 
lie in the transient nature of tph2 mRNA induction. In fact, tph2 mRNA expression 
peaked at 3 pm then decreased at 6pm throughout the majority of the Raphe 
subregions, even though CORT levels continued to rise from 3pm to 6pm in the 
natural circadian profile. Therefore, it seems likely that there is complexity in the 
transcriptional dynamics (Coulon et al., 2013) and/or mRNA stability  (Higgins, 
1991) over time, although the exact nature of these dynamics is not currently known 
for tph2 mRNA.  
With the mentioned above, it would be very interesting to assess this complexity of 
transcriptional dynamics” of tph2. Therefore, further experiments to 
investigate tph2 transcription ie nascent RNA production, mRNA half-life 
and stability, and translation rate would need to be conducted.  The relative 
contribution of glucocorticoids versus time of day, for example would need to be 
assessed in adrenalectomized (ADX) rats to decrease the circulating 
endogenous glucocorticoids. Injection of corticosterone at a dose that matches the 
physiological circadian peak would be performed, alongside vehicle 
injections (to control for time of day). Rats would be killed, and brains would be 
taken over a time course of 1, 3 and 6 hours. ISHH analysis of tph2 mRNA 
and nascent transcript in the DR and MnR would be performed. For detection of 
the nascent transcript, probes for heteronuclear RNA (hnRNA) would need to be 
designed to cross the boundary between an Intron and an Exon, such that dynamic 
increases and decreases in the nascent transcript can be assessed. Furthermore, 
when the transcript is spliced to form the mature transcript (mRNA), the hnRNA 
probe will not be able to bind.  A time course of this type could also provide 
valuable information about the half-life of the mRNA. It would be also important 
to assess whether there is a difference in nascent transcript production and 
mRNA accumulation at different times of the day.  
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It would also be extremely interesting to assess the time course of protein increase 
and decrease, using immunohistochemistry for tph2 in the DR and MnR, in both 
the circadian context (as reported in my thesis) and in the ADX CORT injected time 
course model. Of course, total protein levels do not indicate protein activity, so TPH 
activity would need to be further assessed by TPH enzyme assay, which would need 
to be performed on lysates obtained from micro-punched tissue, although the 
spatial resolution would be absent. To address the mechanisms whereby CORT 
regulates tph2 transcription, we would need to perform Chromatin 
Immunoprecipitation (ChIP) assays on micro-punched tissue to assess GR binding 
to potential regulatory sites in and near the tph2 promoter.   
Finally, in order to show whether GR is required for tph2 mRNA inductions over 
the time course, rats could be co-treated with a GR antagonist such as RU486 
(Mifeprestone). If transcription is significantly decreased by the GR antagonist, 
then this provides good support for a mechanism of GR mediated transcriptional 
regulation of the tph2 gene. 
Continuing with the results, it should be noted that while a unusual ‘biphasic’ 
pattern was detected in the analysis of the whole raphe complex (Figure 4-4), the 
whole and caudal DRD (Figure 4-10), whole, rostral and caudal DRVL/VLPAG 
(Figure 4-14), and the caudal MnR (Figure 4-16), the DRV was the exception (Figure 
4-12). Interestingly, the caudal DRV had a significant circadian rhythm in the 
control rats, yet no significant variation detected over the 24 hours during MPL 
treatment, indicating that MPL treatment resulted in a ‘flattening’ of tph2 mRNA 
expression profile in this region.  Studies have shown that the DRV has widespread 
projections to the caudate putamen and cortical fields (Waterhouse et al., 1986; 
Kirifides et al., 2001; H. H. S. Lee et al., 2003) which could implicate a role in 
motor function and complex cognitive tasks, suggesting that an altered activity of 
tph2 mRNA expression in the DRV could be related to the reported impairment of 
declarative memory after sGC therapy (Brown and Chandler, 2001).  
MPL treatment had a significant overall effect on tph2 mRNA expression in the 
DRD (Figure 4-11). These changes were mainly observed in the caudal levels of 
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this subregion but could also be seen in the rostral part. Interestingly, the DRD 
receives inputs from brain structures which control anxiety states (Peyron et al., 
1997a) and also sends projections to areas related to anxiety-related behavioural 
responses (Lowry et al., 2005). Moreover, many studies have shown that the DRD 
is activated by different stressful stimuli (Commons, Connolley and Valentino, 
2003; Amat et al., 2005; Gardner et al., 2005) and that it can also be activated by 
anxiogenic drugs (Abrams et al., 2005). Therefore, this subregion has been 
proposed to play a role in the regulation of anxiety-related behavioural responses 
and in affective disorders (Commons, Connolley and Valentino, 2003), suggesting 
that the DRD may also be affected in patients who report anxiety and negative mood 
during chronic sGCs treatment.  
The DRVL/VLPAG (Figure 4-15) subregion had a strong response to MPL 
treatment showing a robust change in tph2 mRNA circadian activity, which was 
maintained through the whole, rostral and caudal divisions. Moreover, when 
looking to the rostro-caudal extent of the subregion, MPL treatment had a strong 
effect across all the time points assessed. Hence, I can say with confidence that the 
DRVL/VLPAG subregion was considerably affected by MPL. Because of its 
afferent and efferent connections (Watts, Swanson and Sanchez-Watts, 1987; 
Hurley et al., 1991; H. H. S. Lee et al., 2003) this specific subregion of the DR has 
been associated with emotional behaviours that involve changes in muscle tone. 
Moreover, it is activated by panic-inducing stimuli (Bandler et al., 2000) and 
dysregulated activity of serotonergic neurons in this area increases panic-like 
symptoms (Zangrossi and Graeff, 2014). Interesting, the DRVL/VLPAG project to 
the DRV (Peyron et al., 1997a) and various studies have suggested that this area 
provides a tonic inhibitory input to the DRV (Hollis et al., 2006; Bouwknecht et 
al., 2007b; Johnson et al., 2008),. Therefore, dysregulation of tph2 mRNA 
expression in the DRVL/VLPAG may underlie problems with verbal and 
declarative memory found in patients during sGCs therapy as well as panic-like 
symptoms of psychiatric disorders.  
With regards to the MnR (Figure 4-17), an unusual pattern appeared after MPL 
treatment. It seemed that the nadir in the rostral MnR had not changed from the 
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natural nadir. However, the pattern changed quite dramatically in the caudal levels, 
again showing the twin peak feature described for the DRD (Figure 4-11) and 
DRVL/VLPAG (Figure 4-15). The pattern observed in the whole MnR after MPL 
treatment was significantly different from the natural rhythm of tph2 mRNA 
expression. Moreover, when assessing the rostro-caudal extent of the nucleus, an 
overall effect of MPL treatment can be seen for the MnR. This nucleus has 
extensive efferent and afferent projections, however, for the interest of my study, I 
will focus on the fact that the MnR projects to forebrain structures involved in the 
inhibitory regulation of the HPA axis, mediating its inhibition by a serotonergic 
mechanism (Vertes, Fortin and Crane, 1999; Lowry, 2002). This nucleus has been 
linked to many physiological and behavioural functions, most notably to chronic 
psychosocial stress (Graeff et al., 1996), resistance and tolerance (Deakin, 1996), 
control of rhythmicity (Morin, 1999) and anxiety-related behaviours (Mansur et al., 
2011).  
I believe that the results observed in this particular study can contribute to the 
knowledge of why sGCs have neuropsychiatric side effects. I suggest that there is 
an altered serotonergic activity within the dorsal and median raphe nuclei, which is 
the underlying mechanism connecting abnormal HPA axis activity and the stress-
related psychiatric disorders, such as depression and anxiety (Figure 6-2). 
 
Figure 6-2: Schematic representation of the mechanism involved in the neuropsychiatric side 
effects of sGC therapy. The model shows the effects that long-acting sGCs might have on the 
development of neuropsychiatric disorders via altering the circadian tph2 mRNA expression 
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trigger altered serotonergic system activity which could be the underlying mechanism of 
psychiatric disorders. 
6.4 Effect of chronodisruption on the circadian GC profile 
and tph2 mRNA expression 
In this modern world, exposure to light at night is more prevalent than ever before. 
Evidence has indicated that long periods of light mixed with activity can disturb 
our internal circadian timing system (Navara and Nelson, 2007; Fonken et al., 
2013) and trigger psychiatric symptoms (Gorwood, 2010).  Furthermore, both 
chronic stress and neuropsychiatric disorders such as mayor depressive disorder 
(MDD) often lead to sleep problems (Drake et al., 2004; Tsuno, Besset and Ritchie, 
2005; Germain and Kupfer, 2008; Chrousos, 2009) and hence circadian disturbance 
(Czeisler and Gooley, 2007; Rahman, 2010; Zhu and Zee, 2012). In fact, there is a 
recognised bidirectional relationship between chronic stress and sleep problems 
(Basta et al., 2007). Therefore, these three things – circadian timing, HPA axis, and 
affective state – are inextricably linked in the pathophysiology of neuropsychiatric 
disease. My findings in chapter 5 potentially provide an insight into how the three 
components may be interlinked; namely, via dysregulation of the tph2 mRNA 
expression profile in the LL protocol.  
The mechanisms through which light affects our internal timing system are still 
being investigated. However, the suprachiasmatic nucleus (SCN) has been of great 
interest as it is the “master clock” and is entrained by light. Additionally, the SCN 
has also been related to the regulation of the HPA axis activity (Buijs et al., 1993a) 
as lesions in  the SCN produce an abnormal HPA axis activity (Son et al., 2008; 
Son, Chung and Kim, 2011) which has also been associated with affective disorders 
(Pompili et al., 2010). The experimental model of five weeks constant light 
exposure, described in chapter 5, has been established to both 1) disrupt normal 
HPA axis activity leading to high amplitude CORT pulses throughout both the 
active and inactive phases of the day (Waite et al., 2012) and 2) lead to anxiety and 
depressive-like symptoms (Fonken et al., 2013). Here, I have shown that the 
‘normal’ circadian tph2 mRNA expression profile is also dysregulated as a result 
of five weeks constant light exposure, providing a mechanistic basis for the 
   Chapter 6 
232 
 
depressive and anxious phenotype of the animals subjected to this experimental 
paradigm.    
As expected given previous studies (Claustrat, Valatx, Harthe, et al., 2008; Waite 
et al., 2012; Park et al., 2013), I observed a clear disrupted circadian rhythm in 
circulating CORT was found after five weeks of constant light (Figure 5-3). This 
model was also related to a modified tph2 mRNA expression over the 24-hour 
period. However, because of the scientific knowledge it cannot be established 
whether this modification in expression was solely due to the disrupted HPA axis 
activity. An alternative hypothesis of why the LL model disrupts the serotonergic 
system is given by the fact that there is a direct relationship between the SCN and 
the serotonergic system established by the following findings: 1) the MnR is the 
only source of serotonergic input to the SCN (Meyer-Bernstein and Morin, 1996; 
Hay-Schmidt et al., 2003); 2) tph2 mRNA is found in the rat retina (Liang et al., 
2004) which has a direct projection to the SCN, via the retrino-hypothalamic tract 
(RHT) (Moore and Lenn, 1972); 3) the DR has an indirect influence on the SCN 
via an interaction with the MnR; and 4) an indirect projection from the DR to the 
SCN via the intergeniculate leaflet (IGL) has a strong input to the SCN (Glass et 
al., 2003).  Therefore, the effect of constant light on tph2 mRNA expression most 
likely involves multiple mechanisms which have become dysregulated with the 
removal of normal light-dark cues. The striking LL-induced dysregulation of tph2 
mRNA expression throughout the Raphe complex provides an underlying 
mechanism which may explain the depressive and anxious behavioural phenotype 
reported with this model (Fonken et al., 2009). 
Furthermore,  it has been shown that the LL model induces a disrupted locomotor 
activity (Cassone, 1992), and this altered locomotor activity was observed in the 
experimental groups submitted to 5 weeks of LL. These observations were only 
done “by eye” so no data is shown in regard to this. But why is this important? 
Studies have shown that at least voluntary exercise has an influence in serotonergic 
transmission. For example, rodents housed for 6 weeks with a running wheel, have 
modified levels of 5-HT transporter, 5-HT1A receptor mRNA levels (Greenwood 
et al., 2005b)and an increase in tph2 mRNA levels in the DR and MnR (Malek et 
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al., 2007). Therefore, I can hypothesize that the changes found on tph2 mRNA 
expression after 5 weeks of constant light could also be influenced by the altered 
locomotor activity observed in the animals exposed to 5 weeks of constant light and 
not solely by the GCs altered rhythm. However, this is only speculative and would 
have to be specifically studied in future behavioural experiments.   
A particularly interesting aspect of the LL model is how both the central clock and 
the HPA axis are dysregulated. This is relevant because neuropsychiatric disease 
can often involve altered sleep patterns (Baglioni et al., 2010; Staner, 2010; 
Palagini et al., 2013), and hence circadian disruption. Therefore, my study 
represents a complex system where multiple factors may work together to 
dysregulate tph2 mRNA expression. To test the relative contribution of GC 
hypersecretion in the system, we could infuse high dose pulses to recreate the 
hyperactive HPA axis that we see in the LL treated rats, while maintaining them in 
a normal LD cycle. This would allow us to assess the direct role that GCs play in 
tph2 mRNA expression changes and depressive behaviour, without the additional 
factor of central clock (SCN) dysregulation.   
A well-defined modification in both circulating GCs and tph2 mRNA expression, 
was found after five weeks of constant light. Therefore, and due to the described 
link between the HPA-axis and the serotonergic system, I can speculate that the 
abnormal activity of circulating GCs has an association with altered tph2 mRNA 
expression. Whilst my data cannot answer whether the effect is direct or indirect, it 
does support a functional interaction between circadian disruption, hyperactive 
HPA axis and tph2 mRNA dysregulation, with the potential for development of 
neuropsychiatric symptoms.  
Subsequently, with the described above, the results from the averaged analysis for 
each area, and throughout their rostro-caudal extent, suggest that LL could be 
evoking a chronic stress-like state as the caudal part of these DR subregions and the 
MnR nucleus are reportedly more responsive to stressful stimuli (Singewald and 
Sharp, 2000). These findings could indicate that if LL is evoking a chronic stress-
like state, then GCs may very well be the main driver of the dysregulated tph2 
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pattern. However, other studies would need to be performed to test this hypothesis; 
for example, triggering a hyperactive CORT profile in normal LD conditions, or 
ablating endogenous CORT (adrenalectomy) in LL condition, and assessing the 
effects on tph2 mRNA.  
The constant light model used in this study had an overall effect in the whole DRC 
(Figure 5-6) where a circadian pattern was evident due to very high levels of tph2 
mRNA expression from 9pm to 3am, and very low levels across all other 
timepoints, in contrast to the lack of circadian tph2 mRNA expression in the DRC 
of the control rats. This change may indicate a compensatory mechanism, as the 
DRC has been related to stress-coping behaviour (Bale et al., 2000) via mechanisms 
involving projections to the ventral hippocampus, amygdala and locus coeruleus 
(Imai et al., 1986), and interactions with the DRD (Hale and Lowry, 2011).  The 
DRC receives innervation from the preoptic, arcuate and hypothalamic nuclei (H. 
H. S. Lee et al., 2003); therefore it is possible that the observed effect might be due 
to the neural effects of constant light stimulation. 
The DRD is involved in anxiety and stress-related behavioural responses 
(Commons, Connolley and Valentino, 2003). The overall effect seen in tph2 mRNA 
expression after LL in the DRD is not specific to its caudal levels (Figure 5-10, 
Figure 5-23). However, studies have shown that depending on the type of stressful 
stimuli, the rostral or caudal levels of the DRD could be more reactive. For example, 
the open-field anxiety effect is more restricted to the rostral DRD (Bouwknecht et 
al., 2007b) whereas the effect of uncontrollable stress is more restricted to the 
caudal DRD (Grahn et al., 1999). Thus, the fact that effects were seen in both the 
rostral and caudal regions of the DRD indicate that constant light exposure induces 
both anxiety and chronic stress, consistent with the anxious and depressive-like 
behaviours reported for rats in this experimental model (Fonken et al., 2009).   
The DRV (Figure 5-13, figure 5-25) also showed an altered pattern in tph2 mRNA 
expression after five weeks of constant light. However, it is difficult to interpret as 
only a few changes are seen, which are quite specific to the 3 pm time point, 
when/where a strong reduction in expression was observed when compared to its 
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natural expression. Moreover, because the DRV subdivision has extensive 
projections, few studies have investigated its functional output. However, it has 
been related to motor function and cognitive tasks (Greenwood et al., 2005a), which 
is particularly interesting based on the plethora of evidence for cognitive 
impairments associated with chronic stress and chronic high level GC exposure.  
The DRVL/VLPAG (Figure 5-15, Figure 5-27) subregion seemed to be very 
reactive as tph2 mRNA expression in this subregion was markedly modified after 
exposure to constant light. However, in contrast to the reactivity after MPL 
treatment, only the caudal levels were subject to change, supporting the idea that 
constant light induces a stress-related state. Furthermore, as mentioned before, this 
area has been associated with panic-like behaviours where motor functions are 
involved (fight-or-flight, freezing) (Bandler et al., 2000). Moreover, and of 
particular relevance for this specific model, the DRVL/VLPAG receives afferents 
from the retina (Fite et al., 1999) and also projects to it (Villar et al., 1988), which 
might indicate a direct neural modulation during LL exposure.  These projections 
have furthermore been hypothesised (Shen and Semba, 1994) to play a role in 
regulation of circadian rhythms as well as sleep and wakefulness. 
Finally, regarding the MnR (Figure 5-17, Figure 5-29), an important overall effect 
was observed in tph2 mRNA expression after constant light, which is also caudal 
level dependent and found in almost all the time points assessed. In this specific 
study, the MnR is of great relevance as this nucleus is the unique serotonergic input 
of the SCN (Morin, 1999). Moreover, the interconnection between the MnR and 
DR (Tischler and Morin, 2003) also seems to exert a strong indirect influence on 
the SCN (Morin, 2013). Therefore, when speculating that our model of constant 
light is affecting circulating GCs and tph2 mRNA expression via the SCN, the MnR 
becomes an obvious target of research. Importantly, the MnR has been implicated 
in inhibition of the HPA axis (Lowry, 2002) and to resistance and tolerance of stress 
(Deakin, 1996). Hence, as tph2 mRNA expression reached extremely high levels in 
the MnR at the 9pm and 3am timepoints, it is tempting to speculate that this may 
be a mechanism attempting to reduce the negative effects of LL in the HPA axis. 
Furthermore, the MnR has also been related to the control of circadian rhythmicity 
   Chapter 6 
236 
 
as lesions in the MnR cause premature onset and delayed offset in activity during 
normal LD conditions (Meyer-Bernstein and Morin, 1996). Therefore, again, there 
appears to be a functional association between altered tph2 mRNA expression in 
the MnR and altered activity of the HPA axis.  
Now, with all the aforementioned, I believe that my results indicate that constant 
light affects tph2 mRNA expression throughout the Raphe complex by a 
combination of neural and humoral regulation, hypothesis which is consistent with 
previous reports (Morin and Blanchard, 1991; Azmitia, Liao and Chen, 1993; 
Meyer-Bernstein and Morin, 1996; Clark et al., 2005). Projections directly from the 
retina to the DRVL/VLPAG, from the MnR to the SCN, and from hypothalamic 
regions to the DR and MnR  (Peyron et al., 1997a; H. H. S. Lee et al., 2003) can all 
modulate serotonergic neuron activity as a result of the LL stimuli. Additionally, 
stress-responsive regions such as the DRD, DRVL/VLPAG and MnR appear to also 
be responsive to the fluctuating GC levels over the circadian period, strongly 
suggesting a humoral (GC-dependent transcriptional regulation of tph2 mRNA) 
response. These combined actions, throughout the DR and the MnR, in turn appear 
to be dysregulating tph2 mRNA expression, thus predisposing the rats to the 
depressive and anxiety-related behaviours described previously (Lowry et al., 
2008b; Katherine L. Gardner et al., 2009; Donner, Johnson, et al., 2012)(Figure 6-
3). 




Figure 6-3: Schematic representation of the mechanisms involved in the development of 
psychiatric disorders. This model suggests that exposure to constant light will alter SCN 
activity, inducing an altered circadian rhythmicity, which in turn will cause an abnormal GC 
circadian rhythm and therefore, dysregulate the serotonergic system activity; this could be an 
underlying mechanism in the development of psychiatric disorders. However, an alternative 
mechanism of the consequences of exposure to constant light might be given by a direct 
connection between the SCN and the serotonergic system.  
Many other experiments need to be performed to establish if the effect on tph2 
mRNA expression is given by the altered HPA axis activity or via the SCN. 
Moreover, assessing the unique characteristics of each subregion of the DR and 
MnR nucleus could provide a better understanding of this relationship. Hence, some 
of these experiments will be discussed in the “future directions” section.
Constant Light
Disrupted HPA axis 
circadian rhythm
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6.5 Summary table of changes found after treatments. 
As mentioned before, no comparison between the three treatments was made because the experimental models clearly disrupt tph2 mRNA expression 
by different pathways and no consistency and relationship between them could be observed. However, the following table shows differences 
between the three experiments done for my PhD.  
Table 6-1: Key findings of complete study. Changes in tph2 mRNA expression after MPL tx and LL tx. DRC and DRI do not appear as no change were detected.  








LMM analysis CTRL vs MPL tx LMM analysis CTRL vs LL tx 
DRD 9:00 AM 6:00 PM 3:00 AM 6:00 PM ↓ mRNA 
expression 
from 9 am 
to 6 pm 
↑ mRNA 
expression 
from 9 pm 
to 3 am  
Changes in levels 4, 8 and 9 had   
mRNA expression at 3 am and 3 pm 
after MPL tx. Level 9, 10 11 and 12 
had ↑ mRNA expression at 9 am and 
6 pm. No changes at 9 pm. 
Changes on levels 3 to 9 showed a 
↓ mRNA expression after LL tx at 
3 am, 3 pm and particularly at 6pm.  
↑ mRNA expression from level 10 
to 12 was detected at 9 am and 9 
pm. 






Changes in levels 8 and 11 had ↓ 
mRNA expression at 3 pm. Level 10 
had ↑ mRNA expression at 9 am and 
Changes at 3 pm and 6 pm in level 
8 to 14 showed ↓ mRNA 
expression. In levels 10 and 12 ↑ 
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from 9 am 
to 6 pm 
from 9 pm 
to 3 am  
6 pm.  No changes found at 3 am or 
9pm after MPL tx. 
mRNA expression was detected 
after LL tx.  
DRVL/VLPAG 9:00 AM 3:00 PM 3:00 AM 6:00 PM ↓ mRNA 
expression 
from 9 am 
to 6 pm 
↑ mRNA 
expression 
from 9 pm 
to 3 am  
Changes in levels 6 to 9 showed ↓ 
mRNA expression after MPL tx at 3 
am, 3 pm and 6 pm. Changes in 
levels 10 to 12 showed ↑ mRNA 
expression after MPL tx at 9 am, 6 
pm and 9 pm.  
All changes at 3 pm (levels 8,9,12 
and 13) and at level 6 and 9 at 6 pm 
showed ↓ mRNA expression after 
LL tx. Changes observed in levels 
9 to 13 at 3 am, 9 am and 9 pm 
showed ↑ mRNA expression.  




6:00 PM flattened 
mRNA 
expression 
from 3 am 
to 6 pm 
9:00 PM Changes in level 9 to 13 showed ↓ 
mRNA expression at 3 am, 3 pm and 
6 pm after MPL tx. ↑ mRNA 
expression was detected in level 5 
and 8 at 3 am and 6 pm, respectively. 
No changes detected at 9 pm.  
Changesat 3 pm and 6 pm in levels 
8 9, and 12 to 13 showed ↓ mRNA 
expression after LL tx. Changes at 
9 am and 9 pm in levels 4 to 7 and 
10 to 13, respectively, showed ↑ 
mRNA expression.  
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6.6 Clinical relevance  
There is an extensive list of factors that have all been related to psychiatric 
disorders, many of which are related to the general themes of current research. 
These include but are not limited to: altered circadian rhythms (Bunney and Potkin, 
2008); altered activity of the HPA axis (Swaab, Bao and Lucassen, 2005); high 
dosing of synthetic GCs (Brown and Chandler, 2001); high levels of GCs 
(Skórzewska et al., 2014); hyperactive GRs (Modell et al., 1997; Holsboer, 2000); 
exposure to extended periods of light (Tapia-Osorio et al., 2013); abnormal 
serotonergic system (Arango, Underwood and Mann, 2002); abnormal tph2 mRNA 
expression  (Donner, Johnson, et al., 2012b); polymorphisms in serotonergic 
receptors or the tph2 gene itself  (Tsai et al., 2009); and finally, high (or 
confoundingly low) levels of serotonin (Cowen, 2008). However, the molecular 
mechanisms underpinning these ‘suggestions’ are still quite poorly understood.   
The relationship between HPA axis activity, GCs and psychiatric disorders has long 
been purported. Moreover, the relationship between the brain serotonergic system 
and these types of disorders has been known since the mid-1960s (Dahlström and 
Kjell Fuxe, 1964). However, the relevance of my study was to assess whether the 
relationship observed between the altered HPA axis rhythms and the psychiatric 
disorders is established by a serotonergic mechanism. Therefore, I postulate that 
these three elements form a common triad in the aetiology of affective state 
diseases.  
The reason I have assess this hypothesis based on tph2 mRNA expression was 
firstly because tph2 is responsible for the synthesis of neuronal 5-HT (Walther et 
al., 2003), therefore targeting this enzyme would mean specific effects on brain 
serotonin. Moreover, tph2 expression does corelate to TPH protein activity and 5-
HT levels as shown by different experimental models such as KO mice 
(Domínguez-López, Howell and Gobbi, 2012; Brommage et al., 2015). 
Furthermore, tph2 expression or activity has been linked to a number of stress-
related neuronal correlates (K. L. Gardner et al., 2009), behavioural traits 
(Sadkowski et al., 2013) and psychiatric disorders (Strüber, Strüber and Roth, 
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2014), hence, understanding tph2 rhythmic expression seemed to be the perfect 
target to understand HPA-axis activity, serotonergic activity and psychiatric 
disorders.  
Because my initial interest was on the HPA axis rhythms, two different models of 
manipulation of its activity were used. However, both models have a clinical 
relevance, which implicates understanding how sGCs exert their effects producing 
psychiatric symptoms, and how exposure to long periods of light induce these types 
of symptoms. This becomes very important when one firstly considers that the use 
of sGCs is very common clinically with many patients suffering from side effects 
following long-term use, and secondly when considering why shift workers, 
frequent travellers, and even teenagers (who tend to use smartphones, TVs, tablets 
and computers at night) are at risk of developing depression or anxiety disorders. 
This topic is particularly relevant, because as previously mentioned in this 
dissertation, depression or anxiety disorders have become a huge and widespread 
problem in the modern world. Therefore, my aim was to investigate how tph2 
mRNA expression becomes dysregulated during chronic sGC treatment, and with 
the chronic stress of circadian disruption of five weeks LL exposure, as a potential 
underlying mechanism for the development of these types of stress-related 
psychiatric disorders to ultimately inform about interventions (pharmacological or 
lifestyle) that could help patients.  
I believe that the anatomical detail in my PhD work can set the basis to identify 
novel therapeutic approaches or at least understand how these organized 
subpopulations of serotonergic neurons function, so if treatments for psychiatric 
disorders target specific serotonergic neurons a reduction of adverse side effects 
could be given.  
With the above paragraph it is reasonable to think that if we wanted to use tph2 as 
a therapeutic strategy for psychiatric disorders we would also have to assess or at 
least think in the possible side effects that manipulating tph2 could cause. Studies 
have shown that tph2 Knock out mice have reduced 5-HT in the brain by 90%   
(Savelieva et al., 2008), these mice are born in normal mendelian ratios, but they 
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have severe growth defects that are sustained for the first few postnatal weeks, with 
a recovery by 4 months of age (Alenina et al., 2009).  They have impaired 
thermoregulation, altered sleep patterns and decreased blood pressure (Migliarini 
et al., 2013).  Moreover, tph2 -/- mice have behavioural abnormalities as adults, 
such as anxiety-like behaviour, depression-like behaviour altered nurturing 
behaviour (Savelieva et al., 2008; Alenina et al., 2009; Migliarini et al., 2013). 
Therefore, important changes can be seen by manipulating tph2, hence a careful 
study must be made before considering tph2 as a therapeutic target. However, there 
is an important advantage of using tph2 which is that because tph2 is specific for 
brain serotonin this would not have any peripheral effect, hence, less side-effects 
when compared to re-uptake blocker (SSRIs) and degradation inhibitors (MAOs) 
(Peters et al., 2004; Cowen, 2008; Andrade et al., 2010).  
6.7 Limitations of the study 
During my PhD studies many limitations where found along the process. These 
limitations involved methodological and technical problems. I believe that given 
the novelty of what I was investigating and the fact that the project was also new to 
the research group I belonged to, beginning and finding the correct pathway to 
approach my research question was the most challenging aspect of the project.   
Since the beginning, I was attempting an ambitious project, which implicated not 
only assessing tph2 mRNA, but other two rate-limiting enzymes involved in 
different brain systems; tyrosine hydroxylase (TH) and histidine decarboxylase 
(HDC). It took us a while to understand that this was impossible to do in the time 
frame I had, so we decided to focus on tph2 mRNA expression in the DR and MnR 
nucleus. 
I encountered several problems at the animal experimental stage. The model design 
had to be carefully considered because of the need to adapt the animal experiments 
to the animal facility and the equipment (specialised light boxes). It was physically 
impossible to have a control group in parallel to the experimental groups, due not 
only to the limited time we had to run the experiments at our specific time points 
but also to the space in the light boxes. Therefore, I did not run a group of control 
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animals in parallel to the MPL or LL experiments. Nevertheless, the control group 
used in the analysis were from the same genetic breeding stock (Harlen, UK), age 
matched, and maintained in our ‘state of the art’ environmentally controlled ASU 
animal facility at the DHB in Bristol. We are therefore confident that the ‘normal’ 
control circadian group serves as a representative control group for both the MPL 
treated group, which were run simultaneously, and the LL group which was run at 
a different time. The advantage of using only one control group in the comparison 
is that the ISHH design (recommended by Dr Chris Lowry and described in detail 
in Chapter 2 General methods) involved batch processing so that all the ISHH 
results from control, MPL and LL could be directly compared. All confounding 
factors were carefully considered, with habituation and CORT profiling performed 
for all rats in the study. Most importantly, any individual control group rats that 
exhibited a stress response or abnormally high plasma CORT level in the RIA were 
excluded from the analysis.  
Next, a couple of issues in the brain sectioning stage were found. Again, because 
of the novelty of this project in general and in our research group, there was a lack 
of available protocols, methods and data to carry out the correct sectioning at the 
first attempt. Therefore, it took me a while to get to the point of being able to collect 
126 sections of tissue of 12 mm per brain in a short period of time.  And even when 
I thought the “correct” brain sectioning and collection of tissue was obtained, the 
ISHH showed different, as I believe that the lack of results in the DRC and DRI 
was given by not having all the bregma levels of the subregions since the lack of 
circadian variation contradicts what other experts in the area have found (Donner 
et al., 2012; Hale & Lowry, 2011; Abrams et al., 2004a).  
Thereafter, and which I believe was the biggest limitation of my PhD, was the time 
it took me to make the ISHH experiments work. Nobody in our research group had 
done this type of ISHH nor used such a large number of slides in each ISHH. 
Therefore, between assessing the correct protocol, using the accurate tph2 probe, 
finding the correct hybridization and washing temperatures, doing the correct 
washes, finding the optimal exposure time, etc, optimizations of the ISHH took me 
approximately two years. 
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Then, and again because of the novelty of what I was doing, analysing the images 
and doing the statistical analysis, became another problem in my PhD. I used three 
different methods that did not work. Later, I contacted Dr Chris Lowry, an expert 
in the field, who kindly shared his image analysis protocol. Nonetheless, obtaining 
the values for 2 thousand images took me a while. Then, because the statistical 
analysis used by our group was not appropriate for the type of data I had, I 
undertook a brief internship at the University of Boulder, Colorado in Dr Chris 
Lowry’s lab to learn the basis of the Linear Mixed Model analysis. However, I only 
learned the basics, so I spent some time understanding in depth how this had to be 
done. Moreover, the image analysis also took me a lot of time because each model 
took approximately 5 days to run in SPSS.  
Finally, further behavioural experiments would have been very interesting to 
perform if time had permitted, as they would have confirmed that the modifications 
found in the circadian activity of tph2 mRNA expression after manipulating HPA 
axis activity have a behavioural functional outcome related to psychiatric 
symptoms.  
6.8 Future directions 
As mentioned above, many other experiments were planned for my research 
project. Moreover, there are many possibilities of continuing this work which I 
think could give a better understanding of the relationship described here.  
Firstly, as observed throughout the dissertation, no behavioural tests were 
performed because of the lack of time. However, we manage to start doing them, 
but did not finish. We assessed depressive-like behaviour (test for anhedonia; 
sucrose preference test) and anxiety-like behaviours (elevated plus maze) which 
could confirm that the altered HPA axis activity and the changes in tph2 mRNA 
expression are actually related to psychiatric symptoms. We also thought on doing 
a Novelty Supressed Feeding test (NSFt) for anxiety-like behaviour. These 
experiments will be performed in the near future.  
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Moreover, doing behavioural tests specific to each of the functional subregions of 
the DR and MnR nucleus would be very exciting. For example, as the DRD is 
related to anxiety-like behaviours, therefore an open-field test would be help us 
understand the nature and extent of the disturbance in this region. The MnR is 
related to resistance and tolerance to stress, so the social defeat test would give us 
a better understanding of the impact of tph2 mRNA dysregulation in this region. 
The DRVL/VLPAG is related to panic-like behaviours, so a foot shock test could 
be used to assess the impact of the disturbance in this region. These experiments 
would include other experiments (e.g. ISHH again, TPH immunoreactivity, 
electrophysiology, immunohistochemical detection of protein products) to confirm 
that the specific subregion can be related to the behavioural outcome, however, 
inter-connections between subregions might make this specific-subregion analysis 
difficult to study. These are only a few examples of many other experiments this 
project could motivate.  
Next, as mention before, the need to assess tph2 activity is also important, as the 
need to understand tph2 transcriptional-translational dynamics can give us a better 
insight of what is happening at this level. Moreover, assessing different level of the 
brain serotonin system, for example serotonin release in specific brain areas through 
micro-dialysis, would be of great relevance to understand the complete mechanism 
of how the serotonin system relates to the HPA axis activity. Moreover, western 
blotting (WB) of protein lysates prepared from DR and MnR could be done to 
assess rhythmic changes in protein expression of tph2. 
Finally, there was always a plan to conduct a series of converse experiments, where 
we manipulate the serotonin system using specific agonists/antagonists infused into 
the DR and then assess the effect on glucocorticoid secretion, this would possibly 
give a great insight into the mechanism which relates the HPA axis and the 
serotonergic system.   
6.9 Conclusions 
I believe that this study has given two strong contributions to the knowledge in this 
area of research. First, it has provided a complete characterization of the circadian 
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variation of tph2 mRNA expression in the subregions of the DR and in the MnR 
nucleus, which nobody had done before, not under this strict protocol. And 
secondly, and what I think is more important, it has increased our understanding of 
the underlying mechanism through which the HPA axis and the serotonergic 
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Appendix A: Linear Mixed Models  
Statistical analysis with Linear Mixed Models. Taken from Duricki’s protocol 
(Duricki, Soleman and Moon, 2016a).  
Linear mixed models, also called “multilevel models” or “hierarchical models”, are 
a type of regression model that take into account both (1) variation that is explained 
by the independent variables of interest (fixed effects), and (2) variation that 
is not explained by the independent variables of interest (random effects). Since the 
model includes a mixture of fixed and random effects, it’s called a mixed model. 
These random effects essentially give structure to the error term (Winter, 2015). 
 
For analysis of all in situ hybridization histochemistry data I used a linear mixed 
effect model (LMM), modelling of tph2mRNA expression (CMGVxMA) by 
experiment (CTRL, MPL or LL) or treatment (CTRL vs MPL or CTRL vs LL) in 
five different time point (3am, 9 am, 3 pm, 6 pm and 9 pm) within 5 different 
subregions of the DR (DRC, DRI, DRD, DRV, DRVL/VLPAG) and the MnR 
nuclei at each rostro-caudal bregma level (mm from bregma: −7.328, −7.412, 
−7.496, −7.580, −7.664, −7.748, −7.832, −7.916, −8.000, −8.084, −8.168, −8.252, 
−8.336, −8.420, −8.588, −8.672). 
Additionally, this models were run with 16 covariate structures, including ARMA 
(1,1), Compound Symmetry, Correlation Compound Symmetry, Diagonal, First-
order Analytic, First-order Ante-dependence, First-order Autoregressive, First-
order Factor Analytic, Heterogeneous Compound Symmetry, Heterogeneous First-
order Autoregressive, Heterogeneous Toeplitz, Huynh-Feldt, Identity, Toeplitz, 
Unstructured, and Unstructured Correlations. 
The following steps were done for all LMM analyses.  
1) Diagnostics 
These models included a series of diagnostics to confirm that the assumptions made 




normality test, error variances and a file of analysis of predicted and residual values 
of the fitted model. The SPSS syntax for the descriptives was as follows; 
EXAMINE VARIABLES (tph2 or AREA)* BY Timepoint Treatment 
ROSTROCAUDAL, /PLOT BOXPLOT HISTOGRAM NPPLOT, 
/COMPARE GROUPS, /STATISTICS DESCRIPTIVES, /CINTERVAL 95, 
/MISSING LISTWISE, /NOTOTAL. 
All analyses (overall or secondaries) would include these files. In this case, if we 
were testing the overall model, then the thp2 variable would appear, in secondary 
models AREA* could mean DRC, DRI, DRD, DRV, DRVL/VLPAG or MnR.  
The SPSS syntax for the normality test, the error variances and the predicted and 
residual values analysis for each model was as follows; 
GGRAPH, /GRAPHDATASET NAME="graphdataset" VARIABLES= (one 
COVARIATE TYPE from the sixteen possible)* _RESID 
MISSING=LISTWISE REPORTMISSING=NO, /GRAPHSPEC 
SOURCE=INLINE. BEGIN GPL, SOURCE: 
s=userSource(id("graphdataset")), DATA: (one COVARIATE TYPE from 
the sixteen possible)* _RESID=col(source(s), name("(one COVARIATE 
TYPE from the sixteen possible)* _RESID")), GUIDE: axis(dim(1), 
label("Residuals")), GUIDE: axis(dim(2), label("Frequency")), ELEMENT: 
interval(position(summary.count(bin.rect((one COVARIATE TYPE from 
the sixteen possible)* _RESID))), shape.interior(shape.square)), ELEMENT: 
line(position(density.normal((one COVARIATE TYPE from the sixteen 
possible)* _RESID)), color("Normal")), END GPL. 
* Chart Builder. GGRAPH, /GRAPHDATASET NAME="graphdataset" 
VARIABLES=(one COVARIATE TYPE from the sixteen possible)* 
_RESID (AREA) MISSING=LISTWISE REPORTMISSING=NO 
/GRAPHSPEC SOURCE=INLINE, BEGIN GPL, SOURCE: 
s=userSource(id("graphdataset")), DATA: (one COVARIATE TYPE from 
the sixteen possible)* _RESID=col(source(s), name("(one COVARIATE 
TYPE from the sixteen possible)* _RESID")), DATA: (AREA) 
=col(source(s), name("(AREA) ")), GUIDE: axis(dim(1), label("Predicted 
Values")), GUIDE: axis(dim(2), label("(AREA) ")), ELEMENT: point( 
position ((one COVARIATE TYPE from the sixteen possible)* 
_RESID*(AREA))), END GPL. 
GGRAPH, /GRAPHDATASET NAME="graphdataset" VARIABLES=(one 
COVARIATE TYPE from the sixteen possible)* _PRED (one 
COVARIATE TYPE from the sixteen possible)* _RESID, 
MISSING=LISTWISE REPORTMISSING=NO, /GRAPHSPEC 
SOURCE=INLINE. BEGIN GPL, SOURCE: 
s=userSource(id("graphdataset")), DATA: (one COVARIATE TYPE from 




TYPE from the sixteen possible)* _PRED")), DATA: (one COVARIATE 
TYPE from the sixteen possible)* _RESID=col(source(s), name("(one 
COVARIATE TYPE from the sixteen possible)* _RESID")), GUIDE: 
axis(dim(1), label("Predicted Values")), GUIDE: axis(dim(2), 
label("Residuals")), ELEMENT: point(position((one COVARIATE TYPE 
from the sixteen possible)* _PRED*(one COVARIATE TYPE from the 
sixteen possible)* _RESID)) END GPL. 
NPAR TEST, /K-S(NORMAL)= (one COVARIATE TYPE from the 
sixteen possible)* _RESID, /MISSING ANALYSIS 
PPLOT, /VARIABLES=(one COVARIATE TYPE from the sixteen 
possible)* _RESID, /NOLOG, /NOSTANDARDIZE, /TYPE=P-P, 
/FRACTION=BLOM, /TIES=MEAN, /DIST=NORMAL. 
PPLOT, /VARIABLES=(one COVARIATE TYPE from the sixteen 
possible)* _RESID, /NOLOG, /NOSTANDARDIZE, /TYPE=Q-Q, 
/FRACTION=BLOM, /TIES=MEAN, /DIST=NORMAL. 
All analyses (overall or secondaries) included these files. Therefore, AREA* could 
mean DRC, DRI, DRD, DRV, DRVL/VLPAG or MnR and (one COVARIATE 
TYPE from the sixteen possible) * implicated the fitted model for the particular 
analysis. 
The following tables and plots are an example of the SPSS output for the descriptive 






























2) Overall models 
After diagnostics, two overall models (higher level models) were run for two 
different conditions; 1) to assess the overall effect of time in tph2 mRNA 
expression, for the CTRL, MPL and LL experiments, within each subregion of the 
DR and MnR nucleus throughout all their rostro-caudal extent across the 5 different 
time points measured and 2) to assess the effect of time and treatment, for CTRL 
vs MPL  and CTRL vs LL comparisons, within each subregion of the DR and MnR 
nucleus throughout all their rostro-caudal extent across the 5 different time points 
measured.  
The SPSS syntax for the first condition i.e., 3 higher levels models (CTRL, MPL 
and LL) which assessed the effect of time, was as follows; 
MIXED Tph2 BY Subdivision Rostro-caudalL Timepoint, 
/CRITERIA=CIN(95) MXITER(100) MXSTEP(10), SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, ABSOLUTE) 
LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE), 
/FIXED=ROSTROCAUDAL Subdivision Timepoint 
Timepoint*ROSTROCAUDAL Timepoint*Subdivision, 
ROSTROCAUDAL(Subdivision), 
Timepoint*ROSTROCAUDAL(Subdivision) | SSTYPE(3), 
/METHOD=REML, /PRINT=DESCRIPTIVES  
/REPEATED=ROSTROCAUDAL | SUBJECT(AnimalID*Subdivision) 
COVTYPE((one from the sixteen possible)*), /SAVE=PRED RESID. 
 
The following tables are an example of the SPSS output for the first condition of 










The SPSS syntax for the second condition i.e., 2 higher level models (CTRL vs 
MPL and CTRL vs LL) was as follows;  
MIXED Tph2 BY TREATMENT TIMEPOINT Rostrocaudal Subdivision, 
/CRITERIA=CIN(95) MXITER(100) MXSTEP(10) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, ABSOLUTE) 
LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE), 








TREATMENT*TIMEPOINT*Rostrocaudal(Subdivision) | SSTYPE(3), 
/METHOD=REML, /PRINT=DESCRIPTIVES, /REPEATED=Rostrocaudal 
| SUBJECT(ANIMALID*Subdivision) COVTYPE((one from the sixteen 
possible)*), /SAVE=PRED RESID. 
 
The following tables are an example of the SPSS output for the second condition 












To determine the best fitted model, the 16 different (with different covariance 
structures) output models were compared with their specific Akaike information 
criterion (AIC) score and the one which had the lowest, was the best fitted model 
for the data. Following these overall analyses, if a main effect or interaction 
between a main effect and any other factor reached p < 0.05, secondary LMM were 





3) Secondary Liner Mixed Models  
Secondary models (lower level models) were run again with 16 different covariates 
structures and included all the diagnostic files. 
These models intended to assess 2 different conditions; 1) the effect of time, for the 
CTRL, MPL and LL experiments, in each DR subregion and MnR nucleus 
separately, throughout all their rostro-caudal extent across the 5 different time 
points measured and 2) the effect of time and treatment, for CTRL vs MPL  and 
CTRL vs LL comparisons in each DR subregion and MnR nucleus separately 
throughout all their rostro-caudal extent across the 5 different time points measured. 
The SPSS syntax for the first condition, i.e., six different lower level models one 
for each subregion) was as follows: 
MIXED SUBREGION* BY Timepoint ROSTROCAUDAL, 
/CRITERIA=CIN(95) MXITER(100) MXSTEP(10) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0,ABSOLUTE) 
LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE), 
/FIXED=Timepoint ROSTROCAUDAL Timepoint*ROSTROCAUDAL 
SSTYPE(3), /METHOD=REML, /PRINT=DESCRIPTIVES, 
/REPEATED=ROSTROCAUDAL | SUBJECT(AnimalID) COVTYPE((one 
from the sixteen possible)*), /SAVE=PRED RESID. 
 
The following tables are an example of the SPSS output for the secondary model 








Additionally, the secondary lower level models for the second condition were done 
assessing each timepoint separately, hence, for example CTRL vs MPL in the DRC, 
at 3 am in one LMM analysis, CTRL vs MPL in the DRC at 9 am in another LMM 
CTRL vs MPL in the DRC at 3 pm in a third model, and so on for the 5 time points 
were assessed. However, these analyses only corresponded to the DRC, so the same 
number of LMM analysis for the DRI, DRD, DRV, DRVL/VLPAG and MnR were 
performed. Therefore, for this secondary lower level models 30 different models 
were completed. The SPSS syntax for the first condition, i.e., 30 different lower 
level models (one for each subregion at each time point) was as follows: 
MIXED SUBREGION* BY ROSTROCAUDAL Treatment, 
/CRITERIA=CIN(95) MXITER(100) MXSTEP(10) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0,ABSOLUTE) 
LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE), 
/FIXED=ROSTROCAUDAL Treatment ROSTROCAUDAL*Treatment 




/REPEATED=ROSTROCAUDAL | SUBJECT(AnimalID) 
COVTYPE(AD1), /SAVE=PRED RESID. 
 
The following tables are an example of the SPSS output for the secondary lower 









For the last stage of this analysis, to determine the best fitted model the covariance 
structures were compared to the AIC score. The model with the lowest score was 
the best fitted model. Following these secondary analyses, if a main effect or 
interaction between a main effect and any other factor reached p < 0.05, post hoc 
pairwise comparisons were made with Fisher’s LSD test. The SPSS syntax for the 
post hoc analysis was as follows;  
UNIANOVA SUBREGION*BY Groups, /METHOD=SSTYPE(3), 
/INTERCEPT=INCLUDE, /POSTHOC=Groups(TUKEY LSD 
BONFERRONI SIDAK), /EMMEANS=TABLES(OVERALL), 
/PRINT=DESCRIPTIVE HOMOGENEITY, /CRITERIA=ALPHA(.05) 
/DESIGN=Groups. 
 
The following tables are an example of the SPSS output for the pairwise 








Finally, important to clarify three different conditions had to be accomplished in 
order to performed post hoc analyses; 1) if a main effect or interaction between a 
main effect and any other factor reached p < 0.05, 2) if both the overall and 
secondary LMM reach significance in interaction or a main effect and 3) if the 
sample sizes was not below 50% of the full sample size. 
 
